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Abstract 
The development of novel analgesics would be facilitated if the mechanisms 
underlying nociception and inflammatory pain were fully understood. Adenosine 
5'triphosphate (ATP) and adenosine can cause pain in humans when applied to a 
blister base, but the algogenic mechanism of action is still unclear. Cells contain 
millimolar concentrations of ATP, which is released into the extracellular space 
when the cells are damaged, and is subsequently metabolised to adenosine. 
Consequently, levels of the purines are increased in damaged, inflamed or ischemic 
tissues and this makes them ideal candidates to signal the presence of tissue injury. It 
is thought that ATP and adenosine might be involved in the initiation of pain by 
directly or indirectly activating distinct subtypes of P2 or P 1 receptors respectively. 
In this thesis, behavioural, electrophysiological, and immunohistochemical 
techniques were used to test the hypothesis that ATP and adenosine are involved in 
the initiation of pain by directly and /or indirectly activating nociceptors innervating 
the cornea and the knee joint in vivo. 
ATP and ATP analogues were administered to the normal cat cornea and the 
normal rat knee joint under pentobarbitone anaesthesia and their effects on the 
discharge of nociceptors innervating these tissues were recorded. The effects of 
inflammation caused by photorefractive keratectomy of the cornea or Freund's 
adjuvant induced monoarthritis of the knee joint on the sensitivity to the purines was 
also determined. In behavioural studies, ATP analogues were instilled into the eyes 
of conscious rats and any changes in behaviour indicative of pain were assessed. To 
establish whether the P2X3 receptor subtype for ATP was expressed in the cell 
bodies of mouse corneal and rat knee joint neurones in the trigeminal and dorsal root 
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ganglia respectively, these cells were retrogradely labelled using fluorogold and 
subsequently examined for co- localisation of fluorogold fluorescence with P2X3 
immunoreactivity. Adenosine and adenosine analogues were also administered to the 
normal and arthritic rat knee joint and, in behavioural studies, the effect of adenosine 
agonists, adenosine antagonists and increasing the levels of endogenous adenosine on 
the pain and inflammation associated with experimental arthritis were determined. 
Immunoreactivity to P2X3 receptors was found in cell bodies of mouse 
corneal nociceptors, but none of the ATP analogues tested excited cat corneal 
nociceptors or caused pain when instilled into the eyes of conscious rats. The P2X3 
subtype was also expressed in knee joint neurones in the dorsal root ganglia. ATP, 
the stable P2X1 and P2X3 selective agonist, aß- methylene ATP and the P2 agonists, 
ATPyS and benzoylbenzoyl ATP (BzATP), caused a rapid- onset, short- lasting 
increase in action potential discharge from nociceptors innervating the rat knee joint. 
These responses were antagonised by the P2 antagonist PPADS. ATP and ATPyS 
also caused a delayed- onset, long- lasting increase in firing which was probably 
mediated by adenosine Al receptors since adenosine, and the Al selective agonists 
GR79236 and CPA evoked a similar response. These slow -onset responses were 
antagonised by the Al selective antagonist DPCPX. Paradoxically, systemic 
injections of DPCPX were not analgesic in behavioural studies, while the adenosine 
uptake inhibitor, dipyridamole, which increases the extracellular levels of 
endogenous adenosine, was. GR79236 had no effect on the pain of arthritis but did 
possess anti -inflammatory properties. The ability of ATP to indirectly activate rat 
knee joint nociceptors via P2X7 receptors expressed on inflammatory cells was 
assessed by injecting high concentrations of BzATP, ATPyS and ATP intra- 
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articularly to the knee joint and monitoring their effects on spontaneous and 
bradykinin- evoked neural discharge. BzATP did not cause any increase the basal 
action potential discharge rate nor did it sensitise the nociceptors to bradykinin. The 
data from the other agonists was complicated by their metabolism to adenosine but, 
like BzATP, no evidence was found for a sensitising effect. 
This data supports the hypothesis that ATP and its metabolite, adenosine can 
directly excite nociceptors innervating the rat knee joint via P2X and Al receptor 
subtype(s), respectively. However, it does not support a role for P2X mediated 
initiation of pain from the cat or rat cornea nor does it indicate that ATP could cause 
pain via an indirect action on inflammatory cells. These findings have implications 
for the development of novel therapies for the treatment of pain. 
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List of commonly used abbreviations 
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IP3 inositol triphosphate 






M molar concentration 
m metre 
ni (prefix) milli (10 -3) 
MAN medial articular nerve 
mg milligram 
mg kg i milligrams per kilogram 
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n number of observations 
n (prefix) nanogram 
Na+ sodium ion 
NaCI sodium chloride 
NSAID non- steroidal anti -inflammatory drug 
P statistical probability 
p (prefix) picogram 
PBS phosphate buffered saline 
PLC phospholipase C 
PLD phospholipase D 
PKC protein kinase C 
s second 
sem standard error of the mean 
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Most abbreviations, other than commonly used expressions, are also defined at the 
first point of occurrence in the text. 
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Chapter I: Introduction 
Chapter 1: General introduction 
Severe chronic pain is a major symptom of rheumatoid arthritis (RA) and one of the 
main aims of treating this disease is to improve the quality of life of patients by 
providing pain relief. The non -steroidal anti -inflammatory drugs (NSAIDs) are the 
most effective analgesic compounds used clinically to treat RA pain but their 
prolonged use is associated with severe side effects including renal dysfunction 
(Lifschitz, 1983) and gastrointestinal bleeding (Goodwin, 1987). These drugs inhibit 
the enzymes responsible for the production of a group of peripherally -acting 
inflammatory mediators, the prostanoids, which are largely thought to contribute to 
inflammatory pain by sensitising the primary afferent nociceptor (Levine et al., 1993; 
Vane, 1971). This indicates that the interaction between the nociceptors innervating 
inflamed tissues and the mediators produced during inflammation have a crucial role 
to play in generating and maintaining inflammatory pain. For this reason, 
considerable efforts have been made to establish the effects of endogenous 
inflammatory mediators on nociceptors and nociceptive behaviours in order to 
facilitate the development of novel analgesics to treat inflammatory pain. 
The purines adenosine 5'triphosphate (ATP) and adenosine are prime 
candidates as endogenous mediators of inflammatory pain because extracellular 
levels of both are increased during inflammation (Gordon, 1986). That these purines 
might be involved in producing pain was first alluded to by Stoner and Green (1945) 
after they found that intra- arterial injections of ATP produced "tingling pains" in the 
forearms of humans. Since then, ATP and adenosine have been implicated in many 
of the peripheral and central mechanisms of pain (Cronstein et al., 1996; Keil & 
Salter, 1996). In order to ascertain whether manipulation of purinoceptor 
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pharmacology is a viable therapeutic target for the treatment of pain, it is crucial to 
determine the effects of these purines on nociceptive afferents innervating both 
normal and inflamed tissues, and on nociceptive behaviours in conscious animals. 
In this introductory chapter, the peripheral sensors through which painful 
stimuli are perceived will be described, followed by a description of the mechanisms 
through which inflammatory mediators can modulate nociceptor function. The 
nociceptors innervating the cornea and the knee joint will then be described as these 
tissues were used in the present study. Finally, the literature suggesting that ATP and 
adenosine play a role nociception and inflammatory pain will be reviewed. 
1.1 NOCICEPTION 
The ability to sense pain has two main functions: it allows the organism to detect 
potentially injurious external stimuli resulting in the initiation of the appropriate 
protective response, and it provides the means to sense if tissue has been injured. 
Nociception is the detection of such events by specific pain- sensing receptors called 
nociceptors. The terms "nociception" and "nociceptor" are derived from 
Sherrington's (1906) proposal at the start of this century that "noci- receptors" exist 
that are able to detect stimuli "capable of compromising the integrity of the 
organism ". Although Sherrington proposed the presence of nociceptors almost a 
century ago, definitive evidence of their existence was only presented 30 years ago 
(see below). 
1.1.1 DISCOVERY OF NOCICEPTORS 
The meticulous investigations of the early psychophysicists, in particular von Frey 
(1894; 1922) yielded the first solid scientific evidence that pain was a sense distinct 
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from touch and was mediated by specific sense organs. Von Frey described separate 
sensitivities to pain, touch, warm and cold at different punctate regions of the body. 
Furthermore, the pain spots were always associated with areas that were solely 
innervated by unspecialised nerve endings, the so- called "free" nerve endings. 
Following the introduction of electrophysiological techniques for recording from 
sensory nerves innervating peripheral tissues, it was shown that thinly myelinated 
(AS- fibres) and unmyelinated axons (C- fibres) were activated by noxious stimuli, 
whereas the largest myelinated fibres (Aß- fibres) responded to innocuous stimuli 
(Clarke et al., 1935; Gasser & Erlanger, 1927; Heinbecker et al., 1932; Zotterman, 
1933). These studies suggested that the thin fibres were responsible for the detection 
of potentially injurious stimuli. 
The suggestion that the small diameter fibres were the specific detectors of 
pain was soon disputed. In 1960, Iggo reported that he had recorded from a number 
of individual cat cutaneous C- fibres that responded to mechanical stimuli ranging 
from the innocuous to the noxious and stated that the unmyelinated fibres "can no 
longer be regarded as exclusively nociceptive in function" (Iggo, 1960). Other 
studies at the time also demonstrated that the thin fibres were not exclusively 
nociceptive (Hunt & McIntyre, 1960a -c). The equivocal data from 
electrophysiological experiments led Malzack and Wall (1962) to state that "there 
can no longer be any doubt that the temporal and spatial patterns of nerve impulses 
provide the basis of our sensory perceptions ". Thus even a few decades ago, the very 
existence of receptors for noxious stimuli (Sherrington's "noci- receptors ") was still 
in dispute. 
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The controversy was finally resolved by Perl and colleagues in the late 
sixties. Burgess and Perl (1967) described the response characteristics of over 500 
thinly myelinated cat cutaneous afferents to mechanical and thermal stimulation. 
They reported that 74 of these A8- fibres had mechanical thresholds many times 
higher than the other AS- fibres and they responded to noxious thermal stimulation 
and pinching of the skin. They named these afferents "nociceptors" for the first time 
using a term derived from Sherrington. Shortly thereafter, Bessou and Perl (1969) 
reported the response characteristics of a population of unmyelinated C- fibres 
innervating the skin of the cat's hindlimb. About 50% of the afferents they recorded 
were activated by innocuous mechanical stimulation, but two groups were defined as 
nociceptors: 40% were activated by intense mechanical stimulation, high 
temperatures and chemical stimulation, and 10% responded to intense mechanical 
stimulation only. The former group was called the polymodal nociceptors and the 
second were called mechanonociceptors. 
1.1.2 CLASSIFICATION OF NOCICEPTORS 
To date, nociceptors innervating a wide variety of tissues including the skin 
(Campbell & Meyer, 1996), cornea (Belmonte & Gallar, 1996), joints (Schaible & 
Schmidt, 1996), muscle (Mense, 1996) and viscera (Cervero, 1996) have been 
described. Unfortunately, no one system is used for the classification of nociceptors 
(see Lynn, 1996) and this can lead to difficulties in comparing the work of different 
groups. 
The main criteria used to classify nociceptors are the stimulus required to 
excite them, the conduction velocity of action potentials along their axes and the 
target tissue they innervate. For example, sensory fibres innervating the cat's cornea 
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that are activated by mechanical, chemical and thermal stimulation and which 
conduct in the C -fibre range ( <2ms 1) are termed corneal C -fibre polymodal 
nociceptors (Gallar et al., 1993). Nociceptors innervating the cat cornea and the rat 
knee joint were investigated in the present study and these will be described in more 
detail later in this chapter. 
1.1.3 EXCITATION OF' NOCICEPTORS 
Noxious mechanical, thermal and chemical stimuli are detected when the peripheral 
terminals of nociceptors are depolarised to the threshold for action potential 
initiation. Depolarisation occurs either as a result of an increased permeability of the 
membrane to ions such as sodium (Na +) and calcium (Caz +), or a reduced 
permeability to potassium ions (K +) (Bevan, 1996). The action potential(s) are then 
transmitted to the central nervous system (CNS) and, depending of the state of 
sensitisation of central sites, pain is sensed (Millan, 1999). 
1.1.3.1 Mechanical excitation 
Very little is known about the mechanisms through which high- intensity mechanical 
stimulation causes action potential generation in nociceptors. Most of the current 
knowledge of mechanosensitivity has come from studies of the mechanosensitive 
channel of large conductance (MscL) from Eschericia coli (reviewed by Sukharev et 
al., 1997) and from genetic studies of the nematode, Caenorhabditis elegans 
(reviewed by Tavernarakis & Driscoll, 1997). 
Purified MscL protein forms functional mechanosensitive channels when 
reconstituted into artificial lipid bilayers (Häse et al., 1995) indicating that stretching 
of the lipid bilayer directly opens the channel. In C. elegans, mutations of various 
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genes render the nematode insensitive to touch (Tavernarakis & Driscoll, 1997). One 
of the genes required by C. elegans for mechanosensitivity is thought to encode a 
mechanosensitive ion -channel because it is homologous to the amiloride -sensitive 
sodium channel and amiloride is well known to inhibit mechanosensitive ion - 
channels (Hamill el al., 1992). Similar ion -channels may account for 
mechanosensitivity in mammalian nociceptors, but this is still unknown. Mutations 
of other C. elegans genes, including those encoding extracellular matrix and 
cytoskeletal components, also confer mechanical insensitivity on the nematode. It is 
still unclear what role extracellular matrix and cytoskeletal components play in 
mechanical transduction but it has been suggested that mechanical stimuli produce 
changes in the overall structural architecture of cells which results in intracellular 
biochemical signals (see Ingber, 1997). 
Further functional investigations of the MscL protein from E. coli and studies 
of mutated genes from C. elegans will undoubtedly extend our knowledge of 
mechanosensitivity but for now, the mechanisms underlying selective sensitivity to 
high threshold mechanical stimulation which is characteristic of nociceptors remains 
unknown. 
1.1.3.2 Thermal excitation 
Although relatively little is known regarding the transduction of noxious cold 
stimuli, the mechanism through which noxious heat is detected has largely been 
revealed over the past two years. The first vannilloid receptor (VR -1) was cloned and 
found to be gated by noxious heat and by capsaicin (8- methyl- N- vanillyl -6- 
noneamide), the compound that makes peppers taste hot (Caterina el al., 1997). 
Capsaicin and noxious heat gate a non- selective cation -channel (the VR -1 receptor) 
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which is highly permeable to divalent cations. Capsaicin has long been recognised as 
a peripheral nociceptive excitatory substance and therefore, the detection of tissue - 
damaging heat stimuli probably follows the activation of vannilloid receptors 
expressed on the peripheral terminals of nociceptive afferents (Tominaga et al., 
1998). 
1.1.3.3 Chemical excitation 
In general, acute nociceptor activation, for example during a mechanical insult, leads 
to a transient sensation of pain of little clinical relevance. However, in inflamed 
tissues, a variety of chemical mediators are released which activate and /or sensitise 
the primary afferent nociceptor leading to heightened, and sometimes chronic, pain. 
The mechanisms through which inflammatory mediators excite or sensitise 
nociceptors will be considered in Section 1.2.2 below. 
1.2 INFLAMMATORY PAIN 
When an inflammatory response is triggered by tissue injury or the presence of an 
antigenic foreign body one of the main symptoms is pain. Inflammatory pain is 
characterised by ongoing spontaneous pain, a painful sensation following normally 
innocuous stimuli and enhanced pain to noxious stimuli. Although the nomenclature 
is not clearly defined (Meyer et al., 1996; Woolf et al., 1998), pain arising from a 
normally innocuous stimulus is commonly called allodynia, while an increased 
response to a noxious stimulus is termed hyperalgesia, and this is the context in 
which these terms will be used in this thesis. Sensitisation of both peripheral 
nociceptors and central pathways are involved in causing these enhanced pain states. 
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The present investigation is concerned with changes in the excitability of the 
peripheral terminals of nociceptors and how this contributes to inflammatory pain. 
Thus, in this section, the discovery of peripherally- acting inflammatory pain 
mediators will be outlined, followed an account of the mechanisms through which 
these mediators cause peripheral sensitisation. 
1.2.1 HISTORICAL PERSPECTIVE 
The four main symptoms of inflammation - redness, heat, swelling and pain were 
first stated two millennia ago by Celsus (30 BC - 30 AD). In the late 18111 century, 
Hunter (1894) published one of the most detailed descriptions of the signs of 
inflammation based on his observations in humans and experiments with animals. On 
inflammatory pain, Hunter stated: 
"Thus a tendon has very little sensation when injured in a natural 
state; but let that tendon become inflamed, or otherwise diseased, and 
the sensation shall be very acute." 
Over a century later, Sir Thomas Lewis (1942) was the first to consider the processes 
underlying the hypersensitivity associated with inflamed tissue: 
"The hyperalgesic skin, according to my theory, is one which has 
been brought to this state by the action of certain tissue substances 
upon the nerve endings, the latter being rendered hyperexcitable." 
Lewis had come to his perceptive theory regarding the actions of chemical tissue 
factors after a consideration of his and others' experiments with histamine. Histamine 
(decarboxylated amino acid histidine) caused an inflammation -like response when 
injected into the skin (Eppinger, 1913). Furthermore, a histamine -like substance 
could be extracted from skin which caused itch in addition to the redness, wheal and 
flare of the "triple response" when re- injected into normal skin (Harris, 1927). The 
itching caused by histamine and the histamine -like substance, as well as by minor 
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tissue injuries producing the triple response, was prolonged when the circulation to 
the affected skin was stopped. These observations led Lewis (1927) to conclude that 
stopping the circulation caused the retention in the tissues of an H- substance released 
from the damaged cells. He also suggested that more severe injury caused the release 
of a pain -producing substance from cells because he noted that intra- dermal injection 
of skin extracts could also cause pain (Lewis, 1935). At this time few endogenous 
chemical mediators had been identified but neither of those that were known, namely 
histamine or acetylcholine, nor changes in pH, tonicity or potassium, could account 
for the pain -producing substance in the skin extract (Lewis, 1942). 
Rather surprisingly, the pain aspect of the inflammatory response was largely 
ignored after Lewis until the work of Keele and colleagues (reviewed in Keele & 
Armstrong, 1964). These authors had developed a novel method of testing the 
algogenic properties of chemical substances by applying them to the base of 
experimentally- induced blisters in human volunteers (Armstrong et al., 1951). The 
blisters were raised by placing a plaster containing cantharidin (the active principle 
from Cantharis vesicaforia, the blistering beetle) on the skin of the forearm. 
Subsequently, the base was exposed by aspirating the blister fluid and removing the 
separated epidermis. A large number of chemicals, endogenous mediators, body 
fluids and insect venoms were tested for algogenic properties on the blister base. 
Among the substances found to cause pain were bradykinin, 5- hydroxytryptamine (5- 
HT) and substance P, as well as knee joint fluids from patients with RA. Since then, 
the effects of these and other substances on the primary afferent nociceptor and the 
contribution of inflammatory mediators to the pain associated with inflammation 
have been studied in more detail. 
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1.2.2 PERIPHERAL MECHANISMS 
Combined evidence from various lines of investigation can indicate the mechanism 
through which inflammatory mediators modulate nociceptor function. For example, 
immunohistochemistry can be used to identify the cells in which the receptors for 
inflammatory mediators are expressed. If they are localised to the cell bodies of 
afferents in sensory ganglia, this suggests a direct effect of the mediator on the 
nociceptor. However, if the receptors are expressed on inflammatory cells, this could 
imply an indirect mechanism of action. Functional studies of sensory cell bodies or 
inflammatory cells in vivo or in vitro reinforce these basic investigations. Another 
method of investigating the effect of algogenic mediators on nociceptor function is to 
record from the axon of the afferents in vivo while applying the test substance locally 
to the tissue they innervate. The latency to onset of the expected response usually 
gives indication of indirect. A preferable 
method would be perform intracellular recordings of electrical activity in the 
nociceptive terminal while applying the test substance but this is not possible 
because of the size of the terminals and their close association with the tissues they 
innervate. 
Evidence from these types of studies have indicated that some inflammatory 
mediators act directly on the sensory nerve terminal to excite it and /or to sensitise it 
to other chemical, mechanical or thermal stimuli, whereas others affect nociceptor 
function indirectly by causing the release of algogenic or sensitising mediators from 
other cells (Levine & Tawio, 1994). A schematic diagram of the mechanisms of 
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Figure 1.1 Schematic diagram of the peripheral mechanisms of ii fiammatoiy 
pain. Substances released from iifammatoiy cells, the sympathetic postganglionic 
neurone, the nociceptor itself and derived from other sources can directly or 
indirectly activate and /or sensitise the primary afferent nociceptive afferent. Adapted 
from (Levine & Tawio, 1994). See text, for details. 
1.2.2.1 Directly acting algogenic mediators 
Algogenic chemicals and inflammatory mediators that are thought to cause pain by 
directly activating nociceptive afferents include capsaicin, bradykinin, 5 -HT, 
acetylcholine and protons (Kress & Reeh, 1996). Some algogens (for example, 5 -HT 
via the 5 -HT3 receptor subtype) can depolarise the cell membrane rapidly because 
they bind to specific ligand -gated ion -channel linked receptors. Other algogens (for 
example, bradykinin via the B2 receptor subtype) bind to receptors that are coupled 
to guanyl- nucleotide- binding (G) protein and cause depolarisation via second 
messenger signalling cascades. Although the exact means through which G- protein- 
linked receptors cause membrane depolarisation is still unclear, the pathway through 
which bradykinin B2 receptor subtypes do so is relatively well characterised. Binding 
of bradykinin to B2 receptors expressed on sensory neurones causes the activation of 
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phospholipase C (PLC) which cleaves membrane lipids to form inositol triphosphate 
(IP3) and diacylglycerol (DAG). DAG activates protein kinase C (PKC) which can 
phosphorylate membrane ion -channels and receptors leading to membrane 
depolarisation (Bevan, 1996). 
1.2.2.2 Directly acting sensitising mediators 
Bradykinin, PGE2 and prostacyclin are some of the mediators thought to sensitise the 
nociceptor by directly interacting with specific receptors on the nociceptor terminal 
(Kress & Reeh, 1996). Adenylate cyclase (AC) mediated increases in intracellular 
cyclic adenosine monophosphate (cAMP) have been implicated in nociceptor 
sensitisation (Levine & Tawio, 1994) although the mechanism through which the do 
so is not clear. There is some evidence that sensitising substances which increase 
cAMP levels (for example, prostaglandin E2 (PGE2) via the EP2 receptor subtype) 
reduce the membrane permeability to K +, thus depolarising the terminal and 
increasing the likelihood that action potentials will be initiated (Bevan, 1996). 
1.2.2.3 Indirectly acting mediators 
Interleukin -1ß (IL -1ß) is a potent, indirectly acting pro -nociceptive inflammatory 
mediator which is produced by a variety of non -neuronal cells (including 
macrophages, mast cells, fibroblasts and synoviocytes) during inflammation (Bianchi 
et al., 1998). This cytokine causes the release of a variety of pro -nociceptive 
inflammatory mediators; for example it 1) stimulates PGE2 release from cultured 
human synovial cells (Dayer et al., 1986), 2) induces nerve growth factor production 
in vitro (Yoshida & Gage, 1992) and in vivo (Safieh- Garabedian et al., 1995), and 3) 
up- regulates levels of substance P in sympathetic neurones in vitro (Hart et al., 1991; 
Jonakait et al., 1990) and increases transport of tachykinin receptors to the peripheral 
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terminals of sensory neurones in vivo (Jeanjean et al., 1995). PGE2, substance P and 
nerve growth factor can then cause pain directly and /or indirectly. 
Due to the excitatory and /or sensitising effects of inflammatory mediators, 
nociceptors innervating inflamed tissues have an increased basal rate of discharge, a 
reduced threshold for activation and an augmented response to stimuli. Furthermore, 
during inflammation more nociceptors are excited by any given stimulus and 
nociceptors that were previously inactive are now activated (Coggeshall el al., 1983; 
Guilbaud et al., 1985; Schaible & Schmidt, 1985; Schaible & Schmidt, 1988). The 
elevated C -fibre activity during inflammation increases the excitability of spinal 
neurones by releasing glutamate and substance P so that the response to all sensory 
input, including that to low threshold stimuli, is augmented (Ma & Woolf, 1995; 
Woolf, 1983; Woolf & Thompson, 1991; Woolf & Wall, 1986; Xu et al., 1992). 
Central sensitisation also occurs due to increased activity of A13- fibres which express 
substance P during inflammation (Neumann et al., 1996). 
Both peripheral and central sensitisation contribute to inflammatory pain but 
their relative contribution is not known. This study focused on the peripheral roles of 
ATP and adenosine in nociception and inflammatory pain and this was largely 
investigated in the cornea and the knee joint. 
1.3 NOCICEPTORS INNERVATING THE NORMAL AND INFLAMED 
CORNEA AND KNEE JOINT 
1.3.1 THE CORNEA 
The cornea is an ideal tissue in which to study nociception because it is an 
accessible, avascular, very simple structure with a high density of nociceptive nerve 
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terminals. Apart from the merits of investigating corneal nociceptors in basic 
research, knowledge of the mechanisms of corneal pain would aid the development 
of novel analgesics for corneal inflammatory pain. Although the cornea is an 
avascular tissue, blood- derived inflammatory cells can be detected at the edges of a 
corneal wound within 2 -3 hours of injury, and the tissue has a population of mast 
cells (Bazan, 1990). Intense and prolonged corneal pain can arise as a result of 
accidental corneal erosions, bulbous keratopathy and following photorefractive 
surgery for the correction of myopic conditions. As well as these severe pain states, 
discomfort and irritation are frequent complaints of contact lens wearers. 
1.3.1.1 Corneal innervation 
A vast number of publications dealing with the innervation of the cornea in many 
species, including members of the mammalian, avian, amphibian, reptilian and fish 
classes, have been published (see Zander & Wedell, 1951). The cornea is innervated 
(primarily) by afferents originating in the trigeminal ganglion (TG). The afferents 
travel to the eye via the ophthalmic nerve, which innervates the tissue either directly, 
via long cilliary nerves, or indirectly after first passing to the ciliary body, which in 
turn sends short cilliary nerves to the eye. The long and short ciliary nerves join to 
form the mixed ciliary nerve, which pierces the sclera at the posterior pole of the 
eyeball around the optic nerve (Attias, 1912). From here, they travel radially around 
the eyeball towards the cornea, and at the interface between the conjunctiva and the 
cornea, the limbus, the nerve axons form an "episcleral pericorneal plexus" (Zander 
& Wedell, 1951). It is from this "ring -like scaffold" of nerve bundles that nerves 
penetrate the cornea from the limbus. The nerve axons extend into the cornea parallel 
to the surface where they branch repeatedly resulting in a plexiform arrangement of 
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nerve fibres distributed in many layers of the corneal stroma with the greatest density 
towards the superficial layers. From the plexiform arrangement, many axons ascend 
vertically and penetrate the epithelium between cells of the basal layer. Here they 
divide into as many as 15 daughter axons that continue to branch as they travel 
vertically between cells towards the corneal surface (Zander & Wedell, 1951). 
The resulting enormous number of axon terminals can terminate at any level 
within the epithelium with many ending a few microns from the corneal surface. This 
continuous branching of corneal sensory fibres makes the cornea the most densely 
innervated structure in the body; the cornea is thought to have approximately 300 - 
600 times more sensory endings than the skin and 20 - 40 times more than the tooth 
pulp (Rozsa & Beuerman, 1982). 
1.3.1.2 Corneal nociceptors 
Tower (1940) was the first to record action potentials from corneal afferents. He 
reported that the receptive fields of mechanosensitive corneal afferents were large 
(50- 200mm2) and frequently extended into the adjacent limbus and conjunctiva, an 
observation later confirmed by Lele and Waddell (1959) and Belmonte's group 
(Giraldez et al., 1979). In more recent years, Belmonte and his colleagues (Belmonte 
& Gallar, 1996; Belmonte et al., 1991; Belmonte & Giraldez, 1981; Gallar et al., 
1993; Giraldez et al., 1979) have identified three main functional classes of corneal 
nociceptors; mechanosensitive, polymodal and cold (reviewed by Belmonte & 
Gallar, 1996). 
Mechanonociceptors respond exclusively to high threshold mechanical 
stimulation and always conduct in the AS -fibre range (Belmonte et al., 1991). 
Polymodal nociceptors are activated by mechanical, thermal and chemical 
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stimulation. These units conduct in either the A8 or C -fibre range and are the most 
abundant type of unit found in the cornea (Belmonte et al., 1991; Gallar et al., 1993). 
Cold sensitive afferents are always C- fibres and they respond selectively to cooling 
of the cornea (Gallar et al., 1993). 
The functional properties of nociceptors innervating the cat cornea are 
modified following experimental photorefractive surgery (Gallar et al., 1997). In this 
initial report, a small area (6mm diameter, 7011m depth) of the cornea was removed 
and the properties of nociceptors innervating the area surrounding or within wound 
were examined (12 -48 hours later). Interestingly, only small proportion of 
nociceptors (AS- polymodal; J. Gallar and M.C. Acosta, personal communication) 
with receptive fields in the wound retained sensitivity to mechanical or chemical 
stimulation, whereas fibres bordering the ablation, were sensitised to these stimuli. 
Furthermore, nociceptors with receptive fields in both areas had an increased rate of 
spontaneous discharge. Thus, these spontaneous and stimulus- evoked discharges 
might contribute to inflammatory pain arising from the cornea following laser 
surgery for myopia. 
1.3.2 THE KNEE JOINT 
Knee joint pain is common in RA (Sculco, 1998) and detailed knowledge of the 
peripheral mechanisms that cause articular pain would facilitate research into 
mechanisms of preventing it. The innervation and functional properties of the cat 
knee joint has been studied in detail and will be described in this section. 
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1.3.2.1 Knee joint innervation 
Early comprehensive studies of the anatomy of the cat's knee joint were made by 
Gardner (1944), Skoglund (1956) and Freeman and Wyke (1967). More recently, 
electron microscope studies by Heppelmann et al. (1990) have provided a detailed 
morphological analysis of the nociceptive afferent endings innervating the joint. 
According to Freeman and Wyke (1967), the cat knee joint is innervated by 
two groups of articular nerves which they classified as primary and accessory. The 
former comprises the posterior, medial and lateral articular nerves whereas the latter 
arise from nerves innervating the muscles around the knee joint. Since the medial 
articular nerve (MAN) was recorded from in the present study, it will be the only one 
discussed further. In the cat, the MAN usually arises from the saphenous nerve and 
traverses the antero- medial aspect of the thigh, alongside the descending genicular 
artery and vein, to the medial aspect of the knee joint. At this point it splits into two 
branches which spread out and supply the medial and antero -medial aspects of the 
fibrous capsule of the knee joint, the medial collateral ligament, the medial part of 
the annular ligament attached to the medial meniscus, the ligamentum patellae and 
the infrapatellar fat pad, and the medial part of the patellar periosteum (Freemann & 
Wyke, 1967). 
The MAN of the cat contains approximately 630 afferent fibres and 500 
unmyelinated sympathetic efferent fibres (Langford & Schmidt, 1983). Of the 
afferents, the vast majority are thinly myelinated (AS- fibres, termed Group III by 
Langford and Schmidt) or unmyelinated (C- fibres, Group IV) fibres (21% and 70% 
respectively). The remainder (9 %), are fast conducting, large diameter afferents (Aß- 
fibres, Group II). The terminals of the AS- fibres consist of 3 main areas; 1) the 
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proximal area which is myelinated and runs within a perineural sheath, 2) more 
distally, the nerve is unmyelinated but still runs within the perineural sheath and 3) 
the distal area begins after the perineural sheath ends (Heppelmann et al., 1990). The 
distal endings of the AS- fibres run into the tissues they innervate and split into 2 -4 
branches. The endings of the C- fibres have only two main areas: the proximal area 
runs within the perineural sheath and the distal area, running into the tissues, is 
outside it. Approximately two thirds of the distal terminal of both fibre types are 
covered by Schwann cells, with the remaining one third left bare. These "bare areas" 
were presumed by Heppelmann and his co- workers (1990) to be the receptive sites of 
the afferents. 
1.3.2.2 Knee joint nociceptors 
Detailed studies of the functional properties of the thinly myelinated AS- fibres and 
unmyelinated C- fibres innervating the cat knee joint have been carried out by 
Schaible, Schmidt and colleagues (Coggeshall et al., 1983; Schaible & Schmidt, 
1983a,b). These authors have comprehensively investigated the responses of 
afferents innervating the knee to joint movements and mechanical stimulation and 
have concluded that the majority of M and C -fibre afferents of the MAN are 
probably associated with signalling joint pain. Thus, 55% of AS- fibres and 70% of 
C -fibres are strongly activated by noxious joint movements and high threshold 
mechanical stimulation or are only excited during inflammation. 
The authors have also investigated the properties of thinly myelinated or 
unmyelinated afferents of the MAN following the induction of an acute inflammation 
(induced by intra- articular injection of kaolin and carrageenan, Schaible & Schmidt, 
1985; Schaible & Schmidt, 1988). In the inflamed knee joint, the vast majority of AS 
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and C- fibres are spontaneously active (75% and 83% respectively) and fire at a rate 
more than double that of normal joints. In addition, most have low thresholds and 
enhanced responses to movements and mechanical probing. The increased 
spontaneous discharge of nociceptors innervating the inflamed knee joint is thought 
to contribute to the spontaneous pain associated with inflammation, whereas the 
reduced threshold and augmented discharge of these nociceptors probably 
contributes allodynia and hyperalgesia respectively (Schaible & Schmidt, 1996). 
1.4 EXTRACELLULAR ATP AND ADENOSINE 
1.4.1 SOURCES 
Purines are ubiquitous and essential to man, being involved in the production of 
cellular energy and the synthesis of the nucleic acids, DNA and RNA. The main 
sources of intracellular purines are de novo synthesis and recycling of used 
nucleosides and bases within the cell (reviewed by Stone & Simmonds, 1991). The 
intracellular concentration of ATP is very high, between 5 -10mM, and high local 
concentrations can result when it is released from cells (see DiVirgilio et al., 1996). 
One of the main mechanisms by which this purine is released into the extracellular 
space is through non -specific membrane perturbations. However, it is also released 
from cells during hypoxic stress, as well as from activated inflammatory cells, 
sensory nerves and platelets (Gordon, 
1.4.2 METABOLISM 
1986). 
Once released, ATP is rapidly metabolised by enzymes located at the cell surface as 
outlined in Figure 1.2 (reviewed by Zimmermann et al., 1998). The main enzymes 
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responsible for the hydrolysis of extracellular ATP are ectoATP diphosphohydrolase 
and ectoATPase. The former has an equal preference for ATP and ADP as substrates 
and can therefore hydrolyse ATP to AMP via ADP. EctoATPase specifically 
metabolises ATP to ADP, which is subsequently metabolised to AMP by specific 
ADPases. 5'nucleotidase catalyses the formation of adenosine from AMP and 









Figure 1.2 Main pathways and enzymes (indicated by italic font) involved in the 
extracellular degradation of purifies. See text for details. Modified from 
Zimmermann (1998). 
A number of compounds that inhibit the activity of extracellular ATP metabolising 
enzymes have been reported of which 6- N,N- diethyl -beta, gamma- 
dibromomethylene-D-ATP (ARL67156, formally FPL 67156) is the most effective 
(Zimmermann & Braun, 1996). ARL67156 potentiates the contractile effect of ATP 
in the rabbit ear artery preparation (Crack et al., 1995), sympathetic 
neurotransmission in the guinea pig vas deferens (Westfall et al., 1996) and 
parasympathetic neurotransmission in the guinea pig bladder (Westfall et al., 1997). 
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Interestingly, P2 receptor antagonists, including PPADS and suramin, can also 
inhibit ecto -nucleotidases (Beukers et al., 1995; Bultmann et al., 1996; Chen et al., 
1996; Crack et al., 1994; Stout & Kirley, 1995; van der Ven & Hinds, 1996; 
Ziganshin et al., 1995a,b; Ziganshin et al., 1996). In the study by Crack et al. (1994), 
the data obtained was analysed using a theoretical model which indicated that 
simultaneous receptor antagonism and ecto -nucleotidase inhibition could result in the 
"self- cancellation" of the antagonistic and enzyme- inhibitory effects in certain 
situations. Compounds that inhibit adenosine deaminase have been recognised for a 
number of years and some, such as deoxycoformycin and pentostatin are used 
clinically to treat some types of cancer (Kane et al., 1992; O'Dwyer et al., 1988). 
1.4.3 PURINE RECEPTORS 
1.4.3.1 Historical perspective 
Drury and Szent -Györgi (1929) presented the first evidence of the extracellular 
actions of purines when they reported that adenosine and AMP had various 
biological effects including arterial vasodilation. Five years later, Gillespie (1934) 
showed differential effects of ATP compared to adenosine and AMP on cat and 
rabbit blood pressure and contraction of guinea -pig ileum implying that there were 
different extracellular receptors for ATP compared to adenosine and AMP. The first 
real evidence for the existence of an adenosine receptor was provided by De 
Gubareff & Sleator (1965) who showed that the cardiovascular effects of adenosine 
were blocked by caffeine. 
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Interest in the extracellular actions of endogenous purines grew after Holton 
(1959) demonstrated that ATP was released from sensory nerves and Berne (1963) 
proposed that adenosine was the physiological mediator responsible for the coronary 
vasodilation during occurring during myocardial hypoxia. A few years later, 
Burnstock el al. (1970) suggested that the nonadrenergic noncholinergic substance 
released from autonomic nerves supplying the intestinal smooth muscle was ATP 
and its metabolite adenosine. Thus, the existence of "purinergic nerves" and 
"purinergic receptors" in target tissues were postulated. The first classification 
system for these "purinergic receptors" was proposed by Burnstock in 1978 where 
the putative ATP receptors were termed P2- purinergic and the adenosine receptors 
were termed PI- purinergic (Burnstock, 1978). 
The ability of adenosine to both stimulate and inhibit the activity of adenylate 
cyclase soon led to the subclassification of P 1 purinoceptors into adenosine A1 and 
A2 subtypes (Londos et al., 1980; van Calker et al., 1979). The A2 receptors were 
further subdivided into A2A and A2B subtypes based on the presence of high and low 
affinity binding sites for adenosine in the rat brain (Bruns et al., 1986; Daly et al., 
1983). A third adenosine receptor was proposed to exist based on pharmacological 
studies in atrial tissues (Ribeiro & Sebastiáo, 1986), but this was later disputed 
(Kennedy et al., 1992). However, an adenosine receptor with a novel 
pharmacological profile, different to that proposed by Ribeiro and Sebastiáo, has 
been cloned and termed the A3 subtype (Zhou et al., 1992). 
The P2 purinoceptors were subclassified into P2x and P2y subtypes based on a 
comprehensive review of the effects of ATP and its various analogues in a wide 
variety of biological systems (Burnstock & Kennedy, 1985). In the following year, 
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Gordon (1986) described actions of ATP in platelets and mast cells that did not 
conform to the P2x/P2y classification and he named the receptors responsible P2T and 
P2Z respectively. A fifth P2 receptor subtype, the P2u receptor, at which the 
pyrimidine nucleotide uridine 5'- triphosphate (UTP) and ATP were equipotent was 
soon identified (O'Connor et al., 1991). Finally, a sixth subtype at which adenine 
dinucleotide polyphosphates were effective was termed P2D (Castro et al., 1992; 
Hilderman et al., 1991). These six subtypes of P2 purinoceptor (P2x, Per, P2T, P2z) 
P2U and P2D) were recognised by the first Subcommittee of the International Union of 
Pharmacology Committee on Receptor Nomenclature and Drug Classification (NC- 
IUPHAR) for Purinoceptor Classification (Fredholm et al., 1994). Abbracchio and 
Burnstock (1994) soon proposed that all P2 purinoceptors could be classified as 
subtypes of P2X (ion -channels) and P2Y (G protein- coupled) families. This was 
based on the evidence (summarised by Dubyak (1991)) that all P2 purinoceptors are 
either ion -channel gated or G protein- coupled, and on new data following the cloning 
of a number of receptors in the mid- 1990's. Later Fredholm et al. (1997) suggested 
that the term purinoceptor was no longer valid as there was clear evidence for the 
existence of receptors that were structurally similar to ATP receptors but were 
preferentially activated by. pyrimidines (Communi & Boeynaems, 1997). This 
nomenclature system has now been adopted and for the rest of this thesis the term 
"receptor" will be used instead of "purinoceptor ". 
1.4.3.2 Current classification 
The recent developments in ATP and adenosine receptor classification, structure, 
distribution and function have been comprehensively reviewed by Ralevic and 
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Burnstock (1998). This section will briefly outline the classification and 
pharmacology of the receptors relevant to the present investigation. 
1.4.3.2.1 P1 receptors 
The three adenosine receptor subtypes (Al, A2A and A2B) proposed by 
pharmacological studies, and the fourth subtype (A3) have now been cloned (Ralevic 
& Burnstock, 1998). All are members of the G- protein coupled receptor superfamily 
with seven transmembrane domains. Adenosine receptors mediate their effects by 
initiating a variety of second messenger signalling cascades and can be distinguished 
pharmacologically using selective agonists and antagonists (Table 1.1). 
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Table 1.1 Functional characteristics of cloned PI receptor subtypes expressed 
























2C1- IB -MECA 
DPCPX 
ZM241385 (Maenhaut et al., 1990). 
(Mahan et al., 1991; Reppert 
et al., 1991) 
(Pierce et al., 1992; Rivkees & 
None available Reppert, 1992; Stehle et al., 
1992) 
I-ABOX (Zhou et al., 1992) 
Abbreviations: 2C1 IB MECA, 2 -chl oro- N6- (3- iodoben vl)- 5'- N- methvlcarbamovl)adenosine; CPA, 
N6- cvclopentvladenosine; DPCP.I; 1, 3,- dipropvl- 8- cvclopentvlxanthine; CGS21680, 2- [p -(2- 
carbonyl- ethyl(- phenyletlivlaminoJ -5 - N- ethvlcarboxamidoadenosine; GR79236, N -[1S, trans,2- 
hvdroxvcvclopentylJ adenosine; I -ABOX 3-(3- iodo- 4- aminobenzvl )- 8- (4- oxvacetata)pheny1-1- 
propy/xanthine; ZA1 241385, 4-( 2-[ 7- amino- 2 -(2 -- fury/)[ 1, 2, 4J- triazolo[2,3- a][1,3,5]triazin -5 yl 
ami inoJethvl)phenol. 
1.4.3.2.2 P2 receptors 
1.4.3.2.2.1 P2X receptors 
Seven subtypes of P2X (P2X1 -7) receptors have been cloned from mammalian tissue 
and pharmacologically characterised (see Ralevic & Burnstock, 1998). All of the 
subtypes are ATP -gated ion- channels permeable to Na +, K+ and Cat +. There are 
currently no selective agonists or antagonists available to discriminate responses 
mediated by the various P2X subtypes in vivo. However, recombinant receptors 
expressed in Xenopus oocytes or mammalian cells can be pharmacologically 
distinguished based their sensitivity to a stable ATP analogue, aß- methylene ATP 
(a13meATP), the P2 antagonists pyridoxalphosphate- 6- azophenyl -2', 4'- disulfonic 
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acid (PPADS) and suramin, their rate of desensitisation and the agonist potency order 
at the receptors (Table 1.2). 
Table 1.2 Functional characteristics of cloned P2X receptor subtypes expressed 
in Xenopus oocytes or mammalian cells. Modified from (Collo et al., 1996). 
a(3meATP Antagonist Subtype Desensitisation 
sensitivity sensitivity 
Agonist 
potency ratio Reference 
P2X1 Yes Yes 
P2X2 No Yes 
P2X3 Yes Yes 
P2X4 No No 
P2X6 No Yes 
P2X6 No No 

























(Valera et al., 
1994). 
(Brake et al., 
1994). 
(Chen et al., 
1995; Lewis et 
al., 1995) 
(Bo et al., 1995) 
(Collo et al., 
1996) 
(Collo et al., 
1996) 
(Surprenant et al., 
1996). 
* Rate at which the inward current evoked by agonist application wanes. Rapid desensitisation occurs 
within hundreds of milliseconds in the continued presence of agonist. 
Abbreviations: 2meSATP, 2- methvlthioATP; ATPyS, adenosine 5'- O- (3- thiotriphosphate; Bz4TP, 3'- 
O- (1- benzovl)benzovl ATP. 
1.4.3.2.2.2 PH receptors 
P2Y receptors are receptors for purine and pyrimidine nucleotides that couple to 
second messenger systems through G- proteins causing increases in PLC levels, 
inhibition of AC and N -type Cat+ channels and activation of K+ channels (for a 
comprehensive review see Ralevic & Burnstock, 1998). To date, a number of 
mammalian P2Y receptor subtypes (including P2Y1, P2Y2, P2Y4, P2Y6 and P2Y11) 
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have been cloned, and a number of other sequences have been cloned from non - 
mammalian sources. The focus of this thesis is on the rapid effects of ATP mediated 
by P2X receptors and further discussion of P2Y receptors is not relevant to the 
present investigation. 
1.4.4 THE ROLE OF ATP IN NOCICEPTION 
A number of early studies in humans revealed that intra- arterial or intra- dermal 
injections of ATP caused pain. The first report was that of Stoner and Green (1945) 
who were investigating the cardiovascular reactions to tourniquet application and the 
possible role of ATP in mediating the observed cardiovascular effects. A minor part 
of their study involved injecting ATP into brachial artery and they noted it caused 
"tingling pains" in the forearms. This effect was simply noted and not discussed 
further by the authors. A number of years later, Keele and Armstrong (Armstrong et 
al., 1957) reported that ATP caused pain in humans when applied to the base of a 
cantharidin- induced blister, an observation that was only examined in detail 20 years 
later (Bleehan et al., 1976; Bleehen & Keele, 1977). These studies demonstrated that 
exogenous ATP had the capacity to cause pain but did not reveal anything about the 
mechanism through which it was having it's effect. 
The first indication that ATP might cause pain by directly activating the 
nociceptive afferents was provided by Jahr and Jessell (1983) who reported that ATP 
depolarised rat dorsal root ganglia (DRG) neurones in dissociated cell culture, a 
finding later confirmed by many authors (summarised by Bean & Friel, 1990). 
Interest in the potential role of ATP as an endogenous algogen intensified following 
the cloning of a number of P2X receptor subtypes and the discovery that one of these 
(P2X3) was solely expressed in sensory ganglia (Chen et al., 1995). Even more 
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significantly, the P2X3 subtype was selectively expressed in small diameter cells of 
the DRG and TG; the cell bodies of the thinly myelinated or unmyelinated primary 
afferents. Thus, indirect evidence was accumulating that ATP, acting at P2X receptor 
subtype(s), had a specific role to play in the direct activation of nociceptors. 
Despite all the evidence from cell culture experiments, there was still very little 
evidence that ATP could activate the peripheral terminals of these sensory afferents. 
Research at the Glaxo Institute of Applied Pharmacology (GIAP) at this time 
(Trezise & Humphrey, 1996) showed that P2X receptor agonists excited cutaneous 
afferents of the tail in the neonatal rat tail -spinal cord preparation in vitro, thus 
suggesting that functional P2X receptors were expressed on the peripheral terminals 
of sensory afferents. However, unless it could be shown that these receptors are 
functionally expressed on peripheral nociceptive terminals in vivo, then they could 
not be implicated in the algogenic effects of ATP. 
The study of Chen et aI. (1995 see above) stimulated widespread interest in the 
role of ATP in nociception because P2X receptors represented a previously 
unexplored target for analgesic drug development. Their report was soon followed by 
a number of reviews pointing to the potential therapeutic role of P2X receptor 
antagonists in treating many types of pain, including that of inflammation 
(Burnstock, 1996; Burnstock & Wood, 1996). 
1.4.5 THE ROLE OF ATP IN INFLAMMATORY PAIN 
ATP is an excellent candidate for signalling tissue damage because it is a ubiquitous 
cytoplasmic cell constituent and is released from injured, ischaemic and inflamed 
tissues. Levels of ATP are increased in inflamed tissues (Gordon, 1986) and it is 
found in the synovial fluid of patients with rheumatoid arthritis (Park et al., 1996; 
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Ryan et al., 1991). A variety of cells are thought to release ATP during the 
inflammatory process including activated macrophages and neutrophils (see 
DiVirgilio et al., 1996), activated platelets (Born, 1962) and injured cells. It is also 
possible that ATP is released from the activated sensory nerve terminal itself 
(Holton, 1959) thereby contributing to neurogenic inflammation. Furthermore, it has 
been shown that the activity of ATP metabolising enzymes is attenuated in the 
synovial fluid of patients with rheumatoid arthritis thereby increasing the half -life of 
the purine (Park et al., 1996). Thus, both enhanced release and reduced metabolism 
of ATP probably contributes to its accumulation during inflammation. 
If functional P2X receptors are expressed on the peripheral terminals of 
nociceptive afferents, there is evidence from in vitro studies that they might be 
particularly suited to signalling pain under inflammatory conditions. In dissociated 
cell culture, acidification (Li et al., 1997; Li et al., 1996) and substance P (Hu & Li, 
1996) augment the ATP -induced depolarisation of sensory neurones. If this 
augmentation occurs in nociceptors in vivo, the excitatory effects of ATP could be 
significantly increased during inflammation, because tissue inflammation is 
associated with a decrease in pH (Farr et al., 1985) and an increase in the levels of 
substance P (Marshall et al., 1990). In addition to its potential direct actions on the 
nociceptive afferent, ATP has a multitude of indirect actions through which it may 
contribute to inflammatory pain. 
It has been known for 30 years that ATP causes the release of histamine from 
rat peritoneal mast cells in vitro (Sugiyama & Yamasaki, 1969). The receptor 
mediating this effect has several unusual properties: ATP4" is the most potent agonist 
and low concentrations evoke apparently normal histamine release, whereas high 
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concentrations cause leakage of cytoplasmic cell constituents (Cockcroft & 
Gomperts, 1979a,b; Cockcroft & Gomperts, 1980). Responses mediated by the same 
receptor were subsequently found on a range of inflammatory and immune cells and 
the receptor was termed P2Z (Gordon, 1986), later identified as the seventh member 
of the P2X receptor family (P2X7 Surprenant et al., 1996). The effects of 
endogenous ATP on P2X7 receptors is unknown but evidence from in vitro and in 
vivo studies (see below) suggests that it may contribute significantly to inflammatory 
pain. 
Mast cells contain a multitude of inflammatory mediators including histamine, 
prostaglandin D2 (PGD2), 5 -HT, leukotriene B4 (LTB4), platelet activating factor 
(PAF), tumour neurosis factor (TNF), some interleukins and an IL -1 converting 
enzyme (Amason & Malone, 1995). It is well known that ATP induces histamine and 
PGD2 release from mast cells (Jaffar & Pearce, 1990), but release of other mediators 
has not been investigated. However, because high concentrations of ATP cause the 
formation of a large diameter non -specific pore in mast cells, it is probable that ATP 
releases many of the other mediators too. 
In addition to the effects of ATP on mast cells, it was shown early in this 
decade that the pro -nociceptive and pro -inflammatory cytokine Il -113 was released 
from mouse peritoneal macrophages primed with bacterial cell wall 
lipopolysaccharide (LPS) during apoptosis induced by ATP (Hogquist et al., 199la). 
II -113 is produced as an intracellular biologically inactive 35 kDa precursor, pro -Il- 
lß, in response to inflammatory stimuli such as LPS (Hogquist et al., 1991b). 
However, the production of pro- Il -113, and the processing and release of active I1 -113 
are distinct events (Chin & Kostura, 1993), and a separate stimulus is required to 
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cause an increase in extracellular cytokine levels. The early findings of Hogquist et 
al. (1991) have been confirmed over the past few years and ATP, via the P2X7 
subtype, is now known to be a potent stimulator of pro -Il -113 processing and release 
from LPS- primed macrophages and microglia in vitro (Ferrari et al., 1997a,b; Ferrari 
et al., 1996; Perregaux & Gabel, 1994). This process also occurs in vivo as intra- 
peritoneal injection of ATP in mice also stimulates Il -10 release from LPS -primed 
peritoneal macrophages (Griffiths et al., 1995). It is still not known whether 
endogenous ATP stimulates Il -lß release and contributes to pathophysiological 
conditions. If so, blockade of the P2X7 receptor could inhibit the release of the 
cytokine and prevent its pro -nociceptive and pro- inflammatory effects. 
ATP could also contribute to inflammatory pain via actions at receptors other 
than P2X subtypes. For example, small quantities of PGE2 are released from cultured 
human rheumatoid synovial cells stimulated with ATP and UTP, and the release is 
markedly increased when the cells are pre- treated with Il -1 (Loredo & Benton, 
1998). This effect is mediated by a G- protein coupled P2Y subtype (P2Y2, formerly 
P2U). NSAIDS are currently the most effective analgesic treatment for RA and these 
compounds inhibit the enzymes responsible for prostaglandin production (Schiff, 
1997). Thus, inhibition of PGE2 release from rheumatoid synovial cells through 
pharmacological manipulation of the P2Y2 receptor for ATP may have potential for 
the treatment of arthritic pain. The P2Y2 subtype also mediates the release of 
arachidonic acid from cultured astrocytes (Chen & Chen, 1998; Stella et al., 1997) 
which may contribute to central inflammatory processes, such as following stroke or 
head trauma. 
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Thus, the in vitro evidence that has accumulated to date suggests that 
extracellular ATP may be a direct chemical excitant of nociceptors, which could be 
of particular importance during inflammation. It also indicates that ATP might 
indirectly affect nociceptor function by causing the release of pro -nociceptive 
inflammatory mediators. However, in order to extend these proposals, the effects of 
ATP agonists on the discharge of nociceptive afferents in vivo must be determined. 
ATP release might be doubly important in pain because the nucleotide is rapidly 
metabolised to adenosine, which in- itself is thought to be involved in nociception. 
1.4.6 THE ROLE OF ADENOSINE IN NOCICEPTION 
Evidence from human and animal studies indicates that adenosine plays a complex 
role in the generation of pain (Keil & Salter, 1996; Sawynok, 1998). Like many of 
the potential endogenous inflammatory mediators, adenosine was first shown to 
cause pain in humans following application to the blister base (Bleehen & Keele, 
1977). During the following decade, interest in the algesic properties of adenosine 
grew after it was shown to cause angina pectoris -like pain following intravenous 
infusion in man (Sylven et al., 1986). Because adenosine is released during 
myocardial ischemia (Haneda et al., 1989), it was proposed to be the mediator of 
anginal pain. Another study showed that exercise -induced angina pain was reduced 
by aminophylline, a non -specific adenosine receptor antagonist (Crea et al., 1990), 
thus indicating that ischemia- induced cardiac pain was partly caused by endogenous 
adenosine release. 
Cardiac pain caused by adenosine is thought to result from the activation of 
adenosine Al receptors (Crea & Gaspardone, 1997) because the adenosine A1 
receptor selective antagonists, bamiphylline and N- 6- endonorboran- l -y1-9- 
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methyladenine reduce chest pain induced by the nucleoside (Bertolet et al., 1996; 
Gaspardone et al., 1995). Bamiphylline also reduces exercise -induced anginal pain 
(Gaspardone et al., 1993) further supporting the hypothesis that anginal -pain is 
caused by the release of endogenous adenosine. Adenosine is thought to be a 
directly- acting algesic -agent because it excites canine cardiac sympathetic afferent 
nerves in vivo (Uchida et al., 1969) and this effect appears to be mediated by the Al 
subtype (Dibner- Dunlap et al., 1993). 
In behavioural studies of rodents, local adenosine injections are also pro - 
nociceptive. Following intra- dermal injection into the rat hind paw, adenosine lowers 
the mechanical threshold required to initiate a paw -withdrawal reflex (Taiwo & 
Levine, 1990). The nucleoside also enhances the nociceptive responses to 
subcutaneous formalin in the rat (Doak & Sawynok, 1995) and mouse (Karlsten et 
al., 1992). In these studies, the nucleoside was not inherently algesic, that is, it did 
not elicit nociceptive responses when administered alone. Unlike the human situation 
where Al receptor activation is thought to mediate the algesic effects of adenosine, in 
rodents local A2 receptor activation is thought to be responsible for the pro - 
nociceptive effects of the purine, whereas Al receptor activation prevents the 
adenosine -induced hyperalgesia. Although it is difficult to establish the mechanism 
of action of adenosine from whole animal behavioural studies, Taiwo and Levine 
(1990) suggested that adenosine -induced hyperalgesia was due to a direct action of 
the purine on A2 receptors expressed on the sensory afferent. Thus, the effect had an 
onset -latency similar to that of the directly acting hyperalgesic agent, PGE2, and 
remained after the depletion of neutrophils, sypathectomy and the inhibition of 
cyclooxygenase enzymes (Taiwo & Levine, 1990). 
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Thus it seems that activation of the A2 subtype can excite or sensitise 
nociceptors, whereas activation of the A1 subtype can cause excitation or, somewhat 
paradoxically, inhibition of sensitisation. Both subtypes are expressed on sensory 
neurones (Huang et al., 1995) in the DRG supporting a direct affect of the 
nucleoside. Furthermore, as mentioned above, the nucleoside activates canine cardiac 
sympathetic afferents (Uchida et al., 1969); it also excites cat carotid chemosensory 
afferents (McQueen & Ribeiro, 1981) and has recently been shown to activate 
pulmonary C -fibres (Hong et al., 1998). Activation of carotid body chemosensory 
nerves is apparently mediated by the A2 subtype (Monteiro & Ribeiro, 1987), 
whereas pulmonary C -fibre activation occurs via the Al receptor subtype (Hong et 
al., 1998). The apparent contradictory effects of adenosine on the nociceptive 
afferent nociception are probably effected by various second messenger systems. 
Adenosine induced hyperalgesia is attributed to the increased formation of cAMP, a 
mechanism common to PGE2- induced hyperalgesia, whereas inhibition of 
hyperalgesia by Al receptor activation is thought to be caused by a decrease in 
cAMP levels (Levine & Tawio, 1994). However, A1 receptors are coupled to other 
second messenger systems (Fredholm et al., 1996) and it is feasible that sensory 
neurone excitation may be a result of PKC activation, such as occurs following 
bradykinin activation of B2 receptor. 
Adenosine A1 receptors have a higher affinity for the nucleoside compared to 
A2 subtypes. Thus, at low concentrations of adenosine, A1 effects probably 
predominate with A2 effects becoming apparent at higher concentrations. The overall 
effect of adenosine's actions on the nociceptive afferent terminal probably depends 
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on the local concentration of the purine and could lead to pro- or anti -nociceptive 
effects. 
In addition to the local effects of adenosine on the primary afferent nociceptor, 
the nucleoside is well known to have anti -nociceptive effects in the spinal cord. In 
animals, intrathecal administration of the nucleoside is analgesic in a variety of acute 
and chronic inflammatory pain states, and this effect is primarily attributed to the 
activation of the At receptor (Sawynok, 1998). Activation of spinal Al receptors in 
humans also abolished tactile allodynia in one patient (Karlsten & Gordh T, 1995) 
and intrathecal adenosine was analgesic in a variety of experimental pain tests in 
humans (Rane et al., 1998). 
1.4.7 THE ROLE OF ADENOSINE IN INFLAMMATORY PAIN 
The direct excitatory effects of adenosine on the nociceptive afferent nerve terminal 
may be augmented during inflammation. In vivo, substance P enhances the response 
of canine ischaemia- sensitive ventricular afferents to adenosine (Huang et al., 1995). 
Thus, it is possible that substance P released from activated sensory nerves 
innervating inflamed tissues may increase the local algesic properties of endogenous 
adenosine thereby contributing to inflammatory pain. The nucleoside may also 
contribute to the pain of inflammation by releasing pro -nociceptive mediators from 
inflammatory cells. Stimulation of mast cells with adenosine A3 receptor agonists 
causes 5 -HT and histamine release and produces pain in rats (Sawynok et al., 1997). 
Adenosine is well known to have a variety of effects that can promote or 
inhibit the inflammatory process depending on the receptor activated (see Cronstein 
et al., 1996) and these could lead to downstream pro -nociceptive or anti -nociceptive 
effects respectively. For example, activation of Al receptors on human neutrophil 
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enhances phagocytosis and superoxide anion generation by the cells in vitro, whereas 
stimulation of the neutrophil A2 subtype inhibits these processes (Salmon & 
Cronstein, 1990). Similarly, treatment of cultured human neutrophils with adenosine 
Al receptor agonists promotes adherence to endothelial cells and chemotaxis, 
whereas A2 agonists inhibit neutrophil adherence (Cronstein et al., 1990; Cronstein et 
al., 1992). Adenosine, acting on the A2 subtype, also potently inhibits the release of 
certain pro- inflammatory cytokines including tumour necrosis factor a (TNFa) from 
inflammatory cells (for example see Eigler et al., 1997; Parmely et al., 1993; Sajjadi 
et al., 1996; Thiel & Chouker, 1995; Wagner et al., 1998). It also enhances the 
release of the anti -inflammatory cytokine, I1 -10 from monocytes (Le Moine et al., 
1996), probably via the A2 receptor subtype (Haskó et al., 1996). Thus, in general, 
activation of the Al receptor subtype is pro- inflammatory, whereas activation of the 
A2 subtype is anti -inflammatory. It is thought that the overall outcome of these 
opposing effects is dependent on the local adenosine concentration: at low 
concentrations the pro- inflammatory effects (A1 receptor mediated) prevail, whereas 
at high concentrations the anti -inflammatory effects (A2 receptor mediated) 
predominate (Cronstein et al., 1996). 
The antifolates are a group of compounds used as chemotherapeutic agents in 
the treatment of some cancers (Fleisher, 1993). Interestingly, antifolates (including 
methotrexate and sulphasalazine) are used in low doses as disease modifying anti - 
rheumatic drugs used clinically to treat rheumatoid arthritis and they are thought to 
act by increasing endogenous adenosine levels (Cronstein et al., 1996; Cronstein et 
al., 1993; Gadangi et al., 1996). 
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1.5 AIMS OF THIS STUDY 
In the present study, electrophysiological, behavioural and immunohistochemical 
approaches were used to investigate the potential role of ATP and adenosine in the 
initiation and /or maintenance of pain and the mechanism(s) through which they act. 
The hypothesis that ATP activates nociceptors either directly, by acting on 
functional P2X receptor subtype(s) expressed on nociceptive afferent terminals, or 
indirectly, by activating the P2X7 receptor subtype on inflammatory cells was tested, 
and the hypothesis that the major metabolite of ATP, adenosine, directly excites 
nociceptors was also investigated. The effect of inflammation caused by injection of 
Freund's Complete Adjuvant (FCA) into the rat knee joint on the direct excitatory 
effect of the purines was investigated, and in behavioural studies, the role of 
adenosine in maintaining inflammatory allodynia was assessed. Adjuvant arthritis is 
a commonly used model of human RA and will be described in more detail in the 
next chapter (Section 2.1.2.1). 
The overall aim of this thesis was to contribute to the understanding of how 
extracellular purines modulate nociceptor activity and in doing so, to evaluate the 
validity of peripheral purine receptors as potential targets for therapeutic intervention 
in inflammatory pain. 
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Chapter 2: Methods 
A total of 179 male Wistar rats, 8 adult cats and 4 adult mice were used in the present 
study. The studies using rats were carried out at The University of Edinburgh under 
UK Home Office regulations (Project licence, PPL 60/1860; Personal license, PIL 
60/5794), and the experiments using cats or mice were carried out at the Universidad 
de Alicante, Spain. 
2.1 AFFERENT NERVE RECORDINGS IN VIVO 
2.1.1 THE CAT CORNEA 
2.1.1.1 Anesthesia and surgical preparation 
Adult cats of either sex were anaesthetised with pentobarbitone (40mg kg -1 i.p.) and 
maintained in an areflexic state throughout experiments by slow infusion of 
anaesthetic (3mg kg hour-1, via a cannula in the saphenous vein). The trachea was 
cannulated and the cats breathed room air spontaneously. End tidal CO2 and rectal 
temperature were continuously monitored and maintained at around 4% and 36 -38 °C 
respectively. After finishing an experiment in one eye, cat were kept overnight under 
pentobarbitone anaesthesia (infusion at 3mg kg hour-1 intravenously, i.v.) and the 
other eye was used on the following day. 
2.1.1.2 Cilliary nerve dissection 
The superior and lateral walls of the orbital cavity were removed and the extrinsic 
muscles of the eye were cut to expose the cilliary nerves. The cavity produced was 
filled with warm mineral oil and a mixed cilliary nerve was dissected from the 
underlying connective tissue and cut centrally to eliminate efferent activity. The 
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nerve was split using fine forceps until small filaments containing 1 -3 single afferent 
fibres were isolated. 
2.1.1.3 Recording mixed cilliary nerve activity 
Afferent activity in filaments of mixed cilliary nerve was recorded using bipolar 
silver- silver chloride wire electrodes connected to a computerised recording system. 
The raw nerve signal was amplified (Neurolog NL103 and NL105), filtered 
(Neurolog NL115), and displayed on an oscilloscope (Tektronix 5113) connected to 
a loudspeaker. The amplified nerve signal was also stored on an FM magnetic tape 
for analysis off -line. For data analysis, output from the tape was digitised, filtered 
and passed via a 1401 interface (Cambridge Electronic Design (CED)) to a personal 
computer operating Spike2 software (CED). The arrangement used for storing and 





















Figure 2.1 Schematic diagram of the arrangement used to record, store and 
analyse the afferent activity in mixed cilliary nerves innervating the cal cornea. 
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2.1.1.4 Identification of units 
Afferent units recorded from were classified according to their mechanosensitivity, 
chemosensitivity and conduction velocity. 
Mechal ioseiisiii viiy 
The receptive field of each the afferent was identified by lightly brushing the cornea 
with a fine wet paint brush. 
Chenlosensilivity 
Chemosensitive afferents were identified because they were activated by low pH 
which was achieved by directing a jet of carbon dioxide to the corneal receptive 
field. CO2 (98.5 %) from a gas cylinder was humidified and passed through a flow 
regulator to a glass pipette (inner diameter: 1mm). The pipette was lowered to 5mm 
from the cornea by a micromanipulator and the gas flow was adjusted so that air 
alone did not stimulate the afferents. The pipette was raised from the cornea and 
flushed with CO2 so that the gas would reach the cornea with negligible delay once 
the flow was started. It was then re- lowered and a CO2 pulse of 30s duration was 
applied to the receptive field. 
Conduction Velocity 
Conduction velocities were determined at the end of an experiment by measuring the 
time taken for action potentials to reach the recording electrodes following electrical 
stimulation of the receptive field (conduction velocity = conduction distance /action 
potential delay). A pair of silver wire electrodes were used to apply suprathreshold 
electric shocks (0.1- 0.5ms, 0.5 -3mA) to the afferent receptive field. Conduction 
distance was established by placing a short piece of 8.0 gauge thread on the corneal 
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surface between the recording and stimulating electrodes and measuring its length 
with a ruler. 
2.1.1.5 Drug administration 
Drugs were applied to the cornea for 30s using a piece of solution -soaked tissue 
paper (approximate area: 6mm2). Careful application of vehicle (phosphate buffered 
saline, PBS) by this method did not increase afferent discharge, but in some cases 
placing the tissue on the cornea caused a transient mechanically- evoked stimulation 
easily distinguishable from the drug- induced discharges. In some cases, drugs were 
applied to the receptive field as a 50µ1 drop from a pipette; control drops of PBS had 
no effect on afferent discharge. The area was repeatedly washed with saline from a 
pipette after drug application. To reduce the risk of tachyphylaxis, at least 5 - 20 
minutes were allowed to pass between successive drug applications. 
2.1.1.6 Spike sorting 
Nerve activity from each filament (containing 1 -3 separate afferent fibres) was 
recorded on tape for sorting off -line. Spike2 software was used to generate templates 
for each individual action potential it identified. The experiment on tape was then 
replayed and each separate action potential was sorted, classified as an event and 
displayed on a separate channel. Markers were used to indicate the point at which a 
drug injection was made. 
2.1.1.7 Data analysis 
Event data on each channel was expressed as discharge frequency (the number of 
action potentials per unit time) and the effect of CO2, drug or vehicle application was 
determined by comparing the discharge frequency following application with that 
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before application. The 15s pre- injection period was taken as the control. The 
response was expressed as the change in action potential discharge frequency 
according to the calculation below. When no clear response was obtained, the 
activity in a fixed time of 15s post- injection was measured. 
Definitions: 
Ex: The total number of action potentials counted in the control and test 
time periods, tcontrol and hest respectively (expressed as impulses). 
T The frequency of action potential discharge in the control and test 




xcontrol - E'control tcontrol 
'Zest = Xtest / ttest 
Delta x: The change in action potential discharge frequency evoked by the 
drug. 
Thus, 
2.1.2 THE KNEE JOINT 
delta 7, ='test - 'control 
2.1.2.1 Freund's adjuvant induced arthritis 
Polyarthritis induced by injection of FCA (heat -killed Mycobacterium spp. in mineral 
oil) into the rat tailbase or footpad is a widely used model of human rheumatoid 
arthritis (RA, see Billingham, 1983; Rainsford, 1982). Injection of FCA results in a 
severe polyarthritis after about 10 days which is most severe in the joints of the 
hindlimbs, where there is bone destruction, damage to tendons and loss of cartilage. 
There are also lesions in the ears, eyes, nose, skin, tail and genitals as well as severe 
weight loss (Pearson, 1956; Pearson, 1963; Pearson & Wood, 1963). FCA causes 
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inflammatory allodynia and /or hyperalgesia as measured using the Randall -Selitto 
test (Calvino el al., 1987), tail flick test (Colpaert, 1987), hotplate test (Hara et al., 
1984), rotarod grip strength (Perrine & Takesue, 1968), squeezing with forceps 
(Hirose & Jyoyama, 1971), foot bend procedure (Calvino et al., 1987) and 
transcutaneous electrical stimulation (Okuyama & Aihara, 1984). These tests 
measure the increased sensitivity to an acute stimulus (Colpaert, 1987), but 
spontaneous pain has also been assessed by measuring several parameters that are 
indicative of pain. These include decreases in body weight (Calvino et al., 1987; 
Colpaert, 1987), reduced locomotor activity (Calvino et al., 1987), scratching 
behaviour (De Castro Costa et al., 1981), irritability (Colpaert et al., 1982) and 
hyperventilation (Colpaert & van den Hoogen, 1983). Polyarthritic rats also 
preferentially drink water that contains analgesic drugs indicating that the arthritis is 
associated with chronic pain (see Colpaert, 1987). 
Scientific and ethical questions have been raised regarding the use of severely 
affected polyarthritic animals (see Casey & Dubner, 1989). This has led to the 
development of less severe models of RA where a monoarthritic lesion confined to 
one joint is induced (Butler el al., 1992; Donaldson et al., 1993; Grubb et al., 1991; 
Grubb et al., 1988). In the present investigation, a modified version of the method 
described by these authors was used to induce monoarthritis in the rat knee joint. 
2.1.2.1.1 Induction of monoarthritis 
Localised experimental arthritis was induced in the left knee joint of male Wistar rats 
by intra- articular (i.art.) injection of FCA under transient halothane anaesthesia (5% 
in oxygen). The left knee joint was swabbed with alcohol and FCA was injected i.art. 
(0.15m1 of 1 mg m1 -1 Mycobacterium tuberculosis in paraffin oil) using a 26 -gauge 
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needle inserted through the infrapatellar ligament just beneath the patella. A number 
of rats were injected with sterile paraffin oil (0.15 ml, i.art.) as controls. Following 
recovery from anaesthesia, the rats were housed (up to four animals per cage) on a 
12 -hour light /dark cycle with free access to water and standard laboratory food until 
they were used. 
2.1.2.2 Assessment of arthritis for afferent nerve recordings 
The rats were used for electrophysiological recordings 14 -21 days following 
induction of arthritis. During this time the general condition and mobility of the 
animals was monitored daily by observing their behaviour in the cages. Knee joint 
diameter was measured using a sliding calipers on the day the rats were used for 
neural experiments. 
2.1.2.3 Anesthesia and surgical preparation 
Rats were anaesthetised with pentobarbitone (60mg kg-1 i.p., supplemented hourly 
with 6mg i.v., see below). Body temperature was maintained at 38 °C by an 
automated heating blanket (Harvard Apparatus Limited) connected to a thermistor 
probe inserted into the rectum. A midline incision was made in the ventral aspect of 
the neck and the trachea was cannulated (catheter OD: 2.10mm) to facilitate 
spontaneous breathing of room air. The right carotid artery was cannulated (catheter 
OD: 0.75mm) so that arterial blood pressure could be continuously recorded via a 
pressure transducer (Bell and Howell, 4- 442 -0002) linked to a computerised 
recording system (MacLab /8 and Macintosh LC475). The right femoral vein was 
cannulated (catheter OD: 0.63mm) for hourly administration of pentobarbitone. A 
cannula (catheter OD: 0.63mm) was inserted into the abdominal aorta (at the level of 
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the iliac bifurcation) via the right femoral artery for close -arterial injection of drugs 
to the left knee joint. 
2.1.2.4 Medial articular nerve dissection 
The left leg was fixed to a support and the skin on the medial aspect of the limb was 
cut to expose three branches of the MAN where they leave the saphenous nerve. The 
skin flaps were used to form a trough, which was filled with heavy paraffin oil. The 
saphenous nerve was cut centrally to eliminate efferent neural activity. One of the 
branches of the MAN was dissected from the underlying connective tissue and split 
using fine forceps until a small filament, usually containing 1 -4 individual afferent 
fibres was isolated. 
2.1.2.5 Recording medial articular nerve activity 
Afferent activity of small filaments of the MAN was recorded using bipolar 
platinum- iridium wire electrodes (Figure 2.2). 
a) b) 
Figure 2.2 Photographs of the preparation used to record neural activity in the 
MAN innervating the rat left knee joint. Part a) shows the position of the limb and 
the paraffin- filled pool. Part b) shows an expanded view of the MAN on the 
electrodes. 
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The raw nerve signal was amplified (Neurolog NL103 & NL105), displayed on an 
oscilloscope (Gould 1604), digitised (Sony Digital Audio Processor PCM- 701ES) 
and stored on videotape (Sony VideoCassette Recorder EV- C2000E PAL). The 
digitised signal was also filtered ( Neurolog NL115) and displayed on the 
oscilloscope after passing through a voltage discriminator (Digitimer D.130) 
connected to a loud speaker. For data analysis, the signal was passed via a 
Micro 1401 interface (Cambridge Electronic Design, CED) to a personal computer 
(RM PC -5200) operating Spike2 software (Spike2 version 2.24, CED). All electrical 
activity above positive and negative trigger levels was captured on -line and data files 
were saved for analysis off -line. Figure 2.3 shows the arrangement used for 










Figure 2.3 Schematic diagram of the arrangement used to record, store and 
analyse the afferent activity in the MAN innervating the rat knee joint. 
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2.1.2.6 Identification of units 
Afferent units recorded from were classified according to their mechanosensitivity, 
chemosensitivity and conduction velocity. 
Mechanosensilinily 
The receptive field of each afferent was identified by probing the knee joint capsule 
with a hand held plastic probe of approximately lmm tip diameter. 
Chemosensitivily 
Single low doses of the algogens capsaicin (lOnmol) and bradykinin (9nmol) were 
administered by close intra- arterial (i.a.) injection (see Section 2.1.2.7 below) at 
some point during each experiment to determine the chemosensitivity of the 
afferents. 
Condttclion Velocity 
Conduction velocities were determined as described for the cornea (Section 2.1.1.4). 
In the knee joint, the stimulating electrode consisted of a silver wire core isolated 
from a metal cylinder casing of 1mm external diameter, which was used to deliver 
suprathreshold electrical stimulation to the afferent receptive field (0.3 - 5V, lms 
pulse duration at 1Hz). 
2.1.2.7 Drug administration 
For close i.a. injections, agonists were injected into the abdominal aorta via the 
femoral cannula in a volume of 0.1m1, and washed in with 0.2 ml of saline (NaCl 
0.9% w/v in distilled water). The injection was completed within 2s. To reduce the 
risk of tachyphylaxis, at least 5 - 20 minutes were allowed to pass between 
successive injections. Antagonists were injected over lOs (0.1m1 100g-1 body 
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weight). Injection of drug vehicle, in most cases PBS, did not evoke any afferent 
excitation. 
In a small number of animals, drugs were administered by i.art. injection into 
the knee joint in a volume of 0.05 - 0.1m1 using a 26 -gauge needle inserted beneath 
the patella through the infrapatellar ligament. To determine whether the presence of 
the needle in the knee joint influenced neural activity, spontaneous afferent discharge 
and that evoked by agonists was recorded prior to insertion of the needle. The needle, 
fitted to a syringe containing drug solution, was then inserted into the joint space and 
secured with a clamp. Drawing 20 -30µ1 of air into the syringe after the drug solution 
prevented leakage of drug into the joint during the subsequent recording. 
Spontaneous activity and responses to agonists were then recorded. Because the rat 
knee joint volume is 0.15 -0.20 ml, only one or two injections were performed per 
knee. 
2.1.2.8 Estimation of local drug concentration 
It is not possible to determine the precise local concentration of drugs at the knee 
joint terminals following i.a. or i.art. injection. However, if it is assumed that the 
drugs are distributed in a blood volume of 1ml, or a synovial volume of 0.1m1, 
respectively, it can be estimated from the following equation: 
Molar concentration = number of moles /number of litres 
The estimated local concentration of all drugs used in the rat knee joint neural 
recordings is given in Appendix II. 
2.1.2.9 Data sorting 
Nerve activity from each filament was sorted off-line using Spike2. This program 
was used to scan the waveform channel and generate templates for each individual 
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action potential it identified. The channel was then reclassified and each separate 
action potential was extracted and displayed on a separate channel as individual 
wavemark data. Markers were used to indicate the point at which a drug injection 
was made: 
2.1.2.10 Data analysis 
The knee joint data was analysed in a similar manner as described in Section 2.1.1.7 
above for the corneal data. Briefly, the effect of a drug injection was determined by 
comparing the discharge after drug injection with that before injection, and the 
response was expressed as the change in the action potential discharge frequency. 
The effect of a drug on MAN discharge was also expressed as the change in the total 
number of action potentials firing as given by the calculation below. When no clear 







The change in the total number of action potentials evoked by the 
drug. 
Thus, delta Ex = Zxtest - ffcontrol * ttest) 
This calculation assumes that the basal discharge would remain 
unchanged in the absence of a stimulus. 
The total number of action potentials counted in the test time period, 
ttest (expressed as impulses). 
The frequency of action potential discharge in the control time period. 
The test time period. 
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2.2 BEHAVIOURAL STUDIES 
2.2.1 THE RAT EYE 
In conscious male Wistar rats, the effects of topical application of drugs to the eye on 
eye blinking and wiping was assessed. 
2.2.1.1 Drug administration 
The rats were held while 51l drops of drugs were instilled into the eyes using a 
pipette. The effect of vehicle instillation in one eye was determined initially and 10 
minutes was allowed before drug was applied to the contralateral eye. Twenty 
minutes were allowed between successive instillations to the same eye. 
2.2.1.2 Assessment of nociceptive responses 
Rats were placed in an empty cage and the number of blinks and forepaw wipes of 
the treated eye were counted in the first minute post instillation of drug. 
2.2.2 THE RAT KNEE JOINT 
2.2.2.1 Induction of monoarthritis 
Localised experimental arthritis was induced in the left knee joint of male Wistar rats 
by i.art injection of FCA as described in Section 2.1.2.1.1. For controls, some rats 
were injected with sterile paraffin as described. 
2.2.2.2 Assessment of arthritis in behavioral studies 
Throughout the development and maintenance of monoarthritis the general health of 
the rats was monitored by measuring body weight. The allodynia and swelling 
associated with adjuvant- induced arthritis was assessed by measuring hindlimb 
weight bearing and knee joint swelling as described below. 
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Weight- bearing allodynia 
The distribution of body weight between the arthritic (left) and normal (right) 
hindlimbs of monoarthritic rats was measured quantitatively using a the dual channel 
weight averager (GlaxoWellcome/Linton Instruments, see Clayton et al. (1997)). 
This instrument consisted of a pair of force transducers connected to a digital read- 
out that displayed the mean weight on each transducer over a fixed time (Figure 2.4). 
The rats were placed in a clear perspex box so that they were standing with each 
hindlimb on a separate transducer and the mean weight on each foot was measured 
over a period of 7s. The allodynia induced by walking was assessed qualitatively by 
visual observation of the rats mobility using the following scores: 
0 = normal 
1 = slight limp, paw touched cage floor most of the time 
2 = moderate limp, paw briefly touched cage floor 
3 = severe limp, paw never touched cage floor 
Figure 2.4 Photograph of the weight averager used to assess weight- bearing 
allodynia in monoarthritic rats. 
Swelling: 
The inflammation in the knee joint was measured quantitatively using a sliding 
calipers (Figure 2.5) and qualitatively by visual examination of the arthritic knee 
joint using the following scores: 
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0 = normal 
1 = mild swelling 
2 = moderate swelling 
3 = severe swelling 
Figure 2.5 Photograph of the calipers used to measure knee joint diameter in 
monoarthritic rats. 
2.2.2.3 Data analysis 
The cumulative change in measurements over the duration of the trial from a selected 
control value was determined for each rat, and the change for each rat was expressed 
as a mean for the group. 
2.3 HISTOLOGY AND IMMUNOHISTOCHEMISTRY 
2.3.1 ARTHRITIS INDUCTION 
FCA or sterile paraffm -oil was injected into the left knee joint of male Wistar rats as 
described previously. The rats were used for retrograde labelling one week later 
and/or tissue was removed for histological and immunohistochemical studies two 
weeks later. 
2.3.2 RETROGRADE LABELING OF DORSAL ROOT GANGLIA 
One week after induction of arthritis, both knee joints of one male Wistar rat were 
injected with the retrograde tracer, fluorogold (Schmued & Fallon, 1986), to label 
knee joint afferent nerves in the DRG as described by Salo and Theriault (1997). The 
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rat was transiently anaesthetised with halothane and 5µ1 of 2% fluorogold in distilled 
water was injected into the knee joint just beneath the patella using a Hamilton 
syringe and a 26G needle. This was followed after a few minutes by 1511I of O.1M 
phosphate buffer to precipitate the dye in the synovial space. A survival time of one 
week was allowed before the rat was fixed for immunohistochemistry. 
Corneal afferents in the left TG of four mice were also retrogradely labelled 
using fluorogold, and the right TG were used as controls (performed by Dr. Carmen 
De Felipe at the Universidad de Alicante). The TG were removed five days later, 
post -fixed in paraformaldehyde (4% in 0.01M sodium phosphate buffer) and sent to 
Edinburgh for immunohistochemical studies. 
2.3.3 FIXATION 
Normal, control (paraffin- injected) and arthritic rats were anaesthetised with 
pentobarbitone (60mg kg 1 i.p.). A midline incision was made at the abdomen, the 
abdominal aorta was anterogradely cannulated (catheter OD: 1.34mm) and the vena 
cava was cut to allow bleeding of the animal. The animal was perfused with 10m1 of 
heparinised saline (500units kg-1) followed by 50 -100m1 of 10% formal saline via the 
aortic cannula. The left and right knee joints, and DRGs (levels L3, L4, LS and L6) 
were removed and post -fixed in 10% formal saline. All tissue was then processed 
(post- fixed, decalcified and paraffin- embedded), sectioned (311M sections) and 
mounted on glass slides by Mr. Steven MacKell and Ms. Helen Caldwell 
(Department of Pathology, University of Edinburgh). 
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2.3.4 HISTOLOGY 
Paraffin- embedded sections of normal, in addition to ipsilateral and contralateral 
knee joints of arthritic and control rats were stained using haematoxylin and eosin, 
and covered with glass coverslips using Pertex mountant. The sections were 
subsequently examined using light microscopy by Dr. Donald Salter (Department of 
Pathology, University of Edinburgh). 
2.3.5 IMMUN OHI STO CHEMISTRY 
In the present study, polyclonal antibodies raised in the rabbit against rat P2X3 
receptors (kindly donated by Dr. E.J. Kidd) were used to confirm the presence of 
P2X3 receptors in rat and mouse sensory neurones in the DRG and TG respectively. 
Antibody labelling was indirectly viewed using the Avidin- Biotin Complex method 
(ABC) which is shown schematically in Figure 2.6. In the ABC method used, 
complexes of streptavidin and biotinylated horseradish peroxidase (HRP -ABC), or 
biotinylated alkaline phosphatase (AP -ABC) were visualised using the chromogens 
3,3'- diaminobenzidine tetrahydrochloride (DAB) or Vector Red respectively. 
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Figure 2.6 Schematic diagram showing the principles of the Avidin- Biotin 
method used to locate P2X3 receptor in rat and mouse tissues. 
2.3.6 P2X3 IMMUNOHISTOCHEMISTRY METHOD 
Sections were dewaxed in xylene for 10 minutes and placed in 95% alcohol. If 
horseradish peroxidase was used as the tracer, the sections were put in 3% hydrogen 
peroxide in methanol for 10 minutes to block endogenous peroxidase activity. 
Sections were then dehydrated in alcohol and washed with running tap water. The 
slides were subsequently mounted on individual perspex slide holders, placed in a 
staining trough (Sequenza) and washed with PBS (all washes were 3 -5 minutes). 
Non -specific staining was blocked by incubating the slides with normal swine serum 
diluted 1:5 with 0.1% triton in PBS (NSS -tPBS) for 10 minutes (all incubations were 
at room temperature except where stated). Sections were then incubated with either i) 
P2X3 antibody or ii) pre- immune serum (PI, the serum from the host animal in which 
the primary antibody was raised before exposure to the immunogen) diluted 1:2000 
in NSS -tPBS for 72 hours at 4 °C. After the primary incubation, sections were 
washed with PBS, blocked with NSS -tPBS (10 minutes) and incubated in 
biotinylated secondary swine -anti- rabbit antibody (1:500 in NSS -tPBS) for 2 hours. 
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The secondary antibody was washed off with PBS and the slides were incubated with 
either horseradish peroxidase or alkaline phosphatase Avidin- Biotin Complex (HRP- 
ABC or AP -ABC) for 30 minutes. After washing with PBS, HRP -ABC slides were 
exposed to DAB for 5 minutes and AP -ABC slides were exposed to Vector Red for 
30 minutes. Slides were washed in running tap water, stained with haematoxylin and 
"blued" with Scott's Tap Water Solution. After staining, slides were dehydrated in 
alcohol, cleared in xylene and mounted using Pertex. DAB produced a dark -brown 
reaction end product that was visible under a light microscope. Vector Red produced 
a red end product that was also visible under the light microscope, but since it is a 
red fluorescent dye (maximally absorbent under green light), it was primarily was 
examined under a fluorescence microscope. 
2.4 DETERMINATION OF ATP CONCENTRATION IN SYNOVIAL 
PERFUSATE 
2.4.1 ARTHRITIS INDUCTION 
Arthritic and control rats were induced as described and the rats were used two 
weeks post- induction. 
2.4.2 WITHDRAWAL OF SYNOVIAL FLUID 
Normal and arthritic male Wistar rats were anaesthetised with pentobarbitone (60mg 
kg -1 i.p.). The rats were placed on their backs and one of the hindlimbs was held 
firmly. Two 26 -gauge needles were inserted through the infrapatellar ligament 
beneath the patella as described by Malone (1991). One needle was used as an inflow 
needle and the other as an outflow needle. 1ml of 1mM EDTA in PBS was slowly 
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injected into the knee joint via the inflow needle and the perfusate was aspirated 
from the hub of the outflow needle and collected into ice -cold Epindorf tubes. EDTA 
was used to try to limit ATP degradation (ecto -nucleotidases are dependant on 
divalent cations (Banerjee, 1981)). Samples were immediately centrifuged (200g for 
10 minutes at 4 °C) in a refrigerated centrifuge (Micromax RF, International 
Equipment Company) to remove cells. After centrifugation, the supernatant was 
weighed by transferring it into epindorfs on ice that had been "zeroed" on a balance 
and samples were placed in dry -ice and sent to GIAP for analysis of ATP 
concentration. Although centrifugation was probably traumatic and caused ATP 
release from the cells, it was necessary because freezing and thawing would rupture 
the cell membrane and cause considerable ATP release. This was confirmed in an 
earlier investigation, which showed that the perfusate ATP concentration correlated 
with the level of blood in the samples (data not shown in this thesis). 
2.5 STATISTICAL ANALYSIS 
Unpaired t -tests were used to analyse differences between the means of two normally 
distributed groups of data. When the sample size was too small to determine whether 
or not it followed a Gaussian distribution, the Mann -Whitney test was used. 
Student's paired t -test analysis was used when experiments were performed to 
produce normally distributed data with in- experiment controls. One way analysis of 
variance, followed by Tukey's multiple comparison (post hoc) test, was used to 
compare the means of more than two normally distributed groups. 
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Chapter 3: The direct role of ATP in corneal nociception 
3.1 INTRODUCTION 
Photorefractive keratectomy for myopia is associated with severe post- operative 
ocular pain (Stein et al., 1994). Topical instillation of local anaesthetic is widely used 
to control the pain, but prolonged use causes poor wound healing and other 
complications (Verma & Marshall, 1996). An improved method of treating this type 
of post- operative pain is urgently needed, as reflected by recent clinical trials (for 
example see Assouline et al., 1998; Frangouli et al., 1998; Lim -Bon -Siong et al., 
1998). Research strategies aimed at finding effective treatments for corneal pain 
could be devised if the mechanisms underlying it were fully understood. The cornea 
is innervated by trigeminal afferents and it is known that six subtypes of ATP -gated 
ion -channel receptors (P2X1_6) are expressed in the cell bodies of neurones within the 
trigeminal ganglion (Collo et al., 1996). If it can be shown that P2X receptors are 
involved in nociceptive transmission from the cornea, this would have implications 
for the treatment of corneal pain. 
To establish whether P2X receptors play a role in corneal nociception, it is 
crucial to determine whether functional receptors are expressed on the peripheral 
terminals of trigeminal afferents innervating the cornea. In cell culture, neurites of rat 
tooth pulp trigeminal neurones are depolarised by ATP and also by the P2X1 and 
P2X3 receptor selective agonist aßmeATP (Cook et al., 1997). These neurones were 
assumed to be nociceptive because the predominant sensation evoked from tooth 
pulp by various stimuli is pain (Ahlquist et al., 1984; Anderson & Matthews, 1967; 
Edwall & Olgart, 1977). The Cook et al. (1997) investigation indicates that 
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functional aßmeATP- sensitive P2X receptors are expressed away from the cell 
bodies of assumed nociceptors in vitro, but whether they are on the peripheral 
terminals of defined nociceptors in vivo is still unknown. 
The present investigation used electrophysiological and behavioural methods 
to test the hypothesis that functional P2X receptors are expressed on the peripheral 
terminals of corneal nociceptors in vivo. The neural discharge of nociceptive 
afferents innervating the corneas of anaesthetised cats was recorded and the effects of 
applying P2 agonists to their receptive fields were investigated. The cornea is an 
ideal tissue for electrophysiological studies of nociception because it has a high 
density of nociceptors (20 -40 times more than tooth pulp (Rozsa & Beuerman, 
1982)) with easily explored receptive fields. The effect of photorefractive corneal 
keratectomy on the sensitivity of corneal nociceptors to the purines was also briefly 
investigated as this has previously been shown to alter the sensitivity of corneal 
polymodal nociceptors to chemical or mechanical stimulation (Gallar et al., 1997). 
The cornea is also ideal for behavioural studies since, like the tooth pulp, pain is the 
main sensation aroused from it (see Belmonte & Gallar, 1996). Thus, to determine 
the behavioural correlates of the electrophysiological studies, P2 receptor agonists 
were instilled into the eyes of conscious rats and any resulting behaviours indicative 
of painful stimulation were noted. In the final section of this study, cell bodies of 
corneal afferents in the mouse TG were labelled using a retrograde fluorescent tracer 
and immunohistochemical methods were used to investigate whether P2X receptor 
immunoreactivity co- localised with the tracer. 
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3.2 METHODS 
3.2.1 AFFERENT NERVE RECORDINGS IN VIVO 
Electrophysiological recordings were carried out as described in Section 2.1.1. 
Briefly, seven normal adult cats (3.2 ±0.2kg) were anaesthetised with pentobarbitone 
(40mg kg-1 i.p., supplemented hourly i.v.) and the trachea and right saphenous vein 
cannulated. One cat (3.5kg) following photorefractive keratectomy (performed by 
Dr. A.R. Gutierrez, Departamento de Oftalamologia, Universidad de Murcia, Spain) 
was also used. Extracellular recordings from filaments of mixed ciliary nerves with 
receptive fields in the cornea were performed as described previously (Belmonte et 
al., 1991). Drugs were applied to the cornea for 30s via a piece of solution- soaked 
tissue or in a 50µ1 drop. Data are expressed as mean change in action potential 
frequency ±sem. 
3.2.2 BEHAVIOURAL STUDIES 
Behavioural studies were performed as described in Section 2.2.1. In summary, drug 
solutions (4t1 drop) were instilled into the eyes of four conscious male Wistar rats 
(283 ±7g) and the number of blinks and forepaw wipes of the eye, behaviours 
associated with nociception (see Gonzalez et al., 1993), were counted in the first 
minute post -instillation. 
3.2.3 IMMUNOHISTOCHEMICAL STUDIES 
The left TG of four mice were retrogradely labelled from the left cornea using 
fluorogold and the right TG were used as controls (performed by Dr. C. De Felipe, 
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Instituto de Neurociencias, Universidad de Alicante, Spain). The processing and 
detection of P2X3 immunoreactivity was carried -out as described in Section 2.3. 
3.3 RESULTS 
3.3.1 AFFERENT NERVE RECORDINGS IN VIVO 
Neural discharge was recorded from 56 afferent fibres innervating 13 eyes from 7 
normal cats. Afferent activity was also investigated in 6 fibres innervating 1 eye after 
central corneal keratectomy. 
3.3.1.1 Characterisation of afferent nerve fibres 
3.3.1.1.1 Conduction velocities, mechanosensitivity and chemosensitivity 
The afferents were classified as AS -fibre polymodal nociceptors, C -fibre polymodal 
nociceptors or AS -fibre mechanonociceptors based on their conduction velocities, 
mechanosensitivity and sensitivity to CO2 stimulation. AS -fibre polymodal 
nociceptors were fast conducting (5.02 ±0.0.99ms 1), activated by stroking the 
receptive field with a fine wet paintbrush, and by a 30s pulse of CO2 directed at the 
receptive field (Figure 3.1). C -fibre polymodal nociceptors were slowly conducting 
(0.77 ±0.08ms -1) and responded to mechanical and CO2 stimulation (Figure 3.1). AS- 
fibre mechanonociceptors (conduction velocity: 9.58 ±3.06ms 1) responded to 
mechanical stimulation of the receptive field but were not excited by CO2. 
In normal cats, 64% (36/56 afferents) of the afferents recorded from were AS- 
fibre polymodal nociceptors, 20% (11/56 afferents) were C -fibre polymodal 
nociceptors and 16% (9/56 afferents) were mechanonociceptors. The 6 fibres 
innervating the laser- treated cornea were AS -fibre polymodal nociceptors. 
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3.3.1.1.2 Location of afferent receptive fields 
Nociceptors with corneal receptive fields were selected for this study. However, a 
small number of the afferents had receptive fields that extended into the surrounding 
sclera, that is, they were cornea/scleral afferents. The effect of application of P2X 








Figure 3.1 Neural discharges evoked by a) mechanical (at arrow) and b) CO, 
stimulation (for 30s market) of the corneal receptive field of single A.5- (first panel) 
and C -fibre (second panel) polymodal nociceptors. 
3.3.1.2 CO2- evoked excitation of corneal polymodal nociceptors 
The response latency, response duration and change in action potential discharge 
frequency from the basal rate (AS- polymodal: 0.2 ±0.4 impulses s"1; C- polymodal: 
0.2 ±0.5 impulses s -1) caused by CO2 in 19 AS -fibre and 9 C -fibre polymodal 
nociceptors innervating the cornea were compared. The onset latency of the 
excitation in C- fibres was significantly shorter (P <0.05, unpaired t -test) than that in 
AS- fibres, which may have reflected deeper terminal endings of the latter, but no 


















Figure 3.2 Pooled data showing the a) onset latency, b) duration and c) change 
in discharge frequency of the response evoked by a 30s pulse of CO2 in corneal AS- 
fibre and C -fibre polymodal nociceptors. Coltamts represent nteanisent. AS - fibres 
n =19, C- fibres n =9. *P <0.05 unpaired t -test; faster onset in C- fibres compared to 
AS fibres. 
3.3.1.3 Lack of P2X- mediated activation of corneal polymodal nociceptors 
The P2X1 and P2X3 subtype selective agonist, aßmeATP (100µM), the non -selective 
P2 agonist, ATPyS (10004) and the endogenous ligand at P2 receptors, ATP 
(100µM) did not evoke a response from AS -fibre or C -fibre polymodal nociceptors 
when the drugs were applied to the cornea using a piece of tissue paper (Figure 3.3 
and Figure 3.4). A wider range of doses of a(3meATP was studied these also failed to 
stimulate the nociceptors (30µM: 0.07 ±0.10 impulses s'; 1000µM: 0.65 ±0.14 
impulses s -', n =3 AS- polymodal nociceptors per concentration). aßmeATP (100µM) 
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and ATP (100µM) were also applied to the cornea as a 50111 drop, but application by 
this method also failed to elicit a change in action potential discharge (aßmeATP: 





Figure 3.3 Neural discharge showing the lack of response evoked by application 
(at first arrow) of a) aßmeATP 100 pill, b) ATPyS 100pMand c) ATP 100,uM to the 
receptive field of corneal AS -fibre (first panel) and C -fibre (second panel) polymodal 
nociceptors. The second arrow indicates when the cornea was washed. 
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Figure 3.4 Pooled data showing the absence of effect of PBS, aßineATP 100pM, 
ATPyS 100 pill and ATP 1001M on the action potential discharge frequency in a) 
AS -fibre and b) C -fibre corneal polymodal nociceptors. Data is from the first 10s 
after application of the drugs via a piece of tissue paper. Columns represent 
mean em. PBS.' A5- fibres n =5, C- fibres not done; aßmeATP: AS-fibres n =25, C- 
fibres n =9; ATPyS: AS- fibres n =7, C fibres n =4; ATP: AS- fibres n =5, C- fibres not 
done. 
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3.3.1.4 Capsaicin & nicotine -evoked excitation of corneal polymodal 
nociceptors 
Although polymodal nociceptors were not excited by the purines, the algogens 
capsaicin and nicotine were used to confirm that it was possible to excite them using 
other pharmacological agents. In normal corneas, capsaicin (0.1 µM) evoked a 
significant (P <0.05) response compared to PBS in 4 of 6 aßmeATP- negative C- 
fibres (Figure 3.5b and Figure 3.6) and 1 of 14 aßmeATP- negative AS- fibres (2.03 
impulses s -1) on which it was tested. Nicotine (10001..t.M) evoked a significant 
(P <0.05) response in 3 of 10 aßmeATP -negative A8- fibres (Figure 3.5b and Figure 






Figure 3.5 Neural discharge showing typical responses evoked by application (at 
first arrow) of a) capsaicin O. .11E14 to the corneal receptive field of a C -fibre 
polymodal nociceptor and b) nicotine 1000,uM to the conical receptive field of an 
Ag-fibre polymodal nociceptor. Second arrow indicates when the cornea was 
washed. 
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O PBS 
Ca psaic in ® Nicotine 
* 
Figure 3.6 Pooled data showing the change in action potential discharge 
frequency evoked by capsaicin 0.1 fil and nicotine 100044 from polymodal 
nociceptors. Cohimns represent mean em. Capsaicin: C fibres n =4; nicotine: AS- 
fibres n =3; PBS: AS-fibres n =5. *P <0.05 unpaired t -test versus PBS. 
3.3.1.5 Lack of P2X- mediated modulation of the CO2 response 
Although aßmeATP did not excite corneal nociceptors directly, any potential 
augmentation or attenuation of the CO2 response in polymodal nociceptors was 
determined. The magnitude of the CO2 response in polymodal nociceptors was 
measured 1 or 5 minutes before and 1 or 5 minutes after aßmeATP. The P2X 





Figure 3.7 Pooled data showing the response evoked by a 30s pulse of CO, a) 1 
minute before & I minute after, and b) 5 minutes before & 5 minutes gfter aßmeATP 
(100111). Columns represent mean ein. Pooled data from one ASfibre and two C- 
fibre polymodal nociceptors. 
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3.3.1.6 Lack of P2X- mediated excitation of corneal mechanonociceptors 
In normal cornea, 16% (9/56 afferents) of afferents recorded from were classified as 
AS -fibre mechanonociceptors. The effect of aßmeATP (100µM) on action potential 
discharge was investigated in 2 of these afferents but it failed to elicit a response 
(change in discharge frequency, unit: 0.03 impulses 5-1; 2nd unit: -0.12 impulses s- 
3.3.1.7 Lack of P2X- mediated activation of nociceptors innervating the 
keratectomised cornea 
The location of the afferent receptive field relative to the excised section of the 
cornea, that is, whether they are in, near, or far from the ablation, affects the response 
characteristics of the nociceptors (Gallar et al., 1997). In the present study, the 
polymodal AS- fibres had corneal receptive fields near to the ablation. The afferent 
discharge evoked by CO2 in these nociceptors was not significantly different to that 
in normal corneas (normal AS- fibres: 2.85 ±0.44 impulses s-1, n =19; keratectomy AS- 
fibres: 2.27 ±0.19 impulses s-1, n =4). As in the normal corneas, aßmeATP (100)1M) 
failed to elicit a response (0.13 ±0.05 impulses s-1, n =4). 
3.3.1.8 Lack of P2X- mediated activation of nociceptors innervating the sclera 
Because of the extensive branching of corneal nerve axons (see the General 
Introduction), some of the receptive fields extend into the surrounding sclera. This 
unusual property allows the testing of the same afferent in avascular (cornea) and 
vascularised (sclera) regions. 
Two of the AS- polymodal nociceptors innervating normal eyes and one 
innervating the keratectomised eye had receptive fields that extended into the sclera. 
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No response to aßmeATP (100µM) was observed when it was applied to either the 
corneal or the scleral receptive field of these afferents (Table 3.1). 
Table 3.1 Absence of excitation following application of aßmeATP (100jiM) to 
the conical or scleral receptive fields ofAetfibre polymodal nociceptors. 
Change in discharge frequency 
(impulses s -') 
Corneal Scleral 
A8 -fibre from normal eye 0.1 0 
AS -fibre from normal eye -0.5 0 
AS from keratectomised eye 0 -0.2 
3.3.2 BEHAVIORAL STUDIES 
3.3.2.1 Lack of nociceptive behaviour following instillation of P2X receptor 
agonists into the eye 
In a pilot study in one conscious rat, single instillations of a number of P2 receptor 
agonists into the eyes did not induce any behavioural changes indicative of pain 
(Table 3.2). In a more detailed investigation in four rats, the number of blinks and 
wipes of the eye evoked following instillation of aßmeATP (10- 100011M) did not 
differ significantly from that following vehicle instillation or from the basal rate 
(Figure 3.8). 
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Table 3.2 Blinks and wipes in the first minute post -instillation of ATP and 
ATPgS into the eye. Data are from single instillations. Basal data from Figure 3.8 
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(number min -1) 
Wipes 
(number miri') 
Basal rate 2.3 ±0.9 0 ±0 
ATP 100µM 3 0 
ATP 1000µM 2 0 
ATPgS 10011M 2 0 





O Vehicle (PBS) 
CCU apmeATP 10µM 
apmeATP 104M 
apmeATP 1000µM 
Figure 3.8 Pooled data showing the number of a) blinks and b) wipes in the first 
minute post instillation of aßmeATP (10- 1000,uM) and vehicle into the eye. The 
basal rates are shown for comparison. Columns represent mean. em. 
3.3.2.2 Nociceptive behaviour following instillation of capsaicin and nicotine 
into the eye 
Threshold concentrations of capsaicin (101_1M) and nicotine (100011M) both caused a 
significantly higher (P <0.01) number of eye blinks compared to their respective 
vehicles (Figure 3.9a). However, the mean number of wipes evoked by capsaicin and 
nicotine was not statistically different to that caused by vehicles (Figure 3.9b). 
Higher doses of the algogens would have caused more pain and would presumably 
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Figure 3.9 Pooled data showing the number of a) blinks and b) wipes in the first 
minute post instillation of capsaicin 101M (i) or nicotine 1000,u11'í (ii) into the eye. 
The basal rates and the number evoked by capsaicin vehicle (ethanol & PBS) and 
nicotine vehicle (PBS) are shown for comparison. Cohmms represent mean. em. 
* * *P <0.0001 unpaired Nest capsaicin versus vehicle. * *P <0.01 unpaired t -test 
nicotine versus vehicle. 
3.3.3 IMMUNOHISTOCHEMICAL STUDIES 
3.3.3.1 P2X3 immunoreactivity in corneal trigeminal ganglion cell bodies 
Two sections from the left and right TG, fluorogold- labelled and control 
respectively, of four mice were examined for P2X3 -immunoreactivity and /or co- 
localisation with fluorogold fluorescence. Each section clearly showed P2X3- 
immunoreactivity throughout the cytoplasm in discrete cells using DAB (not shown) 
or Vector Red visualisation (Figure 3.10). Although no attempt was made to quantify 
the proportion of cells labelled, approximately half of the cells in each section were 
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labelled with the P2X3 antibody. Retrogradely labelled cells were identified by the 
presence of scattered particles of silvery fluorescence in the cytoplasm and P2X3- 
immunoreactivity co- localised in some retrogradely labelled cells (Figure 3.11) 
a) b) 
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Figure 3.10 Light field photomicrographs (x40) of two sections from one mouse 
trigeminal ganglion showing a) discrete P2X3 -immunoreactivity visualised with 
Vector Red in a number of cells and b) the absence of staining when the sections 
were incubated with pre- immune serum. 
a) b) 
Figure 3.11 Fluorescence micrographs (x40) of a single mouse trigeminal 
ganglion section illustrating a) P2X3- immunoreactivity visualised with Vector Red 
and b) fluorogold fluorescence. Fluorogold and Vector Red fluorescence co- 
localised in the cells indicated by the arrows. 
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3.3.4 DISCUSSION 
Although P2X3 receptor immunoreactivity was found in mouse corneal trigeminal 
neurones, P2 receptor agonists did not excite or sensitise nociceptors innervating the 
cat cornea nor did they evoke nociceptive behaviours after instillation into the eyes 
of conscious rats (Dowd et al., 1997). These findings do not support the hypothesis 
that functional P2X receptors are expressed on the peripheral terminals of 
nociceptive afferents in vivo. 
Antibodies directed against the rat P2X3 receptor were used (Kidd et al., 
1998) because this receptor subtype is selectively expressed in, and probably 
mediates depolarisation of a population of trigeminal tooth pulp nociceptors in vitro 
(Cook et al., 1997). It was surprising that a(3meATP (a stable P2X1 and P2X3 
subtype selective agonist), ATPyS (a non -selective P2 receptor agonist) and ATP (the 
endogenous ligand at P2 receptors) did not excite cat corneal nociceptors or evoke 
nociceptive behaviours in the rat since P2X3 -immunoreactivity could be located in 
corneal neurones in the mouse TG. Species differences are unlikely to account for 
the negative behavioural data because P2X3 mRNA transcripts or immunoreactivity 
has previously been detected in rat TG (Collo et al., 1996; Llewellyn -Smith & 
Burnstock, 1998; Xiang el al., 1998), and nerve fibres of the rat corneal epithelium 
(Vulchanova, 1998). However, expression of P2X3 receptors in the cat TG or cornea 
have not been investigated and therefore, it is possible that the lack of excitation of 
cat corneal nociceptors reflects an absence of the receptor protein. Species 
differences in expression of P2X3 receptors is known to exist: in rats, it is selectively 
expressed in sensory ganglia (Collo et al., 1996) whereas in humans, it is only 
expressed in the spinal cord and heart (GarciaGuzman et al., 1997). Because the 
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distribution of P2X receptors in the cat TG is unknown, it is not possible to exclude 
that species differences accounted for our electrophysiological results. However, the 
possibility that the P2 agonists.did not penetrate to the nociceptive terminals because 
of biological, physical or electrochemical barriers was also considered. 
ATP and ATPyS are rapidly metabolised to adenosine in vivo (see Chapters 5 
and 6) and corneal ecto -nucleotidase activity could conceivably have prevented them 
from reaching the nociceptors. However, aßmeATP is not degraded by the enzyme 
and therefore the presence of enzymatic barriers cannot be invoked to explain our 
results. The other pharmacological agents tested, capsaicin and nicotine, excited 
polymodal nociceptors, as did CO2, which mediates its effects by lowering interstitial 
pH (Chen et al., 1995). Capsaicin and nicotine have lower molecular weights (162 
and 305 respectively) than ATP, ATPyS or aßmeATP (551, 547 and 505 
respectively) and could potentially have traversed the outer corneal epithelial layers 
more easily than the purines. However, high molecular weight algogenic peptides 
such as bradykinin (MW 1060) can activate corneal nociceptors (Belmonte et al., 
1994) and thus the size of the P2 agonists should not have influenced their ability to 
gain access to the nerve endings. The possibility that the electrically charged form of 
ATP that activates P2X receptors (ATP4 -, see Fedan et al., 1990) may have been 
prevented from penetrating to the nerve terminals was also considered. This is 
unlikely because nicotine is also a charged compound (( -)- nicotine) and it activated 
cat corneal nociceptors and caused behaviours related to pain after instillation into 
the rat eye. 
One of the peculiar aspects of recording from nociceptors innervating the 
cornea is that it is possible to investigate the responses of the same afferent to drugs 
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in avascular and vascular regions. If excitation is observed following application of 
drugs to the sclera but not the cornea, this indicates that vascular effects, such as 
vasoconstriction resulting in hypoxia or production of a blood- derived inflammatory 
mediator, probably account for the response. In the present investigation, no change 
in discharge was observed when c43meATP was applied to the corneal or scleral 
receptive fields of nociceptors. This confirmed that the absence of excitation 
observed in the cornea could not be accounted for by the lack of a vascular effect. 
Another explanation for the lack of a P2X mediated response in this study is 
the very slow penetration of the agonists to the nerve endings. Although nerves in the 
cornea terminate within a few microns of the surface (Zander & Wedell, 1951), the 
capsaicin- evoked response in the electrophysiological studies was delayed in onset 
(approximately 5s, see Figure 3.5, pooled data not shown). In contract, capsaicin, 
when injected into rat lower abdominal artery, activates nociceptors in the knee joint 
with a latency of approximately 1 s even though it has a far greater distance to travel 
(Dowd et al., 1998c, and see Chapter 4). Slow penetration is likely to lead to gradual 
increases in the local concentration of drugs, which may have caused receptor 
desensitisation. Recombinant P2X3 receptors mediate a transient current when 
expressed in HEK 293 cells (Lewis et al., 1995) and therefore this subtype would be 
expected to desensitise rapidly. Interestingly, in small diameter sensory neurones 
(associated with nociception) dissociated from the rat DRG, capsaicin activates a 
slowly- desensitising current (Li et al., 1999). If similar properties are associated with 
capsaicin- induced responses in trigeminal neurones, this could explain why capsaicin 
evoked a response from corneal nociceptors in the present study despite the slowly 
increasing concentration of agonist. 
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Aside from possibility of species differences or receptor desensitisation, the 
obvious implication of this work is that functional P2X receptors are not expressed in 
corneal nociceptive endings in vivo despite the presence of functional P2X receptors 
and P2X3 receptor immunoreactivity in TG (the present immunohistochemical data 
and Cook et al., 1 997). This is supported by recent findings in the tooth pulp because 
ATP and analogues failed to activate tooth pulp afferents in anaesthetised cats (Li et 
al., 1998; Matthews et al., 1997). If these receptors are not expressed functionally on 
the peripheral terminals of sensory afferents, then why are they expressed 
functionally at the cell bodies of sensory neurones? 
Interestingly, P2X3 immunohistochemical staining is very intense in the 
endoplasmic reticulum and Golgi apparatus of trigeminal sensory neurones 
(Llewellyn -Smith & Burnstock, 1998). It is conceivable that under certain conditions 
these receptors might be transported to, and expressed on the sensory cell body 
membrane. Thus, the artificial environment found in dissociated cell culture might 
stimulate the functional expression of the receptors, thereby explaining why P2X 
mediated responses are obtained in trigeminal neurones in vitro. Consistent with this 
is the demonstration that few P2X mediated responses can be obtained from rat DRG 
neurones when they are maintained in vitro with the peripheral roots intact, whereas 
when these cells are dissociated, most of them exhibit ATP and aßmeATP- evoked 
inward currents (Stebbing et al., 1998). If some in vitro conditions stimulate the 
functional expression of P2X receptors, does an equivalent physiological trigger exist 
that would cause the receptors to be functionally expressed on the peripheral 
terminals of nociceptive afferents? 
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One possibility is that the receptors might only be functionally expressed 
under inflammatory conditions or following injury. This is known to happen with 
other receptors. For example, bradykinin B1 receptors are not expressed in normal 
tissue but de novo synthesis and expression occurs after exposure to some 
inflammatory mediators (Bouthillier et al., 1987; deBlois et al., 1991). The 
proportion of rat trigeminal neurones that are immunoreactive to the P2X3 antibody 
increases 4 -10 days following injury to the mandibular inferior alveolar nerve 
(Eriksson et al., 1998). These authors suggested that up- regulation of P2X3 receptors 
following nerve injury could mediate the abnormal firing of injured sensory nerves. 
Consistent with this, the P2X3 subtype accumulates at sites proximal to trigeminal 
nerve injury (Cook et al., 1997; Eriksson et al., 1998). Since photorefractive corneal 
keratectomy undoubtedly injures the nociceptive afferents, it is possible that the 
P2X3 receptor might be up- regulated and functionally expressed at these sites. If so, 
this could represent a novel mechanism underlying the heightened pain in humans 
following laser treatment for myopia. The present pilot investigation does not agree 
with this proposal because aßmeATP did not elicit an increase in action potential 
discharge from polymodal nociceptors innervating the keratectomised cat cornea. 
However, we only performed electrophysiological studies in one cat at 18 hours post - 
surgery and further studies at different time points would better answer the question 
of whether functional P2X expression occurs following corneal nerve injury. 
Furthermore, it is possible that the normal mechanisms underlying post- operative 
corneal sensitisation were unusual in this cat because the responses of polymodal 
nociceptors to CO2 were not augmented in comparison to those normal corneas and 
this is a feature of nociceptors innervating keratectomised cat corneas (Gallar el al., 
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1997). It would be necessary to repeat the experiments in more severely sensitised 
keratectomised corneas before the possibility that P2X receptors mediate post- 
operative pain is excluded. 
Overall, the results do not support the hypothesis that functional P2X 
receptors are expressed on the peripheral terminals of nociceptors innervating the cat 
or rat cornea in vivo despite the finding that the P2X3 subtype is expressed in mouse 
corneal neurones in the TG. However, our data does not preclude a role for the 
functional expression of P2X receptors in certain pain states. It is also possible that 
the negative data may be due to species differences or the slow penetration of P2X 
agonists and the resulting desensitisation of the receptors. Nevertheless, our data 
indicates that pharmacological manipulation of P2X receptor function is unlikely to 
provide a useful therapeutic target for treating corneal pain. 
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Chapter 4: Adjuvant- induced monoarthritis of the rat knee 
joint 
4.1 INTRODUCTION 
Adjuvant- induced polyarthritis, caused by injection of FCA into the rat tailbase or 
footpad, is the best characterised animal model for human RA (see Billingham, 1983; 
Rainsford, 1982). However, the arthritic lesions of polyarthritis are widespread and 
the animal suffers considerable distress and incurs dramatic weight loss (Owen, 
1980). In order to reduce the severity of the arthritis, investigators have developed 
monoarthritic models of arthritis where the inflammation is confined to a single joint, 
frequently the knee or ankle. One of the earliest monoarthritic models was developed 
in this laboratory by administration of a low dose of FCA subdermally around the 
ankle joint of the rat (Grubb et al., 1988). Over the last decade, this model has been 
characterised and used as a tool in pharmacological studies of nociception and 
inflammation (Asghar, 1995; Birrell et al., 1990; Donaldson et al., 1993; Grubb et 
al., 1991; Grubb et al., 1988; McQueen et al., 1991). Although the model has been 
used successfully in these studies, using the ankle joint for arthritis induction and 
electrophysiological studies has a number of disadvantages. 
Some investigators have suggested that injection of FCA into the synovial space is 
the preferable method of arthritis induction and have argued that subdermal 
injections into the tissue overlying the joint causes a superficial inflammation rather 
than a true articular arthritis (Butler et al., 1992). However, i.art. injections into the 
rat ankle joint are very difficult to carry out without causing injury because of the 
complex anatomy and number of small bones in this joint. It is easier to induce 
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arthritis in the rat knee joint because this joint has a relatively large infrapatellar 
ligament through which needles can easily be inserted. 
Electrophysiological recordings of the neural activity in nerves innervating the rat 
ankle joint are made from the primary articulo- cutaneous ramus (PACR), a branch of 
the tibial nerve (Guilbaud et al., 1985). One of main limitations of using this 
preparation is that considerable surgery is required to sever the cutaneous branches 
of the PACR to ensure that the recorded nerve activity is from the articular divisions 
only. This can cause bleeding around the electrodes that can interfere with the 
electrical recording. Furthermore, invasive surgery and the associated tissue damage 
has the potential to sensitise the ankle tissues. There are fewer difficulties associated 
with electrophysiological recordings from the MAN innervating the rat knee joint 
because it is readily accessible and less surgery is required to expose it. To date, most 
of the electrophysiological studies of afferents innervating the knee joint have been 
carried out in the cat by Schaible, Schmidt and colleagues (Coggeshall et al., 1983; 
Schaible & Schmidt, 1983a & b; Kanaka et al., 1985; Schaible & Schmidt, 1985; 
Grigg et al., 1986; Schaible & Schmidt, 1988; Dorn et al., 1991). Since it is desirable 
to limit the use of cats in medical research, a preparation for electrophysiological 
recording from the rat knee joint was developed in this laboratory (Kelly, 1998 and 
see Dowd et al., 1998c). 
FCA- induced monoarthritis of the rat knee joint has been used previously in 
pharmacological studies by a number of authors (Bileviciute et al., 1994; Bileviciute 
et al., 1995; Davis & Perkins, 1993; Laird et al., 1997; McDougall et al., 1995). 
However, to date, none of these arthritic rats have been fully characterised 
electrophysiologically, behaviourally and histologically. The aim of this study was to 
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confirm that i.art. injection of FCA into the rat knee joint induces a monoarthritic 
lesion and that the electrophysiological preparation is a viable method of recording 
from MAN afferents innervating normal and arthritic knee joints. Neural recordings 
were made from filaments of the MAN and the discharge characteristics of afferents 
innervating normal and arthritic joints were compared. In behavioural studies, the 
allodynia and swelling quantified with chronic inflammation were assessed using a 
recently developed weight- bearing device (Clayton et al., 1997) and by measuring 
knee joint diameter respectively. Histological studies were also carried -out to 
confirm that adjuvant injection induced an inflammatory response in the knee joint. 
The overall aim of this study was to evaluate the electrophysiological preparation, 
and the neural and behavioural features of the monoarthritic model for use in 
subsequent investigations of the role of ATP and adenosine in nociception and 
inflammatory pain. 
4.2 METHODS 
4.2.1 AFFERENT NERVE RECORDINGS IN VIVO 
Arthritis induction and neural recordings were carried out as described in Section 
2.1.2. Briefly, arthritis was induced by i.art. injection of FCA (0.10- 0.15m1) into the 
left knee joint of rats under halothane anaesthesia 14 -21 days prior to the neural 
experiments. 80 normal and 24 arthritic rats (body weight range 240 -380g; 
mean ±sem 318 ±10g) were used for the electrophysiological studies. Animals were 
anaesthetised with pentobarbitone (60mg.kg 1 i.p., supplemented hourly i.v.) and the 
trachea, and right carotid and femoral arteries were cannulated. Neural activity in 
small filaments of the MAN was recorded using bipolar platinum- iridium wire 
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electrodes and data was analysed off -line using Spike 2 software. Drugs were 
administered by close -arterial injection via the cannula in the right femoral artery. 
4.2.2 BEHAVIOURAL STUDIES 
Behavioural assessment of the rats was carried out as described in Section 2.2.2. In 
summary, body weight, hindlimb weight bearing and knee diameters were measured 
once daily from three days pre -injection (Day -3) to 15 days post -injection (Day 15) 
of FCA (n =5 rats) or sterile paraffin (n =4 rats) into the knee joint (injections were 
made on Day 0). 
4.2.2.1 Statistical analysis 
To determine whether there were any differences between FCA and paraffin injected 
groups, the cumulative change from a selected control period in body weight, 
hindlimb weight bearing and joint swelling was determined. The control period was 
the mean of the measurements on Days -2 and 0, and this was subtracted from the 
mean of the measurements on Days 1,2,4 and 8. Data was analysed using an unpaired 
t -test. 
4.3 RESULTS 
4.3.1 AFFERENT NERVE RECORDINGS IN VIVO 
4.3.1.1 Characterisation of afferent nerve fibres 
Neural discharge was recorded from 165 afferent fibres innervating 80 normal knee 
joints and 82 afferent fibres innervating 24 arthritic knee joints. The afferents were 
classified as C -fibre polymodal nociceptors or Aö- mechanoreceptors based on their 
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conduction velocities, mechanosensitivity and whether or not they were activated by 
the algogen capsaicin. 
C -fibre polymodal nociceptors had slow conduction velocities (1.07 ±1.03ms 1), were 
excited by capsaicin (3- 30nmol i.a.), and could be activated by probing the knee joint 
capsule with a hand held plastic probe (Figure 4.1 and see Section 4.3.1.3 below). 
M-mechanoreceptors had faster action potential conduction velocities (4. 70 ±0.77ms 
1) and did not respond to capsaicin. 63% (104/165) of afferents innervating normal 
knee joints and 54% (44/82) innervating arthritic knee joints were C -fibre polymodal 
nociceptors and 37% (61/165) of afferents innervating normal knee joints and 46% 
(38/82) innervating arthritic knee joints were AS- mechanoreceptors. A small number 
of Aß- mechanoreceptors were also identified (low threshold mechanosensitive units 
with conduction velocities greater than 10ms-1 that were not activated by capsaicin), 
but these were not studied. The rats used in these experiments were used in 
subsequent investigations of the role of ATP and adenosine in nociception and 
inflammatory pain. Because ATP is released from cells by non -specific membrane 
perturbations (see General Introduction), mechanical stimulation of the joints was 
kept to a minimum and mechanical thresholds were not systematically determined to 
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Figure 4.1 Response evoked from a single C-fibre polymodal nociceptor (far 
right) by a) by mechanical stimulation of the knee joint with a hand-held plastic 
probe (at arrois) and b) close -arterial injection of capsaicin (10nmol, at arrow). 
4.3.1.2 Basal discharge of nociceptors Innervating normal and arthritic joints 
Previous electrophysiological studies have shown that there are two characteristic 
features of the basal discharge of afferents innervating adjuvant arthritic joints in 
comparison with normal joints. Firstly, nerves innervating arthritic joints have a 
higher proportion of afferents with basal discharge and secondly, the rate of 
discharge of those afferents which are spontaneously active is higher in arthritic 
joints (Guilbaud et al., 1985). In the present investigation, AS- fibres innervating 
normal knee joints (n =61) were always silent, and in arthritic joints only 3 of 38 
(8 %) AS afferents were spontaneously active (Figure 4.2 and Figure 4.3). In contrast, 
16% (17/104) of C -fibre polymodal nociceptors innervating normal knee joints had 
on -going discharge, whereas 32% (14/44) of those innervating arthritic joints were 
spontaneously active and discharged at a significantly (P <0.05) higher rate (Figure 
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Figure 4.2 Proportion of a) A8-- mechanoreceptors and b) C -fibre polymodal 
nociceptors with spontaneous discharge innervating normal (first panel) and 
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Figure 4.3 Spontaneous discharge rate of a) A8- niechanoreceptors and b) C- 
fibre polymodal nociceptors innervating normal and arthritic joints. Cohtnins 
represent mean+±sem. Normal joints: AS-fibres none with basal discharge, C- fibres 
ii= 17; arthritic joints: AS-fibres n =3, C- fibres ii= 1 í. *P <0.05, Impaired t -test; 
higher frequency in C fibres innervating arthritic compared to normal joints. 
4.3.1.3 Capsaicin and bradykinin- evoked excitation of C -fibre nociceptors 
innervating normal and arthritic joints 
Capsaicin (3- 30nmol, i.a.) evoked a fast onset, high frequency, transient response 
from all C- fibres innervating normal and arthritic knee joints (Figure 4.1 and Figure 
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4.4). No significant difference between the responses from nociceptors innervating 
normal compared to arthritic joints was evident. 
Bradykinin (2- 30nmol, i.a.) evoked a delayed onset, long lasting increase in action 
potential discharge from 88% (48/54) and 71% (17/24) of C- fibres innervating 
normal and arthritic joints respectively (Figure 4.4). There was no significant 
difference between the onset latency and magnitude of the excitation in C- fibres 
innervating normal compared to arthritic joints (Figure 4.4). However, the duration 
of the bradykinin response in arthritic joints was significantly (P <0.05) prolonged 
compared to normal joints (Figure 4.4) resulting in an increase (although not 
statistically significant) in the total number of action potentials firing in arthritic 
joints (Figure 4.4). None of the AS- fibres recorded from were activated by the kinin. 
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Figure 4.4 Capsaicin (3nnlol, figures on the left) and bradykinin (9llmol, figures 
on the right) evoked excitation of C -fibre polymodal nociceptors innervating the 
normal and arthritic knee joints. Latency to onset (a), duration (b), changes in 
action potential frequency (c) and number (d) are shown. Data are from experiments 
in which capsaicin and bradykinin were alternately the first and second drug 
injected. Cohinins represent mean em. Capsaicin: normal joints 11 =6, arthritic 
joints n =15; bradykinin: normal joints n =10, arthritic joints 11 =9. *P <0.05 unpaired 
t -test; longer duration of bradykinin response in arthritic versus normal joints. 
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4.3.2 BEHAVIOURAL STUDIES 
4.3.2.1 Body weight 
The mean body weight of rats injected into the left knee joint with FCA (0.15m1 of 
lmg ml i.art) was similar to that of rats injected with sterile paraffin oil (0.15m1, 
i.art) up to Day 8 post- injection (Figure 4.5a). There was no statistically significant 
difference when the data was expressed as the mean cumulative change in weight 
from control (Figure 4.5b). 
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Figure 4.5 Body weight of rats injected i.ari. into the left knee joint with FCA 
(0.15/1 of ling riiti suspension) or sterile paraffin oil (0.15m1). Part a) shows the 
change in weight for the duration of the trial and part b) shows the cumulative 
change in body weight from control period (mean of Days -2 and 0, and change was 
determined over Days 1, 2, 4 and 8). Each data point /coluinii represents mean sein. 
FCA group ii =5 animals, paraffin group n=4 animals. 
4.3.2.2 Allodynia 
Following injection of paraffin oil into the left knee joint, there was a small shift in 
hindlimb weight bearing from the left to the right hindlimb (Figure 4.6a). In the FCA 
group, this shift was pronounced and significant (Figure 4.6b), and was manifest as a 
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Day before and after injection 
Figure 4.6 Hindlimb weight bearing on the left and right hindlimbs of the a) 
paraffin -injected and b) FCA- injected groups. Each data point represents 
nleanenl. ***P<0.001 unpaired t -test. Paraffin group rl =4 animals, FCA group 
11 =5 animals. 
To compare differences in hindlimb weight bearing between the two groups, 
cumulative change in weight from control was determined. There was a significant 
(P <0.01) difference between weight bearing on both the contralateral and ipsilateral 
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Figure 4.7 Ciinnrlative change from control period in a) contralateral and b) 
ipsilateral hindlimb weight bearing: effect of paraffin (0.15n)1, i. art. left knee joint) 
and FCA (0.15n11 of 0. 15mg nit' suspension, i.art. left knee joint). Cohanr)s represent 
nleanjsenl. Control was mean of Days -2 and 0, and change was determined over 
Days 1, 2,4,amid 8. * * *P <0.001, * *13<0.01 FCA vs vehicle, unpaired t -test. 
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4.3.2.3 Knee joint diameter 
Subjective examination of the rats showed that there was substantial swelling of the 
FCA- injected, but not the paraffin or contralateral knee joints, which was particularly 
evident up to Day 2 post- injection. Quantitative measurement of the arthritic rats 
confirmed that there was swelling of the FCA -injected knee joint compared to the 
contralateral knee joint, whereas in the control rats, the diameter of the paraffin - 
injected knee was similar to that of the contralateral knee (Figure 4.8). Cumulative 
data is shown in Figure 4.9 and confirms that there was significant (P <0.0001) 
swelling in the ipsilateral joint of the FCA group compared with that of the paraffin 
group, whereas there was no significant difference between the injected and non - 
injected knees of the paraffin group. 
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Figure 4.8 Contralateral and ipsilateral knee joint diameter of the a) paraffin- 
injected (0.15m1, i.art. left knee joint) and b) FCA-injected (0.15m1 of 0.15mg ml-t 
suspension, i. art. left knee joint) groups. Data points represents meanem. Paraffin 
group n=4 animals, FCA group n =5 animals. ***P>0.001, * *P <0.01 ipsilateral vs 
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Figure 4.9 Cumulative change from control period in a) contralateral and b) 
ipsilateral knee joint diameter: effect of paraffin (0.15m1, i.art. left knee joint) and b) 
FCA (0.151111 of 0.1 Sing 111T1 suspension, i.art. left knee joint). Colrain represent 
mean±s em. Control was mean of Days -2 and 0, and change was determined over 
Days 1, 2, 4 and 8. * * *P <0.0001 unpaired t -test vs vehicle. 
4.3.3 HISTOLOGICAL STUDIES 
Sections of injected and non -injected knee joints from 4 arthritic and 4 control (2 
paraffin- injected and 2 normal) rats (14 days post- injection) were stained using 
haematoxylin and eosin by Ms. H. Caldwell and examined using light microscopy by 
Dr. D.S. Salter (both from The Department of Pathology, University of Edinburgh). 
The histological studies confirmed the presence of an inflammatory cell infiltrate, 
synovial proliferation, fibroplastia and new bone formation in the arthritic knee joints 
(photographs not shown in this thesis). The contralateral knee joints showed no signs 
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of an inflammatory pathology and resembled the left and right knee joint of the 
control rats. 
4.4 DISCUSSION 
The main finding of the electrophysiological recordings in this study is that more C- 
fibre polymodal nociceptors innervating the FCA- injected rat knee joint were 
spontaneously active and fired at a higher rate than those innervating normal knee 
joints. These properties are characteristic of nociceptors innervating arthritic rat 
ankle joints (Guilbaud el al., 1985) and inflamed cat knee joints (Schaible & 
Schmidt, 1985). In the behavioural studies, the FCA- injected animals consistently 
shifted their body weight onto the contralateral hindlimbs indicating that they were 
experiencing discomfort in the injected joint, and the FCA- injected knee joints were 
significantly swollen compared to paraffin- injected or non -injected knees. In 
addition, histological studies revealed signs of an inflammatory reaction including 
the presence of inflammatory cell infiltrates and synovial hypertrophy. These 
findings confirm that i.art. injection of FCA into the rat knee joint induces an 
arthritic lesion confined to the ipsilateral knee joint. 
Histological studies have shown that the MAN innervating the cat's knee 
joint contains approximately equal numbers of afferent and sympathetic efferent 
fibres (Langford & Schmidt, 1983). Approximately 70% of the afferents axons are 
unmyelinated (C- fibre) and 21% are thinly myelinated (AS- fibre), whereas only 9% 
have large myelinated (Aß- fibre) axons. In the present study, 63% of all rat MAN 
afferents recorded from were C -fibre polymodal nociceptors and the remainder 
(37 %) were AS -fibre mechanoreceptors. A small number of fibres conducting in the 
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Aß -fibre range were also identified but these were not studied. These proportions 
reflect the histological findings of Langford and Schmidt (1983). No efferent neural 
activity was recorded because the saphenous nerve was cut centrally to ensure all 
discharge was from afferent fibres only. These findings validate this knee joint 
electrophysiological preparation as a viable method of recording from the rat MAN. 
By definition, nociceptors detect potentially tissue damaging stimuli or existing 
tissue damage (see General Introduction). The C -fibre afferents recorded from in the 
present study were undoubtedly nociceptive because they were activated by the pain - 
producing substance, capsaicin, a property that is frequently used to identify 
nociceptors. Furthermore, the majority (70 %, see Schaible & Schmidt, 1996) of C- 
fibres innervating the cat knee joint are thought to serve nociceptive functions. 
However, it is not possible to say definitively whether the AS- mechanoreceptors 
recorded from were nociceptors because no stimuli known to activate knee joint AS- 
fibre nociceptors were applied (for example, high threshold mechanical stimulation 
or extreme knee joint movements, see Coggeshall et al., 1983; Schaible & Schmidt, 
1983a,b). Mechanical thresholds were not investigated in the present study to avoid 
tissue desensitisation, and responses to joint movements were not determined 
because the recording electrodes are located very near to knee joint in the rat 
preparation (approximately 8 -10mm) and manipulations of the knee joint would have 
dislodged them. Despite the limitations of the present study with regard to 
classification of AS -fibre function, studies of the cat knee joint have shown that 55% 
of MAN AS- fibres are nociceptive while the remainder serve proprioceptive 
functions (see Schaible & Schmidt, 1996). Thus, it is not unreasonable to assume that 
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approximately half of the MAN AS- fibres innervating the rat knee joint are also 
nociceptors. 
In FCA- injected rat knee joints (14 -21 days post- injection), twice as many C -fibre 
polymodal nociceptors were spontaneously active compared to normal joints, and 
they had significantly higher (although still low) resting discharges. Previous 
electrophysiological studies of afferents innervating inflamed knee joints have been 
carried -out following kaolin and carrageenan- induced acute inflammation in the cat 
(Coggeshall et al., 1983; Schaible & Schmidt, 1985). In this model, more than twice 
as many C- fibres and AS- fibres are spontaneously active and these have basal 
discharge frequencies more that twice as high as afferents innervating normal knee 
joints. This contrasts with the finding of the present study where very few AS- fibres 
(8 %) innervating FCA- injected joints were spontaneously active. Interestingly, 
Schaible and Schmidt (1988), have reported that some Aß and AS- fibres innervating 
the cat knee joint become spontaneously active within the first hour after inducing an 
acute inflammation, whereas there is a delay of a few hours before C- fibres and other 
populations of AS- fibres display resting discharge. It is possible that the presence of 
spontaneously active C- fibres but not AS- fibres innervating the rat knee joint 2 -3 
weeks following the induction of arthritis reflects differences in the sensitisation or 
recruitment of different sub -classes of nociceptors at different times during the 
development of arthritis. It is not feasible to verify this because it would require 
continuous recording MAN activity in anaesthetised rats over a 2 -3 week period. 
Another feature of nociceptors innervating arthritic or inflamed joints is that they 
have reduced thresholds and increased responsiveness to stimuli such as mechanical 
probing or joint movements (Coggeshall et al., 1983; Guilbaud et al., 1985; Schaible 
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& Schmidt, 1985) but this was not studied in the present investigation for reasons 
given above. 
It has also been reported that C -fibre polymodal nociceptors innervating adjuvant - 
arthritic rat ankle joints have an increased sensitivity of the algogen capsaicin, and a 
reduced sensitivity to bradykinin ( Asghar, 1995). The former was attributed to the 
sensitising actions of inflammatory mediators, whereas desensitisation or down - 
regulation of bradykinin receptors due to elevated levels of endogenous bradykinin 
during inflammation was implicated in the latter. However, in the present study, the 
excitation of rat knee joint C -fibre nociceptors by capsaicin was similar in normal 
and arthritic joints, and the discharge elicited by bradykinin had a longer duration in 
arthritic joints. Interestingly, the enzymes responsible for bradykinin degradation are 
inhibited by acidic pH, such as would be expected to occur during inflammation 
(Edery & Lewis, 1962). This could explain why the bradykinin response duration 
was increased in arthritic joints. However, if high endogenous bradykinin levels 
cause articular receptor desensitisation or down regulation, a reduced response to the 
kinin would have been expected in arthritic joints. Because this was not observed, 
this may indicate that the arthritic lesion in the knee joint was not as severe as that in 
the ankle joint. This would also explain why no sensitisation to capsaicin was 
detected. Consistent with this, Asghar (1995) reported higher spontaneous discharge 
rates of C- fibres innervating arthritic ankle joints (3.4 ±0.46 impulses s-1, n =198 C- 
fibres), compared to that found in the present study in C- fibres innervating arthritic 
rat knee joints knee joints (0.93 ±0.35 impulses s-1). 
In the present behavioural studies, rats that had received an i.art. injection of FCA 
consistently limped or had a three -legged gait suggesting that walking, which is 
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normally painless, was painful after induction of arthritis. The FCA- induced 
allodynia was quantified using a weight bearing device which was recently validated 
as a method of assessing allodynia in rats (Clayton et al., 1997). While the subjective 
observation of the rats gave an indication of "walking allodynia ", the quantitative 
measurement assessed "standing allodynia ", that is, the pain caused by placing 
weight on the injected limb. The arthritic rats redistributed their body weight such 
that most of it was placed on the non -injected hindlimb. Control rats that were 
injected i.art. with sterile paraffin oil also shifted their weight slightly (but not 
significantly) from the ipsilateral hindlimb which probably reflects some tissue 
damage following the insertion of a needle through the infrapatellar ligament. The 
allodynia experienced by the arthritic rats was significantly greater than that 
experienced by the control rats and remained consistent throughout the duration of 
the study. 
FCA also induced swelling in the ipsilateral knee joints that was very pronounced in 
the first two days and subsided to a plateau by the fourth day post- injection. Early 
swelling that drops to a constant but significantly swollen level is a common feature 
of FCA- induced arthritis in the rat ankle joint (Asghar, 1995). Both the early and late 
swelling is reduced by known anti -inflammatory agents and the ability of novel 
agents to reduce it is a method of investigating their anti -inflammatory properties. In 
the present study, the injected knee joint was significantly swollen relative to the 
contralateral knee joint or the paraffin- injected knee joints for the duration of the 
study. However, the difference between the inflamed and non -inflamed joints was 
very small after the initial swelling had subsided. Thus, the potential anti- 
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inflammatory properties of agents would be more easily determined in the early 
phase of adjuvant- induced arthritis in the knee joint. 
The data obtained from the electrophysiological and behavioural studies, in addition 
to the results of the histological studies, confirms that FCA induces a mild 
monoarthritis in the rat knee joint. The overall aim of this investigation was to assess 
the value of the electrophysiological preparation and the monoarthritic model for 
further study into the role of ATP and adenosine in nociception and inflammatory 
pain. 
One of the main disadvantages of this study is that different aspects of inflammatory 
pain were quantified in the neural and behavioural studies: in the former, 
spontaneous discharge, the neural correlate of spontaneous pain was recorded, 
whereas in the latter, standing allodynia was assessed. Thus, it is not possible to state 
which afferents are involved in signalling pain produced by weight bearing on the 
inflamed knee joint. However, during acute inflammation of the cat knee joint, 
almost all of the C- and AS- fibre nociceptors respond to innocuous movements and 
low threshold mechanical stimulation, indicating that they play a role in causing 
articular allodynia (see Schaible & Schmidt, 1996). Therefore it is reasonable to 
assume that the thinly myelinated afferents innervating the rat knee joint also 
contribute to allodynia. The behavioural correlate of elevated spontaneous discharge, 
spontaneous pain was not assessed in this investigation because it is difficult to 
quantify and has been the subject of some debate (Colpaert, 1987). It would have 
been relatively easy to assess the neural and behavioural components of mechanical 
hyperalgesia but this was not done because the clinical relevance of mechanically 
probing the knee joint is questionable. 
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The data indicates that the electrophysiological preparation is a viable method of 
recording from nociceptive C -fibre afferents innervating the rat knee joint. However, 
without further characterisation of the AS- fibres, it is not possible to state 
unequivocally whether they are nociceptive or proprioceptive. Functional 
classification of the afferents would be facilitated if the electrophysiological 
preparation was developed to allow the joint position to be manipulated during the 
experiments (perhaps using a modified version of the model described for the cat 
(Schaible & Schmidt, 1983a,ó). This type of stimulation is more clinically relevant in 
comparison to mechanically probing the joint because the afferents signalling the 
normal movements of the joint can be identified. 
The monoarthritis model is limited as a means to investigate the potential therapeutic 
properties of purine compounds for a number of reasons. The spontaneous discharge 
of nociceptors innervating arthritic joints was very low (0.93 ±0.35 impulses s-1), 
which would make any reductions caused by peripherally- acting compounds with 
putative analgesic effects difficult to assess. For a similar reason, the effect of 
potential anti -inflammatory compounds on the swelling induced by FCA would be 
difficult to determine. Interestingly, the degree of ankle joint monoarthritis induced 
by FCA in the rat is determined by the dose of adjuvant used (Donaldson et al., 
1993). Thus, it would be useful to determine whether higher doses injected into the 
knee would cause a more severe inflammation with higher basal discharge and more 
swelling. Finally, there is currently no means of determining the effects of potential 
analgesic compounds on discharge evoked by quantified innocuous or noxious 
stimulation (the correlates of allodynia or hyperalgesia respectively), which could be 
determined if the neural preparation was developed to allow the joint to be moved. 
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In conclusion, this study confirmed that i.art. injection of FCA into the rat 
knee caused a mild monoarthritis confined to the joint. However, in order to fully 
exploit the potential of the knee joint in pain studies it is recommended that different 
doses of FCA are used to try to induce a more severe arthritic response, and that 
electrophysiological preparation be developed to allow the joint to be moved during 
the recording. 
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Chapter 5: The direct role of ATP in knee joint nociception 
5.1 INTRODUCTION 
One of the primary aims of treating RA is to improve the quality of life of patients 
by providing relief from the chronic pain associated with the condition. The most 
effective analgesic compounds used to treat RA pain are the NSAIDs, but their 
prolonged use is associated with severe side effects including renal dysfunction 
(Lifschitz, 1983) and gastrointestinal bleeding (Goodwin, 1987) which may give rise 
to anaemia (Davies et al., 1996). The other agents used to treat RA (including 
corticosteroids, methotrexate, sulfasalazine, gold, D- penicillamine and 
hydroxychloroquine) are primarily aimed at reducing inflammation and preventing 
joint destruction, and they have little or no inherent analgesic properties (Schiff, 
1997). The inadequacies of the current treatments provide the motivation to search 
for novel analgesics to provide relief from the pain of RA. 
Knee joint pain and tissue damage are common in RA (Sculco, 1998). The 
development of novel analgesics for articular pain would be facilitated if the 
mechanisms responsible for its production were fully understood. The knee is 
innervated by sensory nerves arising in the DRG where mRNA for six of the ATP - 
gated ion -channel receptor subtypes (P2X1_6) are expressed (Collo et al., 1996). ATP 
has long been known to cause cutaneous pain (Bleehen & Keele, 1977; Keele & 
Armstrong, 1964) and, if ATP acting on P2X receptors is involved in mediating joint 
pain, then this would have implications for the treatment of RA pain. 
There is compelling indirect evidence that P2X receptors in the DRG might 
be involved in sensory signalling. In the rat, mRNA for the P2X3 subtype is 
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selectively expressed in sensory ganglia (Collo et al., 1996) and within the DRG the 
message is localised to small diameter afferent neurones commonly associated with 
nociception (Chen et al., 1995). These findings have led investigators to believe that 
P2X receptor subtypes might be involved in the initiation of pain (Burnstock, 1996; 
Burnstock & Wood, 1996). It is known from studies on dissociated cells in culture 
that ATP gates an inward current in DRG neurones (Bean, 1990; Bean et al., 1990; 
Bouvier et al., 1991; Jahr & Jessell, 1983) which has recently been shown to be 
mediated by P2X subtypes (Lewis et al., 1995). However, there is some concern that 
this functional expression of P2X receptors might be an experimental artefact 
induced by the dissociation of neurones and subsequent maintenance in the in vitro 
artificial environment (Stebbing et al., 1998). These authors reported that very few 
DRG neurones were depolarised by P2X receptor agonists when dorsal ganglia, 
dorsal roots and sciatic nerve are maintained together in vitro. In contrast, most of 
the cells displayed a P2X- mediated response when the DRG neurones were 
dissociated. In order to establish whether P2X receptors might be involved in the 
initiation of joint pain, it is crucial to determine whether functional receptors are 
expressed on the peripheral terminals of articular nociceptive afferents in vivo. 
The two electrophysiological studies focusing on P2X mediated excitation of 
nociceptive afferents in vivo have provided no evidence that functional P2X 
receptors are expressed on nociceptors (Dowd et al., 1997; Matthews et al., 1997). 
This is supported by the behavioural data presented in Chapter 3 of this thesis where 
aßmeATP did not evoke nociceptive responses when instilled into the eye (Dowd et 
al., 1997). However, these reports conflict with reports that aßmeATP elicits painful 
behaviours when it is injected into the rat footpad (Bland -Ward & Humphrey, 1997). 
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If it can be shown that functional P2X receptors are present on nociceptive 
terminals in vivo, it follows that ATP might be a directly- acting endogenous mediator 
of inflammatory pain. Levels of the nucleotide are increased in inflamed or damaged 
tissues (Gordon, 1986) and it is present in the synovial fluid of patients with arthritis 
(Park et al., 1996; Ryan et al., 1991). Furthermore, during RA, synovial pH falls 
(Farr et al., 1985) and levels of substance P are increased (Marshall et al., 1990); 
factors that enhance the actions of ATP on dissociated sensory neurones in vitro (Hu 
& Li, 1996; Li et al., 1996). Thus, locally released ATP may contribute to pain by 
acting on P2X receptors associated with nociceptive afferents in the joint, and this 
action could be enhanced in inflammatory conditions such as arthritis. 
The aim of this study was to test the hypothesis that functional P2X receptors 
are expressed on rat knee joint nociceptors, and to investigate whether any excitation 
is modified in afferents innervating monoarthritic joints. Neural discharge was 
recorded from nociceptors innervating normal and arthritic rat knee joints and the 
response to locally injected ATP and ATP analogues was measured. aßmeATP was 
the main ATP analogue used in this study for two reasons: it is resistant to 
metabolism by extracellular ATP metabolising enzymes and it is a relatively 
selective agonist for the P2X1 and P2X3 receptor subtypes. In addition, cell bodies of 
knee joint afferents in the DRG were labelled with the retrograde fluorescent tracer, 
fluorogold, and sections of labelled DRGs were subsequently stained with P2X3 
receptor antibodies to determine whether P2X3 receptors are expressed in knee joint 
neurones. 
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5.2 METHODS 
5.2.1 AFFERENT NERVE RECORDINGS IN VIVO 
Arthritis induction and neural recordings were carried out as described in Section 
2.1.2. A total of 58 normal and 24 arthritic rats (weight range 240 -380g; mean±sem 
323 ±9g; arthritis induced 14 -21 days before the experiments) were used in the 
present investigation. Animals were anaesthetised with pentobarbitone (60mg.kg I 
i.p., supplemented hourly i.v.) and they were prepared surgically as described. Neural 
activity in small filaments of the MAN was recorded and data was analysed off -line. 
In most experiments, drugs were administered by close -arterial injection via a 
cannula in the right femoral artery, but in a small number, they were injected i.art. 
into the knee joint in a volume of 0.1m1. 
5.2.2 IMMUNOHISTOCHEMICAL STUDIES 
Retrograde labelling and immunohistochemical studies were carried out as described 
in Section 2.4. Briefly, sections of the left and right DRGs (at levels L3, L4 and L5) 
of 4 control (2 normal and 2 paraffin- injected) and 4 arthritic (2 weeks arthritic) rats 
were immunohistochemically stained for P2X3 immunoreactivity using Vector Red 
or DAB as chromogens. In one arthritic rat, the cell bodies of knee joint afferents in 
the DRG were retrogradely labelled by injection of fluorogold into both knee joints 
of one rat one week post- induction of arthritis and the DRG were removed one week 
later. 
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5.2.3 DETERMINATION OF ATP CONCENTRATION IN SYNOVIAL PERFUSATE 
Withdrawal of synovial fluid for determination of ATP concentration was performed 
as described in Scetion 2.4. Briefly, normal and arthritic male Wistar rats were 
anaesthetised with pentobarbitone (60mg kg "' i.p.) and two 26 -gauge needles were 
inserted into the joint. lml of 1mM EDTA was injected into the knee joint via one 
needle and the perfusate was aspirated from the hub of the other. Samples were 
immediately centrifuged and the supernatant was stored at -70 °C. 
5.3 RESULTS 
5.3.1 AFFERENT NERVE RECORDINGS IN VIVO 
5.3.1.1 Characterisation of afferent nerve fibres 
Neural discharge was recorded from a total of 114 afferent fibres innervating 58 
normal knee joints and 82 afferent fibres innervating 24 arthritic knee joints. The 
afferents were classified as C -fibre polymodal nociceptors or A6 -fibre 
mechanoreceptors based on their conduction velocities, mechanosensitivity and 
sensitivity to capsaicin (see previous chapter, Section 4.3.1.1.). Of the afferents 
recorded, 66% (75/113) from normal joints and 50% (41/82) from arthritic joints 
were classified as C -fibre polymodal nociceptors, and 34% (38/113) from normal 
joints and 50% (41/82) from arthritic joints were classified as AS -fibre 
mechanoreceptors. 
5.3.1.2 aßmeATP- evoked excitation of articular afferents 
5.3.1.2.1 Proportion of afferents activated by aßmeATP 
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The P2X1 and P2X3 receptor agonist, aßmeATP (1 -600 nmol, injected i.a., evoked a 
rapid onset, short duration increase in action potential discharge in 43% (32/75) of C- 
fibres and 84% (16/19) of AS- fibres on which it was tested in normal joints, and 44% 
(11/25) of C- fibres and 63% (24/38) of AS- fibres in arthritic joints (Figure 5.1 and 
Figure 5.2). The nucleotide vehicle, PBS (0.1m1 i.a.) did not stimulate any of the 
afferents on which it was tested (change in discharge frequency 0.02 ±0.1 impulses s-1 











Figure 3.1 Neural discharge (first panel) showing the response evoked from a 
filament of the MAN innervating a normal knee joint by close -arterial injection of a) 
aßmeATP (60rimol, activated units 1 & 2). The excitation evoked by b) capsaicin 
(10mnol, activated units 3 & 4) and c) bradykinin (9 nmol, activated unit 3) are 
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Figure 5.2 Pie charts showing the proportion of a) C-fibre polymodal 
nociceptors and b) AS -fibre inechanoreceptors activated by a/3meATP (1- 600nmol 
i.a.) in normal (first panel) and arthritic knee joints (second panel). 
5.3.1.2.2 Dose -related increase in action potential discharge evoked by aßmeATP 
Four C- fibres and four AS- fibres from normal joints, and three C- fibres and two AS- 
fibres from arthritic joints were tested for dose -dependent effects of aßmeATP. The 
P2X receptor agonist evoked a dose -related increase in action potential discharge in 
both fibre types (Figure 5.3) but it was difficult to establish the true maximum 
response to the agonist because injection of high doses ( >200 nmol) caused receptor 
desensitisation and marked cardiovascular and ventillatory effects (McQueen et al., 
1998). Consequently, apparent ED50 values for activation of C -fibres and AS- fibres 
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Figure 5.3 Typical log dose -response curves showing the dose related increase in 
action potential discharge frequency evoked by close -arterial injection of aßmeATP 
in a) a single C- fibre polymodal nociceptor innervating a normal knee joint and b) a 
single AS -fibre mechanoreceptor innervating an arthritic joint. 
The mean apparent ED50 for aßmeATP- evoked excitation of C- fibres was not 
significantly different to that of AS- fibres, nor was there any significant difference 
between the mean apparent ED50 values of the nucleotide in normal and arthritic 
joints Table 5.1. 
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Table 5.1 Mean apparent ED50 (nnrol) for aßmeATP mediated excitation of 
afferents innervating the normal and arthritic rat knee joint. Mean em. No 
significant differences between means were found using the Mann - Whitney test. 
Normal joints Arthritic joints 
C -fibre polymodal nociceptors 
AS- mechanoreceptors 
41±34, n=4 96±17, n=3 
26±8, n=4 47±22, n=2 
5.3.1.2.3 Features of the aßmeATP- evoked response 
The delay to onset, duration and magnitude of the excitation caused by a single dose 
of aßmeATP (60nmol, i.a.) was studied in more detail. The data was analysed to 
determine 1) whether there were any differences between the responses evoked from 
afferents innervating normal compared to arthritic joints and 2) whether the 
responses evoked from C- and AS- fibres were similar. 
5.3.1.2.3.1 Onset -latency 
aßmeATP rapidly activated the knee joint neurones following injection into the 
lower abdominal artery (Figure 5.1). Figure 5.4 shows the pooled data from C -fibre 
polymodal nociceptors and AS -fibre mechanoreceptors innervating normal and 
arthritic joints. The latencies were similar in C- fibres and AS- fibres, and were not 
significantly changed in arthritic joints. 
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a) b) O Normal Joints 
1.25- ®Arthritic Joint 
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Figure 5.4 Pooled data showing the response onset latency in a) C -fibre 
polymodal nociceptors and b) A8-fibre mechanoreceptors following injection of 
aßmeATP (60nn1ol i.a.) in normal and arthritic joints. Columns represent 
meanem. C fibres: normal joints n =5, arthritic joints 11 =9; AS fibres: normal 
joints n =11, arthritic joints n =9. 
5.3.1.2.3.2 Duration 
The nucleotide transiently increased action potential discharge in knee joint articular 
fibres (Figure 5.5). As shown in Figure 5.5, there was no significant difference 
between the response duration in each fibre type between normal or arthritic joints. 


























Figure 5.5 Pooled data showing the response duration in a) C -fibre polymodal 
nociceptors and b) A5-fibre mechanoreceptors following injection of aßmeATP 
(60mno1 i. a.) in normal and arthritic joints. Columns represent meanisem. C- fibres: 
normal joints 11 =5, arthritic joints 11 =9; ACS fibres: normal joints 11 =11, arthritic 
joints n =9. 
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5.3.1.2.3.3 Magnitude 
To take into account the transience of the response to aßmeATP, the instantaneous 
discharge frequency and the total number of action potentials that fired were 
quantified. As with the response latency and duration, there was no significant 
difference between the action potential discharge frequency or number of action 
potentials that fired following close- arterial injection of aßmeATP in normal or 
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Figure 5.6 Pooled data showing the change in a) the action potential discharge 
frequency and b) the total number of action potentials that fired from C -fibre 
polymodal nociceptors (i) and A8 -fibre mechanoreceptors (ii) following injection of 
aßmeATP (60imrol i.a) in normal and arthritic joints. Columns represent 
meanisem. C-fibres: normal joints n =5, arthritic joints n =9; A8 fibres: normal 
joints n =11, arthritic joints n =9. 
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5.3.1.3 ATP -evoked excitation of articular afferents 
5.3.1.3.1 Proportion of afferents activated by ATP 
The endogenous ligand for P2X receptors, ATP (2000nmo1, La.), evoked a rapid - 
onset, short- lasting increase in action potential discharge in 40% (6/15) of C- fibres 
and 69% (9/13) of AS- fibres on which it was tested in normal joints, and 38% 
(14/37) of C- fibres and 39% (15/38) of AS- fibres in arthritic joints (Figure 5.7 and 
Figure 5.8). It also caused a delayed activation of nociceptive afferents as can be 
seen in Figure 5.7. This was probably due to the metabolism of ATP to adenosine by 
ecto -nucleotidases (Dowd el al., 1998a). The slow excitatory response and the 
afferent populations excited by ATP during the fast and slow -onset components will 
be discussed in more detail in the next chapter (and see final discussion). Preliminary 
investigations revealed that lower doses of ATP did not excite the afferents (data not 











Figure 5.7 Neural discharge first panel) showing the response evoked from a 
filament of the MAN by close -arterial injection of a) ATP (2000nmol, activated units 
1 & 2 during the fast response and units 3 & 4 during the slow response), b) 
capsaicin (10nmol, activated unit 3 & 4) and c) bradykinin (9 mol, activated unit 3). 
The afferent fibres that responded are shown (second panel). Note that different units 
were excited during the fast and slow components. 
a) 
b) 
O Non- responsive 
O Responsive 
Figure 5.8 Pie charts showing the proportion of a) Gftbre polymodal 
nociceptors and b) AS -fibre mechanoreceptors that were rapidly activated by ATP 
(2000nmol i. a.) in normal (first panel) and arthritic knee joints (second panel). 
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5.3.1.3.2 Features of the ATP -evoked response 
As was observed for the excitation caused by aßmeATP, the latency, duration and 
magnitude of the fast response evoked by ATP (2000nmol) were similar in C- and 
AS- fibres (separate data not shown). In order to assess the effect of adjuvant arthritis 
on this excitation, the data was pooled from both fibre types. No significantly 
differences were found between normal and arthritic joints respect to the delay, 
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Figure 5.9 Pooled data showing the a) response onset latency and b) response 
duration following injection of ATP (2000nmol i.a.) ill afferents innervating normal 
and arthritic joints. Columns represent lnean±sem. Normal joints 11 =7 afferents; 










Figure 5.10 Pooled data showing the change in a) the action potential discharge 
frequency and b) the number of action potentials firing in afferents innervating 
normal and arthritic joints following injection of ATP (2000nmol i.a.). Colinnns 
represent nieaniseni. Normal joints ii= 7 afferents; arthritic joints n =7 afferents. 
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5.3.1.4 Comparison between the aßmeATP and ATP -evoked excitations 
During experiments in which aßmeATP (60nmol i.a.) and ATP (2000nmol i.a.) were 
both tested, fibres which were excited by aßmeATP also invariably responded to 
ATP (normal joints n =26 afferents; arthritic joints n =37 afferents) and there was no 
significant difference between the responses evoked by the two nucleotides with 
respect to response onset latency, duration or size (Figure 5.11 and Figure 5.12). 
a) b) 
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Normal Joints Arthritic Joints 
Figure 5.11 Pooled data showing the a) latency and b) duration of the response 
following injection of aßmeATP (60nmol i.a) and ATP (2000nmol i.a) in afferents 
innervating normal and arthritic joints. Cohmms represent meanisem. Normal 
joints: aßmeATP n =14 afferents; ATP 11=7 afferents; arthritic joints: aßmeATP 
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Normal Joints Arthritic Joints 
Figure 5.12 Pooled data showing the change in a) the action potential discharge 
frequency and b) the number of action potentials firing in afferents innervating 
normal and arthritic joints following injection of aßmeATP (60nmol) and ATP 
(2000nmol i.a.). Cohtmns represent mean. em. Normal joints: ofteATP n =14 
afferents; ATP 11 =7 afferents; arthritic joints: aßmeATP n =15 afferents; ATP n =7 
afferents. 
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5.3.1.5 Factors affecting the ATP- evoked excitation 
In three experiments, normal saline (NaCI 0.9% (w /v) in distilled water) was 
acidified (pH 4) by perfusing with CO2 and the resulting carbonic acid was injected 
(0.2ml i.a., n =3 afferents) lOs before ATP. In two separate experiments, the effect of 
injecting substance P (20nmol i.a., n =3 afferents) lOs before ATP was investigated. 
Neither pre -injection significantly affected the ATP- evoked excitation (data not 
shown). 
5.3.1.6 Comparison between the nucleotide and known algogen- evoked 
excitations 
The increases in C -fibre polymodal nociceptor discharge caused by aßmeATP and 
ATP were compared to those evoked by the potent exogenous and endogenous 
algogens, capsaicin (10nmol) and bradykinin (9nmol) respectively. Figure 5.1 and 
Figure 5.7 clearly show that the response evoked by aßmeATP and the fast response 
evoked by ATP resemble (in terms of latency and duration) the capsaicin- evoked 
response, whereas the slow ATP response is similar to the bradykinin- evoked 
response. 
In C -fibre polymodal nociceptors (pooled data from both normal and arthritic 
joints), the latencies of the aßmeATP and ATP responses were significantly 
(P <0.05) shorter than that of the bradykinin- evoked excitation (Figure 5.13a), 
whereas they were similar to that evoked by capsaicin (Figure 5.14a). The increased 
action potential discharge following injection of the nucleotides also had a 
significantly (P <0.05) shorter duration than that evoked by bradykinin (Figure 
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5.13b), but it was also significantly (P <0.05) more transient that that evoked by 
capsaicin (Figure 5.14b). 
Although equipotent doses were not used, the size of the responses evoked by 
capsaicin, bradykinin and the purines are compared in Figure 5.15. The change in 
action potential discharge frequency elicited by the purines was smaller than that 
evoked by capsaicin (though this did not reach statistical significance for ATP) but 
was significantly higher that that evoked by bradykinin (Figure 5.15a). The change in 
the total number of action potentials that fired following injection of aßmeATP or 
ATP was significantly (P <0.05) smaller than the change evoked by capsaicin or 
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Figure 5.13 Pooled data from C- fibre polymodal nociceptors innervating normal 
and arthritic joints showing the a) onset latency and b) duration of the response 
evoked by capsaicin (10nmol), bradykinin (9nmol), afimeATP (60nmol) and ATP 
(2000nmol). Cohnnns represent mean-±s em. Capsaicin n =21, bradykinin n =19, 
aßmeATP n =14, ATP n =7. * * *P <0.0001, * *P <0.01 unpaired t -tests compared to 
bradykinin. 
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a) b) O Capsaicin 











Figure 5.14 Data from the figure above for capsaicin (10nmol), aßmeATP 
(60nmol) and ATP (2000nmo1) with an expanded y -axis scale showing the a) onset 
latency and b) duration of the responses evoked. Columns represent mean em. 







Iç U E. 
. E 20 b 









s c` 100 
C Ú N 
GcÑ 75 
v .9 ,` 50 
o ç. 25 
* 
* ** 
Figure 5.15 Pooled data from C -fibre polymodal nociceptors innervating normal 
and arthritic joints showing the change in a) the action potential discharge 
frequency and b) the total number of action potentials that fired in response to 
capsaicin (10nmol), bradykinin (9nnlol), aißmeATP (60nmol) and ATP (2000nmol). 
Columns represent mean±sem. Capsaicin n =21, bradykinin ii =19, aßmeATP ii =14, 
ATP ii =7. Part a) * *P <0.01 unpaired t -test versus capsaicin. 
+ + +P <0.0001 unpaired 
t -test versus bradykinin. Part b) * * *P <0.0001 and * P <0.05 unpaired t -test 
compared to capsaicin. 
+ + +P <0.0001 and +13<0.05 unpaired t -test versus bradykinin. 
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5.3.1.7 Effect of PPADS on the aßmeATP and ATP -evoked excitation 
The dose -related increase in discharge evoked by aßmeATP (1 -600 nmol i.a.) in 
normal and arthritic joints was antagonised by a single bolus injection of the P2 
receptor antagonist, PPADS (161.tmol kg -1 i.a.), 10 minutes before re- testing the 
agonists (Figure 5.16). The effect of the antagonist waned after approximately 10 
minutes, so doses were usually given at 10- minute intervals when constructing dose - 
response curves. PPADS also antagonised the fast response evoked by a single dose 
of aßmeATP (60nmol) or ATP (2000nmo1) (Figure 5.17) without affecting the 
delayed response to ATP (see Chapter 6). The lack of effect of the adenosine Al 
receptor antagonist DPCPX (31imol kg-1 i.a., 10 minutes pre -treatment) on the fast 
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Figure 5.16 Effect of PPADS (16pinol kg-1 i. a.) on a) the dose related increase in 
afferent discharge evoked by aßmeATP in a single C -fibre polymodal nociceptor and 
b) on the mean apparent ED50 for aßineATP. Cohnnns represent mean em. 
*P <0.05 unpaired t -test compared to control responses. Pooled data from normal 
and arthritic joints. Control n =8 afferents; PPADS n =4 afferents. 
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a) b) 
o Control ® PPADS 







Figure 5.17 Pooled data from C fibres and A8-fibres innervating normal and 
arthritic joints showing the effect of PPADS (16 /mot kg 1 i.a.) and DPCPX (3,umol 
kg' i.a) on the, fast increase in afferent discharge evoked by a) aßmeATP (60nmol) 
and b) ATP (2000nmol). Columns represent mean etn. * * *P <0.0001 and * *P <0.01 
Student's paired t -test compared to control responses. aßmeATP: PPADS n =10, 
DPCPX n =-1; ATP: PPADS n =5, DPCPX n =4. 
5.3.1.8 Effect of PPADS on the spontaneous discharge of nociceptors 
innervating arthritic joints 
As discussed in the previous chapter, one of the features of adjuvant- induced arthritis 
is an increased rate of spontaneous discharge in afferents innervating arthritic joints 
compared to normal joints. In order to establish whether endogenous ATP 
contributed to the increased basal discharge, the effect of PPADS on spontaneous 
discharge was examined in 15 of the 24 arthritic joints. Activity was recorded from 
53 afferent fibres; 26 were C -fibre polymodal nociceptors and 27 were 
AS- mechanoreceptors. Ten (38 %) of the C- fibres were spontaneously active but 
only two were excited by exogenous aßmeATP (60nmol, i.a.) or ATP (2000nmol, 
i.a.). Two (7 %) of the AS- fibres were spontaneously active but neither were excited 
by aßmeATP. Administration of PPADS (16 µmol kg " i.a.) did not reduce the firing 
rate of the 10 C -fibre afferents nor did it reduce the firing rate of the two 
spontaneously active AS- fibres (Figure 5.18). However, PPADS would only be 
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expected to influence the two spontaneously active aßmeATP /ATP -positive fibres: 
the antagonist reduced the discharge in one of the recordings, but it increased it 
slightly in the other (unit 1 before PPADS: 0.5 impulses s-1, after PPADS: 0.3 
impulses s -1; unit 2 before PPADS: 0.3 impulses s 1, after PPADS: 0.4 impulses s-1). 
a) b) 
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Figure 5.18 Data from a) 10 C- fibres and b) 2 AS- fibres showing the lack of any 
significant effect of PPADS (161tmol kg' i.a.) on the elevated discharge frequency of 
afferents innervating arthritic joints. 
5.3.1.9 Excitation following intra- articular injection of aßmeATP and ATP 
In order to exclude vascular mediated effects and to confirm that close- arterial 
injections of the P2 receptor agonists were exciting joint afferents, single doses of 
aßmeATP (60nmol) and ATP (2000nmol) were injected directly into the normal 
knee joint synovial space in a three experiments. When these nucleotides were 
injected i.art., the response lasted for a significantly longer time (P <0.05) than that 
evoked from the same afferents when injected i.a., and thus the total number of 
action potentials that fired was also significantly greater (Table 5.2). 
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Table 5.2 Comparison of the response evoked from the same afférents by i.a. 
and i.art. injection of aßineATP (60mnol) and ATP (2000nmmol). Mean em, 11=4 
afferents per injection, either C or AS fibres. 20 minutes were allowed between 
successive injection in the same animals. *P <0.05 unpaired t -test, duration and 
number of impulses greater following i.art. injection. 
aßmeATP 
i. a. i.art. i.a. 
ATP 
i.art. 
Latency (s) 2.46 ±0.15 2.50 ±0.30 2.5 ±0.02 1.5 ±0.05 
Duration (s) 0.58 ±0.08 *4.92 ±1.72 0.45 ±0.04 *4.9 ±1.46 
Change in number of 
action potentials 
(impulses) 
2.5 ±0.62 *21.66 ±9.57 3.39 ±1.06 *54.66 ±23.99 
Change in action 
potential discharge 
frequency (impulses s "1) 
3.93 ±0.98 4.4 ±0.99 7.56 ±1.23 9.88 ±2.00 
Vehicle injection (PBS 0.1 nil) evoked no response (0.01±002 impulses 5.-1, n =3 afferents). 
The presence of the needle in the knee joint for the duration of the recording had no significant effect 
on spontaneous discharge (control: 0.0110.02 impulses 5-1; after insertion of needle: 0.0100.03 
impulses s1). 
5.3.1.10 ATPyS and BzATP- evoked excitation 
The P2 agonist ATPyS (900nmol i.a.) was tested on 19 afferents from three normal 
knee joints (12 C- fibres and 7 M- fibres). Like ATP, it evoked a biphasic response 
consisting of a fast component followed by a delayed increase in action potential 
discharge (see next chapter) in three of the AS- fibres on which it was tested (latency 
0.9 ±0.4s, duration 0.7±0.2s, change in action potential frequency 9.78 ±3.6 impulses 
s1). In one afferent on which they were tested, PPADS but not DPCPX, antagonised 
the ATPyS evoked fast -onset response (Table 5.3). 
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Table 5.3 Characteristics of the fast -onset response evoked by close- arterial 
injection of ATPyS (900nmol) in one AS -fibre mechanoreceptor. Mean em, 









Change in number of action 
potentials (impulses) 
Change in action potential 
discharge frequency (impulses s -1) 
0.15 ±0.06 
1.10 ±0.24 
6. 50±0. 60 







ATPyS (900nmol i.art) was also tested on 16 afferents (9 C- fibres and 7 AS- fibres) 
by i.art. injection. Injection by this route also evoked a fast -onset, short duration, 
increase in action potential discharge (latency 5.1±2.5s, duration 5.8 ±1.9s, change in 
discharge frequency 7.3 ±2.3 impulses s-') in 1 C -fibre and 3 AS- fibres. A delayed 
increase in action potential discharge was also evoked (see next chapter). 
The P2X agonist, BzATP (700nmol i.a.) was tested on two C- fibres and 5 AS- 
fibres; it also evoked a fast and transient excitation from two of the AS afferents 
(latency 1.30±0.10s, duration 0.65±0.15s, change in discharge frequency 9.8 ±6 
impulses s-'). No delayed onset response was evident. Intra- articular injection of this 
agonist in two normal knee joints did not evoke any increase in action potential 
discharge. 
5.3.2 CARDIORESPJRATORY EFFECTS OF P2X RECEPTOR AGONISTS 
During the course of these experiments, it was noticed that intra- arterial injection of 
aßmeATP (1- 600nmol) and ATP (2000nmol) evoked a Bezold -Jarisch 
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cardiorespiratory reflex (B -J; Bezold, 1867) comprising of bradycardia, hypotension 
and apnoea (which was preceded by a transient hyperventilation). This reflex was 
studied in more detail in separate experiments following i.v.injection of the agonist 
(via the right external jugular vein) because administration by this route was 
approximately 10 times more potent at eliciting it (McQueen et al., 1998; McQueen 
et al., 1997). The nucleotide -evoked B -J reflex was largely investigated by Dr. D.S. 
McQueen and the results will only be summarised here (for more details see 
McQueen et al., 1998). 
The reflex bradycardia (and resulting hypotension) evoked by af3meATP 
(0.6- 600nmol i.v.; EDS0 for aßmeATP- induced bradycardia 14.6 ±3.8nmol) was 
significantly (P <0.05) reduced by bilateral vagotomy, atropine (2.8µmol kg 1, i.v.) or 
PPADS (17 µmol kg-1, i.v.), and was unaffected by cutting the carotid sinus nerves. 
The apnoeic component of the reflex (ED50 for aßmeATP -induced apnoea: 
47.1 ±8.5nmol) was significantly (P <0.05) reduced by vagotomy or PPADS, and was 
unaffected by atropine or by cutting the carotid sinus nerves. The hyperventilation 
that proceeded the apnoea (ED50 for aßmeATP -induced hyperventilation: 23.3 ±6.0 
nmol) was significantly reduced (P <0.05) by cutting the sinus nerves, potentiated by 
vagotomy or PPADS, and was unaffected by atropine. 
Interestingly, neural recordings from vagal afferents showed that 62% of 
units recorded from (primarily pulmonary inflation receptors but also some 
unidentified units) were rapidly activated by aßmeATP (ED50 22 ±5 nmol) and this 
was blocked by PPADS. The nucleotide also excited carotid chemoreceptor afferents 
(ED50 23 ±9 nmol), an action that was unaffected by PPADS. 
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5.3.3 IMMUNOHISTOCHEMICAL STUDIES 
Two sections from the left and right L3, L4 and L5 DRG of 4 arthritic, 2 paraffin - 
injected and 2 normal rats were examined for P2X3- immunoreactivity using DAB or 
VR visualisation. P2X3 -immunoreactivity was clearly seen throughout the cytoplasm 
in discrete cells (Figure 5.19 and Figure 5.20) in all sections examined. Although, no 
attempt was made to quantify the proportion or distribution of cells labelled, 
approximately half of the small cells, and only a small number of large cells were 
labelled. The DRG of one monoarthritic rat were retrogradely labelled from both 
knee joints using fluorogold. Retrogradely labelled cells were identified by the 
presence of scattered particles of silvery fluorescence in the cytoplasm and P2X3- 
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Figure 5.19 Light field photomicrographs (x40) of two sections from one normal 
rat DRG (L3) showing a) discrete P2X3- immunoreactivity visualised with DAB in a 
number of small cells and b) the absence of staining when the sections were 
incubated with pre- immune serum. 
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b) 
Figure 5.20 Fluorescence micrographs (x1000) of a single section from an 
arthritic rat DRG (L3) showing a) P2X3- immunoreactivity visualised with Vector 
Red and b) fluorogold fluorescence. Fluorogold and Vector Red fluorescence co- 
localised in this cell. 
5.3.4 DETERMINATION OF ATP CONCENTRATION IN SYNOVIAL PERFUSATE 
The results of the firefly- luminescence assay for ATP concentration in the synovial 
perfusate are pending. 
5.4 DISCUSSION 
The main finding of this study is that P2 and P2X receptor agonists evoke a rapid, 
short- lasting excitation from approximately half of the C -fibre polymodal 
nociceptors innervating the rat knee joint. This evidence supports the hypothesis that 
functional P2X receptors are present on the peripheral terminals of a sub -population 
of nociceptive afferents innervating the rat knee joint in vivo. However, the purine 
analogues also excited most of As -fibre mechanoreceptors recorded from, of which 
half are probably nociceptors (see previous chapter). This precludes a purely 
nociceptive function for rat articular afferent P2X receptors. 
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Afferents that that were activated by the P2X1 and P2X3 receptor agonist, 
af3meATP, also invariable responded to ATP, the endogenous ligand at P2 receptors. 
No significant difference between the responses evoked by the agonists at the doses 
used were evident, and the response to both was antagonised by the P2 antagonist 
PPADS. This data suggests that aßmeATP and ATP were acting on the same P2 
receptor subtype(s). 
The evidence supports the hypothesis that the receptor(s) mediating the 
excitation is a ligand -gated ion -channel expressed on the peripheral terminals of the 
articular afferents. Following close -arterial injections, fast -onset excitation is 
typically observed with algogens known to mediate their effects through specific ion - 
channels receptors expressed on sensory nerve terminals, whereas slow onset 
responses are observed with algogens acting through G- protein coupled receptors 
expressed on the nerve terminal (Birrell et al., 1990). Capsaicin rapidly increased C- 
fibre nociceptor discharge with a delay to onset that was similar to that observed 
following injections of aßmeATP or ATP in the same recordings, whereas the 
bradykinin evoked response was significantly longer in onset. Since capsaicin acts 
directly on the sensory nerve terminal via a specific vanilloid ion -channel receptor 
(Caterina et al., 1997), it is probable that the fast responses to aßmeATP and ATP 
are also mediated via direct actions on the afferent nerve terminals. Furthermore, the 
nucleotides also evoked a response when injected into the knee joint, which indicates 
that the excitation was not secondary to vascular effects. 
The cell bodies of knee joint sensory fibres are in the DRG where mRNA for 
six of the ATP -gated cation -channel receptor subtypes (P2X1_6) are expressed (Collo 
et al., 1996). There are currently no selective pharmacological tools available for use 
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in vivo that would enable us to discriminate definitively between responses mediated 
by these subtypes. To complicate the matters even further, aßmeATP can evoke a 
variety of responses from sensory neurones in vitro, which suggests that different 
aßmeATP- sensitive P2X receptors are functionally expressed in the cells. Thus, 
aßmeATP evokes transient and persistent currents from dissociated rat DRG 
neurones (Li et al., 1999) and from cultured trigeminal nociceptors (Cook et al., 
1997). Since the P2X1 and P2X3 subtypes are the only P2X receptors sensitive to 
aßmeATP, either or both might underlie the nucleotide evoked excitation of sensory 
neurones. However, the P2X3 subtype, but not to the P2X1 subtype, is present in 
trigeminal nociceptors (Cook et al., 1997) indicating that the latter cannot be 
responsible for the aßmeATP- evoked currents in these cells. aßmeATP and ATP 
evoke a rapidly- desensitising inward current from HEK293 cells expressing 
recombinant P2X3 receptors (Lewis et al., 1995) which is analogous with the 
transient phenotype of sensory neurones. Persistent current in trigeminal nociceptors 
is explained by heteropolymerisation of P2X3 subunits with P2X2 subunits because 
nucleotides stimulate a slowly -desensitising current from HEK293 cells 
cotransfected with P2X3 and P2X2 cDNA (Lewis et al., 1995). Thus, functional P2X3 
homomeric and P2X2/3 heteropolymeric channels, associated with rapidly and 
slowly- desensitising inward current phenotypes respectively, seem to be expressed in 
sensory neurones. Which, if any of these receptors was responsible for the excitation 
observed in the present study? 
Selective agonists or antagonists for the various P2X receptor subtypes, as 
well as analogues which would discriminate between heteropolymeric and 
homopolymeric receptors, would enable the receptor(s) underlying the excitation of 
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the rat knee joint afferents to be characterised. Unfortunately, these are not available 
yet. The other P2 agonists used in the present investigation, ATPyS and BzATP, are 
not selective at P2X subtypes. Another possible method of identifying the receptors 
would be to perform neural experiments in P2X2 and /or P2X3 knockout rats, but 
again, these have not yet been generated. A mouse P2X3 receptor knock -out line has 
been generated at GIAP, but a method of recording from the mouse MAN would 
have to be developed in order to investigate the responses to nucleotides in these 
animals. One potential means of determining whether rapidly or slowly -desensitising 
P2X receptor(s) mediated the excitation observed in the present study is to closely 
examine the duration of the action potential discharge elicited by the nucleotides. 
When they were injected i.a., aßmeATP and ATP evoked a transient (0.5 -1s) 
excitation but when they were injected i.art. the nucleotides evoked a significantly 
discharge ( -5s). If rapidly -desensitising P2X3 channels mediated 
the discharge then concentration -dependant effects (considerably higher local 
concentration following i.art. injection) would not account for the longer duration 
because these would still have desensitised rapidly. This data suggests that rapid 
clearance of the nucleotides by the blood largely accounted for the transience of the 
excitation following i.a. injection. These findings largely implicate the slowly - 
desensitising P2X2/3 heteropolymer, at which inward current fades within seconds 
(Cook & McCleskey, 1997), in the nucleotide- evoked afferent excitation. However, 
it is not possible to exclude a role for homomeric P2X3 receptors for a number of 
reasons. Firstly, following i.art. injection of ATP, the duration of the action potential 
firing evoked was quite varied (range 1.9s -8.9s, data not shown), possibly indicating 
the involvement of more than one type of receptor. Secondly, Cook et aI. (1997) 
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found that transient (milliseconds) inward current evoked by P2X receptor agonists 
from trigeminal nociceptors was associated with considerably longer action potential 
discharge (- 0.5s). Thus, rapidly- desensitising P2X3 homomers may underlie the 
shorter duration excitation evoked by the nucleotides. It would be interesting to 
perform more experiments where the purines are injected i.am to determine if there 
are populations of afferents with distinct action potential discharge kinetics. 
The functional expression of P2X receptor subtype(s) on the peripheral 
terminals of sensory afferents represents a novel mechanism through which 
extracellular ATP may contribute to sensory processing. One of the in vivo situations 
where local levels of endogenous ATP are increased is during inflammation. Since 
the present study has confirmed that functional P2X receptors are expressed on the 
peripheral terminals of a subpopulation of knee joint nociceptors, the ATP released 
during articular inflammation might contribute to pain. As mentioned in the General 
Introduction, inflammatory pain is characterised by ongoing pain, in addition to 
stimulus -induced allodynia and hyperalgesia. For reasons discussed in the previous 
chapter, the latter two components were not investigated using electrophysiological 
techniques in this thesis. The spontaneous pain associated with knee joint 
inflammation is manifest as an increase in the number and rate of discharge of 
spontaneously active nociceptive afferents (Schaible & Schmidt, 1996), a feature of 
the monoarthritic model used in the present investigation. One of the main incentives 
for investigating P2X receptors is the possibility that antagonists at these receptors 
may have therapeutic potential in treating in inflammatory pain. However, it is 
unlikely that endogenous ATP acting on the P2X subtype(s) expressed on 
nociceptive afferents contributed to the increased basal discharge of C -fibre afferents 
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innervating arthritic joints because very few of the spontaneously active afferents 
were ATP sensitive. Because exogenous ATP (i.a. injection) excited these afferents, 
this suggests that the endogenous ATP concentration was not high enough to activate 
the P2X receptor(s). Perfusate from normal and arthritic knee joints was collected for 
determination of ATP concentration, but as mentioned, the results of the assay are 
pending. It could be argued that the dose of exogenous ATP (2000nmol, i.a.) was 
higher than endogenous levels expected during chronic monoarthritis. The dose of 
ATP injected in this study was estimated to have yielded a local concentration of 
2mM at the afferent terminals (see Appendix III). This concentration is lower than 
that that could potentially accumulate under conditions of continuous ATP release 
during inflammation (the intracellular concentration of ATP is between 5 -10mM, 
leading to high local levels due to release from damaged, necrotic or aptotic cells 
(see DiVirgilio et al., 1996)). It is probable that the chronic arthritic lesion was not 
severe enough to cause adequate ATP release, and that any ATP released was rapidly 
metabolised. Perhaps a more severe inflammation would cause more ATP release, or 
possibly ATP release varies during different stages of adjuvant -arthritis 
development. It would be interesting to measure the ATP concentration in severely 
arthritic joints or at different stages of the arthritic process, and to correlate these 
with spontaneous nociceptor discharge. 
Based on recent evidence gained from in vitro and in vivo studies, it is rather 
surprising that the afferents innervating the arthritic joints were not sensitised to the 
exogenous nucleotides. Experimental arthropathies are associated with lowered pH 
and increased substance P concentrations (Ahmed et al., 1995; Tulamo et al., 1989) 
and both of these factors augment the ATP -evoked current in rat DRG neurones in 
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vitro (Hu & Li, 1996; Li et al., 1996). In vivo, ATP and aßmeATP evoke nociceptive 
behaviour following intra- plantar injection (see below) and these are enhanced 
during carrageenan or ultraviolet irradiation- induced inflammation, or following 
injection of PGE2 (Hamilton et al., 1999). Although the levels of hydrogen ions, 
substance P or PGE2 in arthritic rat knee joints was not determined in the present 
investigation, the absence of any sensitisation could indicate that the monoarthritic 
lesion was not severe enough to induce changes that would alter the sensitivity of the 
afferents to P2X receptor agonists. In order to resolve this, it would be desirable to 
investigate the responses evoked from afferents innervating more severely inflamed 
joints. An alternative explanation is that, for example, pH and Substance P- sensitive 
P2X receptors were not responsible for the nucleotide responses in the present 
experiments. Consistent with this, bolus i.a. injections (10s, pre -injection) of acidic 
saline or substance P did not augment the ATP evoked excitation of knee joint 
afferents. However, is unlikely that transient exposure of the terminals to these 
"sensitising- agents" following i.a. injection would have given time for sensitisation 
to occur. Other methods of exposing the afferents to carbonic acid or substance P, 
perhaps by infusing them or even injecting them i.art., would probably reveal 
whether they can sensitise rat knee joint afferents to P2X receptor agonists. 
This study has revealed that P2X receptors are present on approximately half 
of the C -fibre polymodal nociceptors and most of the AS- fibres innervating the rat 
knee joint. Given that (in the cat), 1) the C- fibres and half of the A8- fibres of the 
MAN innervating the knee joint are nociceptive (see previous chapter), whereas the 
remainder of the AS- fibres innervating the joint are proprioceptive, and 2) that the 
role of knee joint afferents largely seems to relate to signalling joint movements 
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(Schaible & Schmidt, 1996), the most important question to ask is what is the 
functional significance of these receptors? At this point it is worth considering the 
pathophysiological or physiological events that might cause ATP release. One is 
during inflammation, but it is also known that membrane distortions release ATP and 
that the nucleotide is released when cells are mechanically stimulated (Nakamura & 
Strittmatter, 1996). It is conceivable that tissue -deforming but non -injurious stimuli, 
such as low intra- articular pressure, low -intensity mechanical pressure or stretch, 
might cause low levels of ATP release in vivo, whereas noxious events, such as high 
intra- articular pressure, acute tissue -damaging mechanical insults or stretch (or 
inflammation), might cause high levels of ATP release. Interestingly, in dissociated 
rat DRG neurones, lower concentrations of aßmeATP are required to activate 
transient inward current, whereas higher concentrations are needed to evoke 
persistent current (Li et al., 1999). Therefore, it is tempting to speculate that transient 
current might be associated with non -nociceptive afferents, and persistent current 
with nociceptive afferents. 
In this scheme, proprioceptive AS- afferents innervating the joint would be 
transiently activated by ATP release during innocuous joint movements, thereby 
rapidly signalling to the CNS that the joint has moved. During an acute stretching of 
the joint beyond its normal working range, the P2X receptor on nociceptive A8 and 
C -fibre afferents would be activated, because higher levels of the nucleotide would 
be released (see Figure 5.21). In the absence of a continued signal (motor reflexes 
would return the joint to its normal position and ATP would be hydrolysed) the 
noxious stimulus would only be transient. Although there is little evidence to support 
this proposal at present, the proposed structure for P2X receptors resembles that of 
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the channel thought to be responsible for mechanosensitivity in Caenorhabditis 
elegans (Surprenant et al., 1995 and see General Introduction), and it has been 
suggested that these receptors might be involved in mechanosensation (Cook et al., 
1997). Furthermore, one of the metabotropic ATP receptor subtypes (P2Y1) has been 
implicated in proprioceptive mechanosensation because mRNA for this subtype is 
present in large diameter DRG neurones and functional expression of the protein in 
Xenoptts oocytes renders the cells sensitive to touch (Nakamura & Strittmatter, 
1996). However, excitation of metabotropic receptors on sensory neurones (such as 
that excited by bradykinin in this thesis) usually has a relatively long onset latency, 
whereas mechanical stimuli are sensed rapidly. It is possible that P2X receptors 
might be responsible for the initial detection of mechanical stimuli, but other, 
perhaps metabotropic receptors, may be involved in signalling sustained mechanical 
stimuli. 
AS-proprloceptor AS or C-fibre nociceptor 
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Figure 5.21 A proposed mechanism for P2X receptor mediated detection of 
innocttotts and noxious joint movements. Innocuous movement causing low 
extracellular ATP (eATP) concentrations would activate the rapidly- desensitising 
P2X subtype (P2X3 homomer ?), whereas high concentrations would activate the 
slowly -desensitising subtype (P2X 13 heteromtltimer ?). The former would not evoke 
painful sensations, whereas the latter would. 
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This proposal could also be accommodated to provide a role for P2X 
receptors in inflammatory pain. During inflammation local release of high 
concentrations of ATP would cause fluctuating activation and desensitisation of the 
population of afferents with slowly- desensitising P2X receptors. P2X receptors on 
nociceptors are highly permeable to calcium (Cook et al., 1997) and increases in 
intracellular calcium concentration, particularly if mediated via persistent inward 
current, may produce longer -term changes in excitability. This is thought to occur 
following capsaicin activation of sensory neurones in vitro: vannilloid receptor(s) 
activation causes calcium influx which triggers nitric oxide synthase activity, leading 
to cyclic guanosine monophosphate (cGMP) production (Wood et al., 1989). cGMP 
may then activate protein kinases that sensitise the afferent (for example see Qian et 
al., 1996). Furthermore, there has been speculation the ATP itself may be released 
from activated sensory nerve terminals (Holton, 1959), if so, this could create a 
positive feedback mechanism for sensory activation and sensitisation. It has also 
been suggested that P2X receptors may contribute to neurogenic inflammation (Cook 
et al., 1997). However, in the rat DRG, very few cells express both substance P and 
P2X3 subtype immunoreactivity (Vulchanova et al., 1998), which largely excludes a 
P2X3 mediated initiation of neurogenic inflammation. Nevertheless, the ATP -evoked 
action potential discharge may be augmented by substance P release from other C- 
fibre terminals (Hu & Li, 1996). In this way, P2X subtypes may play a role in 
sustaining the neurogenic inflammation caused by substance P (see Figure 5.22). If 
more ATP is released from cells that are that are compromised during inflammation 
by membrane distortions - thus P2X receptors may also play a role in allodynia or 
hyperalgesia during inflammation. 
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Figure 5.22 A proposed mechanism for initiation of it fammatoly pain by P2X 
receptors. The high concentrations of extracelhilar ATP (eATP) during inflammation 
lwonild stimulate the slowly-desensitising P2X subtype (P2X213 heteromrtltimer ?) 
expressed on C- or A5 -fibre nociceptors. Inn the continued presence of agonist, the 
intracellular Cal+ concentration would be increased which could lower the threshold 
of the nociceptors and contribute to allodynia and hyperalgesia. Excitation of the 
afferents would induce the release of ATP, which could feedback on the terminals. 
The substance P released from neuropeptide containing C -fibre nociceptors would 
enhance the excitation of afferents by ATP and promote neurogenic n flaniniation. 
However, the data provided by the current study can be interpreted in many other 
ways, and the proposal outlined in Figure 5.21 and Figure 5.22 is highly speculative 
and it cannot be tested at present because of the lack of pharmacological tools. 
Nevertheless, it could probably be determined whether i.art. injection of ATP or 
aßmeATP evokes rapidly -adapting action potential discharge from proprioceptive 
afferents, and slowly -adapting discharge from nociceptive afferents by performing 
i.art. injections as described above. The hypothesis that P2X receptors are involved 
in signalling joint movements, or afferent sensitisation to movement during 
inflammation could also be determined by injecting PPADS i.a. while flexing or 
extending the normal or arthritic joint respectively. The effect of the antagonist on 
"weight- bearing" allodynia in the monoarthritis model was not investigated in this 
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study because its effects lasted for only 10 minutes in the neural experiments and it 
was unlikely to serve any useful role in behavioural testing. In addition, 
interpretation of experiments involving PPADS is complicated by the fact that it also 
inhibits the enzymes responsible for ATP metabolism (for example see Chen et al., 
1996). Simultaneous antagonism of P2X receptors and inhibition of ATP breakdown 
leads to apparent antagonist insensitivity in some preparations (Crack et al., 1994). 
The development of selective P2X receptor antagonists, which lack this ecto- 
nucleotidase blocking property, would better answer the question of whether 
endogenous ATP contributes to mechanosensation in normal joints, and /or 
spontaneous pain, allodynia or hyperalgesia in chronically inflamed joints. 
Although there is no evidence that the suggested proposal (in Figure 5.21 and 
Figure 5.22) has any functional relevance, there are a number of observations that 
support it. In the present study, fewer M- mechanoreceptors innervating arthritic 
joints were excited by aßmeATP (normal 84 %, arthritic 63 %) or ATP (normal 69 %, 
arthritic 39 %) which would be consistent with desensitisation of rapidly -adapting 
P2X receptors on proprioceptors by higher ATP levels in inflamed tissues. 
Furthermore, sub -plantar (Bland -Ward & Humphrey, 1997), or intra- plantar 
(Hamilton et al., 1999) injections of stable and unstable P2X receptor agonists into 
the rat hindpaw stimulate nociceptive behaviours lasting for up to 5 minutes that are 
abolished by neonatal capsaicin treatment. It is very unlikely that slow clearance of 
the analogues from the tissue accounted for this since 1) ATP is rapidly metabolised 
by nucleotides and therefore would not be in the tissue for this length of time, 2) 
even the slow -desensitising P2X receptor desensitises within seconds (Cook & 
McCleskey, 1997), and 3) i.art. injection of nucleotides evokes an excitation lasting 
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Chapter 6: The direct role of adenosine in knee joint 
nociception 
6.1 INTRODUCTION 
Antifolate drugs, including methotrexate and sulfasalazine, are some of the main 
disease -modifying treatments for RA (vanEde et al., 1998). These compounds 
increase the levels of endogenous adenosine and it has been proposed that this effect 
accounts for their anti -inflammatory properties (Baggott et al., 1993; Cronstein, 
1994; Cronstein et al., 1996; Cronstein et al., 1993). However, antifolate therapy is 
limited by adverse side effects (Sandoval et al., 1995; Schnabel & Gross, 1994; 
vanEde et al., 1998) and investigators have started to investigate alternative, more 
selective methods of increasing endogenous adenosine as potential anti -inflammatory 
treatments (Cronstein et al., 1996; Firestein, 1996). 
One of the main rationales for developing anti -rheumatic drugs is to provide 
relief from the pain of the disease. Novel anti -inflammatory treatments that increase 
peripheral adenosine levels may have severe limitations as analgesic agents and may 
even exacerbate inflammatory pain because the nucleoside is known to cause pain in 
humans when it is applied to a blister base (Bleehen & Keele, 1977) and when it is 
injected intradermally (Pappagallo et al., 1993) or intravenously (Gaspardone et al., 
1995). Research strategies aimed at developing adenosine compounds for the 
treatment of RA would be facilitated if the mechanisms underlying the pain - 
producing effects of adenosine were fully understood. 
The peripheral pro -nociceptive effects of adenosine could be mediated by 
direct and /or indirect actions on the primary afferent nociceptor either to excite it or 
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sensitise it to other stimuli. Adenosine can depolarise the cell bodies of primary 
afferent nociceptors in vitro (Huang et al., 1995) and it excites primary sensory 
nerves in vivo (McQueen & Ribeiro, 1981). The nucleoside also induces mechanical 
hyperalgesia in conscious rats following intradermal injection, apparently through 
direct actions on the nociceptive afferent (Taiwo & Levine, 1990). In addition to 
these direct actions, sub -cutaneous administration of the purine causes nociceptive 
behaviours in rats by releasing histamine and 5- hydroxytryptamine from mast cells 
(Sawynok et al., 1997). 
A major source of extracellular adenosine is the metabolism of ATP by ecto- 
nucleotidases (Gordon, 1986). As reported in the previous chapter (and see Dowd et 
al., 1998a), close -arterial injection of ATP to the rat knee joint, evokes a biphasic 
excitation of joint afferents consisting of a rapid response, followed by a delayed 
increase in discharge. The stable ATP analogue, aß- methylene ATP, which is not 
metabolised to adenosine, did not elicit the slow response. These findings suggest 
that adenosine might be responsible for the delayed increase in afferent discharge 
following i.a. injection of ATP, and indicates that the nucleoside might be involved 
in nociception in the knee joint by directly activating articular nociceptors. 
The primary aim of the present electrophysiological study was to test the 
hypothesis that adenosine directly activates nociceptive afferents innervating the rat 
knee joint. Because substance P is released during adjuvant- induced arthritis (Ahmed 
et al., 1995) and this tachykinin has previously been shown to augment the response 
of canine ventricular sensory afferents to adenosine (Huang et al., 1995), 
experiments were also performed to determined whether the afferent responses to the 
nucleoside were affected in the arthritic rat knee joint. In order to determine the role 
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of endogenous adenosine in maintaining inflammatory pain associated with 
monoarthritis, the effects of adenosine receptor agonists, antagonists and the 
nucleoside uptake inhibitor, dipyridamole, on weight- bearing allodynia was 
investigated in behavioural studies. 
6.2 METHODS 
6.2.1 AFFERENT NERVE RECORDINGS IN VIVO 
These experiments were carried out as described in Section 2.1.2. Briefly, arthritis 
was induced in the left knee joint and rats were used for neural recordings 14 -21 days 
later. A total of 17 normal and 19 arthritic rats (weight range 235 -350g; mean±sem 
313 ±10g) were used in the present investigation. Animals were anaesthetised with 
pentobarbitone (60mg.kg 1 i.p., supplemented hourly i.v.) and surgically prepared. 
Bipolar platinum- iridium wire electrodes were used to record extracellular neural 
activity in MAN afferents and data was analysed off -line using Spike2. In most 
experiments, drugs were administered by close -arterial injection via a cannula in the 
right femoral artery, but in a small number, they were injected i.art. into the knee 
joint. 
6.2.2 BEHAVIOURAL STUDIES 
Body weight, knee joint swelling and weight- bearing allodynia were assessed as 
described in Sections 2.2.2. 
6.2.2.1 Dipyridamole and DPCPX trial 
In this study, four treatment groups (dipyridamole, DPCPX, DPCPX & 
dipyridamole, and vehicle) each with six male Wistar rats were used. Body weight, 
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weight- bearing and knee diameters were measured from Day -3 to Day 14 post - 
induction of arthritis, where arthritis was induced on Day 0. From Day -1 to Day 5, 
the rats were injected as follows: the dipyridamole group received DPCPX vehicle 
(5% DMSO, 2% 1M NaOH, 93% PBS; 0.1m1 kg1 i.p.) followed 10 minutes later by 
dipyridamole (40mg kg -1 i.p.); the DPCPX group received DPCPX (lmg kg -1 i.p.) 
followed 10 minutes later by dipyridamole vehicle (PBS; 0.1m1 kg-1 i.p.); the 
combined group received DPCPX (1mg kg-1 i.p.) followed 10 minutes later by 
dipyridamole (40mg kg-1 i.p.) and the vehicle group received DPCPX vehicle (0.1m1 
kg-1 i.p.) followed 10 minutes later by dipyridamole vehicle (0.1m1 kg1 i.p.). All 
measurements were made blind to drug treatment one hour after the injections. 
6.2.2.2 GR79236 and DPCPX trial 
Four treatment groups with six rats each were used in this study (GR79236, DPCPX, 
DPCPX & GR79236, and vehicle). As in the dipyridamole study, arthritis was 
induced after the measurements on Day 0 and the rats were measured from Day -3 to 
Day 14 post- induction of arthritis. From Day -1 to Day 5, the rats were injected as 
follows: the GR79236 group received DPCPX vehicle (0.1m1 kg-1 i.p.) and GR79236 
(0.3mg kg -1 s.c.); the DPCPX group received DPCPX (lmg kg -1 i.p.) and GR79236 
vehicle (PBS; 0.05m1 kg -1 s.c.); the combined group received DPCPX (lmg kg-1 i.p.) 
and GR79236 (0.3mg kg-1 s.c.) and the vehicles group received DPCPX vehicle 
(0.1m1 kg-1 i.p.) and dipyridamole vehicle (0.05m1 kg 1 s.c.). The DPCPX injections 
(including vehicle) were administered three times daily (lam, 1 pm and 6:30pm) and 
the GR injections (including vehicle) were given 30 minutes after the first and last 
DPCPX injection (7:30am and 7pm). The rats were measured blind to drug treatment 
1 hour after the morning injections (8:30am). 
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6.2.2.3 Statistical analysis 
To determine whether there were any differences between drug treatment groups, the 
cumulative change from a selected control period in body weight, hindlimb weight 
bearing and joint swelling was determined. The control period was the mean of the 
measurements on Days -1 and 0, and this was subtracted from the mean of the 
measurements on Days 1 -5. The data was analysed using one way AVOVA followed 
by Tukey's multiple comparison test. 
6.3 RESULTS 
6.3.1 AFFERENT NERVE RECORDINGS IN VIVO 
6.3.1.1 Characterisation of afferent nerve fibres 
Neural discharge was recorded from a total of 40 single afferent fibres innervating 17 
normal knee joints and 77 single afferent fibres innervating 19 arthritic knee joints. 
The afferents were classified as C -fibre polymodal nociceptors or AS -fibre 
mechanoreceptors based on their conduction velocities, mechanosensitivity and 
sensitivity to capsaicin as described in Section 4.3.1.1. Of the afferents recorded, 
58% (23/40 afferents) from normal joints and 51% (39/77 afferents) from arthritic 
joints were classified as C -fibre polymodal nociceptors and 43% (17/40 afferents) 
from normal joints and 49% (38/77) from arthritic joints were classified as AS -fibre 
mechanoreceptors. 
6.3.1.2 Adenosine -evoked excitation of articular afferents 
6.3.1.2.1 Proportion of afferents activated by adenosine 
142 
Chapter 6: Knee joint nociceptor adenosine receptors 
A single bolus injection of adenosine (370nmol i.a.) evoked an increase in action 
potential discharge, that was delayed in onset and long lasting from 82% (18/22 
afferents) of C- fibres and 19% (3/16 afferents) of A6- fibres on which it was tested in 
normal joints and 71% (15/21 afferents) of C- fibres and 17% (2/12 afferents) of AS- 
fibres in arthritic joints (Figure 6.1 and Figure 6.2). The representative nerve 
recordings in Figure 6.1 show the adenosine -evoked excitatory response in 
comparison with the discharge elicited by the algogens capsaicin and bradykinin. 
Because so few M- fibres were activated by the purine, the data presented in this 
chapter will be from C -fibre nociceptors only. Adenosine was dissolved in PBS, and 
as reported in the previous chapter, vehicle did not excite any of the afferents on 
which it was tested (0.1m1 i.a., change in discharge frequency 0.02 ±0.1 impulses s-1 










Figure 6.1 Neutral discharge (first panel) showing the response evoked from a 
filament of the MAN innervating a normal knee joint by close -arterial injection of a) 
adenosine (370nmol, activated units 1 & 2), b) capsaicin (10nmol, activated units 1 
& 2) and c) bradykinin (9 nmol, activated unit 1). The afferent fibres that responded 
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Non -responsive 
Responsive 
Figure 6.2 Pie charts showing the proportion of a) Gfibre polymodal 
nociceplors and b) A8 -fibre mechanoreceptors that were activated by adenosine 
(370nmol i.a.) in normal first panel) and arthritic knee joints (second panel). 
6.3.1.2.2 Features of the adenosine- evoked response 
The excitation following i.a. injection of adenosine (370nmol) was compared 
between normal and arthritic joints to determine whether adjuvant -arthritis affected 
the onset latency, duration or magnitude of the response. 
6.3.1.2.2.1 Onset -latency 
The increase in action potential discharge evoked by adenosine was delayed in onset 
in normal joints (Figure 6.3) and the latency was not significantly different in 
arthritic joints. 
144 
Chapter 6: Knee joint nociceptor adenosine receptors 
Normal Joints 
12.5- ® Arthritic Joints 
10.0- 
v w 








Figure 6.3 Pooled data showing the response onset latency following injection 
of adenosine (37Onmol i. a.) in C fibres innervating normal and arthritic joints. 
Columns represent mean±sem. Normal joints n =9; arthritic joints 71 =7. 
6.3.1.2.2.2 Duration 
As illustrated in Figure 6.4, adenosine caused a long- lasting increase in C -fibre 
discharge that was similar in normal and arthritic joints. 
40- 










Figure 6.4 Pooled data showing the duration of the response evoked by 
adenosine (37Onmol i. a.) from C- fibres innervating normal and arthritic joints. 
Columns represent mean ±sem. Normal joints i1 =9; arthritic joints 71 =7. 
6.3.1.2.2.3 Magnitude 
The change in action potential discharge frequency evoked by adenosine in C- fibres 
innervating normal joints was not significantly different from that in arthritic joints 
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(Figure 6.5a). The total number of action potentials that fired was also not 
significantly affected by the presence of adjuvant -arthritis in the knee joint (Figure 
6.5b). 
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Figure 6.5 Pooled data showing the change in a) the C-fibre discharge frequency 
and b) the total intinber of action potentials that fired following close- arterial 
injection of adenosine (370nmol) to normal and arthritic knee joints. Columns 
represent meanem. Normal joints n =9; arthritic joints 11 =7. 
6.3.1.3 ATP -evoked excitation of articular afferents 
6.3.1.3.1 Proportion of afferents activated by ATP 
As mentioned in the previous chapter, ATP (2000nmol) evoked a biphasic increase 
in neural discharge from a multiunit filament of the MAN that consisted of fast and 
slow -onset components (Figure 6.6). Data analysis of responses in single afferent 
fibres revealed that some fibres were rapidly and slowly activated by the nucleotide 
whereas others exhibited one component only. There was also a small population of 
knee joint afferents that were not activated following injection of ATP. The 
populations of C -fibre nociceptors and A6 -fibre mechanoreceptors innervating 
normal and arthritic joints which were (or not) excited following i.a. injection of 
ATP are shown in Figure 6.7. 
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The fast onset response was apparently mediated by the action of ATP on 
P2X receptors (Dowd et al., 1998c and see previous chapter) and will not be 
discussed further in this chapter. The slow component of the ATP excitation was 
observed in 73% (11/15 afferents) of C- fibres and 8% (1/13 afferents) of AS- fibres in 
normal joints, and 62% (23/37 afferents) of C- fibres and 13% (5/38 afferents) of AS- 
fibres in arthritic joints (Figure 6.8). All of the data presented in this section will be 












Figure 6.6 Neural discharge (first panel) showing the response evoked from a 
filament of the MAN by close -arterial injection (at arrow) of a) ATP (2000n11nol, 
activated units 1 & 2 during the fast response and units 3 & 4 during the slow 
response), b) capsaicin (10nmol, activated unit 3 & 4) and c) bradykinin (9 nmol, 
activated unit 3). The individual units that responded are shown (second panel). Note 
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Figure 6.7 Pie charts showing the proportion of a) C-fibre polymodal 
nociceptors and b) A8- mechanoreceptors innervating normal (first panel) and 
arthritic (second panel) knee joints from which ATP (2000nmol i. a.) evoked rapid - 
onset, delayed-onset, rapid and delayed -onset excitation, or neither components. 
a) 
b) 
I I Non- responsive O Responsive 
Figure 6.8 Pie charts showing the proportion of a) C-fibre polymodal 
nociceptors and b) A8-fibre mechanoreceptors innervating normal first panel) and 
arthritic (second panel) knee joints from which ATP (2000nmol i. a.) evoked a slow - 
onset response. 
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6.3.1.3.2 Features of the ATP -evoked response 
No significant differences were found between normal and arthritic joints with 
respect to the delay, duration and magnitude of the delayed response evoked by ATP 
(Figure 6.9 and Figure 6.10). 
a) b) 
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Figure 6.9 Pooled data showing the a) onset latency and b) duration of the slow - 
onset response evoked by ATP (2000nmol i.a.) in C-fibres innervating normal and 




O Normal Joints 
II= Arthritic Joints 80- 
0 
Figure 6.10 Pooled data showing the change in a) in the number of action 
potentials firing and b) the action potential discharge frequency evoked by ATP 
(slow, 2000nniol i.a) nt C-fibres innervating normal and arthritic joints. Columns 
represent nieanieni. Normal joints n =10; arthritic joints n =19. 
6.3.1.4 Comparison between the excitation evoked by adenosine and ATP 
In experiments where adenosine and ATP were both injected, all of the C- fibres that 
were excited by adenosine also responded with a delayed excitation to ATP (normal 
n =8; arthritic n =14). In normal joints the delay to onset of the responses caused by 
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the purines were similar but in arthritic joints, the latency of the ATP evoked 
excitation was significantly (P <0.05) longer compared to that of adenosine (Figure 
6.l1a). The duration of the response evoked ATP tended to be longer than the 
response evoked by adenosine in both normal and arthritic joints but this difference 
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Normal Joints Arthritic Joints 
Figure 6.11 Pooled data showing the a) latency and b) duration of the slow 
response following injection of adenosine (370nmol i.a.) and ATP (2000nmol i.a) in 
C fibres innervating normal and arthritic joints. Columns represent mean em. 
*P <0.05 latency for ATP compared to adenosine in arthritic joints. Normal joints: 
adenosine n =9; ATP n =10; arthritic joints: adenosine n =7; ATP n =19. 
In normal joints, the total number of action potentials that fired in response to ATP 
was significantly (P <0.05) greater than the total number that fired in response to 
adenosine although the frequencies of the responses were similar (Figure 6.12). The 
same pattern was seen in arthritic joints but the total number of action potentials that 
fired following injection of ATP was not significantly greater that the total number 
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Normal Joints Arthritic Joints Normal Joints Arthritic Joints 
Figure 6.12 Pooled data from C fibres innervating normal and arthritic joints 
showing the change in a) the action potential discharge frequency and b) the number 
of action potentials evoked by adenosine (60mmol i.a.) and ATP (2000nmol i.a., slow 
response). Columns represent meanem. *P <0.05 impulses evoked by ATP 
compared to adenosine in normal joints. Normal joints: adenosine n =9, ATP n =10; 
arthritic joints: adenosine n =7, ATP 17=19. 
6.3.1.5 Comparison between the purine and known algogen- evoked excitations 
The increases in C -fibre nociceptor discharge caused by adenosine and ATP were 
compared to those evoked by the potent exogenous and endogenous algogens, 
capsaicin and bradykinin respectively. Figure 6.1 and Figure 6.6 clearly show that 
the temporal pattern of the response evoked by adenosine and the slow response 
evoked by ATP resemble the bradykinin- evoked response, whereas the fast ATP 
response is similar to the capsaicin- evoked response. 
In order to compare response caused by the purines to those following 
capsaicin and bradykinin, data from normal and arthritic joints was pooled. In C- 
fibres, there was no significant difference between the latency or duration of the 
slow -onset response evoked by adenosine and ATP in comparison with bradykinin, 
but they did differ significantly from capsaicin (Figure 6.13). 
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Figure 6.13 Pooled data from C fibre polymodal nociceptors innervating normal 
and arthritic joints showing the a) onset latency and b) duration of the responses 
evoked by i.a. injection of capsaicin (10nmol), bradykinin (9nmol), adenosine 
(370ninol) and ATP (2000nmol, slow response). Columns represent mean-lsem. 
Capsaicin n =21, bradykinin n =19, adenosine n =16, ATP n =29. * * *P <0.0001 
unpaired t -test compared to capsaicin. 
The size of the response evoked by capsaicin, bradykinin and the purines are 
compared in Figure 6.14. The change in the action potential discharge frequency 
following the injection of the purines was significantly smaller (P <0.001) than that 
evoked by capsaicin, but was similar to that evoked by bradykinin. The change in the 
total number of action potentials that fired following injection of adenosine, but not 
ATP, was significantly (P <0.05) smaller than the change evoked by capsaicin or 
bradykinin (Figure 6.14). 
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Figure 6.14 Pooled data from C fibre polymodal nociceptors innervating normal 
and arthritic joints showing the change in a) the action potential discharge 
frequency and b) the total number of action potentials that fired in response to i. a. 
injection of capsaicin (10nmol), bradykinin (9ninol), adenosine (370nmo1) and ATP 
(2000mnol, slow response). Cohnnns represent mean- I-sell!. Capsaicin n =21, 
bradykinin n =19, adenosine n =16, ATP n =29. Part a) * * *P <0.001 unpaired t -test 
compared to capsaicin. Part b) **P<0.01 unpaired t -test compared to capsaicin, 
+ +P <0.01 unpaired t -test compared to bradykinin. 
6.3.1.6 Characterisation of the receptor mediating the slow response to 
adenosine and ATP 
6.3.1.6.1 Responses evoked by selective adenosine receptor agonists 
The adenosine Al receptor selective agonists, CPA (30nmol i.a.) and GR79236 (85 
nmol i.a.) also evoked a slow -onset, long duration increase in the discharge of 
adenosine -positive C- fibres (Figure 6.15). In contrast, the adenosine A2 receptor 
agonist CGS21680 (190nmol i.a.) had no effect on adenosine -positive C -fibre 
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Figure 6.15 Summary of a) response onset latency b) response duration c) change 
in discharge frequency and d) change in action potential number following injection 
of CPA (30nntol i.a.) or GR79236 (85nmol i.a). Pooled data from C-fibres 
innervating normal and arthritic joints. Columns represent meanisent. CPA: normal 
joints n =11, arthritic joints n =5; GR79236 :: normal joints n =4. 
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6.3.1.6.2 Effect of purinoceptor antagonists on the purine- evoked responses. 
The adenosine Al receptor antagonist, DPCPX (3p.mol kg 1 i.a., 10 minutes pre- 
treatment) antagonised the slow excitation evoked by adenosine, ATP and CPA 
(Figure 6.16) but it did not affect the fast response evoked by ATP (see previous 
chapter). In contrast, the P2 receptor antagonist PPADS (16µmol kg -1 i.a., 10 minutes 
pre- treatment) antagonised the ATP -evoked fast response (see previous chapter) but 
did not block the adenosine, slow -ATP or CPA responses (Figure 6.16). 
=Control 
® DPCPX e PPADS 
T 
Figure 6.16 Pooled data from C- fibres innervating normal and arthritic joints 
showing the effect of DPCPX (3,umol kg 1 i.a.) and PPADS (16,umol kg 1 i.a) on the 
magnitude of the responses evoked by a) adenosine (370nmol), b) ATP (2000nmol) 
and c) CPA (30rmtol). The changes in action potential discharge frequency (i) and 
number of action potentials (ii) are shown. Columns represent meanent. *P <0.05 
and **P<0.01 Student 's paired t -test compared to control responses. Adenosine: 
DPCPX n =5, PPADS n =4; ATP: DPCPX n =6, PPADS n =3; CPA: DPCPX n =5, 
PPADS not done. 
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6.3.1.7 Effect of DPCPX on the spontaneous discharge of nociceptors 
innervating arthritic joints 
In order to establish whether endogenous adenosine contributed to the increased 
basal discharge seen in arthritic joints, the effect of DPCPX on spontaneous 
discharge was examined in 9 arthritic joints. The neural discharges of 21 C- fibres 
and 15 A6- fibres were recorded. Ten (48 %) of the C- fibres were spontaneously 
active and all were excited by adenosine or ATP (slow). Two (13 %) of the A6- fibres 
were spontaneously active but neither was excited by adenosine or ATP (slow). 
Administration of DPCPX (3p.mol kg -1 i.a.) did not reduce the basal firing rate of the 
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Figure 6.17 Pooled data from 10 adenosine positive CT-fibres showing the lack of 
effect of DPCPX (3,umol kg i.a.) on the elevated rate of spontaneous discharge of 
nociceptors innervating arthritic joints. 
6.3.1.8 Excitation following intra- articular injection of adenosine and ATP 
Adenosine (370 nmol) evoked a delayed increase in C -fibre discharge when injected 
i.art, and ATP (2000 nmol) caused a biphasic increase (Table 6.1). The slow 
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excitation following i.art. injection had a similar onset -latency and discharge 
frequency to those following i.a. injection in the same afferents. However, the 
increase in action potential discharge lasted for a significantly (P <0.001) longer time 
following i.art. injection and thus, significantly (P <0.001) more action potentials 
fired in total. 
Table 6.1 Comparison of the responses evoked by i.art. and i.a. injection of 
adenosine (370nmol) or ATP (2000nmol). * ** P <0.001 Mann- Whitney test vs i.a. 







Change in action potential 
frequency (impulses s -1) 







** *202 ±37 
1.37±0.34 








** *245 ±41 
6.3.1.9 ATPyS- evoked excitation of articular afferents 
The P2 agonist, ATPyS (900nmol i.a.) was tested on 19 afferents from four normal 
knee joints (12 C- fibres and 7 AS- fibres). Like ATP, it evoked a biphasic increase in 
action potential discharge consisting of a fast -onset (see previous chapter), followed 
by a delayed -onset increase in action potential discharge. The slow -onset response 
was evoked in 6 of 19 afferents tested (delay 15 +4s, duration 22 ±4, change in 
number of action potentials 50 ±15 impulses, n =6 (3 C- fibres and 3 AS- fibres)). The 
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adenosine Al receptor antagonist DPCPX was tested on the response evoked from 
three afferents and it was found to antagonise the slow component (see Table 6.2). 
Table 6.2 Characteristics of the slow -onset response evoked from C -fibre 
nociceptors by close- arterial injection of ATPyS (900nmol). * * *P <0.0001 Mann - 




Change in action potential 
frequency (impulses s-1) 







* * *5 ±3 
ATPyS (900nmol) was also tested on 16 afferents (9 C- fibres and 7 AS- fibres) by 
i.art. injection. Injection by this route also evoked a fast -onset (see Chapter 5) and a 
slow onset response, the latter was evoked from 20% (4/16 afferents, 2 C- fibres and 
2 AS- fibres) of afferents. As with ATP and adenosine, the duration and total number 
of impulses evoked by i.art. injection of this agonist were significantly greater than 
those following i.a. injection, whereas the latency and change of discharge frequency 
were similar (Table 6.3). 
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Table 6.3 Comparison of the responses evoked by i.art. and i.a. injection of 
ATPyS (7OOmnol,. * ** P <0.001 Mann - Whitney test versus i.a. injections, n =3 C- 
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6.3.2 BEHAVIOURAL STUDIES 
6.3.2.1 Dipyridamole and DPCPX trial 
6.3.2.1.1 General observations 
In this study, four treatment groups each with six male Wistar rats were used 
(dipyridamole, DPCPX, DPCPX & dipyridamole, and vehicle). The groups injected 
with the nucleoside transport inhibitor, dipyridamole, either alone or after DPCPX, 
appeared sluggish and lethargic during the drug treatment period. This was probably 
due to the known sedative and motor inhibitory effects of adenosine (see Sawynok & 
Sweeney, 1989). The effects were not apparent in rats injected with DPCPX alone or 
vehicles. 
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6.3.2.1.2 Body weight 
The weight of the rats was measured throughout the trial to monitor their general 
health (Figure 6.18). All rats, including the vehicle group, lost weight during the drug 
treatment period. In order to assess differences in weight loss, the mean cumulative 
change in weight from a selected control (mean of Days -1 and 0) over Days 1 -5 was 
determined (Figure 6.19). The group injected with DPCPX (lmg kg-1 i.p., once daily) 
10 minutes before dipyridamole, lost significantly (P <0.01) more weight over Days 
1 -5 in comparison with vehicle. Rats injected with either compound alone also lost 
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Figure 6.18 Effect of injection of dipyridamole (40mg kg' i.p., once daily), 
DPCPX (ling kg"' i.p., once daily), both compounds and vehicles (0.1m1 kg' i.p.) on 
the body weight of monoarthritic rats. Rats were injected with DPCPX 10 minutes 
before dipyridamole. The thick line above the x -axis indicates the 7 -day treatment 
period. 
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Figure 6.19 Cumulative change in body weight from control period: effect of 
dipyridamole (40nig kg' i.p., once daily), DPCPX (1mg kg' i.p., once daily), both 
compounds and vehicles (0.1ní1 kg-1 i.p.). Rats were injected with DPCPX 10 minutes 
before dipyridamole. Columns represent mean +sem. Control was mean of Days -1 
and 0, and change was determined over Days 1 -5. "P<0.01 01 vs vehicle, one way 
AVOVA followed by Tukey's multiple comparison test. 
6.3.2.1.3 Allodynia 
The weight placed on each hindlimb was measured using the dual channel weight 
averager (Clayton et al., 1997) and original data is shown in Figure 6.20. 
a) b) 
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Figure 6.20 Effect of injection of dipyridamole (40mg kg' i.p., once daily), 
DPCPX (lnig kg-' i.p., once daily), both compounds and vehicles (0.1m1 kg' i.p.) on 
a) ipsilateral and b) contralateral hindlimb weight bearing in monoarthritic rats. 
Rats were injected with DPCPX 10 minutes before dipyridaniole. The thick lisle 
above the x -axis indicates the 7 -day treatment period. 
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The cumulative change in left and right hindlimb weight bearing is shown in Figure 
6.21. When compared to the vehicle- treated group, rats injected with dipyridamole, 
which increases endogenous extracellular adenosine concentrations, placed 
significantly (P <0.05) more weight on their ipsilateral hindlimbs, and significantly 
less weight on their contralateral hindlimbs, indicating an analgesic effect of the 
compound. When DPCPX was injected before dipyridamole, this effect was not 
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Figure 6.21 Cumulative change from control period in a) contralateral and b) 
ipsilateral hindlimb weight- bearing: effect of dipyridamole (40mg kg' i.p., once 
daily), DPCPX (1mg kg i.p., once daily), both compounds and vehicles (0.1ml kg' 
i.p.). Rats were injected with DPCPX 10 minutes before dipyridamole. Columns 
represent meanem. Control was mean of Days -1 and 0, and change was 
determined over Days 1 -5. *P <0.05 dipyridamole vs vehicle one way AVOVA 
followed by Tukey 's multiple comparison test. 
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6.3.2.1.4 Knee diameter 
The knee joint diameter was measured in order to give an indication of the potential 
anti -inflammatory properties of the adenosine -related compounds. The original joint 







1.75 - -0- Vehicle 
--- Dipyridamole 
1.50 - DPCPX 
Dipyridamole 
1.25- & DPCPX 
1.00 - 
0.75- 
-5 0 5 10 15 -5 0 5 10 15 
Day before and after 
arthritis induction 
Day before and after 
arthritis induction 
Figure 6.22 Effect of injection of dipyridamole (40mg kg t i.p., once daily), 
DPCPX (1mg kg t i.p., once daily), both compounds and vehicles (0.1ml kg-.1 i.p.) on 
a) ipsilateral and b) contralateral knee joint diameter in monoarthritic rats. Rats 
were injected with DPCPX 10 minutes before dipyridamole. The thick line above the 
x -axis indicates the 7-day treatment period. 
To assess differences between groups, data was expressed as the cumulative change 
over Days 1 -5 from control. No significant differences between any of the groups 



















Figure 6.23 Cumulative change from control period in a) contralateral and b) 
ipsilateral knee joint diameter: effect of dipyridamole (40mg kg' i.p., once daily), 
DPCPX (1 mg kg' i.p., once daily), both compounds and vehicles (0.1 ml kg' i.p.). 
Rats were injected with DPCPX 10 minutes before dipyridamole. Columns represent 
meaiilem. Control was mean of Days -1 and 0, and change was determined over 
Days 1 -5. No significant differences between groups were detected using one way 
AVOVA followed by 7ukey's multiple comparison test. 
6.3.2.2 GR79236 and DPCPX trial 
6.3.2.2.1 General observations 
Four treatment groups with six rats each were used in this study (GR79236, DPCPX, 
DPCPX & GR79236, and vehicle). Sedative and locomotor inhibitory effects were 
apparent in the rats injected with the adenosine Al receptor selective agonist 
GR79236. No apparent motor or depressant effects were seen in the other groups. 
6.3.2.2.2 Body weight 
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The mean body weight of the rats is shown in Figure 6.24 and the cumulative 
changes over Days 1 -5 from control (mean of Days 1 and 2) are shown in Figure 
6.25. The group that were injected with DPCPX (lmg kg-1 i.p., 3 times daily), lost a 
significant amount of weight in comparison with the vehicle injected group. The 
groups that were injected with GR79236 (0.3mg kg -1 s.c., 2 times daily) or DPCPX 
followed by GR97236 did not suffer significant weight loss. 
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Figure 6.24 Effect of injection of GR79236 (0.3mg kg' s.c., 2 times daily), 
DPCPX (ling kg' i.p., 3 times daily), both compounds and vehicles (0.1ml kg' i.p.) 
on the body weight of monoarthritis rats. Rats were injected with DPCPX 30 minutes 
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Figure 6.25 Cumulative change in body weight from control period: effect of 
GR79236 (0.3mg kg' s.c., 2 times daily), DPCPX (1mg kg' i.p., 3 times daily), both 
compounds and vehicles (0. Iml kg' i.p.). Rats were injected with DPCPX 30 minutes 
before GR79236. Columns represent mean-fsem. Control was mean of Days -1 and 
0, and change was determined over Days 1 -5. *P <0.05 DPCPX vs vehicle, one way 
AVOVA followed by Tukey's multiple comparison test. 
165 
Chapter 6: Knee joint nociceptor adenosine receptors 
6.3.2.2.3 Allodynia 
Original data is shown in Figure 6.26 and cumulative results are shown in Figure 
6.27. No significant differences between groups were found. 
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Figure 6.26 Effect of injection of GR79236 (0.3mg kgf s.c., twice daily), DPCPX 
(1mg kgf i.p., 3 times daily), both compounds and vehicles (0.1m1 kgf i.p.) on a) 
ipsilateral and b) contralateral hindlimb weight bearing in monoarthritic rats. Rats 
were injected with the DPCPX solutions 30 minutes before GR79236 solutions. The 
thick line above the x -axis indicates the 7-day treatment period. This figure is for 
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Figure 6.27 Cumulative change in a) contralateral and b) ipsilateral hindlimb 
weight -bearing from control period: effect of GR79236 (0.3mg kg-1 s.c., 2 times 
daily), DPCPX (1mg kg-1 i.p., 3 times daily), both compounds and vehicles (0.1m1 kg- 
. Rats were injected with DPCPX 30 minutes before GR79236. Columns 
represent mean ene. Control was mean of Days -1 and 0, and change was 
determined over Days 1 -5. No significant differences between groups were observed 
using one way AVOVA followed by Titkey's multiple comparison test. 
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6.3.2.2.4 Knee diameter 
The original knee joint diameter measurements are illustrated for information only in 
Figure 6.28 and cumulative measurements are shown in Figure 6.29. GR79236 
significantly (P <0.05) reduced the swelling in the knee joint compared to vehicle, 
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Figure 6.28 Effect of injection of GR79236 (0.3mg kg -1 s. c., twice daily), DPCPX 
(1mg kg t i.p., 3 times daily), both compounds and vehicles (0.1ml kg 1 i.p.) on a) 
ipsilateral and b) contralateral knee joint diameter in monoarthritic rats. Rats were 
injected with the DPCPX solutions 30 minutes before GR79236 solutions. The thick 
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Figure 6.29 Cumulative change in a) contralateral and b) ipsilateral hindlimb 
knee joint swelling from control period: effect of GR79236 (0.3mg kg 1 s. c., 2 times 
daily), DPCPX (ling kgt i.p., 3 times daily), both compounds and vehicles (0.1m1 kg 
i.p.). Rats were injected with DPCPX 30 minutes before GR79236. Columns 
represent meanfsem. Control was mean of Days -1 and 0, and change iwas 
determined over Days 1 -5. *P <0.05 GR79236 vs vehicle, +P <0.05 DPCPX pre- 
treatment on GR79236 one way AVOI''A .followed by Titkey's multiple comparison 
test. 
6.4 DISCUSSION 
The main finding from the work in this section is that adenosine excites the majority 
of C -fibre polymodal nociceptors innervating the rat knee joint (Dowd et al., 1998a; 
Dowd et al., 1998b). However, the adenosine Al receptor antagonist, DPCPX, which 
antagonised the adenosine -evoked response, does not reduce the elevated basal 
discharge of adenosine -positive C- fibres innervating arthritic joints, nor does it 
reduce the weight -bearing allodynia associated with adjuvant arthritis. Paradoxically, 
dipyridamole, which increases extracellular adenosine levels, is anti- rather than pro - 
nociceptive in adjuvant arthritic rats. These findings support the hypothesis that 
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adenosine excites rat knee joint nociceptors, but they do not support an algogenic 
role for endogenous adenosine in inflammatory pain induced by FCA in the rat knee 
joint. 
The C -fibre excitation induced by adenosine appears to be mediated by 
adenosine Al receptors because it was antagonised by the Al receptor selective 
antagonist, DPCPX, and mimicked by the Al receptor selective agonists CPA and 
GR79236. In contrast, CGS21680, a selective agonist for the adenosine A2A receptor 
subtype, did not excite nociceptors innervating the rat knee joint. These findings are 
consistent with reports that the Al receptor is responsible for adenosine -induced pain 
in humans (Ahlgren & Levine, 1993; Gaspardone et al., 1995; Lee & Yaksh, 1996; 
Pappagallo et al., 1993) and for activating canine cardiac and rat pulmonary afferents 
in vivo (Dibner- Dunlap et al., 1993; Hong et al., 1998; Huang et al., 1995). 
However, the results of the present investigation contrast with findings of Taiwo and 
Levine (1990) who reported that intra- dermal injection of A2, but not Al adenosine 
receptor agonists caused mechanical hyperalgesia in the rat hind -paw. These authors 
also found that adenosine Al receptor activation prevented the sensitisation induced 
by A2 receptor agonists or by PGE2, and these effects were attributed to direct effects 
on the primary afferent nociceptor. However, the effects of adenosine receptor 
agonists on noxious stimulus- evoked discharge (neural correlate of hyperalgesia) 
were not investigated in the present study. Thus, the present data is not directly 
comparable with the Taiwo and Levine investigation. It also cannot be excluded that 
the second messenger systems activated by adenosine receptors expressed on the 
knee joint nociceptors differs from those stimulated in the rat hindpaw. In the rat 
hindpaw, increases in intracellular cAMP levels were implicated in adenosine A2 
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receptor mediated hyperalgesia in the hindpaw, whereas, decreases in cAMP 
accounted for At receptor mediated inhibition of sensitisation (Taiwo & Levine, 
1990). Adenosine A, receptors, like bradykinin B2 receptors, are also coupled to 
PKC ( Fredholm el al., 1996), which may have accounted for the excitation seen in 
the present investigation. This could be tested by pre -treating rats with a PKC 
inhibitor and determining whether afferent excitation by adenosine can still be 
elicited. 
The nucleotide, ATP, evoked a biphasic increase in afferent discharge. In 
normal knee joints, the slow component was similar in size, latency and duration to 
the adenosine- evoked response, and was antagonised by DPCPX. Thus, the delayed 
increase was likely to be mediated by adenosine, produced by metabolism of ATP, 
also acting at metabotropic adenosine A1 receptors. Interestingly, different 
populations of afferents were excited during the fast and slow components of the 
ATP -evoked excitation. As this chapter is largely concerned with adenosine's 
effects, the potential significance of this will be considered in the General 
Discusssion. 
The latency to onset of the slow responses evoked by adenosine and ATP did 
not differ significantly from that of the directly acting algogen, bradykinin, a finding 
compatible with adenosine having a direct mode of action on the primary afferent 
terminals. Excitation of joint nociceptors by adenosine and ATP could be evoked by 
i.art. injection of the purines, suggesting that the excitatory responses obtained were 
not secondary to effects on the vasculature. The evidence obtained makes it probable 
that the excitation of nociceptive afferents evoked by adenosine, either injected or 
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produced by the metabolism of ATP, resulted from a direct action on nociceptive 
nerve terminals. 
The latency of the ATP -evoked slow response in arthritic knees was 
increased relative to its latency in normal joints, and with respect to the latency of the 
response to adenosine in arthritic joints. This might be due to changes in the activity 
of ATP -metabolising enzymes in the arthritic knee joints because it is known that the 
half -life of ATP in the synovial fluid of patients with arthritis is increased (Park et 
al., 1996), that is, it is metabolised more slowly. This would explain why the latency 
to onset of the ATP response is increased in arthritic joints, but the latency to onset 
of the adenosine response is not. 
The cellular concentration of ATP is in the millimolar range and release of 
the nucleotide into the extracellular space during inflammation is expected to lead to 
high local concentrations of both ATP and adenosine (Gordon, 1986). The dose of 
exogenous adenosine used in the present study (370nmol i.a.) was estimated to 
produce a local concentration of 0.37mM, considerably less than that which is 
estimated to occur in vivo during inflammation. Since exogenous adenosine activated 
most knee joint C -fibre polymodal nociceptors, it was expected that endogenous 
adenosine might have contributed to the elevated discharge of nociceptors 
innervating arthritic joints. However, DPCPX, which antagonised the excitatory 
effects of close -arterially injected nucleoside, did not reduce the elevated 
spontaneous activity of adenosine -sensitive nociceptors, suggesting that these 
afferents were not tonically activated by endogenous adenosine. However, as 
discussed in the previous chapter, the mild chronic arthritis induced by FCA may not 
have been sufficient to cause adequate ATP release, and hence sufficiently high 
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extracellular adenosine production. Consistent with the suggestion that the arthritis 
was too mild, it was expected that afferents innervating arthritic joints might be 
sensitised to the effects of the purines because substance P levels are increased in 
adjuvant arthritis (Ahmed et al., 1995) and this tachykinin augments the adenosine - 
evoked excitation of canine cardiac neurones (partly mediated by the Al subtype, 
Huang el al., 1995). However, the afferent responses to adenosine and ATP were 
unaffected by arthritis in the knee joint in the present study, possibly indicating that 
levels of the tachykinin were not increased in the knee joints (or that substance P 
does not enhance the response of rat knee joint nociceptors to adenosine). It would be 
valuable to assess the effect of DPCPX on spontaneous discharge during 
electrophysiological studies of more severely inflamed rat knee joints. 
Although the electrophysiological studies do not support a causative role for 
endogenous adenosine (acting via the Al subtype) in spontaneous nociceptor 
discharge in the monoarthritic rat, the present study does not preclude a role for 
adenosine in stimulus- evoked afferent discharge. Furthermore, the nucleoside may be 
released in a phasic manner, be enhancing the actions of another endogenous 
algogen, or influencing nociceptors over a longer time scale than the 3 -4 hours 
investigated in the present experiments. In order to study the longer term effects of 
endogenous adenosine, the effects of the nucleoside uptake inhibitor, dipyridamole, 
the adenosine A1 receptor selective antagonist, DPCPX, and the Al receptor selective 
agonist, GR79236, were investigated during the early phase of adjuvant arthritis. 
Despite the finding that adenosine excites nociceptors via Al receptors, 
DPCPX, injected either once or three times daily, did not have any analgesic effects 
in the hindlimb weight bearing test during the initial phase of monoarthritis. This 
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finding suggests that insufficient levels of the adenosine are released during the early 
phase, or that adenosine is not involved in causing this type of inflammatory pain. 
However, interpretation of the behavioural studies is complicated because the drugs 
were injected systemically and could have mediated their effects through peripheral, 
spinal and /or supraspinal sites. Adenosine is well known to cause analgesia 
following spinal administration, an effect primarily mediated by Al receptors and 
thought to contribute to opioid analgesia (see Keil, 1996; Sawynok, 1998). If spinal 
adenosine is tonically released during this phase of experimental arthritis, 
antagonism of spinal adenosine Al receptors could have disguised any analgesic 
effects of antagonising Al receptors on the nociceptive afferents. In order to separate 
the spinal and peripheral effects of Al receptor antagonism, it would be interesting to 
investigate the effect of administration of DPCPX into the joint on the development 
of arthritic pain. However, this would not be feasible because the effects of DPCPX 
last for only 4 hours (N. Clayton, personal communication) and it would be injurious 
to repeatedly inject the rat knee joint. Furthermore, DPCPX is usually dissolved in a 
solution containing the noxious agent, dimethylsulphoxide, which would have a local 
algesic effect following i.art. injection. Thus, unless 1) a method of infusing the rat 
joint (perhaps by implanting a cannula) is developed and 2) a "non- noxious solution 
soluble" selective Al receptor antagonist is used, then it will not be possible to 
determine the effects of antagonising articular Al receptors on inflammatory pain. 
In contrast to the results of the neural recordings, dipyridamole, which raises 
endogenous extracellular adenosine levels, was analgesic in the weight -bearing test. 
This effect was not observed when the rats were pre- treated with DPCPX indicating 
an Al receptor mediated analgesic effect. This analgesia could have been due the 
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actions of adenosine at spinal Al receptors. In order to examine further the effects of 
Al receptor activation, the adenosine Al receptor agonist, GR79236, was 
administered. This agonist had no effect on inflammatory pain as assessed using the 
weight- bearing device. Considering that Al receptors have consistently been shown 
to mediate analgesia at spinal sites in many acute and chronic pain models 
(Sawynok, 1998), and that i.p. dipyridamole was analgesic in the present study, it is 
surprising that no analgesia was observed following i.p. injection of GR79236. This 
is a relatively new adenosine agonist and its use in vivo has been limited to date. 
Therefore, little is known about the penetration of this agonist to spinal sites 
following subcutaneous injection. Thus, analgesic levels of the compound may not 
have been reached in the spinal cord. 
The knee joint diameter was measured in order to assess the anti - 
inflammatory potential of the adenosine compounds. Agents that raise endogenous 
adenosine levels have repeatedly been shown to have anti -inflammatory effects 
largely thought to be due to adenosine A2 receptor activation (Cronstein, 1994; 
Cronstein, 1995; Cronstein et al., 1996; Firestein, 1996; Firestein et al., 1994). In the 
present investigation, rats injected with dipyridamole, either alone or following 
DPCPX, tended to have less inflamed joints than the other groups although this did 
not reach statistical significance. Nevertheless, this suggests that adenosine 
accumulation may also be anti -inflammatory in this monoarthritis model, and that the 
Al subtype does not mediate this effect. It would be valuable to explore this 
possibility further by trying different dipyridamole injection protocols in order to 
generate high endogenous adenosine levels. Interestingly, GR79236 significantly 
reduced swelling of arthritic knee joints during the drug treatment period indicating 
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that it has anti- inflammatory properties in the monoarthritis model. Although the 
anti- inflammatory effects of adenosine are largely attributed to A2 receptor activation 
(Cronstein, 1994; Cronstein et al., 1996), activation of Al receptors is also known to 
have anti -inflammatory properties (it prevents neutrophil accumulation) in vivo 
(Lesch et al., 1991; Schrier et al., 1990). The mechanism through which GR79236 
mediated its anti -inflammatory effect is not known, but it is possible that the agonist 
prevented neutrophil accumulation at the site of the arthritic lesion. Detailed 
histological studies of GR79236- treated monoarthritic rat knee joints would confirm 
this. Interestingly, A1 receptors are normally associated with pro -inflammatory 
effects in vitro (Cronstein, 1994; Cronstein et al., 1996). Since the present study has 
demonstrated an anti -inflammatory effect of GR79236, the physiological relevance 
of the pro -inflammatory effects of Ai receptors is questionable. 
In summary, the data presented in this chapter have shown that half of the C- 
fibre nociceptors innervating the rat knee joint express functional adenosine Al 
receptors. Thus, extracellular adenosine, which increases following ATP release 
during inflammation, could act directly on the nociceptors to exacerbate 
inflammatory pain. The present investigation has not explored the contribution of 
adenosine to stimulus -evoked afferent discharge, but as discussed in the previous 
chapter, ATP, and therefore adenosine, is released from cells during mechanical 
stimulation indicating a possible role in allodynia and /or hyperalgesia. The effects of 
endogenous adenosine on weight- bearing allodynia were investigated in behavioural 
studies, and despite the peripheral algesic effects of adenosine, dipyridamole, which 
increases endogenous extracellular adenosine levels, was anti -allodynic in this test, 
possibly via a central mechanism of action. This suggests that the potential peripheral 
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algesic effects of adenosine accumulation by agents such as nucleoside transport, 
adenosine kinase and adenosine deaminase inhibitors is overcome probably through 
opposing central effects. Thus, if these agents are developed as disease -modifying 
anti -rheumatic drugs, they are unlikely to exacerbate the pain of RA, and may even 
alleviate it. 
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Chapter 7: The indirect role of ATP in knee joint nociception 
7.1 INTRODUCTION 
Interleukin -1ß (Il -lß) is a potent pro- inflammatory cytokine that is released from a 
variety of cells including macrophages, mast cells, synoviocytes and fibroblasts 
during inflammation and which plays a key role in the pathogenesis of RA 
(Feldmann et al., 1996). The significance of this cytokine as a pro- inflammatory 
mediator in RA is highlighted by the fact that agents that inhibit the effects of Il -113 
are currently in clinical trials for the treatment of the disease (see Arend & Dayer, 
1995). II -13 is also known to have potent pro -nociceptive properties (Bianchi et al., 
1998) and probably contributes to the pain associated with RA. This is supported by 
the preliminary results of an early clinical trial showing that treatment of RA patients 
with interleukin receptor antagonist alleviates joint pain (Campion et al., 1996). If 
the mechanisms underlying the release of I1-1 f3 during disease states were fully 
understood, novel therapeutic strategies for the treatment of RA could be developed. 
Il -13 is synthesised in the cytoplasm from an inactive precursor, pro- Il -113, by 
Il -10- converting enzyme (ICE, Cerretti et al., 1992; Molineaux et al., 1993; 
Thornberry et al., 1992). One of the best characterised triggers of intracellular pro-II- 
113 accumulation in vitro is LPS (Giri et al., 1985). In LPS treated cells, the 
interleukin precursor and ICE coexist in the cell and a secondary stimulus is needed 
to activate ICE and release active II -113 (Hogquist et al., 199lb; Perregaux & Gabel, 
1994). ATP is one of the known triggers of II -113 release from LPS -primed 
macrophages both in vitro (Ferrari et al., 1997a; Perregaux & Gabel, 1994) and in 
vivo (Griffiths et al., 1995). This effect is mediated by the P2X7 subtype of ATP- 
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gated cation -channel receptors (Ferrari et al., 1997a) which are expressed on a 
variety of inflammatory and immune cells (Collo et al., 1997; Divirgilio, 1995). If 
this action is physiologically relevant in vivo, then the actions of ATP at the P2X7 
receptor could contribute significantly to inflammatory pain by releasing Il -lß. Thus, 
antagonists of P2X7 receptors could have potential for the treatment of RA. 
This study tested the hypothesis that ATP indirectly excites and /or sensitises 
articular nociceptors by causing I1 -113 release from LPS pre- treated cells in the rat 
knee joint in vivo via P2X7 receptors. Intra- articular injection of II -1ß into the knee 
joint has previously been shown to increase the spontaneous and bradykinin- evoked 
discharge of nociceptors innervating the joint (Kelly, 1998; Kelly et al., 1996; Kelly 
et al., 1997). Thus, in the present study, two P2 receptor agonists at the P2X7 
subtype, ATPyS and BzATP were injected i.art. into the knee joint, either alone or 
following pre- treatment with LPS, and their effects on spontaneous and bradykinin- 
evoked discharge of nociceptors innervating the knee joint were recorded. 
7.2 METHODS 
7.2.1 AFFERENT NERVE RECORDINGS IN VIVO 
Electrophysiological studies were carried out as described in Section 2.1.2. In brief, 
extracellular neural activity in the MAN innervating the left knee joint was recorded 
under pentobarbitone anaesthesia and data was analysed off -line. 
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7.2.1.1 Experimental protocols 
These experiments were carried -out as a number of pilot studies to determine the 
appropriate dose and pre- treatment time of LPS. In most experiments, drugs were 
injected i.art. to the knee joint, but in a small number, they were injected i.p. 
7.2.1.1.1 Intra- articular injections 
Six normal male Wistar rats, and eight rats following pre- treatment with LPS (see 
below) were used in this section (weight range 286 -342g; mean ±sem 317 ±24g) 
Normal joints: 
Dose -response data for bradykinin- evoked excitation of the knee joint nociceptors 
following close -arterial injection (i.a.) was obtained. The P2 agonists ATPyS 
(900nmol, i.art.) and BzATP (700nmol, i.art.) were then injected i.art. and the 
spontaneous discharge over the following 30 minutes was recorded. 30 -45 minutes 
post- injection of the nucleotides, the bradykinin injections were repeated. 
LPS pre- treated joints: 
In four joints LPS (0.01 -1µg, i.art.) was injected 2 hours prior to injection of the P2 
receptor agonists during the neural recordings. The rest of the experiment was 
performed as described for normal joints. In four other rats, LPS (1 -5µg, i.art.) was 
injected the day before the neural recording, 24 hours prior to the nucleotide 
injections. 
7.2.1.1.2 Intra- peritoneal injections 
In a seven male Wistar rats (weight range 298 -310g; mean±sem 306 ±4g), LPS 
(10mg kg') was injected i.p. 2 hours before ATP (9000nmol, i.p.). Spontaneous 
discharge was recorded throughout the experiment. 
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7.3 RESULTS 
7.3.1 AFFERENT NERVE RECORDINGS IN VIVO 
7.3.1.1 Intra- articular injections 
Neural discharge was recorded from a total of 23 single afferent fibres innervating 
six normal knee joints, 11 afferents innervating four knee joints before and /or 2 
hours after i.art injection of lipopolysaccharide (LPS, 0.01 - 11..tg) and 16 afferents 
innervating four knee joints 24 hours after pre- treatment with LPS (1 - 4tg i.art.). 
The fibres were classified as C -fibre polymodal nociceptors or AS -fibre 
mechanooreceptors as described in Section 4.3.1.1. Of the afferents recorded from, 
42% (28/66 afferents) were classified as C -fibre polymodal nociceptors and 58% 
(38/66) were classified as AS -fibre mechanooreceptors. 
7.3.1.1.1 Effect of LPS pre -treatment on neural discharge 
The effect of LPS pre- treatment alone was analysed to determine what effect the 
endotoxin had on the discharge of knee joint afferents. No difference was detected 
between the results obtained with the different doses of LPS and therefore, data were 
pooled for each dose. 
7.3.1.1.1.1 Spontaneous discharge 
The effect of LPS (0.01 - 1µg i.art., 2 hours pre- treatment) on the spontaneous 
discharge of 11 afferents was investigated in 4 experiments. Of the afferents 
recorded, only 2 of 9 C- fibres (22 %) and 1 out of 2 A8- fibres (50 %) were 
spontaneously active before LPS. After injection of LPS (2 hours post- injection), no 
additional nociceptors were recruited. The two C- fibres, but not the AS- fibre, 
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continued to display basal activity (Figure 7.1a). It was not possible to determine 
whether LPS had any significant effect on the neural discharge because so few 
nociceptors were spontaneously active (Figure 7.1b). 
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Figure 7.1 Effect of LPS (0.01 - 1,ug i.art.) on the spontaneous discharge of 
nociceptors. Part a) shows the percentage of nociceptors firing spontaneously before 
and 2 hours after LPS (C fibres: before and after n =2/9; AS- fibres: before fr =1/2, 
after n =0/2). Part b) shows the rate of action potential discharge of the two C-fibres 
and the AS-fibre before and over the 2 hours following injection of LPS. 
In four animals LPS (1 - 5µg) was injected i.art. into the left knee joint under 
transient halothane anaesthesia 24 hours before the neural experiment. To determine 
whether the LPS pre- treatment significantly affected the basal discharge of afferents 
innervating these joints, the results obtained were compared with those from 
afferents innervating the 10 normal knee joints investigated in this section. A greater 
proportion of afferents discharged spontaneously after LPS (3/5 C- fibres and 4/11 
AS- fibres) compared to normal knee joints (5/23 C- fibres and 3/27 AS- fibres) but 
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Figure 7.2 Effect of LPS (1 - 5,ug i.art., 24 hours pre -treatment) on a) the 
percentage of nociceptors firing spontaneously and b) the rate of action potential 
discharge frequency in normal compared to LPS pre -treated joints. Number of 
spontaneous c-fibres: normal n =5/23, LPS n =3/5; A6-fibres: normal n =3/27, after 
n =d /11. 
7.3.1.1.1.2 Bradvkinin- evoked neural discharge 
Five of the 11 C- fibres recorded before and after LPS (0.01 - 1µg i.art., 2 hours pre- 
treatment) were activated by bradykinin (3, 10 and 30nmol i.a.). The effect of LPS 
on the response evoked by each individual dose of bradykinin was investigated in 
these afferents. Ideally, it would have been more appropriate to investigate the effect 
of LPS on the bradykinin ED50 for activation of the afferents, but this was not 
feasible because only a three -point dose -response curve was constructed. 
LPS had no significant effect on the latency or duration of the response 
evoked by bradykinin (Figure 7.3), but both the discharge frequency and the total 
number of action potentials evoked by the algogen tended to be increased following 
LPS pre- treatment (Figure 7.4). However, only the number of action potentials 
evoked by the highest dose (30nmol) of bradykinin was significantly (P <0.05) 
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Figure 7.3 Pooled data showing the a) 
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Six (3 C- fibres and 3 M- fibres) of the afferents recorded from after LPS (1 -5µg 
i.art., 24 hours pre- treatment) were excited by bradykinin. When compared to normal 
joints, the response evoked by bradykinin in LPS pre- treated joints was not 
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Figure 7.5 Pooled data from 3 C fibres and 3 A5-fibres innervating the knee joint 
showing the a) onset latency and b) duration of the response evoked by bradykinin 
(3, 9 and 30nmol, i. a.) in normal and LPS pre- treated (1 - Sftg, i. art., 24 hours pre- 
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Figure 7.6 Pooled data from 3 C- fibres and 3 A5-fibres innervating the knee joint 
showing the change in action potential a) frequency and b) number evoked by 
bradykinin (3, 10 and 30mnol, i. a.) in normal and LPS pre- treated (1 - S,ug, i. art. , 24 
hours pre -treatment) joints. Columns represent mean em. 
7.3.1.1.2 Effect of ATPyS on neural discharge 
7.3.1.1.2.1 Spontaneous neural discharge 
ATPyS (900nmol, i.art.) was tested on 15 afferents (8 C- fibres and 7 AS- fibres) 
innervating 4 normal knee joints and 24 afferents (11 C- fibres and 13 M- fibres) 
innervating 4 knee joints 2 hours after pre- treatment with LPS (0.01 - lug i.art.). 
Intra- articular injection of the agonist evoked a biphasic increase in action potential 
discharge consisting of a fast -onset response, apparently mediated by the P2X 
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subtype(s) expressed on the afferent terminals, and a sustained, slow -onset response, 
apparently mediated by adenosine Al receptors, as described in Sections 5.3.1.8 and 
6.3.1.8. The fast response has been discussed previously (Chapter 5) and not be 
considered further in this chapter, but the slow response will be described because it 
caused difficulties in the present experiments. This delayed excitation was seen in 
33% (5/15) and 71% (17/24) of afferents innervating normal and LPS pre- treated 
joints respectively. Fibres that were slowly activated following i.art. injection of the 
nucleotide were also slowly activated by i.a. administration of adenosine (370nmol) 
or ATP (2000nmol, data not shown). Similarly, fibres from which i.art. ATPyS did 
not elicit a delayed excitation, were not activated by i.a. injection of adenosine. No 
difference in the discharge of C- fibres and M- fibres was evident, so data from both 
fibre types were pooled for this section. 
Discharge of afferents from which ATPyS evoked a slow response: 
In normal joints, the increase in action potential discharge in afferents from which 
ATPyS evoked a slow response (2 C- fibres and 3 AS- fibres) was greatest at 1 minute 
post -injection and declined over the following 20 minutes but did not return to pre - 
injection levels (Figure 7.7a). After pre -treatment with LPS, a similar pattern was 
observed in 10 C- fibres and 7 AS- fibres, but the increase in frequency remained 
elevated for longer (Figure 7.7a). However, this augmentation did not reach 
statistical significance when the data was expressed as a cumulative change from the 
pre -injection discharge frequency (Figure 7.7b). Because evidence from earlier 
experiments suggested that the slow response evoked by ATPyS was mediated by 
adenosine acting at adenosine Al receptors, the Al receptor selective antagonist 
DPCPX (3 - 6µmol, i.a., 10 minutes pre -treatment) was used to try to block the 
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sustained increase. However, the antagonist had no significant effect on the elevated 
rate of action potential discharge following ATPyS injection in LPS pre- treated knees 
(Figure 7.7). DPCPX was not studied in normal joints. 
a) 
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Figure 7.7 The delayed response evoked by ATPyS (900nmol, i.art) from 
afferents innervating normal and LPS pre -treated (0.01 - 1 p i.art., 2 hours pre - 
injection) joints. Part a) shows the discharge .frequency up to 25 ininrttes post- 
injection, and part b) shows the crnnttlative change. from the pre -injection frequency. 
The lack of effect of the adenosine Al receptor antagonist DPCPX (3 - bumol, i.a. 10 
minutes pre -treatment) on the delayed increase in afferent discharge is shown. The 
fast response evoked by ATPyS is not included in this graph. Data pointsícolunms 
represent mean -sem. Normal joints: n =5 afferents; LPS treated joints: without 
DPXPX n= 7afferents, with DPCPX n =10 afferents. 
Discharge of afferents. from which ATPyS did not evoke a slow response: 
ATPyS did not evoke a slow response from 10 afferents (6 C- fibres and 4 AS- fibres) 
innervating normal joints and 7 afferents (2 C- fibres and 5 AS- fibres) innervating 
LPS pre- treated joints. In these afferents, no effect on basal discharge was observed 
following injection of ATPyS when measured over 25 minutes (Figure 7.8). 
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Figure 7.8 Lack of delayed response following injection of ATPyS (900nmol, 
Lan) from afferents innervating normal and LPS pre- treated (0.01 - 1 p Lail., 2 
hours pre-injection) joints. The fast response evoked by ATPyS is not included in this 
graph. Data points represent mean-fsem. Normal joints: n =10 afferents; LPS treated 
joints: without n =7 afferents. 
7.3.1.1.2.2 Bradvkinin- evoked neural discharge 
The effect of a single bolus i.art. injection of ATPyS (900nmol, 30 minutes pre- 
treatment) on the response evoked by bradykinin (3, 9 and 30nmol, i.a.) was 
investigated in 7 afferents (6 C- fibres and 1 AS- fibre) innervating 4 normal knee 
joints and 8 afferents (7 C- fibres and 1 AS- fibre) innervating 4 knee joints 2 hours 
after i.art. injection of LPS (0.01 - 1µg). ATPyS had no significant effect on the 
latency, duration, or size of the response evoked by bradykinin either in normal or 
LPS pre- treated joints (Figure 7.9 and Figure 7.10). 
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Figure 7.9 Pooled data showing the a) onset latency and b) duration of the 
response evoked by bradykinin (3, 9 and 30nmol, i.a.) before and after injection of 
ATPyS (900nmol i.art, 30 minutes pre -treatment) from nOciceptOrs innervating 
normal (i) and LPS injected (0.01 -Lug, i.art., 2 hours pre -treatment) knee joints 
(ii). Columns represent meanfsem. Normal joints n =7 afferents; LPS pre -treated 
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Figure 7.10 Pooled data showing the change in action potential a) discharge 
frequency and b) number evoked by bradykinin (3, 9 and 30rnnol, i. a.) before and 
after injection of A TPyS (900nmol i.art, 30 minutes pre -treatment) from nociceptors 
innervating normal (i) and LPS injected (0.01 - 1 jig, i.art., 2 hours pre -treatment) 
knee joints (ii). Data points represent mean ±em. Normal joints n =7 afferents; LPS 
pre -treated joillts n =8. 
7.3.1.1.3 Effect of BzATP on neural discharge 
7.3.1.1.3.1 Spontaneous neural discharge 
BzATP (700nmol, i.art.) was tested on 7 afferents (2 C- fibres and 5 AS- fibres) 
innervating two normal knee joints and 10 afferents (3 C- fibres and 7 AS- fibres) 
innervating three knee joints 24 hours after pre- treatment with LPS (1 - 5µg i.art.). 
Intra- articular injection of the agonist evoked a fast -onset increase in action potential 
discharge, which was probably mediated by the afferent P2X receptor(s) because it is 
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known to activate all seven P2X receptor channels (I.C. Chessell, personal 
communication, and see Section 6.3.1.10). Unlike ATPyS, BzATP did not evoke any 
slow -onset increase in action potential discharge. There was no change in basal 
discharge of afferents innervating normal or LPS pre- treated joints when studied over 
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Figure 7.11 Lack of effect of BzATP (700nmol, i.art.) on the spontaneous 
discharge of afferents innervating normal and LPS pre- treated joints (1 -5 p i. art., 
24 hours pre-injection). The fast response evoked by BzATP is not included in this 
graph. Data points represent mean ent. Normal joints n =7 afferents, LPS joints 
n =10 afferents. 
7.3.1.1.3.2 Bradvkinin- evoked neural discharge 
The effect of BzATP (700nmol i.art., 30 minutes pre- treatment) on the response 
evoked by bradykinin (3, 9 and 30nmol, i.a.) was investigated in 2 afferents (C- 
fibres) innervating two normal knee joints and 6 afferents (3 C- fibres and 3 AS- 
fibres) innervating three knee joints 24 hours after an i.art injection of LPS (1 - 
Snmol). BzATP had no significant effect on the latency or duration (Figure 7.12) of 
the response evoked by bradykinin either in normal or LPS pre- treated joints. 
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However, there was a tendency for bradykinin to evoke a smaller response both in 
terms of the change in action potential discharge frequency and number after BzATP 
in LPS pre- treated joints (Figure 7.13). But only the number of action potentials 
evoked by the middle dose (9nmol) of bradykinin in LPS joints was significantly 
(P <0.05) reduced after BzATP (Figure 7.13). 
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Figure 7.12 Bar charts showing the a) onset latency and b) duration of the 
response evoked by bradykinin (3, 9 and 30irmol, i.a.) front nociceptors before and 
after injection of BzATP (700nmol i. art, 30 minutes pre -treatment) innervating 
normal (i) and LPS injected (0.01 - 1 Ng, i. art. , 24 hours pre -treatment) knee joints 
(n). Cohmins represent original data (i) or mean-I.-sent (ii). Normal joints n =2 
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Figure 7.13 Pooled data showing the change in action potential a) discharge 
frequency and b) number evoked by bradykinin (3, 9 and 30nmol, i.a.) from 
nociceptors innervating normal (i) and LPS injected (0.01 - 1 fig, i. art., 2 hours pre- 
treatment) knee joints (ii). Cohrmns represent original data (i) or meanem (ii). 
Normal joints n =2 afferents; LPS pre- treated joints n =6 afferents. 
7.3.1.2 Intra- peritoneal injections 
Neural discharge was recorded from a total of 32 single afferent fibres innervating 7 
knee joints: 75% (24/32) were classified as C -fibre polymodal nociceptors and 25% 
(8/32) were classified as AS -fibre mechanooreceptors. 
7.3.1.2.1 LPS on spontaneous discharge 
The effect of i.p. injection of ATP (9000nmol) on the spontaneous discharge of 11 C- 
fibres and 5 A6-fibres 2 hours after injection of LPS (10mg kg 1) was investigated in 
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3 experiments. Neither LPS nor ATP had any significant effect on the rate of 
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Figure 7.14 Pooled data from C fibres and A5-fibres showing the lack of effect of 
i.p. injection of a) LPS (10mg kgf) and b) ATP 9000nntol (2 hours after LPS pre- 
treatment) on the rate on spontaneous discharge of afferents. Data is from 11 
afferents innervating 3 knee. joints. 
7.4 DISCUSSION 
Intra- articular injections of ATPyS and BzATP, compounds that are agonists at P2X7 
receptors, did not significantly increase either the basal or the bradykinin- evoked 
discharge of nociceptors innervating the normal or LPS pre- treated joint that did not 
respond to adenosine. However, injection of ATPyS, but not BzATP led to a 
prolonged increase in discharge of afferents that were excited by adenosine. The 
response peaked within minutes of the injection and slowly declined over the next 30 
minutes. This pattern of activity does not correspond to that previously observed 
following injection of Il -l3 into the knee (Kelly, 1998) and so it is unlikely to 
involve release of this cytokine. These findings do not support the hypothesis that 
activation of P2X7 receptors in the knee joint leads to the release of I1-10 in vivo. 
The main problem experienced during this investigation was the lack of 
stable and selective P2X7 receptor agonists. ATPyS is an agonist at many of the P2X 
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and P2Y receptor subtypes and although it was originally thought to be resistant to 
ecto -nucleotidase hydrolysis, it is now known to be metabolised in certain tissues 
(Cascalheira & Sebastido, 1992). Furthermore, the nucleotide seems to be rapidly 
metabolised to adenosine following i.a. injection in the rat because, analogous with 
the endogenous ligand at P2 receptors, ATP, it evokes a biphasic increase in knee 
joint afferent discharge consisting of fast and slow -onset excitations (see Chapters 5 
and 6 of this thesis), and the latter component is antagonised by the adenosine Al 
receptor selective antagonist DPCPX (see Section 6.3.1.9). Thus, ATPyS can also act 
at P1 receptor subtypes following its degradation to adenosine. The other P2 agonist 
used in this study, BzATP, is also unstable ill vivo and is not selective for the P2X7 
receptor subtype (I.C. Chessell, personal communication). Interestingly, BzATP does 
not evoke a slow -onset increase in afferent discharge, indicating that its metabolite is 
not an agonist at the adenosine Al receptors expressed on the knee joint afferent 
terminals. Despite these obstacles, the fact that both of these agonists evoked a rapid - 
onset increase in action potential discharge, probably mediated by the P2X 
subtype(s) expressed on the afferent terminals (see Section 5.1.1.9), indicates that 
they were active as parent compounds before metabolism and therefore would have 
had time to act at P2X7 receptors. 
ATPyS has previously been shown to evoke the release of II -113 from LPS- 
primed but not normal murine peritoneal macrophages in vivo (Griffiths et al., 1995). 
Release of sufficient Il -113 would be expected to increase the activity of nociceptors 
(Fukuoka et al., 1994; Kelly, 1998; Kelly et al., 1996; Kelly et al., 1997). In the 
present study, injection of ATPyS led to a sustained slow -onset increase in action 
potential discharge in 33% of nociceptors innervating normal joints and 71% of 
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nociceptors innervating LPS pre- treated joints. Initially these results suggested that 
the nucleotide might be releasing some algogenic mediator such as I1 -113, but further 
studies indicated that this increase in discharge was probably mediated by adenosine 
because 1) adenosine itself causes a sustained increase in discharge when injected 
into the knee joint (see Section 6.3.1.8) and 2) ATPyS causes a biphasic increase in 
action potential discharge following close -arterial injection, the slow component of 
which is antagonised by DPCPX (see Section 6.3.1.9). In this thesis, the duration of 
the knee joint afferent discharge evoked by purines has consistently been longer 
following i.art. injection in comparison with i.a. injection, probably because of 
different clearance rates from the terminals. The other result indicating that the 
sustained increase in discharge following i.art. injection of ATPyS did not result from 
Il -lß release was the unexpected pattern of the elevated activity. In the work by 
Kelly (1998), the basal discharge increases within minutes after injection of Il -1ß 
into the knee joint and continues to rise for up to one hour post- injection. In the 
present study, the elevated discharge peaked within the first minute or so following 
injection and thereafter, declined for the remainder of the recording time. The pattern 
of discharge observed following injection of ATPyS is consistent with the slow 
removal of an excitatory substance rather that the release of a pro- inflammatory and 
pro -nociceptive mediator. 
The delayed excitation observed following injection of ATPyS was a 
considerable complication in the present studies because it would have masked any 
increase in discharge due to Il -1ß release. DPCPX was used to try to block this 
excitation but it failed to do so. This is probably because of the relatively high local 
concentration of adenosine in the knee joint compared to the antagonist. DPCPX is a 
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competitive antagonist at adenosine Al receptors (von der Leyen et al., 1989) and 
high concentrations of agonist would displace the antagonist from the receptors. 
Because the delayed increase in discharge evoked by ATPyS could not be 
antagonised by DPCPX, the only way to reveal whether the P2 agonist could have 
caused 11-1 f3 release was to examine the discharge of afferents from which the 
nucleotide did not evoke a slow response. However, no increase in basal discharge or 
enhancement of bradykinin- induced excitation was observed in these fibres. BzATP 
would not have masked any increase secondary to the release of inflammatory 
mediators because this agonist did not cause any sustained increase in action 
potential discharge. However, there was no indication that this ATP analogue 
released I1-113 or any other algogenic mediator. 
Overall, the data obtained do not support the hypothesis that activation of 
P2X7 receptors in the knee joint leads to Il -113 release. Since ATP and ATPyS have 
previously been shown to release Il -lß from LPS- primed macrophages in vivo 
(Griffiths et al., 1995), it was rather surprising that an I1-113 induced increase in 
afferent discharge was not seen in the present study. A range of LPS doses (0.01- 
1µg) were injected 2 hours before injection of the P2 agonists. This correlates with 
the doses and pre- treatment times used by Griffiths et al. (1995) where 1µg of the 
endotoxin was administered i.p. two hours before injection of the purine nucleotides. 
The doses of P2 agonists used in the present study were also based on those 
previously reported to release Il -113 from LPS -primed macrophages in vivo. Thus, in 
the mouse peritoneal macrophage study, ATPyS was injected at concentrations up to 
10mM (Griffiths et al., 1995). In the present investigation, the nucleotide probably 
achieved a synovial fluid concentration of 9mM following i.art. injection (see 
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APPENDIX II). Interestingly, the dose -response relationship for ATP -evoked release 
of I1-1I3 from human macrophages in vitro is bell shaped (Ferrari et al., 1997a). Thus, 
higher ATP concentrations (5mM) release less Il -113, whereas lower concentrations 
(1mM) release more of the cytokine. Although it is not possible to extrapolate from 
ill vitro studies of isolated human macrophages to in vivo studies of the rat knee joint, 
this finding indicates that a wider dose range of the purine nucleotides should be 
investigated in future studies. 
The probable explanation for the lack of enhanced spontaneous and 
bradykinin- evoked discharge seen in our studies is that insufficient Il -113 was 
released to alter the responsiveness of nociceptors innervating the joint. In the study 
by Griffiths et al. (1995), nanogram quantities of the cytokine were released from 
LPS- primed peritoneal macrophages. This level of Il -lß is adequate to increase the 
spontaneous discharge of cutaneous afferents in the rat hindpaw (100pg -1µg used by 
Fukuoka et al., 1994), and to induce spontaneous discharge and bradykinin 
sensitisation of nociceptors innervating the rat knee joint in vivo (1 -100ng used by 
Kelly, 1998). However, it is unlikely that the levels of cytokine release measured by 
Griffiths et al. (1995) were achieved in the present study because of the different 
resident macrophage populations in the peritoneal cavity and the synovial space. The 
peritoneal cavity has high numbers of resident macrophages which can easily be 
detected in lavage fluid (De Halleux et al., 1973), whereas normal synovial fluid is 
acellular. In contrast, the synovial fluid of RA joints is enriched with cells, including 
neutrophils and macrophages and furthermore, the RA synovium has high numbers 
of macrophages in the cellular infiltrate known as pannus (Feldmann et al., 1996). 
Thus, the lack of Il -1ß release in our experiments may be because of low numbers of 
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resident articular macrophages. It would be valuable to repeat the present 
experimental protocols using the monoarthritic rat knee joint as pronounced cellular 
infiltration occurs in the synovial layer of the knee joint in this model (see Section 
4.3.3). 
Despite the findings of the present study, ATP (probably via the P2X7 
subtype) is a potent trigger of I1 -10 processing and release from inflammatory cells 
in vivo (Griffiths et al., 1995) and in vitro (Ferrari et al., 1997a; Ferrari et al., 1997b; 
Perregaux & Gabel, 1994). The methods used in the present study may not be 
appropriate for determining the role of macrophage P2X7 receptors in nociception 
because of the low number of resident macrophages in the normal knee joint. It is 
also difficult to selectively investigate P2X7 receptor activation in vivo because of the 
lack of stable and selective agonists for this subtype. The only known antagonist with 
selectivity for P2X7 receptors is oxidised ATP, but this antagonist is unsuitable for 
use in vivo because it requires long (2 hour) incubation times in the presence of the 
receptors (Murgia et al., 1993). Whether or not P2X7 receptors play a role in 
inflammation and inflammatory pain will only be revealed if a potent, selective P2X7 
receptor antagonist suitable for use in vivo is developed and tested in animal models. 
Alternatively, the development of inflammation and arthritic states could be 
investigated in genetically modified rodents that do not express the P2X7 receptor. In 
addition, the levels of I1 -113 could be measured in the synovial fluid of normal and 
arthritic P2X7 knockouts to investigate the contribution of this receptor subtype to II- 
1[3 release in vivo. Future studies should reveal whether release of Il -1 f3 by ATP's 
actions at P2X7 receptors contributes significantly to the pain of RA or other 
inflammatory diseases. If so, antagonists at the P2X7 receptor would have potential, 
198 
Chapter 7: Knee joint P2.I7 receptors 
not only for the treatment of arthritic pain, but also as disease modifying anti - 
rheumatic drugs by preventing the pro- inflammatory effects of Il -10. 
199 
Chapter 8: Discussion 
Chapter 8: General Discussion 
The results obtained in this thesis have shown that distinct populations of nociceptive 
and probable proprioceptive afferents innervating the rat knee joint express 
functional P2X receptor subtype(s) and /or Al receptors, for ATP and its metabolite 
adenosine, respectively. In contrast, no indication that functional P2X receptors are 
expressed on nociceptors innervating the cat or rat cornea was found. These findings 
support the hypothesis that nociceptors innervating the rat knee joint can be directly 
excited by ATP and adenosine, but they do not support a direct role for these purines 
in activating corneal nociceptors. The indirect excitatory effects of ATP were also 
investigated in the rat knee joint, but no evidence that the purine releases pro - 
nociceptive mediators from synovial cells was obtained. The findings of this thesis 
contribute to the understanding of how extracellular purines modulate nociceptor 
activity. 
The direct -excitatory role of ATP and adenosine in nociception was largely 
investigated through electrophysiological recordings of the rat knee joint. Neural 
recordings from MAN afferents innervating this joint showed that most of them 
express P2X and /or Al receptor subtypes. Close -arterial injection of ATP, which was 
rapidly metabolised to adenosine, revealed that there were substantial differences in 
purine receptor expression between C -fibre nociceptors and A6- fibres, which 
immediately suggested different sensory roles for the purines (see Figure 6.6). 
Because the majority (approximately 70 %) of C -fibre nociceptors were 
slowly excited following ATP injection (attributed to the action of adenoisne), this 
suggested a direct algesic role for adenosine, a proposal which is supported by 
human studies (Bertolet et al., 1996; Bleehen & Keele, 1977; Gaspardone et al., 
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1995; Sylven et al., 1986). Interestingly, previous authors have reported a peripheral 
anti -nociceptive role for adenosine acting at the A1 subtype in the rat hind -paw 
(Karlsten el al., 1992; Sawynok el al., 1998; Taiwo & Levine, 1990), and this has led 
to the suggestion that i.art. injections of adenosine might be analgesic (Keil & Salter, 
1996). However, it is well known that nociceptors innervating different tissues have 
different functional properties (Walters, 1996), and there is no reason to assume that 
identical sensory mechanisms exist in the rodent hindpaw and knee joint. 
Remarkably, very few (approximately 10 %) AS- fibres were slowly excited by ATP, 
which largely indicates a largely C -fibre nociceptor -specific role for the nucleoside. 
The excitation of C -fibre nociceptors by adenosine was not prone to desensitisation 
because when it, ATPyS or ATP (both degraded to adenosine) were injected into the 
rat knee, the elevation in discharge lasted for up to 25 minutes (for example, see 
Figure 7.7). This indicates that the adenosine receptors on the peripheral terminals of 
knee joint nociceptors are slowly -adapting in the continued presence of agonist, a 
property that would be important in signalling the pain associated with chronically 
inflamed tissues. Moreover, prolonged activation of neuropeptide- containing C -fibre 
terminals could contribute to neurogenic inflammation. Thus, based on the evidence 
obtained in this thesis, it is reasonable to speculate that extracellular adenosine, 
resulting from the metabolism of ATP, plays a significant role in the initiation and 
maintenance of inflammatory pain. 
In contrast to the population of afferents excited by adenosine, ATP activated 
the majority of AS- fibres (approximately 70% in normal joints), and almost half of 
the C- fibres (approximately 40 %) innervating the knee joint (mediated by P2X 
receptor subtype(s)), indicating that the nucleotide may play nociceptive and 
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proprioceptive roles. Whereas the Al receptor- mediated excitation lasted for over 20 
minutes following i.art. injection, that mediated by P2X receptor(s) only lasted for 
seconds. This adapting response would not be very advantageous in terms of 
signalling chronic inflammatory pain. However, this does not preclude a role for P2X 
receptors in sensitising the nociceptive afferent or contributing to neurogenic 
inflammation. As discussed in Chapter 5, P2X receptors might be involved in 
signalling noxious and /or innocuous joint movements. This was not investigated in 
the present thesis because the neural preparation was not set -up to allow the joint to 
be moved. Therefore, this proposal is largely based on circumstantial evidence: the 
proposed structure for P2X receptors resembles that of mechanosensitive ion - 
channels (Surprenant el al., 1995); ATP is released from cells that are mechanically 
stimulated (Nakamura & Strittmatter, 1996), and the thinly myelinated afferents 
innervating the cat knee joint are activated by joint movements (Coggeshall et al., 
1983). 
The role of ATP and adenosine in inflammatory pain was investigated using 
electrophysiological and behavioural techniques. The antagonists, PPADS and 
DPCPX, blocked the effects of exogenous ATP and adenosine respectively, but did 
not lower the spontaneous discharge afferents innervating arthritic joints. This 
indicates that endogenous extracellular purine levels were too low to excite the 
afferents and argues against a role for the purines in contributing to the spontaneous 
pain associated with chronic adjuvant arthritis. However, as described in Chapter 4, 
the arthritis induced was mild, and sufficient ATP might not have been released from 
synovial cells during the chronic phase. Furthermore, the effects of antagonists on 
stimulus- induced afferent discharge, the neural correlate of allodynia and /or 
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hyperalgesia, were not examined. In the behavioural studies, the effects of 
pharmacological agents on the development of joint pain was examined. It was not 
possible to investigate the role of ATP however, because of the lack of suitable 
antagonists for use in vivo. Interestingly, there was no indication that systemic 
injection of DPCPX had any anti -allodynic effect, but paradoxically, dipyridamole, 
which prevents adenosine uptake, had. Interpretation of the behavioural studies is 
complicated by concurrent peripheral, spinal and central effects, which can be 
opposing. Nevertheless, the findings indicate that increasing the levels of 
endogenous extracellular adenosine causes analgesia, perhaps though activation of 
spinal adenosine Al receptors (Sawynok, 1998) because the effect was not seen when 
DPCPX was injected prior to dipyridamole. 
The direct excitatory effects of ATP were also investigated using 
electrophysiological techniques in the cat cornea, and behavioural techniques in the 
rat eye. In contrast to the knee joint, there was no evidence that functional P2X 
receptors are expressed on nociceptors innervating the cat or rat cornea, despite 
finding that P2X3 immunoreactivity was present in trigeminal ganglion cells 
retrogradely labelled from the mouse cornea. This may reflect differences in 
nociceptor characteristics between the knee joint and the cornea, perhaps indicating 
that whatever functional role P2X receptors play in the knee joint is not required in 
the highly- specialised corneal tissue. Alternatively, the receptors that are 
constitutively expressed in the rat knee joint may only be expressed in the cornea 
under certain situations, perhaps during inflammation or following injury. However, 
there is the possibility that slow penetration of the nucleotides to the afferent 
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terminals caused receptor desensitisation and thus, the cornea may not be a suitable 
preparation for studying P2X receptors. 
In addition to the direct excitatory effects of ATP, the indirect excitatory 
effects of this nucleotide were investigated by monitoring spontaneous and 
bradykinin- evoked discharge following administration of P2X7 receptor agonists into 
the normal and LPS pre- treated knee joint. The experiments were complicated by the 
lack of a stable, selective P2X7 agonist: ATPyS and BzATP were both rapidly 
degraded, the former to adenosine and the latter to an unknown compound. Despite 
these complications, no evidence was obtained that P2X7 receptor activation caused 
Il -113 release. Previous experiments in vivo have shown that a single bolus i.p. 
injection of ATP is sufficient to release Il -113 from LPS -primed mouse peritoneal 
macrophages (Griffiths et al., 1995). This makes it unlikely that rapid nucleotide 
metabolism and insufficient exposure of the P2X7 receptors to agonist accounted for 
the lack of sensitisation following ATPyS and BzATP. The probable explanation is 
that the resident macrophage population in the normal rat knee joint was too low 
thereby not producing adequate levels of I1-1 f3. 
8.1 FUTURE WORK AND CONCLUSIONS 
The experiments described in this thesis have answered certain questions and raised 
several. One of the main unanswered questions is the subtype of P2X receptor 
mediating the rat knee joint afferent excitation. In order to determine this, P2X 
subtype selective agonists or antagonists, or specific P2X subtype knock -out rats 
would have to be developed. The main question that will then remain is the 
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functional significance of the P2X receptor subtype(s) for ATP and the Al receptors 
for adenosine that are expressed on rat knee joint afferents. 
It is crucial to determine whether distinct P2X subtypes are expressed on 
different populations of afferents. With the currently available pharmacological and 
genetic tools, it would only be possible to determine whether rapidly -adapting and /or 
slowly -adapting P2X subtypes are involved in mediating the afferent excitation. As 
discussed in Chapter 5, this could be achieved by careful quantification of the 
duration of action potential discharge following i.art. injection of nucleotides into the 
joint. In order to reveal whether these are expressed on, for example, nociceptive vs 
proprioceptive afferents, the rat knee joint preparation would have to be developed to 
allow the different sensory classes to be distinguished. A mechanical indentation 
generator, which delivers quantitative mechanical stimuli to the knee joint, has been 
developed in -house (Department of Preclinical Veterinary Sciences, University of 
Edinburgh) for use in the laboratory. This will enable future researchers to 
distinguish afferents responding to innocuous and noxious mechanical stimuli. 
However, delivering acute mechanical stimuli to the knee joint capsule has little 
clinical relevance and damages the tissue. Therefore, it would be preferable to use a 
modified version of the technique described by Schaible and Schmidt (1983a,b) to 
enable to joint to be moved during the neural recordings. If this was done, the 
hypothesis that P2X receptors are involved in signalling joint stretch could be 
determined by measuring the afferent discharge to innocuous and noxious 
movements before and after PPADS. 
One of the surprising aspects of the electrophysiological investigations was 
that there was no indication that purines were released during chronic inflammation 
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or that afferents innervating arthritic joints were sensitised to exogenous ATP and 
adenosine. As this may have resulted from the mildness of the arthritic lesion, it is 
recommended that higher doses of adjuvant be used to induce arthritis in future 
studies. It could then be determined whether PPADS and /or DPCPX could reduce the 
elevated basal discharge in afferents innervating these joints. Furthermore, the role of 
P2X and /or A1 receptors in causing the enhanced response of articular afferents to 
movement during inflammation (Schaible & Schmidt, 1985) could also be 
determined. Once P2X subtype selective antagonists are developed that are suitable 
for use in vivo, the effect of P2X subtypes on spontaneous pain, allodynia and 
hyperalgesia could be determined in behavioural studies of monoarthritic rats. 
Until these studies are completed, it will not be possible to conclude that the 
direct actions of ATP and /or adenosine on the nociceptive afferent terminal play a 
role in causing the inflammatory pain associated with chronic FCA- induced arthritis 
in the rat knee joint. Regarding the indirect effects of ATP that were preliminarily 
investigated in this thesis, P2X7 receptor knock -out mice have become available at 
GIAP and it will be interesting to monitor the development of arthritis in these 
rodents. Meanwhile, it would be valuable to repeat the experiments described in 
Chapter 7 using arthritic rat knee joints in order to test the hypothesis that ATP 
would induce sensitisation in joints with a higher synovial macrophage population. 
One of the aims of this thesis was to evaluate the potential of purine receptors 
as targets for treating inflammatory pain. Given the widespread expression of 
excitatory Al receptors for adenosine on rat knee joint nociceptors, it is probable that 
endogenous nucleoside has a role to play in modulating articular nociceptor function. 
However, adenosine has a variety of pro -nociceptive and pro- inflammatory effects, 
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in addition to opposing anti -nociceptive and anti -inflammatory actions and any 
therapy aimed at modulating adenosine receptor function will have to take this into 
account. P2X receptors for ATP are also widely expressed on rat knee joint afferents, 
and it is probable that endogenous nucleotide has an important role in modulating 
afferent input from the joint to the CNS. However, because of the lack of 
pharmacological and genetic tools for investigating these receptors, this can not be 
determined yet, and it is too early to tell whether manipulation of P2X receptor 
pharmacology will have any clinical relevance for the treatment of pathological pain. 
207 
References 
Abbracchio, M.P. & Burnstock, G. (1994). Purinoceptors - are there families of P2X 
and P2Y purinoceptors. Pharmacology & Therapeutics, 64, 445 -475. 
Ahlgren, S.C. & Levine, J.D. (1993). Analgesic effect of bamiphylline on pain 
induced by intradermal injection of adenosine. Pain, 53, 199 -204. 
Ahlquist, M.L., Edwall, L.G., Franzen, O.G. & Haegerstam, G.A. (1984). Perception 
of pulpal pain as a function of intradental nerve activity. Pain, 19, 353 -66. 
Ahmed, M., Bjurholm, A., Schultzberg, M., Theodorsson, E. & Kreicbergs, A. 
(1995). Increased levels of substance P and calcitonin gene- related peptide in 
rat adjuvant arthritis. Arthritis & Rheumatism, 38, 699 -709. 
Anderson, D.J. & Matthews, B. (1967). Osmotic stimulation of human dentine and 
the distribution of dental pain thresholds. Archives of Oral Biology, 12, 417- 
26. 
Arend, W.P. & Dayer, J.M. (1995). Inhibition of the production and effects of 
interleukin -1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis 
And Rheumatism, 38, 151 -60. 
Armstrong, D., Dry, R.M.L., Keele, C.A. & Markham, J.W. (1951). Method for 
studying chemical excitants of cutaneous pain in man. Journal of Physiology - 
London, 115, 59 -61P. 
Armstrong, D., Dry, R.M.L.J., J.B., Keele, C.A. & Stewart, J.W. (1957). Pain - 
producing substance in human inflammatory exudates and plasma. Journal of 
Physiology -London, 135, 350 -370. 
Arnason, J.A. & Malone, D.G. (1995). Role of mast cells in arthritis. Chemical 
Immunology, 62, 204 -38. 
Asghar, A.R. (1995). Pharmacological studies of bradykinin and other inflammatory 
mediators in rat neural preparations. PhD thesis: Edinburgh University. 
Assouline, M., Renard, G., Arne, J.L., David, T., Lasmolles, C., Malecaze, F. & 
Pouliquen, Y.J. (1998). A prospective randomized trial of topical soluble 
0.1% diclofenac versus placebo for the control of pain following excimer 
laser photorefractive keratectomy. Ophthalmic Surgery & Lasers, 29, 365 -74. 
Attias, G. (1912). Die nerven der hornhaut des menschen. Grafe's Arch. Opthalmol., 
83, 207 -316. 
Banerjee, R.K. (1981). Ecto -ATPase. Molecular And Cellular Biochemistry, 37, 91- 
9. 
208 
Bazan, H.E.P. (1990). Response of inflammatory lipid mediators following corneal 
injury. In Lipid Mediatory in Eye If flanmation. ed. N.G., B. pp. 1 -11. 
Karger: Basel. 
Bean, B.P. (1990). ATP -activated channels in rat and bullfrog sensory neurons: 
concentration dependence and kinetics. Journal of Neuroscience, 10, 1 -10. 
Bean, B.P. & Friel, D.D. (1990). ATP -activated channels in excitable cells. Ion- 
channels, 2, 169 -203. 
Bean, B.P., Williams, C.A. & Ceelen, P.W. (1990). ATP -activated channels in rat 
and bullfrog sensory neurons: current -voltage relation and single- channel 
behavior. Journal of Neuroscience, 10, 11 -9. 
Belmonte, C. & Gallar, J. (1996). Corneal nociceptors. In Neurobiology of 
Nociceptors. ed. Belmonte, C. & Cervero, F. pp. 146 -183. New York: Oxford 
University Press. 
Belmonte, C., Gallar, J., Lopez -Briones, L.G. & Poxo, M.A. (1994). Polymodality in 
nociceptive neurons: experimental models of chemotransduction. In Cellular 
mechanisms of sensory processing. ed. Urban, L. pp. 87 -117. Berlin: 
Springer- Verlag. 
Belmonte, C., Gallar, J., Pozo, M.A. & Rebollo, I. (1991). Excitation by irritant 
chemical substances of sensory afferent units in the cat's cornea. Journal of 
Physiology- London, 437, 709 -25. 
Belmonte, C. & Giraldez, F. (1981). Responses of cat corneal sensory receptors to 
mechanical and thermal stimulation. Journal of Physiology- London, 321, 
355 -68. 
Berne, R.M. (1963). Cardiac nucleotides in hypoxia: possible role in regulation of 
coronary blood flow. American Journal of Physiology, 204, 317 -322. 
Bertolet, B.D., Belardinelli, L., Franco, E.A., Nichols, W.W., Kerensky, R.A. & Hill, 
J.A. (1996). Selective attenuation by N -0861 (N6- endonorboran- 2 -y1 -9- 
methyladenine) of cardiac Al adenosine receptor- mediated effects in humans. 
Circulation, 93, 1871 -6. 
Bessou, P. & Perl, E.R. (1969). Response of cutaneous sensory units with 
unmyelinated fibers to noxious stimuli. Journal of Neurophysiology, 32, 
1025 -43. 
Beukers, M.W., Kerkhof, C.J., van Rhee, M.A., Ardanuy, U., Gurgel, C., Widjaja, 
H., Nickel, P., IJzerman, A.P. & Soudijn, W. (1995). Suramin analogs, 
divalent cations and ATP gamma S as inhibitors of ecto -ATPase. Naunyn- 
Schmiedebergs Archives Of Pharmacology, 351, 523 -8. 
209 
Bevan, S. (1996). Intracellular messengers and signal transduction in nociceptors. In 
Neurobiology of Nociceptors. ed. Belmonte, C. & Cervero, F. pp. 298 -324. 
New York: Oxford University Press. 
Bianchi, M., Dib, B. & Panerai, A.E. (1998). Interleukin -1 and nociception in the rat. 
Journal of Neuroscience Research, 53, 645 -650. 
Bileviciute, I., Lundeberg, T., Ekblom, A. & Theodorsson, E. (1994). Substance P -, 
neurokinin A -, calcitonin gene- related peptide- and neuropeptide Y -like 
immunoreactivity ( -LI) in rat knee joint synovial fluid during acute 
monoarthritis is not correlated with concentrations of neuropeptide -LI in 
cerebrospinal fluid and plasma. Neuroscience Letters, 167, 145 -8. 
Bileviciute, I., Stenfors, C., Theodorsson, E., Beckman, M. & Lundeberg, T. (1995). 
Significant changes in neuropeptide concentrations in the brain of 
normotensive (WKY) and spontaneously hypertensive (SHR) rats following 
knee joint monoarthritis. Brain Research, 704, 71 -8. 
Billingham, M.E. (1983). Models of arthritis and the search for anti -arthritic drugs. 
Pharmacology & Therapeutics, 21, 389 -428. 
Birrell, G.J., McQueen, D.S., Iggo, A. & Grubb, B.D. (1990). The effects of 5 -HT on 
articular sensory receptors in normal and arthritic rats. British Journal of 
Pharmacology, 101, 715 -21. 
Bland -Ward, P.A. & Humphrey, P.P.A. (1997). Acute nociception mediated by 
hindpaw P2X receptor activation in the rat. British Journal of Pharmacology, 
122, 365 -371. 
Bleehan, T., Hobbiger, F. & Keele, C.A. (1976). Identification of algogenic 
substances in human erythrocytes. Journal of Physiology - London, 262, 131- 
149. 
Bleehen, T. & Keele, C.A. (1977). Observations on the algogenic actions of 
adenosine compounds on the human blister base preparation. Pain, 3, 367 -77. 
Bo, X.N., Zhang, Y., Nassar, M., Burnstock, G. & Schoepfer, R. (1995). A P2 
purinoceptor cDNA conferring a novel pharmacological profile. Febs Letters, 
375, 129 -133. 
Born, G.V.R. (1962). Aggregation of blood platelets by adenosine diphosphate and 
its reversal. Nature, 194, 927 -929. 
Bouthillier, J., Deblois, D. & Marceau, F. (1987). Studies on the induction of 
pharmacological responses to des -Arg9- bradykinin in vitro and in vivo. 
British Journal of Pharmacology, 92, 257 -64. 
Bouvier, M.M., Evans, M.L. & Benham, C.D. (1991). Calcium Influx Induced By 
Stimulation of Atp Receptors On Neurons Cultured From Rat Dorsal -Root 
Ganglia. European Journal of Neuroscience, 3, 285 -291. 
210 
Brake, A.J., Wagenbach, M.J. & Julius, D. (1994). New structural motif for ligand - 
gated ion -channels defined by an ionotropic ATP receptor. Nature, 371, 519- 
523. 
Bruns, R.F., Lu, G.H. & Pugsley, T.A. (1986). Characterization of the A2 adenosine 
receptor labeled by [3H]NECA in rat striatal membranes. Molecular 
Pharmacology, 29, 331 -46. 
Bultmann, R., Wittenburg, H., Pause, B., Kurz, G., Nickel, P. & Starke, K. (1996). 
P2- purinoceptor antagonists: III. Blockade of P2- purinoceptor subtypes and 
ecto -nucleotidases by compounds related to suramin. Naunyn- Schmiedebergs 
Archives Of Pharmacology, 354, 498 -504. 
Burgess, P.R. & Perl, E.R. (1967). Myelinated afferent fibres responding specifically 
to noxious stimulation of the skin. Journal of Physiology - London, 190, 541- 
62. 
Burnstock, G. (1978). A basis for distinguishing two types of purinergic receptor. In 
Cell Membrane Receptors for Drugs and Hormones. ed. Bolis, L. & Straub, 
R.W. pp. 107 -118. New York: Raven Press. 
Burnstock, G. (1996). A unifying purinergic hypothesis for the initiation of pain. 
Lancet, 347, 1604 -1605. 
Burnstock, G., Campbell, G., Satchell, D. & Smythe, A. (1970). Evidence that 
adenosine triphosphate or a related nucleotide is the transmitter substance 
released by non -adrenergic inhibitory nerves in the gut. British Journal Of 
Pharmacology, 40, 668 -88. 
Burnstock, G. & Kennedy, C. (1985). Is there a basis for distinguishing two types of 
P2- purinoceptor? General Pharmacology, 16, 433 -40. 
Burnstock, G. & Wood, J.N. (1996). Purinergic receptors - their role in nociception 
and primary afferent neurotransmission. Current Opinion in Neurobiology, 6, 
526 -532. 
Butler, S.H., Godefroy, F., Besson, J.M. & Weil -Fugazza, J. (1992). A limited 
arthritic model for chronic pain studies in the rat. Pain, 48, 73 -81. 
Calvino, B., Crepon- Bernard, M.O. & Le Bars, D. (1987). Parallel clinical and 
behavioural studies of adjuvant- induced arthritis in the rat: possible 
relationship with 'chronic pain'. Behavioural Brain Research, 24, 11 -29. 
Campbell, J.N. & Meyer, R.A. (1996). Cutaneous nociceptors. In Neurobiology of 
Nociceptors. ed. Belmonte, C. & Cervero, F. pp. 117 -145. New York: Oxford 
University Press. 
Campion, G.V., Lebsack, M.E., Lookabaugh, J., Gordon, G. & Catalano, M. (1996). 
Dose -range and dose -frequency study of recombinant human interleukin -1 
211 
receptor antagonist in patients with rheumatoid arthritis. The IL -1Ra Arthritis 
Study Group. Arthritis And Rheumatism, 39, 1092 -101. 
Cascalheira, J.F. & Sebastiáo, A.M. (1992). Adenine nucleotide analogues, including 
gamma- phosphate- substituted analogues, are metabolised extracellularly in 
innervated frog sartorius muscle. European Journal Of Pharmacology, 222, 
49 -59. 
Casey, K.L. & Dubner, R. (1989). Animal models of chronic pain: scientific and 
ethical issues. Pain, 38, 249 -52. 
Castro, E., Pintor, J. & Miras- Portugal, M.T. (1992). Ca(2 +)- stores mobilization by 
diadenosine tetraphosphate, Ap4A, through a putative P2Y purinoceptor in 
adrenal chromaffin cells. British Journal Of Pharmacology, 106, 833 -7. 
Caterina, M.J., Schumacher, M.A., Tominaga, M., Rosen, T.A., Levine, J.D. & 
Julius, D. (1997). The capsaicin receptor: a heat -activated ion -channel in the 
pain pathway. Nature, 389, 816 -24. 
Cerretti, D.P., Kozlosky, C.J., Mosley, B., 
T.A., March, C.J., Kronheim, S.R. 
(1992). Molecular cloning of the 
Science, 256, 97 -100. 
Nelson, N., Van Ness, K., Greenstreet, 
, Druck, T., Cannizzaro, L.A. & et, a. 
interleukin -1 beta converting enzyme. 
Cervero, F. (1996). Visceral nociceptors. In Neurobiology of Nociceptors. ed. 
Belmonte, C. & Cervero, F. pp. 220 -240. New York: Oxford University 
Press. 
Chen, B.C., Lee, C.M. & Lin, W.W. (1996). Inhibition of ecto -ATPase by PPADS, 
suramin and reactive blue in endothelial cells, C6 glioma cells and RAW 
264.7 macrophages. British Journal Of Pharmacology, 119, 1628 -34. 
Chen, C.C., Akopian, A.N., Sivilotti, L., Colquhoun, D., Burnstock, G. & Wood, J.N. 
(1995). A P2X purinoceptor expressed by a subset of sensory neurons. 
Nature, 377, 428 -431. 
Chen, W.C. & Chen, C.C. (1998). ATP -induced arachidonic acid release in cultured 
astrocytes is mediated by Gi protein coupled P2Y1 and P2Y2 receptors. Glia, 
22, 360 -70. 
Chen, X., Gallar, J., Pozo, M.A., Baeza, M. & Belmonte, C. (1995). CO2 stimulation 
of the cornea: a comparison between human sensation and nerve activity in 
polymodal nociceptive afferents of the cat. European Journal of 
Neuroscience, 7, 1154 -63. 
Chin, J. & Kostura, M.J. (1993). Dissociation of IL -1 beta synthesis and secretion in 
human blood monocytes stimulated with bacterial cell wall products. Journal 
Of Immunology, 151, 5574 -85. 
212 
Clarke, D., Hughes, J. & Gasser, H.S. (1935). Afferent function in the group of nerve 
fibres of slowest conduction velocity. American Journal of Physiology, 114, 
69 -76. 
Clayton, N.M., Oakley, I., Thompson, S., Wheeldon, A., Sargent, B. & Bountra, C. 
(1997). Validation of the dual channel weight averager as an instrument of 
the measurement of clinically relevant pain. British Journal of 
Pharmacology, 120, 219P. 
Cockcroft, S. & Gomperts, B.D. (1979a). Activation and inhibition of calcium - 
dependent histamine secretion by ATP ions applied to rat mast cells. Journal 
of Physiology- London, 296, 229 -43. 
Cockcroft, S. & Gomperts, B.D. (1979b). ATP induces nucleotide permeability in rat 
mast cells. Nature, 279, 541 -2. 
Cockcroft, S. & Gomperts, B.D. (1980). The ATP4- receptor of rat mast cells. 
Biochemical Journal, 188, 789 -98. 
Coggeshall, R.E., Hong, K.A., Langford, L.A., Schaible, H.G. & Schmidt, R.F. 
(1983). Discharge characteristics of fine medial articular afferents at rest and 
during passive movements of inflamed knee joints. Brain Research, 272, 185- 
8. 
Collo, G., Neidhart, S., Kawashima, E., Kosco -Vilbois, M., North, R.A. & Buell, G. 
(1997). Tissue distribution of the P2X7 receptor. Neuropharmacology, 36, 
1277 -83. 
Collo, G., North, R.A., Kawashima, E., Merlo -Pich, E., Neidhart, S., Surprenant, A. 
& Buell, G. (1996). Cloning of P2X5 and P2X6 receptors and the distribution 
and properties of an extended family of ATP -gated ion -channels. Journal of 
Neuroscience, 16, 2495 -507. 
Colpaert, F.C. (1987). Evidence that adjuvant arthritis in the rat is associated with 
chronic pain. Pain, 28, 201 -22. 
Colpaert, F.C., Meert, T., De Witte, P. & Schmitt, P. (1982). Further evidence 
validating adjuvant arthritis as an experimental model of chronic pain in the 
rat. Life Sciences, 31, 67 -75. 
Colpaert, F.C. & van den Hoogen, R.H. (1983). Time course of the ventilatory 
response to adjuvant arthritis in the rat. Life Sciences, 33, 1065 -73. 
Communi, D. & Boeynaems, J.M. (1997). Receptors responsive to extracellular 
pyrimidine nucleotides. Trends In Pharmacological Sciences, 18, 83 -6. 
Cook, S.P. & McCleskey, E.W. (1997). Desensitization, recovery and Cat+ - 
dependent modulation of ATP -gated P2X receptors in nociceptors. 
Neuropharmacology, 36, 1303 -1308. 
213 
Cook, S.P., Vulchanova, L., Hargreaves, K.M., Elde, R. & McCleskey, E.W. (1997). 
Distinct ATP receptors on pain- sensing and stretch -sensing neurons. Nature, 
387, 505 -508. 
Crack, B.E., Beukers, M.W., McKechnie, K.C., Ijzerman, A.P. & Leff, P. (1994). 
Pharmacological analysis of ecto -ATPase inhibition: evidence for combined 
enzyme inhibition and receptor antagonism in P2X- purinoceptor ligands. 
British Journal of Pharmacology, 113, 1432 -8. 
Crack, B.E., Pollard, C.E., Beukers, M.W., Roberts, S.M., Hunt, S.F., Ingall, A.H., 
McKechnie, K.C., AP, I.J. & Leff, P. (1995). Pharmacological and 
biochemical analysis of FPL 67156, a novel, selective inhibitor of ecto- 
ATPase. British Journal of Pharmacology, 114, 475 -81. 
Crea, F. & Gaspardone, A. (1997). New look to an old symptom: angina pectoris. 
Circulation, 96, 3766 -3773. 
Crea, F., Pupita, G., Galassi, A.R., el- Tamimi, H., Kaski, J.C., Davies, G. & Maseri, 
A. (1990). Role of adenosine in pathogenesis of anginal pain. Circulation, 81, 
164 -72. 
Cronstein, B.N. (1994). Adenosine, an endogenous antiinflammatory agent. Journal 
of Applied Physiology, 76, 5-13. 
Cronstein, B.N. (1995). A novel -approach to the development of adenosine release at 
inflamed sites. Journal of Investigative Medicine, 43, 50 -57. 
Cronstein, B.N., Bouma, M.G. & Becker, B.F. (1996). Purinergic mechanisms in 
inflammation. Drug Development Research, 39, 426 -435. 
Cronstein, B.N., Daguma, L., Nichols, D., Hutchison, A.J. & Williams, M. (1990). 
The adenosine /neutrophil paradox resolved: human neutrophils possess both 
Al and A2 receptors that promote chemotaxis and inhibit 02 generation, 
respectively. Journal Of Clinical Investigation, 85, 1150 -7. 
Cronstein, B.N., Levin, R.I., Philips, M., Hirschhorn, R., Abramson, S.B. & 
Weissmann, G. (1992). Neutrophil adherence to endothelium is enhanced via 
adenosine Al receptors and inhibited via adenosine A2 receptors. Journal Of 
Immunology, 148, 2201 -6. 
Cronstein, B.N., Naime, D. & Ostad, E. (1993). The antiinflammatory mechanism of 
methotrexate. Increased adenosine release at inflamed sites diminishes 
leukocyte accumulation in an in vivo model of inflammation. Journal Of 
Clinical Investigation, 92, 2675 -82. 
Daly, J.W., Butts -Lamb, P. & Padgett, W. (1983). Subclasses of adenosine receptors 
in the central nervous system: interaction with caffeine and related 
methylxanthines. Cellular And Molecular Neurobiology, 3, 69 -80. 
214 
Davies, N.M., Jamali, F. & Skeith, K.J. (1996). Nonsteroidal antiinflammatory drug - 
induced enteropathy and severe chronic anemia in a patient with rheumatoid 
arthritis. Arthritis & Rheumatism, 39, 321 -4. 
Davis, A. & Perkins, M.N. (1993). The effect of capsaicin and conventional 
analgesics in two models of monoarthritis in the rat. Agents & Actions. 
Dayer, J.M., de Rochemonteix, B., Burrus, B., Demczuk, S. & Dinarello, C.A. 
(1986). Human recombinant interleukin 1 stimulates collagenase and 
prostaglandin E2 production by human synovial cells. Journal Of Clinical 
Investigation, 77, 645 -8. 
De Blois, D., Bouthillier, J. & Marceau, F. (1991). Pulse exposure to protein 
synthesis inhibitors enhances vascular responses to des -Arg9- bradykinin: 
possible role of interleukin -1. British Journal of Pharmacology, 103, 1057- 
66. 
De Castro Costa, M., De Sutter, P., Gybels, J. & Van Hees, J. (1981). Adjuvant - 
induced arthritis in rats: a possible animal model of chronic pain. Pain, 10, 
173 -85. 
De Gubareff, T. & Sleatot, W. (1965). Effects of adenosine on mammalian atrial 
muscle and its interaction with adenosine and calcium. Journal of 
Pharmacology and Experimental Therapeutics, 148, 202 -214. 
De Halleux, F., Taper, H.S. & Deckers, C. (1973). A simple procedure for 
identification of macrophages in peritoneal exudates. British Journal Of 
Experimental Pathology, 54, 352 -8. 
Dibner -Dunlap, M.E., Kinugawa, T. & Thames, M.D. (1993). Activation of cardiac 
sympathetic afferents: effects of exogenous adenosine and adenosine 
analogues. American Journal of Physiology, 265, H395 -400. 
DiVirgilio, F. (1995). The P2Z purinoceptor - an intriguing role in immunity, 
inflammation and cell- death. Immunology Today, 16, 524 -528. 
DiVirgilio, F., Ferrari, D., Chiozzi, P., Falzoni, S., Sanz, J.M., dalSusino, M., Mutini, 
C., Hanau, S. & Baricordi, O.R. (1996). Purinoceptor function in the immune 
system. Drug Development Research, 39, 319 -329. 
Doak, G.J. & Sawynok, J. (1995). Complex role of peripheral adenosine in the 
genesis of the response to subcutaneous formalin in the rat. European Journal 
of Pharmacology, 281, 311 -318. 
Donaldson, L.F., Seckl, J.R. & McQueen, D.S. (1993). A discrete adjuvant- induced 
monoarthritis in the rat: effects of adjuvant dose. Journal of Neuroscience 
Methods, 49, 5 -10. 
215 
Dorn, T., Schaible, H.G. & Schmidt, R.F. (1991). Response properties of thick 
myelinated group II afferents in the medial articular nerve of normal and 
inflamed knee joints of the cat. Somatosensoiy & Motor Research, 8, 127 -36. 
Dowd, E., Gallar, J., McQueen, D.S., Chessell, I.P., Humphrey, P.P.A. & Belmonte, 
C. (1997). Nociceptors of the cat and rat cornea are not excited by P2X 
purinoceptor agonists. British Journal of Pharmacology, 122, 348P. 
Dowd, E., McQueen, D.S., Chessell, I.P. & Humphrey, P.P.A. (1998a). Adenosine 
A(1) receptor- mediated excitation of nociceptive afferents innervating the 
normal and arthritic rat knee joint. British Journal of Pharmacology, 125, 
1267 -1271. 
Dowd, E., McQueen, D.S., Chessell, I.P. & Humphrey, P.P.A. (1998b). Adenosine 
excites nociceptive afferents of the rat knee joint via adenosine A(1) 
receptors. Journal of Physiology -London, 509P, 162-P163. 
Dowd, E., McQueen, D.S., Chessell, I.P. & Humphrey, P.P.A. (1998c). P2X 
receptor- mediated excitation of nociceptive afferents in the normal and 
arthritic rat knee joint. British Journal of Pharmacology, 125, 341 -346. 
Drury, A.N. & Szent- Györyi, A. (1929). The physiological activity of adenine 
compounds with especial reference to their action upon the mammalian heart. 
Journal of Physiology-London, 68, 213 -237. 
Dubyak, G.R. (1991). Signal transduction by P2- purinergic receptors for 
extracellular ATP. American Journal Of Respiratory Cell And Molecular 
Biology, 4, 295 -300. 
Edery, H. & Lewis, G.P. (1962). Inhibition of plasma kininase activity at slightly 
acidic pH. British Journal of Pharmacology, 19, 299 -305. 
Edwall, L. & Olgart, L. (1977). A new technique for recording of intradental sensory 
nerve activity in man. Pain, 3, 121 -5. 
Eigler, A., Greten, T.F., Sinha, B., Haslberger, C., Sullivan, G.W. & Endres, S. 
(1997). Endogenous adenosine curtails lipopolysaccharide- stimulated tumour 
necrosis factor synthesis. Scandinavian Journal Of Immunology, 45, 132 -9. 
Eppinger, H. (1913). Uber eine eigentumliche Hautreaktion, hervorgerufen durch 
Ergamin. Weiner medizinisce Wochenschrist, 63, 1414. 
Eriksson, J., Bongenhielm, U., Kidd, E., Matthews, T. & Fried, K. (1998). 
Distribution of P2X(3) receptors in the rat trigeminal ganglion after interior 
alveolar nerve injury. Neuroscience Letters, 254, 37 -40. 
Farr, M., Garvey, K., Bold, A.M., Kendall, M.J. & Bacon, P.A. (1985). Significance 
of the hydrogen ion concentration in synovial fluid in rheumatoid arthritis. 
Clinical & Experimental Rheumatology, 3, 99 -104. 
216 
Fedan, J.S., Dagirmanjian, J.P., Attfield, M.D. & Chideckel, E.W. (1990). Evidence 
that the P2x purinoceptor of the smooth muscle of the guinea pig vas deferens 
is an ATP4- receptor. Journal of Pharmacology & Experimental 
Therapeutics, 255, 46 -51. 
Feldmann, M., Brennan, F.M. & Maini, R.N. (1996). Role of cytokines in 
rheumatoid arthritis. Annual Review Of Immunology, 14, 397 -440. 
Ferrari, D., Chiozzi, P., Falzoni, S., DalSusino, M., Melchiorri, L., Baricordi, O.R. & 
DiVirgilio, F. (1997a). Extracellular ATP triggers IL -1 beta release by 
activating the purinergic P2Z receptor of human macrophages. Journal of 
Immunology, 159, 1451 -1458. 
Ferrari, D., Chiozzi, P., Falzoni, S., Hanau, S. & Di Virgilio, F. (1997b). Purinergic 
modulation of interleukin -1 beta release from microglial cells stimulated with 
bacterial endotoxin. Journal of Experimental Medicine, 185, 579 -82. 
Ferrari, D., Villalba, M., Chiozzi, P., Falzoni, S., Ricciardi -Castagnoli, P. & Di 
Virgilio, F. (1996). Mouse microglial cells express a plasma membrane pore 
gated by extracellular ATP. Journal of Immunology, 156, 1531 -9. 
Firestein, G.S. (1996). Anti- inflammatory effects of an adenosine kinase in chronic 
inflammation. Drug Development Research, 39, 371 -376. 
Firestein, G.S., Boyle, D., Bullough, D.A., Gruber, H.E., Sajjadi, F.G., Montag, A., 
Sambol, B. & Mullane, K.M. (1994). Protective effect of an adenosine kinase 
inhibitor in septic shock. Journal of Immunology, 152, 5853 -9. 
Fleisher, M. (1993). Antifolate analogs: mechanism of action, analytical 
methodology, and clinical efficacy. Therapeutic Drug Monitoring, 15, 521 -6. 
Frangouli, A., Shah, S., Chatterjee, A., Morgan, P.B. & Kinsey, J. (1998). Efficacy 
of topical nonsteroidal drops as pain relief after excimer laser photorefractive 
keratectomy. Journal of Refractive Surgery, 14, S207 -8. 
Fredholm, B.B., Abbracchio, M.P., Burnstock, G., Daly, J.W., Harden, T.K., 
Jacobson, K.A., Leff, P. & Williams, M. (1994). Nomenclature and 
classification of purinoceptors. Pharmacological Reviews, 46, 143 -56. 
Fredholm, B.B., Abbracchio, M.P., Burnstock, G., Dubyak, G.R., Harden, T.K., 
Jacobson, K.A., Schwabe, U. & Williams, M. (1997). Towards a revised 
nomenclature for P 1 and P2 receptors. Trends in Pharmacological Sciences, 
18, 79 -82. 
Fredholm, B.B., Arslan, C., Kull, B. & Kontny (1996). Adenosine (Pl) receptor 
signalling. Drug Development Research, 39, 262 -268. 
Freemann, M.A.R. & Wyke, B. (1967). The innervation of the knee joint: an 
anatomical and histological study in the cat. The Journal of Anatomy., 101, 
505 -532. 
217 
Fukuoka, H., Kawatani, M., Hisamitsu, T. & Takeshige, C. (1994). Cutaneous 
hyperalgesia induced by peripheral injection of interleukin -1 beta in the rat. 
Brain Research, 657, 133 -40. 
Gadangi, P., Longaker, M., Naime, D., Levin, R.I., Recht, B.M.T., Carlin, G. & 
Cronstein, B.N. (1996). The anti -inflammatory mechanism of sulfasalazine is 
adenosine release at inflamed sites. Journal of Immunology, 156, 1937 -1941. 
Gallar, J., Acosta, M.C., Gutierrez, A.R., Villegas, M.P., Miralles, J. & Belmonte, C. 
(1997). Pain nerve activity in corneal sensory fibers after photorefractive 
surgery. Investigative Ophthalmology & Visual Science, 38, 1334. 
Gallar, J., Pozo, M.A., Tuckett, R.P. & Belmonte, C. (1993). Response of sensory 
units with unmyelinated fibres to mechanical, thermal and chemical 
stimulation of the cat's cornea. Journal of Physiology- London, 468, 609 -622. 
GarciaGuzman, M., Stuhmer, W. & Soto, F. (1997). Molecular characterization and 
pharmacological properties of the human P2X3 purinoceptor. Molecular 
Brain Research, 47, 59 -66. 
Gardner, E. (1944). The distribution and termination of nerves in the knee joint of the 
cat. The Journal of Comparative Neurology., 80, 11 -32. 
Gaspardone, A., Crea, F., Iamele, M., Tomai, F., Versaci, F., Pellegrino, A., 
Chiariello, L. & Gioffré, P.A. (1993). Bamiphylline improves exercise - 
induced myocardial ischemia through a novel mechanism of action. 
Circulation, 88, 502 -8. 
Gaspardone, A., Crea, F., Tomai, F., Versaci, F., Iamele, C.L. & Gioffre, P.A. 
(1995). Muscular and cardiac adenosine -induced pain is mediated by Al 
receptors. Journal of the American College of Cardiology, 25, 251 -257. 
Gasser, H.S. & Erlanger, J. (1927). The role played by the sizes of the constituent 
fibres of a nerve trunk in determining the form of its action potential wave. 
American Journal of Physiology, 80, 522 -547. 
Gillespie, J.H. (1934). The biological significance of the linkages in adenosine 
triphosphoric acid. Journal of Physiology- London, 80, 345 -349. 
Giraldez, F., Geijo, E. & Belmonte, C. (1979). Response characteristics of corneal 
sensory fibers to mechanical and thermal stimulation. Brain Research, 177, 
571 -6. 
Giri, J.G., Lomedico, P.T. & Mizel, S.B. (1985). Studies on the synthesis and 
secretion of interleukin 1. Journal Of Immunology, 134, 343 -9. 
Gonzalez, G.G., Garcia de la Rubia, P., Gallar, J. & Belmonte, C. (1993). Reduction 
of capsaicin- induced ocular pain and neurogenic inflammation by calcium 
antagonists. Investigative Ophthalmology & Visual Science, 34, 3329 -35. 
218 
Goodwin, J.S. (1987). Toxicity of nonsteroidal anti -inflammatory drugs. Archives of 
Internal Medicine, 147, 34 -5. 
Gordon, J.L. (1986). Extracellular ATP: effects, sources and fate. Biochemical 
Journal, 233, 309 -19. 
Griffiths, R.J., Stam, E.J., Downs, J.T. & Otterness, I.G. (1995). ATP induces the 
release of IL -1 from LPS- primed cells in vivo. Journal of Immunology, 154, 
2821 -8. 
Grigg, P., Schaible, H.G. & Schmidt, R.F. (1986). Mechanical sensitivity of group III 
and IV afferents from posterior articular nerve in normal and inflamed cat 
knee. Journal of Neurophysiology, 55, 635 -43. 
Grubb, B.D., Birrell, G.J., McQueen, D.S. & Iggo, A. (1991). The role of PGE2 in 
the sensitization of mechanoreceptors in normal and inflamed ankle joints of 
the rat. Experimental Brain Research, 84, 383 -92. 
Grubb, B.D., McQueen, D.S., Iggo, A., Birrell, G.J. & Dutia, M.B. (1988). A study 
of 5 -HT- receptors associated with afferent nerves located in normal and 
inflamed rat ankle joints. Agents & Actions, 25, 216 -8. 
Guilbaud, G., Iggo, A. & Tegner, R. (1985). Sensory receptors in ankle joint capsules 
of normal and arthritic rats. Experimental Brain Research, 58, 29 -40. 
Hamill, O.P., Lane, J.W. & McBride DW, J.r. (1992). Amiloride: a molecular probe 
for mechanosensitive channels. Trends In Pharmacological Sciences, 13, 
373 -6. 
Hamilton, S.G., Wade, A. & McMahon, S.B. (1999). The effects of inflammation 
and inflammatory mediators on nociceptive behaviour induced by ATP 
analogues in the rat. British Journal of Pharmacology, 126, 326 -332. 
Haneda, T., Ichihara, K., Abiko, Y. & Onodera, S. (1989). Release of adenosine and 
lactate from human hearts during atrial pacing in patients with ischemic heart 
disease. Clinical Cardiology, 12, 76 -82. 
Hara, A., Sakurada, T., Sakurada, S., Matsumura, H. & Kisara, K. (1984). 
Antinociceptive effects of neonatal capsaicin in rats with adjuvant arthritis. 
Naunzyn- Schmiedebergs Archives of Pharmacology, 326, 248 -53. 
Harris, K.E. (1927). Observations on a histamine -like substance in skin extracts. 
Heart, 14. 
Hart, R.P., Shadiack, A.M. & Jonakait, G.M. (1991). Substance P gene expression is 
regulated by interleukin -1 in cultured sympathetic ganglia. Journal Of 
Neuroscience Research, 29, 282 -91. 
219 
Häse, C.C., Le Dain, A.C. & Martinac, B. (1995). Purification and functional 
reconstitution of the recombinant large mechanosensitive ion -channel (MscL) 
of Escherichia coli. Journal Of Biological Chemistry, 270, 18329 -34. 
Hasid), G., Szabó, C., Németh, Z.H., Kvetan, V., Pastores, S.M. & Vizi, E.S. (1996). 
Adenosine receptor agonists differentially regulate IL -10, TNF- alpha, and 
nitric oxide production in RAW 264.7 macrophages and in endotoxemic 
mice. Journal Of Immnology, 157, 4634 -40. 
Heinbecker, P., Bishop, G.H. & O'Leary, J. (1932). Fibres in mixed nerves and their 
dorsal roots responsible for pain. Proceedings of the Society for Experimental 
Biology and Medicine, 29, 928 -930. 
Heppelmann, B., Messlinger, K., Neiss, W.F. & Schmidt, R.F. (1990). Ultrastructural 
three -dimensional reconstruction of group III and group IV sensory nerve 
endings ('free nerve endings') in the knee joint capsule of the cat: evidance for 
multiple receptive sites. The Journal of Comparative Neurology, 292, 103- 
116. 
Hilderman, R.H., Martin, M., Zimmerman, J.K. & Pivorun, E.B. (1991). 
Identification of a unique membrane receptor for adenosine 5',5'- P1,P4- 
tetraphosphate. Journal Of Biological Chemistry, 266, 6915 -8. 
Hirose, K. & Jyoyama, H. (1971). Measurement of arthritic pain and effects of 
analgesics in the adjuvant- treated rat. Japanese Journal of Pharmacology, 21, 
717 -20. 
Hogquist, K.A., Nett, M.A., Unanue, E.R. & Chaplin, D.D. (1991a). Interleukin 1 is 
processed and released during apoptosis. Proceedings Of The National 
Academy Of Sciences Of The United States Of America, 88, 8485 -9. 
Hogquist, K.A., Unanue, E.R. & Chaplin, D.D. (1991b). Release of IL -1 from 
mononuclear phagocytes. Journal Of Immunology, 147, 2181 -6. 
Holton, P. (1959). The liberation of adenosine triphosphate on antidromic stimulation 
of sensory nerves. Journal of Physiology -London, 145. 
Hong, J.L., Ho, C.Y., Kwong, K. & Lee, L.Y. (1998). Activation of pulmonary C 
fibres by adenosine in anaesthetised rats: role of adenosine Al receptors. 
Journal of Physiology- London, 508, 109 -118. 
Hu, H.Z. & Li, Z.W. (1996). Substance P potentiates ATP -activated currents in rat 
primary sensory neurons. Brain Research, 739, 163 -8. 
Huang, M.H., Sylven, C., Horackova, M. & Armour, J.A. (1995). Ventricular 
sensory neurons in canine dorsal root ganglia: effects of adenosine and 
substance P. American Journal of Physiology, 269, R318 -24. 
220 
Hunt, C.C. & McIntyre, A.K. (1960a). An analysis of fibre diameter and receptor 
characteristics of myelinated cutaneous afferent fibres in cat. Journal of 
Physiology - London, 153, 99 -112. 
Hunt, C.C. & McIntyre, A.K. (1960b). Characteristics of responses from receptors 
from the flexor longus digitorum muscle and the adjoining interosseous 
region of the cat. Journal of Physiology -London, 153, 74 -87. 
Hunt, C.C. & McIntyre, A.K. (1960c). Properties of cutaneous touch receptors in cat. 
Journal of Physiology- London, 153, 88 -98. 
Hunter, J. (1894). A Treatise on the Blood, Inflammation and Gun -shot Wounds. 
London: George Nicol. 
Iggo, A. (1960). Cutaneous mechanoreceptors with afferent C fibres. Journal of 
Physiology - London, 152, 337 -353. 
Ingber, D.E. (1997). Tensegrity: the architectural basis of cellular 
mechanotransduction. Annual Review Of Physiology, 59, 575 -99. 
Jaffar, Z.H. & Pearce, F.L. (1990). Histamine secretion from mast cells stimulated 
with ATP. Agents & Actions, 30, 64 -6. 
Jahr, C.E. & Jessell, T.M. (1983). ATP excites a subpopulation of rat dorsal horn 
neurones. Nature, 304, 730 -3. 
Jeanjean, A.P., Moussaoui, S.M., Maloteaux, J.M. & Laduron, P.M. (1995). 
Interleukin -1 beta induces long -term increase of axonally transported opiate 
receptors and substance P. Neuroscience, 68, 151 -7. 
Jonakait, G.M., Schotland, S. & Hart, R.P. (1990). Interleukin -1 specifically 
increases substance P in injured sympathetic ganglia. Annals Of The New 
York Academy Of Sciences, 594, 222 -30. 
Kanaka, R., Schaible, H.G. & Schmidt, R.F. (1985). Activation of fine articular 
afferent units by bradykinin. Brain Research, 327, 81 -90. 
Kane, B.J., Kuhn, J.G. & Roush, M.K. (1992). Pentostatin: an adenosine deaminase 
inhibitor for the treatment of hairy cell leukemia. Annals Of 
Pharmacotherapy, 26, 939 -47. 
Karlsten, R., Gordh, T. & Post, C. (1992). Local antinociceptive and hyperalgesic 
effects in the formalin test after peripheral administration of adenosine 
analogues in mice. Pharmacology & Toxicology, 70, 434 -8. 
Karlsten, R. & Gordh T, J.r. (1995). An Al-selective adenosine agonist abolishes 
allodynia elicited by vibration and touch after intrathecal injection. 
Anesthesia And Analgesia, 80, 844 -7. 
221 
Keele, C.A. & Armstrong, D. (1964). Substances producing pain and itch. London: 
Edward Arnold. 
Keil, G.J. & Salter, M.W. (1996). Multiple roles of ATP and adenosine in 
somatosensory processing: therapeutic implications. Drug Development 
Research, 39, 279 -288. 
Kelly, D.C. (1998). The role of kinins in inflammatory pain and their modulation by 
other inflammatory mediators. PhD thesis: Edinburgh University. 
Kelly, D.C., Asghar, A.U.R., McQueen, D.S. & Perkins, M.N. (1996). Effects of 
bradykinin and desArg(9)- bradykinin on afferent neural discharge in 
interleukin -1 beta -treated rat knee joints. British Journal of Pharmacology, 
117, 90. 
Kelly, D.C., McQueen, D.S. & Perkins, M.N. (1997). Indomethacin prevents the IL- 
1 beta- induced increase in neural discharge and enhancement of kinin- 
mediated activation of C -fibre mechanociceptors innervating the rat knee 
joint. British Journal of Pharmacology, 122, 357. 
Kennedy, I., Gurden, M. & Strong, P. (1992). Do adenosine A3 receptors exist? 
General Pharmacology, 23, 303 -7. 
Kidd, EJ., Miller, K.J., Sansum, A.J. & Humphrey, P.P.A. (1998). Evidence for 
P2X(3) receptors in the developing rat brain. Neuroscience, 87, 533 -539. 
Kress, M. & Reeh, P.W. (1996). Chemical excitation and sensitization in 
nociceptors. In Neurobiology of Nociceptors. ed. Belmonte, C. & Cervero, F. 
pp. 370 -389. New York: Oxford University Press. 
Laird, J.M., Herrero, J.F., Garcia de la Rubia, P. & Cervero, F. (1997). Analgesic 
activity of the novel COX -2 preferring NSAID, meloxicam in mono -arthritic 
rats: central and peripheral components. It jlamnation Research, 46, 203 -10. 
Langford, L.A. & Schmidt, R.F. (1983). Afferent and efferent axons in the medial 
and posterior articular nerves of the cat. Anatomical Research, 206, 71 -78. 
Le Moine, O., Stordeur, P., Schandené, L., Marchant, A., de Groote, D., Goldman, 
M. & Devière, J. (1996). Adenosine enhances IL -10 secretion by human 
monocytes. Journal Of Immunology, 156, 4408 -14. 
Lee, Y.W. & Yaksh, T.L. (1996). Effects of Al adenosine receptor blockade by 
bamiphylline on ischaemic preconditioning during coronary angioplasty. 
European Heart Journal, 17, 846 -53. 
Lele, P.P. & Waddell, G. (1959). Sensory nerves of the cornea and cutaneous 
sensibility. Experimental Neurology, 1, 334 -359. 
Lesch, M.E., Ferin, M.A., Wright, C.D. & Schrier, D.J. (1991). The effects of (R) -N- 
(1- methyl -2- phenylethyl) adenosine (L -PIA), a standard Al- selective 
222 
adenosine agonist on rat acute models of inflammation and neutrophil 
function. Agents And Actions, 34, 25 -7. 
Levine, J.D., Fields, H.L. & Basbaum, A.I. (1993). Peptides and the primary afferent 
nociceptor. Journal Of Neuroscience, 13, 2273 -86. 
Levine, J.D. & Tawio, Y.O. (1994). Inflammatory pain. In Textbook of Pain. ed. 
Wall, P.D. & Melzack, R. pp. 45 -56. London: Churchill Livingstone. 
Lewis, C., Neidhart, S., Holy, C., North, R.A., Buell, G. & Surprenant, A. (1995). 
Coexpression of P2X2 and P2X3 receptor subunits can account for ATP - 
gated currents in sensory neurons. Nature, 377, 432 -435. 
Lewis, T. (1935). Experiments relating to cutaneous hyperalgesia and its spread 
through somatic nerves. Clinical Science, 2, 373 -423. 
Lewis, T. (1942). Pain. New York: The Macmillan Company. 
Lewis, T., Grant, R.T. & Marvin, H.M. (1927). Vascular reactions of the skin to 
injury. Part X. The intervention of a chemical stimulus illustrated especially 
by the flare. The response to faradism. Heart, 14, 139 -160. 
Li, C., Peoples, R.W., Lanthorn, T.H., Li, Z. & Weight, F.F. (1999). Distinct ATP - 
activated currents in different types of neurons dissociated from rat dorsal rot 
ganglion. Neuroscience Letters, 263, 57 -60. 
Li, C., Peoples, R.W. & Weight, F.F. (1997). Enhancement of ATP- activated current 
by protons in dorsal root ganglion neurons. Pflugers Archiv. European 
Journal of Physiology, 433, 446 -54. 
Li, C.Y., Peoples, R.W. & Weight, F.F. (1996). Acid pH augments excitatory action 
of ATP on a dissociated mammalian sensory neuron. Neuroreport, 7, 2151- 
2154. 
Li, F., Khakh, B.S., Vongsavan, N. & Matthews, B. (1998). Effects of ATP on 
intradental sensory receptors in the cat. Journal of Dental Research, 77, 314. 
Lifschitz, M.D. (1983). Renal effects of nonsteroidal anti -inflammatory agents. 
Journal of Laboratory & Clinical Medicine, 102, 313 -23. 
Lim -Bon -Siong, R., Valluri, S., Gordon, M.E. & Pepose, J.S. (1998). Efficacy and 
safety of the ProTek (Vifilcon A) therapeutic soft contact lens after 
photorefractive keratectomy. American Journal of Ophthalmology, 125, 169- 
76. 
Llewellyn- Smith, I.J. & Burnstock, G. (1998). Ultrastructural localization of P2X3 
receptors in rat sensory neurons. Neuroreport, 9, 2545 -50. 
223 
Londos, C., Cooper, D.M. & Wolff, J. (1980). Subclasses of external adenosine 
receptors. Proceedings Of The National Academy Of Sciences Of The United 
States Of America, 77, 2551 -4. 
Loredo, G.A. & Benton, H.P. (1998). ATP and UTP activate calcium- mobilizing 
P2U -like receptors and act synergistically with interleukin -1 to stimulate 
prostaglandin E2 release from human rheumatoid synovial cells. Arthritis & 
Rheumatism, 41, 246 -55. 
Lynn, B. (1996). Principles of classification and nomenclature relevant to studies of 
nociceptive neurones. In Neurobiology of Nociceptors. ed. Belmonte, C. & 
Cervero, F. pp. 1 -2. New York: Oxford University Press. 
Ma, Q.P. & Woolf, C.J. (1995). Involvement of neurokinin receptors in the induction 
but not the maintenance of mechanical allodynia in rat flexor motoneurones. 
Journal of Physiology- London, 486, 769 -77. 
Maenhaut, C., Van Sande, J., Libert, F., Abramowicz, M., Parmentier, M., 
Vanderhaegen, J.J., Dumont, J.E., Vassart, G. & Schiffmann, S. (1990). 
RDC8 codes for an adenosine A2 receptor with physiological constitutive 
activity. Biochemical And Biophysical Research Communications, 173, 1169- 
78. 
Mahan, L.C., McVittie, L.D., Smyk -Randall, E.M., Nakata, H., Monsma FJ, J.r., 
Gerfen, C.R. & Sibley, D.R. (1991). Cloning and expression of an Al 
adenosine receptor from rat brain. Molecular Pharmacology, 40, 1 -7. 
Malone, D.G., Verbsky, J.W. & Dolan, P.W. (1991). A lavage method for dynamic 
intraarticular monitoring of animal joints in situ: quantification and release 
kinetics of histamine after selective synovial mast cell activation by diverse 
secretagogues. Journal of Laboratory & Clinical Medicine, 118, 269 -79. 
Marshall, K.W., Chiu, B. & Inman, R.D. (1990). Substance P and arthritis: analysis 
of plasma and synovial fluid levels. Arthritis & Rheumatism, 33, 87 -90. 
Matthews, B., Li, F., Khakh, B.S. & Vongsavan, N. (1997). Effects of ATP on 
sensory receptors in the dental pulp of cats. Journal of Physiology - London, 
504, 128P. 
McDougall, J.J., Karimian, S.M. & Ferrell, W.R. (1995). Prolonged alteration of 
vasoconstrictor and vasodilator responses in rat knee joints by adjuvant 
monoarthritis. Experimental Physiology, 80, 349 -57. 
McQueen, D.S., Bond, S.M., Moores, C., Chessell, I., Humphrey, P.P.A. & Dowd, E. 
(1998). Activation of P2X receptors for adenosine triphosphate evokes 
cardiorespiratory reflexes in anaesthetized rats. Journal of Physiology - 
London, 507, 843 -855. 
224 
McQueen, D.S., Iggo, A., Birrell, G.J. & Grubb, B.D. (1991). Effects of paracetamol 
and aspirin on neural activity of joint mechanonociceptors in adjuvant 
arthritis. British Journal of Pharmacology, 104, 178 -82. 
McQueen, D.S., Moores, C., Dowd, E., Bond, S.M., Chessell, I.P. & Humphrey, 
P.P.A. (1997). P2X receptor activation evokes a Bezold -Jarisch -like reflex in 
anaesthetised rats. British Journal of Pharmacology, 122, 246P. 
McQueen, D.S. & Ribeiro, J.A. (1981). Effect of adenosine on carotid 
chemoreceptor activity in the cat. British Journal of Pharmacology, 74, 129- 
36. 
Melzack, R. & Wall, P.D. (1962). On the nature of cutaneous sensory mechanisms. 
Brain, 85, 331 -356. 
Mense, S. (1996). Nociceptors in skeletal muscle and their reaction to pathological 
tissue changes. In Neurobiology of Nociceptors. ed. Belmonte, C. & Cervero, 
F. pp. 184 -201. New York: Oxford University Press. 
Meyer, R.A., Raja, S.N. & Campbell, J.N. (1996). Neural mechanisms of primary 
hyperalgesia. In Neurobiology of Nociceptors. ed. Belmonte, C. & Cervero, 
F. pp. 370 -389. New York: Oxford University Press. 
Millan, M.J. (1999). The induction of pain: an integrative review. Progress In 
Neurobiology, 57, 1 -164. 
Molineaux, S.M., Casano, F.J., Rolando, A.M., Peterson, E.P., Limjuco, G., Chin, J., 
Griffin, P.R., Calaycay, J.R., Ding, G.J., Yamin, T.T. & et, a. (1993). 
Interleukin 1 beta (IL -1 beta) processing in murine macrophages requires a 
structurally conserved homologue of human IL -1 beta converting enzyme. 
Proceedings Of The National Academy Of Sciences Of The United States Of 
America, 90, 1809 -13. 
Monteiro, E.C. & Ribeiro, J.A. (1987). Ventilatory effects of adenosine mediated by 
carotid body chemoreceptors in the rat. Naunyn- Schmiedebergs Archives Of 
Pharmacology, 335, 143 -8. 
Murgia, M., Hanau, S., Pizzo, P., Rippa, M. & Di Virgilio, F. (1993). Oxidized ATP. 
An irreversible inhibitor of the macrophage purinergic P2Z receptor. Journal 
Of Biological Chemistmy, 268, 8199 -203. 
Nakamura, F. & Strittmatter, S.M. (1996). P2Y1 purinergic receptors in sensory 
neurons: contribution to touch -induced impulse generation. Proceedings Of 
The National Academy Of Sciences Of The United States Of America, 93, 
10465 -70. 
Neumann, S., Doubell, T.P., Leslie, T. & Woolf, C.J. (1996). Inflammatory pain 
hypersensitivity mediated by phenotypic switch in myelinated primary 
sensory neurons. Nature, 384, 360 -4. 
225 
O'Connor, S.E., Dainty, I.A. & Leff, P. (1991). Further subclassification of ATP 
receptors based on agonist studies. Trends in Pharmacological Sciences, 12, 
137 -41. 
O'Dwyer, P.J., Cheson, B.D., Leyland- Jones, B., King, S.A. & Hoth, D.F. (1988). 
Deoxycoformycin: an active new drug for indolent lymphomas and hairy cell 
leukemia. Oncology (Hunting!), 2, 17 -23, 26 -7. 
Okuyama, S. & Aihara, H. (1984). Inhibition of electrically- induced vocalization in 
adjuvant arthritic rats as a novel method for evaluating analgesic drugs. 
Japanese Journal of Pharmacology, 34, 67 -77. 
Owen, R.T. (1980). Adjuvant induced polyarthritis - an overview. Methods & 
Findings in Experimental & Clinical Pharmacology, 2, 199 -204. 
Pappagallo, M., Gaspardone, A., Tomai, F., Iamele, M. & Crea (1993). Analgesic 
effect of bamiphylline on pain induced by injection of adenosine. Pain, 53, 
199 -204. 
Park, W., Masuda, I., Cardenal- Escarcena, A., Palmer, D.L. & McCarty, D.J. (1996). 
Inorganic pyrophosphate generation from adenosine triphosphate by cell -free 
human synovial fluid. Journal of Rheumatology, 23, 665 -71. 
Parmely, M.J., Zhou, W.W., Edwards, C.K. & Borcherding, M.D. (1993). Adenosine 
and a related carbocyclic nucleoside inhibit tumor necrosis factor -alpha 
production and protect mice against endotoxin challenge. Journal of 
Immunology, 151, 389 -396. 
Pearson, C.M. (1956). Development of arthritis, periarthritis and periositis in rats 
given adjuvants. Preceedings of the Society of Experimental Biology, 91, 95- 
101. 
Pearson, C.M. (1963). Experimental joint disease. Observations on adjuvant- induced 
arthritis. Journal of Chronic Diseases, 16, 863 -874. 
Pearson, C.M. & Wood, F.D. (1963). Studies of arthritis and other lesions induced in 
rats by the injection of mycobacteria adjuvant. VII. Pathogenic details of the 
arthritis and spondylitis. American Journal of Pathology, 42, 73 -95. 
Perregaux, D. & Gabel, C.A. (1994). Interleukin -1 beta maturation and release in 
response to ATP and nigericin. Journal of Biological Chemistry, 269, 15195- 
203 . 
Perrine, J.W. & Takesue, E.I. (1968). Use of the rotarod in determining grip strength 
in rats with adjuvant -induced arthritis. Archives Internationales de 
Pharmacodynamie et de Therapie, 174, 192 -8. 
Pierce, K.D., Furlong, T.J., Selbie, L.A. & Shine, J. (1992). Molecular cloning and 
expression of an adenosine A2b receptor from human brain. Biochemical And 
Biophysical Research Communications, 187, 86 -93. 
226 
Qian, Y., Chao, D.S., Santillano, D.R., Cornwell, T.L., Nairn, A.C., Greengard, P., 
Lincoln, T.M. & Bredt, D.S. (1996). cGMP- dependent protein kinase in 
dorsal root ganglion: relationship with nitric oxide synthase and nociceptive 
neurons. Journal Of Neuroscience, 16, 3130 -8. 
Rainsford, K.D. (1982). Adjuvant polyarthritis in rats: is this a satisfactory model for 
screening anti -arthritic drugs? Agents & Actions, 12, 452 -8. 
Ralevic, V. & Burnstock, G. (1998). Receptors for purines and pyrimidines. 
Pharmacological Reviews, 50, 413 -492. 
Rane, K., Segerdahl, M., Goiny, M. & Sollevi, A. (1998). Intrathecal adenosine 
administration: a phase 1 clinical safety study in healthy volunteers, with 
additional evaluation of its influence on sensory thresholds and experimental 
pain. Anesthesiology, 89, 1108 -1115. 
Reppert, S.M., Weaver, D.R., Stehle, J.H. & Rivkees, S.A. (1991). Molecular 
cloning and characterization of a rat Al- adenosine receptor that is widely 
expressed in brain and spinal cord. Molecular Endocrinology, 5, 1037 -48. 
Ribeiro, J.A. & Sebastiáo, A.M. (1986). Adenosine receptors and calcium: basis for 
proposing a third (A3) adenosine receptor. Progress In Neurobiology, 26, 
179 -209. 
Rivkees, S.A. & Reppert, S.M. (1992). RFL9 encodes an A2b- adenosine receptor. 
Molecular Endocrinology, 6, 1598 -604. 
Rozsa, A.J. & Beuerman, R.W. (1982). Density and organization of free nerve 
endings in the corneal epithelium of the rabbit. Pain, 14, 105 -20. 
Ryan, L.M., Rachow, J.W. & McCarty, D.J. (1991). Synovial fluid ATP: a potential 
substrate for the production of inorganic pyrophosphate. Journal of 
Rheumatology, 18, 716 -20. 
Safieh -Garabedian, B., Poole, S., Allchorne, A., Winter, J. & Woolf, C.J. (1995). 
Contribution of interleukin -1 beta to the inflammation -induced increase in 
nerve growth factor levels and inflammatory hyperalgesia. British Journal of 
Pharmacology, 115, 1265 -75. 
Sajjadi, F.G., Takabayashi, K., Foster, A.C. & Domingo (1996). Inhibition of TNF- 
alpha expression by adenosine - adenosine receptors. Journal of Immunology, 
156, 3435 -3442. 
Salmon, J.E. & Cronstein, B.N. (1990). Fc gamma receptor -mediated functions in 
neutrophils are modulated by adenosine receptor occupancy. Al receptors are 
stimulatory and A2 receptors are inhibitory. Journal Of Immunology, 145, 
2235 -40. 
Salo, P.T. & Theriault, E. (1997). Number, distribution and neuropeptide content of 
rat knee joint afferents. Journal of Anatomy, 190, 515 -22. 
227 
Sandoval, D.M., Alarcon, G.S. & Morgan, S.L. (1995). Adverse events in 
methotrexate- treated rheumatoid arthritis patients. British Journal of 
Rheumatology, 2,49-56. 
Sawynok, J. (1998). Adenosine receptor activation and nociception. European 
Journal of Pharmacology, 347, 1 -11. 
Sawynok, J. & Reid, A. (1997). Peripheral adenosine 5'- triphosphate enhances 
nociception in the formalin test via activation of a purinergic p2X receptor. 
European Journal of Pharmacology, 330,115 -21. 
Sawynok, J., Reid, A. & Poon, A. (1998). Peripheral antinociceptive effect of an 
adenosine kinase inhibitor, with augmentation by an adenosine deaminase 
inhibitor, in the rat formalin test. Pain, 74, 75 -81. 
Sawynok, J. & Sweeney, M.I. (1989). The role of purines in nociception. 
Neuroscience, 32,557-69. 
Sawynok, J., Zarrindast, M.R., Reid, A.R. & Doak, G.J. (1997). Adenosine A3 
receptor activation produces nociceptive behaviour and edema by release of 
histamine and 5- hydroxytryptamine. European Journal of Pharmacology, 
333,1 -7. 
Schaible, H.-G. & Schmidt, R.F. (1983a). Activation of groups III and IV sensory 
units in medial articular nerve by local mechanical stimulation of knee joint. 
Journal of Neurophysiology., 49, 35 -44. 
Schaible, H. -G. & Schmidt, R.F. (1983b). Responses of fine medial articular nerve 
afferents to passive movements of knee joint. Journal of Neurophysiology., 
49,1118 -1126. 
Schaible, H.G. & Schmidt, R.F. (1985). Effects of an experimental arthritis on the 
sensory properties of fine articular afferent units. Journal of 
Neurophysiology, 54,1109 -22. 
Schaible, H.G. & Schmidt, R.F. (1988). Time course of mechanosensitivity changes 
in articular afferents during a developing experimental arthritis. Journal of 
Neurophysiology, 60, 2180 -95. 
Schaible, H.G. & Schmidt, R.F. (1996). Neurobiology of articular nociceptors. In 
Neurobiology of Nociceptors. ed. Belmonte, C. & Cervero, F. pp. 203 -219. 
New York: Oxford University Press. 
Schiff, M. (1997). Emerging treatments for rheumatoid arthritis. American Journal of 
Medicine, 102,11S -15S. 
Schmued, L.C. & Fallon, J.H. (1986). Fluoro -Gold: a new fluorescent retrograde 
axonal tracer with numerous unique properties. Brain Research, 377,147 -54. 
228 
Schnabel, A. & Gross, W.L. (1994). Low -dose methotrexate in rheumatic diseases- - 
efficacy, side effects, and risk factors for side effects. Seminars in Arthritis & 
Rheumatism, 23, 310 -27. 
Schrier, D.J., Lesch, M.E., Wright, C.D. & Gilbertsen, R.B. (1990). The 
antiinflammatory effects of adenosine receptor agonists on the carrageenan- 
induced pleural inflammatory response in rats. Journal Of Immunology, 145, 
1874 -9. 
Sculco, T.P. (1998). The knee joint in rheumatoid arthritis. Rheumatic Diseases 
Clinics of North America, 24, 143 -56. 
Sherrington, C.S. (1906). The Integrative Action of the Nervous System. New York: 
Charles Scribner's Sons. 
Skoglund, S. (1956). Anatomical and physiological studies of knee joint innervation 
in the cat. Acta Physiologica Scandinavia., 124, 1 -101. 
Stebbing, M.J., McLachlan, E.M. & Sah, P. (1998). Are there functional P2X 
receptors on cell bodies in intact dorsal root ganglia of rats? Neuroscience, 
86, 1235 -1244. 
Stehle, J.H., Rivkees, S.A., Lee, J.J., Weaver, D.R., Deeds, J.D. & Reppert, S.M. 
(1992). Molecular cloning and expression of the cDNA for a novel A2- 
adenosine receptor subtype. Molecular Endocrinology, 6, 384 -93. 
Stein, R., Stein, H.A., Cheskes, A. & Symons, S. (1994). Photorefractive 
keratectomy and postoperative pain. American Journal of Ophthalmology, 
117, 403 -5. 
Stella, N., Estelles, A., Siciliano, J., Tence, M., Desagher, S., Piomelli, D., 
Glowinski, J. & Premont, J. (1997). Interleukin -1 enhances the ATP -evoked 
release of arachidonic acid from mouse astrocytes. Journal of Neuroscience, 
17, 2939 -2946. 
Stone, T.W. & Simmonds, H.A. (1991). Purines: Basic and Clinical Aspects. 
London: Kluwer Acadimic Press. 
Stoner, H.B. & Green, H.N. (1945). Experimental limb ischeamia in man with 
especial reference to the role of adenosine triphosphate. Clinical Science, 5, 
159 -175. 
Stout, J.G. & Kirley, T.L. (1995). Inhibition of purified chicken gizzard smooth 
muscle ecto -ATPAse by P2 purinoceptor antagonists. Biochemistry And 
Molecular Biology International, 36, 927 -34. 
Sugiyama, K. & Yamasaki, H. (1969). Calcium -dependent histamine release by ATP 
from isolated rat mast cells. Japanese Journal Of Pharmacology, 19, 175 -6. 
229 
Sukharev, S.I., Blount, P., Martinac, B. & Kung, C. (1997). Mechanosensitive 
channels of Escherichia coli: the MscL gene, protein, and activities. Annual 
Review Of Physiology, 59, 633 -57. 
Surprenant, A., Buell, G. & North, R.A. (1995). P2X receptors bring new structure to 
ligand -gated ion- channels. Trends in Neurosciences, 18, 224 -229. 
Surprenant, A., Rassendren, F., Kawashima, E., North, R.A., Buell, G., Chow, S.C., 
Kass, G.E. & Orrenius, S. (1996). The cytolytic P2Z receptor for extracellular 
ATP identified as a P2X receptor (P2X7). Science, 272, 735 -8. 
Sylven, C., Beermann, B., Jonzon, B. & Brandt, R. (1986). Angina- pectoris like pain 
provoked by intravenous adenosine in healthy -volunteers. British Medical 
Journal, 293, 227 -230. 
Taiwo, Y.O. & Levine, J.D. (1990). Direct cutaneous hyperalgesia induced by 
adenosine. Neuroscience, 38, 757 -762. 
Tavernarakis, N. & Driscoll, M. (1997). Molecular modeling of 
mechanotransduction in the nematode Caenorhabditis elegans. Annual 
Review Of Physiology, 59, 659 -89. 
Thiel, M. & Chouker, A. (1995). Acting via A2 receptors, adenosine inhibits the 
tumour necrosis factor alpha production of endotoxin- stimulated human 
polymorphonuclear leukocytes. Journal of Laboratory and Clinical Medicine, 
126, 275 -282. 
Thornberry, N.A., Bull, H.G., Calaycay, J.R., Chapman, K.T., Howard, A.D., 
Kostura, M.J., Miller, D.K., Molineaux, S.M., Weidner, J.R., Aunins, J. & et, 
a. (1992). A novel heterodimeric cysteine protease is required for interleukin- 
1 beta processing in monocytes. Nature, 356, 768 -74. 
Tominaga, M., Caterina, M.J., Malmberg, A.B., Rosen, T.A., Gilbert, H., Skinner, 
K., Raumann, B.E., Basbaum, A.I. & Julius, D. (1998). The cloned capsaicin 
receptor integrates multiple pain- producing stimuli. Neuron, 21, 531 -43. 
Tower, S. (1940). Units for sensory reception in the cornea; with notes on nerve 
impulses from sclera, iris and lens. Journal of Neurophysiology, 3, 486 -500. 
Trezise, D.J. & Humphrey, P.P.A. (1996). Activation of peripheral sensory neurones 
in the neonatal rat tail by ATP. British Journal of Pharmacology, 117, 103. 
Tulamo, R.M., Bramlage, L.R. & Gabel, A.A. (1989). Sequential clinical and 
synovial fluid changes associated with acute infectious arthritis in the horse. 
Equine Veterinary Journal, 21, 325 -31. 
Uchida, Y., Kamisaka, K. & Ueda, H. (1969). Responses of the cardiac sympathetic 
receptors to various substances. Japanese Heart Journal, 10, 225 -42. 
230 
Valera, S., Hussy, N., Evans, R.J., Adami, N., North, R.A., Surprenant, A. & Buell, 
G. (1994). A new class of ligand -gated ion -channel defined by P2X receptor 
for extracellular ATP. Nature, 371, 516 -519. 
van Calker, D., Müller, M. & Hamprecht, B. (1979). Adenosine regulates via two 
different types of receptors, the accumulation of cyclic AMP in cultured brain 
cells. Journal Of Neurochemistry, 33, 999 -1005. 
van der Ven, P. & Hinds, T.R. (1996). Characteristics of ecto -ATPase of Xenopus 
oocytes and the inhibitory actions of suramin on ATP breakdown. Flingers 
Archiv. European Journal Of Physiology, 431, 993 -6. 
Vane, J.R. (1971). Inhibition of prostaglandin synthesis as a mechanism of action for 
aspirin -like drugs. Nature. New Biology, 231, 232 -5. 
van Ede, A.E., Laan, R., Blom, H.J. & DeAbreu (1998). Methotrexate in rheumatoid 
arthritis: an update with mechanisms involved in toxicity. Seminars in 
Arthritis and Rheumatism, 27, 277 -292. 
Verma, S. & Marshall, J. (1996). Control of pain after photorefractive keratectomy. 
Journal of Refractive Surgery, 12, 358 -64. 
von der Leyen, H., Schmitz, W., Scholz, H., Scholz, J., Lohse, M.J. & Schwabe, U. 
(1989). Effects of 1, 3- dipropyl- 8- cyclopentylxanthine (DPCPX), a highly 
selective adenosine receptor antagonist, on force of contraction in guinea -pig 
atrial and ventricular cardiac preparations. Nanyn- Schmiedebergs Archives 
Of Pharmacology, 340, 204 -9. 
von Frey, M. (1894). Beitrag zur physiologie des schmerzsinns. Koenigl. Saechs. 
Ges. Wiss., Math. -Phys., 46, 185 -196. 
von Frey, M. (1922). Versuche uber schmerzerregende reize. Z. Biol., 76, 1 -24. 
Vulchanova, L., Riedl, M.S., Shuster, S.J., Stone, L.S., Hargreaves, K.M., Buell, G., 
Surprenant, A., North, R.A. & Elde, R. (1998). P2X3 is expressed by DRG 
neurons that terminate in inner lamina II. European Journal Of Neuroscience, 
10, 3470 -8. 
Wagner, D.R., McTiernan, C., Sanders, V.J. & Feldman, A.M. (1998). Adenosine 
inhibits lipopolysaccharide -induced secretion of tumor necrosis factor -alpha 
in the failing human heart. Circulation, 97, 521 -4. 
Walters, E.T. (1996). Comparative and evolutionary aspects of nociceptor function. 
In Neurobiology of Nociceptors. ed. Belmonte, C. & Cervero, F. pp. 92 -114. 
New York: Oxford University Press. 
Westfall, T.D., Kennedy, C. & Sneddon, P. (1997). The ecto -ATPase inhibitor ARL 
67156 enhances parasympathetic neurotransmission in the guinea -pig urinary 
bladder. European Journal Of Pharmacology, 329, 169 -73. 
231 
Westfall, T.D., Kennedy, C. & Sneddon, P. (1996). Enhancement of sympathetic 
purinergic neurotransmission in the guinea -pig isolated vas deferens by the 
novel ecto -ATPase inhibitor ARL 67156. British Journal Of Pharmacology, 
117, 867 -72. 
Wood, J.N., Coote, P.R., Minhas, A., Mullaney, I., McNeill, M. & Burgess, G.M. 
(1989). Capsaicin- induced ion fluxes increase cyclic GMP but not cyclic 
AMP levels in rat sensory neurones in culture. Journal Of Neuochemistiy, 
53, 1203 -11. 
Woolf, C.J. (1983). Evidance for a central component of post- injury pain 
hypersensitivity. Nature, 306, 686 -688. 
Woolf, C.J., Bennett, G.J., Doherty, M., Dubner, R., Kidd, B., Koltzenburg, M., 
Lipton, R., Loeser, J.D., Payne, R. & Torebjork, E. (1998). Towards a 
mechanism -based classification of pain? Pain, 77, 227 -9. 
Woolf, C.J. & Thompson, S.W. (1991). The induction and maintenance of central 
sensitization is dependent on N- methyl -D- aspartic acid receptor activation; 
implications for the treatment of post- injury pain hypersensitivity states. 
Pain, 44, 293 -9. 
Woolf, C.J. & Wall, P.D. (1986). Relative effectiveness of C primary afferent fibers 
of different origins in evoking a prolonged facilitation of the flexor reflex in 
the rat. Journal Of Neuroscience, 6, 1433 -42. 
Xiang, Z., Bo, X. & Burnstock, G. (1998). Localization of ATP -gated P2X receptor 
immunoreactivity in rat sensory and sympathetic ganglia. Neuroscience 
Letters, 256, 105 -8. 
Xu, X.J., Dalsgaard, C.J. & Wiesenfeld- Hallin, Z. (1992). Spinal substance P and N- 
methyl-D- aspartate receptors are coactivated in the induction of central 
sensitization of the nociceptive flexor reflex. Neuroscience, 51, 641 -8. 
Yoshida, K. & Gage, F.H. (1992). Cooperative regulation of nerve growth factor 
synthesis and secretion in fibroblasts and astrocytes by fibroblast growth 
factor and other cytokines. Brain Research, 569, 14 -25. 
Zander, E. & Wedell, G. (1951). Observations on the innervation of the cornea. 
Journal of Anatomy, 85, 68 -99. 
Zhou, Q.Y., Li, C., Olah, M.E., Johnson, R.A., Stiles, G.L. & Civelli, O. (1992). 
Molecular cloning and characterization of an adenosine receptor: the A3 
adenosine receptor. Proceedings Of The National Academy Of Sciences Of 
The United States Of America, 89, 7432 -6. 
Ziganshin, A.U., Ziganshina, L.E., Bodin, P., Bailey, D. & Burnstock, G. (1995a). 
Effects of P2- purinoceptor antagonists on ecto -nucleotidase activity of 
guinea -pig vas deferens cultured smooth muscle cells. Biochemistiy And 
Molecular Biology International, 36, 863 -9. 
232 
Ziganshin, A.U., Ziganshina, L.E., King, B.E. & Burnstock, G. (1995b). 
Characteristics of ecto -ATPase of Xenopus oocytes and the inhibitory actions 
of suramin on ATP breakdown. Pflugers Archiv. European Journal Of 
Physiology, 429, 412 -8. 
Ziganshin, A.U., Ziganshina, L.E., King, B.F., Pintor, J. & Burnstock, G. (1996). 
Effects of P2- purinoceptor antagonists on degradation of adenine nucleotides 
by ecto -nucleotidases in folliculated oocytes of Xenopus laevis. Biochemical 
Pharmacology, 51, 897 -901. 
Zimmermann, H. & Braun, N. (1996). Extracellular metabolism of nucleotides in the 
nervous system. Journal of Autonomic Pharmacology, 16, 397 -400. 
Zimmermann, H., Braun, N., Kegel, B. & Heine, P. (1998). New insights into 
molecular structure and function of ectonucleotidases in the nervous system. 
Neurochemistry International, 32, 421 -5. 
Zotterman, Y. (1933). Studies in the peripheral nervous mechanism of pain. Acta 
Medica Sccandinavica, 80, 185 -242. 
233 
APPENDEX I 
Drugs and solutions used in this investigation 
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Abbreviation 
Sources and solvents of drugs used 







































Tween 80 10 %, 
ethanol 10 %, 
PBS 
Sigma PBS 
8- cyclopentyl -1,3- 
Sigma 
DMSO 5 %, 
dipropylxanthine 1M NaOH 2%, PBS 
N -[(1 S,trans)- 2- hydroxypentyl] 
adenosine 
Pyridoxalphosphate-6-azophenyl- 
2',4'-disulphonic acid tetrasodium 
Saline: 






Dissolved in distilled 
H20, with NaC1 to 
0.9% added 
PBS: 
100m1 contained 40.5m10.2M Na2HPO.1.12H70 in saline, 9.5ml 0.2M NaH2PO4.2H20 in saline 
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Sources of reagents used in immunohistochemical procedures 
Reagent Supplier 
P2X3 antiserum Gift from GIAP 
S -100 antiserum DAKO 
Normal swine serum Harlan Serolabs 
Biotinylated swine- anti -rabbit DAKO 
antiserum 
P2X3 Pre -immune antiserum Gift from GIAP 
Alkaline phosphatase ABC kit DAKO 
Horseradish peroxidase ABC kit DAKO 
Vector red Vector 
DAB Sigma 
10% Formalin: 
100m1 had 10m140% formaldehyde, 0.9g NaC1 and 90m1 distilled water. 
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Solutions used in immunohistochemical procedures 
Solution Method of preparation 
Avidin Biotin Complex Buffer: pH 
7.6 
DAB solution: 
Frozen DAB aliquot: 
DAB buffer: pH 7.6 
0.2k! Tris: 
0.1N HCI: 
Phosphate buffered saline: 
pH 7.3 
Scott's Tap Water: 
Tris buffered saline: 
pH 7.6 
Normal saline: 
Tris 10 *: 
0.5M Tris: 
Normal HCI: 
Vector Red Buffer: 
pH 8.2 
Trypsin Digestion Solution: 
pH 7.6 -7.8 
To 24m1 0.2M Tris and 38ml 0.1N HC1 
added distH2O to 80m1; 
checked pH, added distH2O to 100m1 
To l000 frozen DAB aliquot 
added 100µ1 H2O2 and 4.8ml DAB buffer 
125mg DAB in 5m1 distH2O. 
Aliquoted into 1000 volumes. 
To 24ml 0.2M Tris, 38ml 0.1N HCl 
and 38ml distH2O 
added 68mg imiadazole; checked pH. 
24.23g Trisma base in 1000m1 distH2O 
8.5ml conc. HCI in 1000m1 distH2O 
Made from commercial tablets (OXOID). 
Dissolved 1 tablet in 100m1 distH2O. 
Autoclaved at 115 °C for 10 minutes 
2g K(CO3)2 and 20g MgSO4 in distH2O 
Diluted Tris 10* 1/10 in nonnal saline; 
checked pH 
42.5g NaCI in 5000m1 distilled water (distH2O) 
To 500m1 of 0.5M Tris 
added N HCL to pH 7.6. 
Made up to 2000m1 with distH2O; checked pH 
237 
30.25g Trisma base in 500m1 distH2O 
85ml conc. HCI in 1000m1 distH2O 
25ml 0.2M Tris, 22.9m1 0.1N HC1 
and 32.1m1 distH2O; 
checked pH; made to 100m1 with distH2O. 
100mg trvpsin and 100mg CaCI in distH20 
APPENDEX II 
Estimated concentrations of drugs used 
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Estimated local concentrations of drugs 











Adenosine 370 1.0 0.3 70 
ATP 2000 1.0 2.000 
ATPyS 900 1.0 0.900 
ar3meATP 1 -600 1.0 0.001 -0.600 
60 1.0 0.060 
Bradykinin 2 -30 1.0 0.002 -0.030 
9 1.0 0.009 
BzATP 700 1.0 0.700 
CGS21680 190 1.0 0.190 
Capsaicin 3 -30 1.0 0.003 -0.030 
10 1.0 0.010 
CPA 30 1.0 0.030 
GR79236 85 1.0 0.085 
Substance P 20 1.0 0.020 










Adenosine 370 0.1 3.7 
ATP 2000 0.1 20.0 
ATPyS 900 0.1 9.0 
a(3 meATP 60 0.1 0.6 
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286P AC 11VATION BY P2X PURINOCEPTOR AGONISTS OF SENSORY NERVES INNERVATING THE RAT KNEE JOINT 
E. Dowd, D.S. McQueen, I.P. Chessell' & P.P.A. Humphrey', 
Department of Pharmacology University of Edinburgh, 
Edinburgh, EH8 9JZ and IGlaxo Institute of Applied 
Pharmacology, Cambridge, CB2 1QJ. 
Six different types of ATP -gated ion -channel receptors 
(P2X,,) are expressed in dorsal root ganglia (DRG) and ATP 
evokes a depolarising current when applied to isolated DRG 
neurones (Jahr & Jessell, 1983). These findings have led 
investigators to believe that P2X purinoceptors, in particular 
the P2X,subtype, which is found only in sensory ganglia, may 
be involved in peripheral nociception (see Burnstock & Wood, 
1996). The aim of this study was to determine whether aß 
methylene ATP (aßmeATP), a P2X agonist, can activate noci- 
ceptive DRG afferents innervating the rat knee joint in vivo. 
Male Wistar rats (mean weight 335g, range 250 -420g) were 
anaesthetised with pentobarbitone (60mg.kg' i.p., sup- 
plemented hourly i.v.) and the trachea, right carotid artery, 
right femoral artery and vein were cannulated. Extracellular 
recordings were made from filaments of the medial articular 
nerve (MAN) innervating the left knee joint using techniques 
similar to those described previously for the rat ankle joint 
(Birrell et al. 1991). Drugs were applied by close intra- arterial 
injection into the lower abdominal aorta via the femoral 
cannula. Data are expressed as the mean change in action 
potential frequency ± s.e.mean. 
Recordings were made from 60 mechanosensitive fibres with 
receptive fields in the knee joint. Conduction velocities were 
mainly in the C -fibre range (<2 m.s') but some Ad fibres (2 -5 
m.s.') were also recorded. 49% of these afferents were excited 
by aßmeATP (6- 600nmol, Table 1). The responses had a very 
short delay to onset (200nmol: 0.68±0.2s) and were of short 
duration (200nmol: 1.6±0.3s). Half of the aßmeATP- sensitive 
afferents also responded to capsaicin (3- 20nmol) with a 
similar duration of response (10nmol: 1.6 ±0.4s) but with a 
longer onset latency (10nmol: 1.9±0.3s). 
Table 1. Change in action potential frequency evoked by 
saline, capsaicin and aßmeATP injected i.a. Mean±s.e.mean, n 













Preliminary data suggests that P2X receptor antagonists may 
inhibit the aßmeATP- evoked discharge (suramin 60mg.kg' 
i.a., apparent mean agonist ED,, before: 24 ±8 nmol; after: 
267 ±168 nmol n =3; PPADS 10mg.kg' i.a., apparent agonist 
EDso before: 13 ±3 nmol; after: 81±14 nmol n =4). 
Our results shows that nociceptors in the rat knee joint can be 
excited by a P2X purinoceptor agonist. This suggests that 
aßmeATP- sensitive P2X receptors are involved in the 
initiation of nociceptive input to the central nervous system 
which is consistent with recent finding of algesic responses to 
aßmeATP in the conscious rat (Bland -Ward Sr Humphrey, 
1997). 
Birrell, G.J., McQueen, D.S. et al. (1991) Br. J. Pharmacol., 101, 
715 -721. 
Bland -Ward, P. & Humphrey, P.P.A. (1997) Br. J. Pharmacol. 
(in press). 
Burnstock, G. Sr Wood, J.N. (1996) Curr. Opin. Neurobiol., 6, 
526 -532. 
Jahr, C.E. Sr Jessell, T.M. (1983) Nature, 304, 730 -733. 
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348P NOCICEPTORS OF THE CAT AND RAT CORNEA ARE NOT EXCITED BY P2X PURINOCEPTOR AGONISTS 
E. Dowd, J. Gallar , D.S. McQueen, I.P. Chesse112, P.P.A. 
Humphrey2 & C. Belmonter. Department of Pharmacology, 
Edinburgh University, Edinburgh, EH8 9JZ, 'Instituto de 
Neurociencias, Universidad de Alicante, Alicante, Spain and 2Glaxo 
Institute of Applied Pharmacology, Cambridge, CB2 1QJ. 
ATP causes pain when applied to a blister base in humans ( Bleehan 
and Keele, 1977) and the recent finding that six of the seven known 
ATP -gated ion -channel receptors (P2X1.6) are expressed in the 
trigeminal and dorsal root ganglia (Collo et al., 1996) suggests that 
ATP may play a role in peripheral nociception. The aim of our 
studies was to establish electrophysiologically whether P2X 
purinoceptor agonists activate polymodal nociceptors in an 
avascular preparation, the cat cornea, and to determine if there is a 
behavioural correlate when the drugs are applied to the rat eye. 
Five adult cats were anaesthetised with pentobarbitone (40mg.ke 
i.p., supplemented hourly i.v.) and the trachea and right saphenous 
vein cannulated. Extracellular recordings from filaments of mixed 
ciliary nerves with receptive fields in the cornea were performed as 
described previously (Belmonte et al., 1991). Drugs were applied to 
the cornea for 30s via solution- soaked tissue. Data are expressed as 
mean change in action potential frequency ± s.e.mean. For 
behavioural studies, drug solutions (5111 drop) were instilled into the 
eyes of conscious male Wistar rats (283±7g; n=4) and the number of 
blinks and forepaw wipes of the eye, behaviours associated with 
nociception, were counted in the first minute post- instillation. 
Recordings were made from C -fibre polymodal nociceptors 
(conduction velocity 0.77±0.08ms'I, basal discharge 0.20±0.50 
impulses.s r, n=9) all of which were excited by a 30s jet of CO2 
(2.86±0.40 impulses.s 1) and 4 of which were also excited by 
capsaicin 0.1µM (2.48±0.89 impulses.s"r). Application of a(3meATP 
(30-10011M), ATPyS (100 -1000µM) or ATP (100µM) did not cause 
any significant change in action potential frequency (aj3meATP 
10011M; 0.20±0.04 impulses.s 1). Similar results were obtained with 
29 AS fibres (conduction velocity 5.80±0.70ms.1). In conscious rats, 
threshold concentrations of capsaicin and nicotine caused a 
significant blink response whereas aßmeATP did not (Table l). 
Table 1. Number of blinks and wipes in the first minute post -instillation of 
vehicles, capsaicin, nicotine and al3meATP into the rat eye. 




Basal (events.miri 2.31-0.9 0±0 4 
Capsaicin vehicle (EtOH/PBS) 2.8±2.0 01-0 5 
Capsaicin 10µM 21.1±2.8* 2.4±1.1 10 
Phosphate buffered saline (PBS) 4.0±1.2 0.41-0.4 5 
Nicotine 1000µM in PBS 13.5±1.7* 0.6±0.3 12 
al3meATP 10 µM in PBS 2.3±1.2 0±0 6 
a(ImeATP 100 µM in PBS 3.7±1.7 0±0 6 
aßmeATP 1000 µM in PBS 5.0±1.5 01-0 6 
In conclusion, nociceptors of the cornea were not excited by P2X 
purinoceptor agonists in our experiments. Our data Suggests that 
functional P2X receptors are not expressed on peripheral terminals 
of trigeminal afferents in the cat cornea and aßmeATP sensitive 
P2X receptors, if present, do not stimulate nociceptive responses in 
the rat cornea. Thus it is unlikely that P2X receptors are involved in 
pain sensation from the cornea of the cat or rat. 
Belmonte, C., Gallar, J., Pozo, M.A. et al. (1991).1. Physiol., 437, 709 -725. 
Bleehan, T. & Keele, C.A. (1977) Pain, 3, 367 -377. 
Collo, G., North, R.A., Kawashima, E. et al. (1996).1. Neurosci., 16, 2495- 
2507. 
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P2X receptor- mediated excitation of nociceptive afferents in the 
normal and arthritic rat knee joint 
1E. Dowd, ''3D.S. McQueen, 2I.P. Chessell & 2P.P.A. Humphrey 
'Department of Pharmacology, University of Edinburgh Medical School, Edinburgh, EH8 9JZ and 2Department of Pharmacology, 
Glaxo Institute of Applied Pharmacology, University of Cambridge, Cambridge, CB2 1QJ 
1 We tested the hypothesis that functional P2X receptors are present on peripheral terminals of 
primary afferent articular nociceptors in the rat knee joint. Neural activity was recorded extracellularly 
from the medial articular nerve innervating the knee joint in rats anaesthetized with pentobarbitone. 
2 The selective P2X receptor agonist, aß methylene ATP (aßmeATP), and the endogenous ligand, ATP, 
caused a rapid short -lasting excitation of a sub -population of C and AS nociceptive afferent nerves 
innervating normal knee joints when injected intra- arterially or intra- articularly, and this effect was 
antagonized by the non -selective P2 receptor antagonist PPADS. 
3 Induction of a chronic (14 -21 days) unilateral inflammatory arthritis of the knee joint using locally 
injected Freund's adjuvant neither increased or decreased responsiveness of joint nociceptors to 
aßmeATP or ATP. 
4 Our results support the hypothesis that aßmeATP- sensitive P2X receptors are expressed on peripheral 
nociceptive afferents in the rat knee joint suggesting that they may be involved in the initiation of 
nociception and pain. 
Keywords: ATP; P2X receptors; pain; nociception; sensory neurones; arthritis 
Introduction 
Adenosine 5'- triphosphate (ATP) causes pain when applied to 
a blister base in humans (Bleehan & Keele, 1977) and the 
nucleotide also depolarises rat dorsal root ganglion neurones 
in vitro (Jahr & Jessell, 1983), suggesting that it may play a role 
in nociception. The effects of extracellular ATP are mediated 
through ionotropic (P2X) and metabotropic (P2Y) receptors 
(Fredholm et al., 1994), and seven of each have been cloned to 
date (for review see North & Barnard, 1997). Indirect evidence 
is accumulating which supports a role for ATP in the initiation 
of pain by acting on putative P2X receptors expressed on 
nociceptive afferent nerve terminals (see Burnstock & Wood, 
1996). 
It has been established that mRNA for six of the seven 
known subtypes of P2X receptor are expressed in sensory 
ganglia (Collo et al., 1996) and the P2X3 subtype is selectively 
expressed in these ganglia (Chen et al., 1995; Lewis et al., 
1995). P2X3 mRNA in rat dorsal root ganglia is localized to 
small diameter afferent neurones (Chen et al., 1995) which are 
commonly associated with nociception. In rat trigeminal 
ganglia, cell bodies of nociceptors innervating the tooth pulp 
are immunoreactive to antibodies for this receptor, whereas 
non -nociceptive neurones are not (Cook et al., 1997). 
However, the results from behavioural studies that have been 
performed to investigate the role of P2X receptors in 
nociception are conflicting. For example, the stable P2X, and 
P2X3 receptor agonist, aß methylene ATP (aßmeATP), evokes 
nociceptive responses when injected into the rat food pad 
(Bland -Ward & Humphrey, 1997), but not when it is instilled 
into the rat eye (Dowd et al., 1997a). 
Functional P2X receptors are thought to be expressed on 
some sensory afferent nerves in the rat because ATP and 
aßmeATP excite vagal and chemosensory primary afferents in 
this species (Trezise et al., 1993; Khakh et al., 1995; McQueen 
'Author for correspondence. 
et al., 1997, 1998). Although there is indirect evidence that 
ATP excites peripheral nociceptors (Bland -Ward & Hum- 
phrey, 1997), there is little direct evidence concerning the 
actions of ATP on nociceptive afferents, and that which exists 
does not appear to support a role for aßmeATP -sensitive P2X 
receptors in nociception. For example, in the cat, polymodal 
nociceptors innervating the cornea (Dowd et al., 1997a), and 
sensory afferents innervating tooth pulp (Matthews et al., 
1997), were not excited by aßmeATP. There is currently no 
direct evidence linking functional P2X receptors and periph- 
eral nociceptive neurones in rat. 
Levels of ATP are increased in inflamed or damaged tissues 
(Gordon, 1986) and the nucleotide is found in the synovial 
fluid of patients with arthritis (Ryan et al., 1991; Park et al., 
1996). The actions of ATP on sensory neurons in vitro are 
enhanced by acidification (Li et al., 1996, 1997), and a fall in 
synovial pH occurs in human rheumatoid arthritis (Farr et al., 
1985) and in experimentally- induced inflammatory arthritis 
(Tulamo et al., 1989). Thus, locally released ATP may 
contribute to pain by acting on P2X receptors associated with 
nociceptive afferents in the joint, and this action could be 
enhanced in inflammatory conditions such as arthritis. 
Alternatively, desensitization or down -regulation of P2X 
receptors might result from the continued presence of ATP 
within the inflamed joint capsule. What effect exogenous ATP 
actually has on nociceptive afferents innervating chronically 
inflamed joints needs to be established. 
The aim of our study was to test the hypothesis that 
functional P2X receptors are expressed on primary afferent 
articular nociceptors. We recorded the neural discharge of 
nociceptors innervating the rat knee joint and measured the 
response to locally injected P2 receptor agonists. We also 
determined whether thes0.e responses were modified in joints 
with adjuvant- induced arthritis, a commonly used model for 
human arthritis (Rainsford, 1982). A preliminary account of 
some of the work has been presented (Dowd et al., 1997b). 
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Methods 
Experiments, licensed under U.K. Home Office regulations, 
were performed on 30 normal and 18 arthritic male Wistar rats 
(body weight range 240 -380 g; mean ±s.e.mean 325± 11 g). 
Induction of arthritis 
Freund's Complete Adjuvant (FCA, 0.10 -0.15 ml of 
1 mg ml - Mycobacterium tuberculosis in paraffin oil, Sigma) 
was injected intra- articularly into the left knee joint of rats 
under halothane anaesthesia (5% in oxygen). Animals were 
used for electrophysiological recordings 14 -21 days post - 
induction at which time a mild persistent unilateral arthritis 
was present and associated with swelling of the knee (mean 
increase in diameter of 30% from 1.0 ±0.01 cm to 
1.3 ±0.03 cm, n =18). 
Surgical procedures 
Animals were anaesthetized with pentobarbitone (60 mg kg -' 
i.p., supplemented hourly with 6 mg i.v. via a cannula inserted 
into the right femoral vein). The trachea and right carotid 
artery were cannulated, and respiration and arterial blood 
pressure were continuously monitored. Body temperature was 
maintained at 38 °C by an automated heating blanket 
connected to a thermistor probe inserted into the rectum. A 
cannula was inserted into the lower abdominal artery through 
the right femoral artery for close arterial injection of drugs to 
the left knee joint. 
Electrophysiological recordings 
The left leg was fixed to a support and the skin on the medial 
aspect of the limb was cut to expose three branches of the 
medial articular nerve (MAN) where they leave the saphenous 
nerve. The skin flaps were used to form a trough, which was 
filled with heavy paraffin oil. 
The saphenous nerve was cut centrally to eliminate efferent 
neural activity. One of the branches of the MAN was dissected 
from the underlying connective tissue and neural discharge 
from small filaments containing 1 -4 afferent fibres was 
recorded using bipolar platinum -iridium wire electrodes as 
described previously for the ankle joint (Grubb et al., 1991). 
Briefly, neural activity was recorded digitally on videotape and 
analysed off -line using a pulse -height voltage discriminator 
linked to a personal computer operating Spike 2 (CED, 
Cambridge) software. Single action potentials, identified by the 
size and shape of the spike, were counted separately. The 
receptive fields of the afferents were identified by probing the 
knee joint's capsule with a hand held plastic probe to activate 
fibres with mid -high mechanical thresholds. However, because 
ATP is released from damaged tissues, the mechanical 
thresholds were not systematically measured to avoid 
damaging or desensitizing the capsular tissue. Conduction 
velocities (conduction distance /action potential delay) were 
determined at the end of an experiment from the time taken for 
the action potential to reach the recording electrodes following 
a depolarizing stimulus applied to the receptive field using a 
stimulating electrode. 
Drug administration 
For intra- arterial (i.a.) injections, agonists were injected in a 
volume of 0.1 ml, washed in with 0.2 ml of saline (0.9% w/v 
sodium chloride), the injection being completed within 2 s. 
Repeatable responses to agonists were obtained before using 
antagonists. The minimum interval between successive agonist 
doses was 20 min. Antagonist was injected i.a. over 10 s 
(0.1 nil 100 g -' -body weight) at least 10 min before agonists 
were re- tested. In some cases it was necessary to administer an 
additional dose of antagonist if its effects were observed to be 
waning. 
In six normal animals, drugs were administered by intra- 
articular (i.art.) injection to the knee joint using a 26 -gauge 
needle inserted through the infrapatellar ligament just beneath 
the patella. To determine whether the presence of the needle in 
the knee joint influenced neural activity, spontaneous afferent 
discharge and that evoked by agonists was recorded prior to 
insertion of the needle. The needle, fitted to a syringe 
containing drug solution, was then inserted into the joint 
space and secured with a clamp. Drawing 20 -30 µl of air into 
the syringe after the drug solution prevented leakage of drug 
into the joint during the subsequent recording. Spontaneous 
activity and responses to agonists were then recorded. Because 
the rat knee joint volume is 0.15 -0.20 ml, we performed only 
one or two injections (0.1 ml i.art.) per knee. 
Data analysis 
The effect of a drug or vehicle injection was determined by 
comparing the action potential discharge frequency following 
drug injection with that in the 15 s pre- injection period. Data 
are expressed as the mean change in action potential frequency 
± s.e.mean. Marked receptor desensitization and cardiovas- 
cular effects can occur following injection of aßmeATP 
(McQueen et al., 1997), so high doses ( > 200 nmol) were not 
routinely used. Consequently, it was difficult to establish the 
true maximum response to this agonist, and data from 
individual experiments were expressed as apparent ED50 
values. Differences between means were analysed statistically 
using the Mann -Whitney test and the null hypothesis rejected 
at the P 0.05 level. 
Drugs 
Adenosine 5' triphosphate disodium salt (ATP), aß- methylene 
ATP lithium salt and 8- methyl- N- vanillyl -6- nonenamide 
(capsaicin) were purchased from Sigma and pyridoxalphos- 
phate -6 - azophenyl - 2',4'- disulphonic acid tetrasodium 
(PPADS) was from Tocris. All drugs were dissolved in 
phosphate buffered saline (PBS) except for capsaicin, which 
was dissolved in Tween 80 (10% v /v), ethanol (10% v /v) and 
PBS. 
Results 
Characterization of afferent fibres 
Neural discharge was recorded from a total of 104 single 
afferent fibres from 42 knee joints. The afferents were classified 
as C -fibre polymodal nociceptors (61 %) or A8- mechanonoci- 
ceptors (39 %) based on their conduction velocities, 
mechanosensitivity and whether or not they were activated by 
the algogen, capsaicin. C -fibre polymodal nociceptors were 
slowly conducting (1.08 ±0.17 ms -'), excited by capsaicin 
(10 nmol: 24.0±3.9 impulses s -'), and were activated by 
mechanical stimulation of the joint capsule. A6- mechanono- 
ciceptors were faster conducting (3.42 ± 0.54 ms -') and did not 
respond to capsaicin. Some Aß- mechanoreceptors were also 
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lion velocities greater than 10 ms -'), but these were not 
studied. 
Comparison of basal discharge in nociceptive afferents 
from normal and arthritic joints 
We recorded from 57 afferent fibres (57% C, 43% AS) 
innervating normal knee joints and 47 (53% C, 47% M) 
innervating arthritic knee joints. Previous electrophysiological 
studies in the rat ankle joint have shown two characteristic 
features in adjuvant -induced arthritis. These are: (1) that 
nerves innervating arthritic joints have a higher proportion of 
spontaneously active afferents than those innervating normal 
joints (2) the rate of discharge of those afferents which are 
spontaneously active is higher in arthritic joints (Guilbaud et 
al., 1985). In our experiments M-mechanonociceptors in- 
nervating normal knee joints (n= 23) were always silent, and in 
arthritic joints only 1 of 17 (6 %) AS afferents was 
spontaneously active (0.1 impulses s -'). In contrast, 16% (5/ 
34 afferents) of C -fibre polymodal nociceptors innervating 
normal knee joints had low basal levels of spontaneous activity 
(0.10±0.01 impulses s -'), whereas 32% (10/31 afferents) of 
those innervating arthritic joints were active and discharged at 
significantly higher rate (0.39 ± 0.01 impulses s -', P< 0.05 
versus normal joints). 
Histological assessment of the injected and contralateral 
knee joints of six rats (one normal, one vehicle- treated, and 
four injected with adjuvant) confirmed the presence of an 
inflammatory lesion manifest as an inflammatory cell infiltrate, 
synovial proliferation, fibroplastia, oedema and new bone 
formation in the adjuvant- injected knees (data not shown). 
Responses to aßmeATP in normal and arthritic knee 
joints 
The P2X receptor agonist, aßmeATP (1 -600 nmol i.a.), evoked 
an increase in action potential discharge frequency in 55% of 
C -fibre polymodal nociceptors and 65% of M-mechanonoci- 
ceptors recorded from normal joints. Pooled data are shown 
because the responses evoked from both types of afferent fibre 
were similar. The increase in discharge following aßmeATP 
was rapid in onset, of short duration (Figure 1) and was dose - 
related (Figure 2); injection of vehicle evoked no response 
a 
is 
Figure 1 Oscilloscope traces showing the discharge evoked from a 
nerve filament innervating a normal knee joint by close -arterial 
injection (at arrow) of (a) aßmeATP (60 nmol) and (b) ATP 
(2000 nmol). The first panel shows the control responses and the 
second panel shows the responses 10 -30 min after injection of the P2 
purinoceptor antagonist, PPADS (16 µmol kg -' i.a.). The third 
panel shows the two action potentials that were counted. 
(PBS 0.1 ml: 0.01 ±0.01 impulses s -'). Injection of higher 
doses of aßmeATP, or repeating lower doses at short 
( <15 min) intervals, caused tachyphylaxis, i.e. a loss of 
responsiveness to previously effective doses (but not to 
mechanically- induced excitation) which lasted for about 20- 
30 min. 
aßmeATP also evoked an increase in action potential 
discharge in 46% of C -fibres and 89% of AS -fibres recorded 
from arthritic joints. Adjuvant -induced arthritis did not affect 
the mean apparent ED50 for excitation of the afferents caused 
by aßmeATP (normal: 31+ 12 nmol, n= 9; arthritic: 
57 ±24 nmol, n =5). Similarly, as shown in Figure 3, the 
magnitude, latency to onset, and duration of the response 
evoked by a single mid -range dose of aßATP (60 nmol i.a.) did 
not differ significantly between normal and arthritic joints. 
Responses to ATP in normal and arthritic knee joints 
ATP, the endogenous ligand for P2X receptors, also evoked a 
rapid short- lasting increase in action potential discharge in 
51% of C -fibre polymodal nociceptors and 81% of M- 
mechanonociceptors on which it was tested in normal joints, 
and in 43% of C -fibres and 88% of AS -fibres in arthritic joints. 
Adjuvant- induced arthritis of the knee joint did not affect the 
magnitude, latency to onset, or duration of the response 
evoked by a single high dose of ATP (2000 nmol; see Figure 3). 
During experiments in which ATP and aßmeATP were both 
tested (n = 58 afferents), fibres which were excited by ATP also 
invariably responded to aßmeATP and there was no significant 
difference between the responses evoked by the two nucleotides 
with respect to response amplitude, onset latency and duration 
(Figure 3). Seventeen of the fibres that responded to both 
aßmeATP and ATP were C -fibre polymodal nociceptors that 
also responded to capsaicin. The latency to onset of responses 
to aßmeATP and ATP did not differ significantly from that to 
capsaicin in these fibres (aßmeATP 60 nmol: 0.8 ±0.1 s; ATP 
2000 nmol: 0.6 ±0.3 s; capsaicin 10 nmol: 1.1 ±0.2 s). ATP 
also evoked a delayed increase in discharge which may be due 
to activation of adenosine receptors following metabolism of 
ATP by ectonucleotidase to adenosine (data not shown). 
Effect of aßmeATP and ATP injected i.art. into the knee 
joint 
To confirm that we were investigating responses in joint 
afferents, we injected aßmeATP and ATP directly into the 
knee. Injection of either substance evoked a transient increase 
in action potential discharge, whereas i.art. injection of the 
same volume of vehicle had no effect (aßmeATP 60 nmol: 
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Figure 2 Dose -related increase in afferent discharge evoked by close - 
arterial injection of aßmeATP in a single C -fibre innervating a 
normal knee joint before and after PPADS (16 /Imo] kg - i.a.). 




























Figure 3 Summary of (a) increase in nociceptive discharge (b) 
latency to onset of the excitation and (c) duration of the response 
following i.a. injection of either aßmeATP (60 nmol) or ATP 
(2000 nmol). Data is shown for normal (aßmeATP: n=14; ATP 
n=7) or chronically arthritic joints (aßmeATP: n=15; ATP n=7). 
There was no significant difference with either agonist between the 
responses obtained from normal and arthritic joints. 
saline (PBS) 0.1 ml: 0.01 ±0.02 impulses s -'; n =3 for each). 
The presence of the needle in the knee joint for the duration of 
the recording had no significant effect on the spontaneous 
discharge of the afferents (control: 0.01 ±0.02 impulses s -'; 
after insertion of needle: 0.01 ±0.03 impulses s -', n = 9 units). 
Effects of PPADS on the nociceptive responses to 
aßmeATP and ATP 
The increase in discharge evoked by aßmeATP (1 -600 nmol 
i.a.) in normal and arthritic joints was antagonized by the P2X 
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Figure 4 Response evoked by close -arterial injection of (a) 
aßmeATP (60 nmol) and (b) ATP (2000 nmol) before and after 
PPADS (16 ¡ mol kg -' i.a., 10 min pre -treatment). Pooled data from 
afferents innervating normal and arthritic knee joints (aßmeATP: 
n = 27 afferents before, n=11 afferents after; ATP: n=10 afferents 
before, n =6 afferents after). Columns represent mean ±s.e.mean. P <0.05 compared to control responses, Mann -Whitney test. 
in Figure 1, Figure 2 and Figure 4. The mean apparent ED5o 
for aßmeATP was 31 ± 12 nmol (n = 9) before and 
258 ±84 nmol (n =4) after PPADS (P <0.01). PPADS also 
antagonized the initial - response to ATP (Figure 4), without 
affecting the delayed ATP response (data not shown). 
Effect of PPADS on spontaneous discharge from 
nociceptive afferents innervating arthritic joints 
In order to establish whether endogenous ATP contributed to 
the increased basal discharge, the effect of PPADS on 
spontaneous discharge was examined in nine of the eighteen 
arthritic joints. Activity was recorded from 17 afferent fibres; 
nine of which were C -fibre polymodal nociceptors, five of 
which were excited by ATP. The other eight were AS- 
mechanonociceptors which lacked any spontaneous discharge, 
and six of these were responsive to ATP. Four (44 %) of the C- 
fibres were spontaneously active, and two were excited by 
ATP. Administration of PPADS (16 jowl kg -1, i.a.) did not 
reduce the firing rate of the four C -fibre afferents (frequency 
before PPADS: 0.5 ±0.5 impulses s -'; 10 min after PPADS: 
0.4 ±0.4 impulses s'). However, PPADS would only be 
expected to influence the two spontaneously active ATP - 
positive fibres: the antagonist reduced the discharge in one of 
the recordings, but it increased it slightly in the other (unit 1 
before: 0.50 impulses s'; after 0.3 impulses s'', unit 2: before 
0.3 impulses s'; after 0.4 impulses s-'). 
Discussion 
The main finding from this in vivo pharmacological study is 
that ATP and aßmeATP both cause a rapid short -lasting 
excitation of a sub -population of nociceptive afferent nerve 
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fibres innervating the rat knee joint. Chronic adjuvant- induced 
arthritis did not significantly affect the responsiveness of these 
joint sensors to the purinoceptor agonists studied. This 
evidence supports the hypothesis we were testing, namely that 
functional P2X receptors are present on the peripheral 
terminals of primary afferent articular nociceptors. Activation 
of these purinoceptors excites nociceptive afferents in normal 
as well as in chronically inflamed arthritic joints. 
The delay to onset of joint afferent responses to intra- 
arterially injected alogogens gives some indication of the 
transduction mechanism through which these substances 
mediate their effects. Thus, excitation with fast onset is 
typically observed with algogens known to mediate their 
effects through specific ion channels receptors expressed on the 
sensory nerve terminals, whereas slow onset responses are 
observed with algogens acting through G- protein coupled 
receptors expressed on the nerve terminal (Birrell et al., 1990). 
We found that capsaicin rapidly increased afferent discharge 
with a delay to onset which was similar to that observed 
following injections of aßmeATP or ATP in the same 
recordings. Since capsaicin acts directly on the sensory nerve 
terminal via a specific vanilloid ion -channel receptor ( Caterina 
et al., 1997), it is probable that the fast responses to aßmeATP 
and ATP are also mediated via direct actions on the afferent 
nerve terminals, rather than through an intermediary. We also 
established that injection of aßmeATP or ATP directly into the 
knee joint evoked rapid excitation, which provides additional 
evidence that responses observed following i.a. injection of the 
agonists were not secondary to effects on the vasculature. 
In the dorsal root ganglia, where the cell bodies for knee 
joint nociceptors are located, mRNA for six of the ATP -gated 
cation channel receptors (P2X1_6) are expressed (Collo et al., 
1996). Only two of these receptors, namely the P2X, and P2X3 
subtypes, are sensitive to the P2X agonist, aßmeATP, and the 
non -selective P2 antagonist, PPADS. There are currently no 
selective pharmacological tools available for use in vivo that 
would enable us to discriminate between responses mediated 
by these subtypes. However, previous studies have shown P2X3 
mRNA to be selectively expressed in sensory ganglia (Lewis et 
al., 1995) and nociceptive afferents in the rat tooth pulp have 
recently been shown to possess immunoreactivity for the P2X3, 
but not the P2X,, receptor subtype (Cook et al., 1997). This 
restricted localization of the P2X3 receptor suggests that it may 
play an important role in the initiation of primary afferent 
depolarization. 
However, the properties of homomeric P2X3 receptors 
expressed in HEK293 cells are very different from those of the 
native receptor in isolated sensory (nodose ganglion) neurones 
(see Lewis et al., 1995), and this had led to the suggestion that 
heteropolymerization of P2X receptors may occur in vivo. The 
only heteropolymer which displays the phenotype of the native 
P2X receptor of sensory neurones (aßmeATP sensitive, slowly 
desensitizing and increases in affinity for ATP with decreasing 
pH) is the P2X_,,3 heteropolymer (Lewis et al., 1995; Stoop et 
al., 1997). In our experiments, the excitation of joint 
nociceptors by aßmeATP and ATP lasted for approximately 
0.5 -1.0 s which is longer than expected if the responses were 
mediated by homomeric P2X3 since responses to ATP at these 
receptors desensitize within milliseconds. Thus it is possible 
that the P2X213 heteropolymer mediated the fast excitation 
evoked by aßmeATP and ATP in our experiments. 
One of the features of the ATP -evoked response in cultured 
sensory neurones is an augmentation of the response with 
decreasing pH (Li et al., 1996, 1997). This may mean that the 
fall in tissue pH during inflammation (see Introduction) could 
sensitise nociceptive terminals to ATP. However, we found the 
overall response of joint nociceptors to injected aßmeATP and 
ATP was not significantly affected by the presence of adjuvant 
arthritis in the knee joint. Although the pH of synovial fluid 
was not measured in our experiments, we consider it 
reasonable to assume that it fell because pH is known to 
decrease in rheumatoid arthritis (Farr 1985) and during 
synovitis associated with infectious arthritis in horses (Tulamo 
et al., 1989). Our results suggest that the augmentation of 
ATP -evoked responses by the decrease in pH observed in 
sensory neurones in vitro does not occur during adjuvant - 
induced arthritis in vivo. Alternatively, pH- sensitive P2X 
receptors are not responsible for the excitation mediated by 
ATP in our experiments. 
Inflammation is also associated with an increase in the level 
of extracellular ATP which can be released from damaged cells 
(Gordon, 1986), platelets (Born & Kratzer, 1984), some 
inflammatory cells (Di Virgilio et al., 1996; Ferrari et al., 
1997) and perhaps the sensory nerve terminal itself (Holton, 
1959). The continuous exposure of nociceptors to endogenous 
ATP could cause chronic desensitization, equivalent to that 
observed in some inflammatory cells where the P2X- mediated 
response is only unmasked following pre- treatment with the 
ATP -metabolising enzyme apyrase which metabolizes the ATP 
released from the cells themselves (see Di Virgilio et al., 1996). 
However, in the chronically inflamed arthritic knee joints, the 
nociceptive afferents remained sensitive to the P2X receptor 
agonists, suggesting that either high levels of extracellular ATP 
are not found in the inflamed joint in this model of arthritis, or 
that endogenous ATP does not desensitize the afferent P2X 
receptor involved. Since nociceptive afferents retain their 
sensitivity to ATP during chronic inflammation, endogenously 
released ATP could contribute to the associated pain and 
hyperalgesia by exciting them. 
The pain and hyperalgesia of adjuvant- induced arthritis is 
manifest as an increase in the number and rate of discharge of 
spontaneously active nociceptive afferents (Guilbaud et al., 
1985; McQueen et al., 1991). In our experiments, basal 
discharge was higher in afferents innervating arthritic joints, 
but it was not possible to establish the extent to which 
endogenous ATP contributed to this sensitization because only 
a small proportion of the spontaneously active afferents were 
ATP -sensitive. Further studies, perhaps involving a more 
severe arthritis to cause greater ATP release from more 
severely inflamed tissues, are required. In addition, interpreta- 
tion of experiments involving PPADS is complicated by the 
fact that, in common with other P2 receptor antagonists, it also 
inhibits the enzymes responsible for ATP metabolism (Khakh 
et al., 1995). Simultaneous antagonism of P2X receptors and 
inhibition of ATP breakdown leads to apparent antagonist 
insensitivity in some preparations (Crack et al., 1994). The 
development of selective P2X receptor antagonists, which lack 
this ectonucleotidase -blocking property, would better answer 
the question of whether endogenous ATP contributes to the 
sensitization of nociceptors seen in inflammatory models. 
It is worth speculating as to why activation of P2X 
receptors excites nociceptors in joints, whereas this did not 
occur when aßmeATP was tested electrophysiologically on cat 
corneal nociceptors (Dowd et al., 1997a) or cat tooth pulp 
afferents (Matthews, 1997). Species differences could be 
invoked to explain the discrepancies, or fundamental differ- 
ences may exist in the populations of P2X receptor subtypes 
associated with particular afferent nerve terminals at different 
sites in the body. Further studies would be needed to explore 
these possibilities. However, since the response elicited is 
dependent on the concentration of drug, the speed with which 
the agonists reach the receptor is important; slow penetration 
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may be associated with receptor desensitization, which is one 
possible explanation for the differences observed. We may 
have detected P2X- mediated excitation of joint afferents by 
our use of close -arterial bolus injections to deliver optimal 
concentrations of agonists to the receptors. 
Our results support the hypothesis that functional 
aßmeATP- sensitive P2X receptors are present on a sub- 
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Adenosine excites nociceptive afferents of the rat 
knee joint via adenosine Al receptors 
E. Dowd, D.S. McQueen, I.P. Chessell* and 
P.P.A. Humphrey* 
Department of Pharmacology, University of Edinburgh 
Medical School, Edinburgh EH8 9JZ and *Glaxo Institute 
of Applied Pharmacology, Cambridge CB21QJ 
Adenosine causes pain in humans when injected intra- 
dermally (Gaspardone et al. 1995), but it is not clear whether 
it has a direct action on nociceptive nerve terminals. The aim 
of this study was to determine whether adenosine excites 
nociceptive afferents innervating the rat knee joint and to 
characterize the receptor involved. 
Male Wistar rats (mean weight 305 g, range 250 -355 g, 
n = 10) were anaesthetized with pentobarbitone (60 mg kg ' 
I.P., supplemented hourly i.v.) and the trachea, right carotid 
artery, right femoral artery and vein were cannulated. 
Extracellular recordings were made from filaments of the 
medial articular nerve innervating the left knee joint as 
described previously for the rat ankle joint (Birrell et al. 
1990). Drugs were injected into the abdominal aorta via the 
femoral cannula. 
Recordings were made from twenty -two mechano- 
sensitive afferent fibres with receptive fields in the knee joint 
(basal activity 0.06 ± 0.02 impulses s1 (i.p.$); mean + s.E.m.). 
Adenosine evoked an increase in increased afferent discharge 
in ten (46%) of the fibres (370 nmol: 2.8 ± 0.7 i.p.s.). All the 
adenosine- sensitive afferents were slowly conducting C -fibres 
(1.1 -1- 0.2 m s '), which were also excited by capsaicin 
(10 nmol: 18.7 ± 3.4 i.p.$) and bradykinin (9 nmol: 
2.2 ± 0.8 i.p.s.). The latency of the adenosine- evoked 
response was not significantly different from that of 
bradykinin (adenosine: 9.3 + 2.6 s; bradykinin: 
10.2 ± 2.5 s; P> 0.05, Mann -Whitney test), and this delay 
is consistent with nociceptor activation via G protein 
coupling. The adenosine A, receptor agonist CPA also excited 
the adenosine- positive afferents (30 nmol: 1.3 ± 0.2 i.p.s., 
n = 3) and the A, receptor- selective antagonist DPCPX 
(3 fcmol kg-`) antagonized adenosine- mediated excitation 
(370 nmol: before, 2-8 ± 0.7 i.p.s; after, 0.1 ± 0.1 i.p.s.; 
P < 0.05, Mann -Whitney). 
Our results show that adenosine acts via adenosine 
A, receptors to activate a population of C -fibre nociceptors 
innervating the rat knee joint. Since adenosine levels are 
elevated in inflamed tissues, the nucleoside may contribute 
to the development and maintenance of pain associated with 
arthritis. 
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Adenosine Al receptor- mediated excitation of nociceptive afferents 
innervating the normal and arthritic rat knee joint 
0E. Dowd, 'D.S. McQueen, 2I.P. Chessell & 2P.P.A. Humphrey 
'Department of Pharmacology, University of Edinburgh, 1 George Square, Edinburgh, EH8 9JZ; 2Glaxo Institute of Applied 
Pharmacology, Department of Pharmacology, University of Cambridge, Cambridge, CB2 1QJ 
1 We tested the hypothesis that adenosine excites nociceptive primary afferents innervating the knee 
joint. 
2 Neuronal recordings were made from fine nerve filaments innervating the knee joint in rats 
anaesthetized with pentobarbitone. Drugs were injected close -arterially (i.a.) or into the articular space 
(i.art.). We studied normal and chronically inflamed arthritic joints, the latter 14 -21 days after a single 
intra- articular injection of Freund's Complete Adjuvant, performed under halothane anaesthesia. 
3 Adenosine injected i.a. caused delayed (approximately 10 s) excitation of the majority of polymodal 
C -fibre afferents, and had similar effects when injected directly into the joint. 
4 Adenosine triphosphate (ATP) had biphasic effects on discharge, a fast (<1 s) excitation was 
followed by a delayed increase similar to that seen with adenosine. 
5 The adenosine AI receptor agonists N6- cyclopentyladenosine (CPA) and N-[(1S,trans)-2- hydro- 
xypentyl] adenosine (GR79236) also excited the C -fibre afferents. The A, antagonist 8-cyclopentyl-1,3- 
dipropylxanthine (DPCPX) antagonized the responses evoked by adenosine, CPA, and the delayed 
increase seen after ATP, indicating that excitation of the nociceptive afferents was mediated via 
adenosine A, receptors. 
6 Adenosine and ATP evoked delayed excitatory effects of similar magnitude, regardless of whether or 
not the knee joint was chronically inflamed. The increased basal discharge observed in arthritic joints 
was unaffected by DPCPX, which implies that the increase in spontaneous activity associated with 
arthritis is unlikely to involve tonically released adenosine. 
7 The results support the hypothesis that adenosine excites primary afferent nociceptive nerve terminals 
in the rat knee joint, an effect mediated by adenosine Al receptors. ATP, adenosine, and A, receptors 
may play a role in generating the peripheral nociceptive (pain) signal. 
Keywords: Adenosine; A, receptors; pain; nociception; sensory neurones; arthritis 
Introduction 
Evidence from human and animal studies suggests that 
adenosine plays a complex role in the generation and 
modulation of peripheral nociception (Keil & Salter, 1996; 
Sawynok, 1998). Adenosine has been reported to cause pain in 
humans when it is applied to a blister base (Bleehan & Keele, 
1977), injected intradermally (Pappagallo et al., 1993), or 
injected intravenously (Gaspardone et al., 1995); it is also 
associated with the pain of angina pectoris (Sylven, 1993). 
However, others report that adenosine is anti -nociceptive in, 
for example, neuropathic pain (Belfrage et al., 1995). Similarly, 
in animal studies adenosine is reported to cause both 
hyperalgesia and analgesia (Taiwo & Levine, 1990). 
The complexity of adenosine's actions in nociception may 
result from activation of different adenosine, receptors, four of 
which have been cloned (Al, A2A, A2B and A3; Collis & 
Hourani, 1993), and a combination of indirect actions 
mediated via inflammatory cells, and direct actions on primary 
afferent nociceptors. For example, adenosine acts on A3 
receptors to cause pain indirectly via the release of histamine 
and 5- hydroxytryptamine from mast cells (Sawynok et al., 
1997). It might also cause pain by directly exciting primary 
afferent nociceptors; adenosine -induced cardiac pain is 
considered to be mediated by a direct action on adenosine 
AI receptors located on cardiac afferents (Sylven, 1993). This 
Author for correspondence. 
suggestion is supported by the observation that neurones in 
dorsal root (sensory) ganglia, which are excited by ischaemia 
and thought to mediate the pain of angina, are excited by 
adenosine in the dog (Huang et al., 1995). 
A major source of extracellular adenosine is the 
metabolism of ATP by ectonucleotidases (Gordon, 1986). 
We have recently shown that ATP excites nociceptive 
afferents innervating the rat knee joint (Dowd et al., 
1998a): it evoked a biphasic excitation consisting of a rapid 
increase in discharge (mediated by P2X receptors) followed 
by a delayed excitation. The delayed increase did not occur 
when we used the stable ATP analogue, aß- methylene -ATP, 
which is resistant to ectoATPase and therefore not rapidly 
metabolized to adenosine. This evidence suggested that 
adenosine might be responsible for the delayed increase in 
afferent discharge that we obtained with ATP. If so, this 
would support the view that adenosine causes pain by 
exciting primary afferent nociceptors. 
The present study was undertaken to test the hypothesis 
that adenosine excites nociceptive primary afferents innervat- 
ing the rat knee joint. We used selective agonists and 
antagonists to characterize the type of adenosine receptor(s) 
involved, and also investigated whether chronic adjuvant - 
induced inflammatory arthritis affected the responsiveness of 
knee joint afferents to adenosine in anaesthetized rats. A 
preliminary report on this work has been published (Dowd et 
al., 1998b). 
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Methods 
Experiments were licensed under U.K. Home Office regula- 
tions and performed on 11 normal and 13 arthritic male Wistar 
rats (mean body weight 360 g, range 270 -450 g). 
Induction of arthritis 
Freund's Complete Adjuvant (0.10 -0.15 ml of Mycobacter- 
ium tuberculosis 1 mg ml - in paraffin oil, Sigma) was injected 
intra- articularly into the left knee joint of rats under halothane 
anaesthesia (5% in oxygen). Animals were used for electro- 
physiological recordings 14 -21 days post- induction, at which 
time a mild persistent unilateral arthritis was present and 
associated with swelling (30% increase in diameter) and 
hyperalgesia of the knee. 
Surgical procedure 
Animals were anaesthetized with pentobarbitone 
(60 mg kg -' i.p., supplemented hourly with 6 mg i.v. via a 
cannula inserted into the right femoral vein). The trachea and 
right carotid artery were cannulated and arterial blood 
pressure was continuously monitored. Body temperature was 
maintained at 38 °C by an automated heating blanket 
connected to a thermistor probe inserted into the rectum. A 
cannula was inserted into the lower abdominal artery through 
the right femoral artery for close arterial injection of drugs to 
the left knee joint. 
Electrophysiological recordings 
Afferent neural discharge was recorded from a branch of the 
medial articular nerve which was cut centrally to eliminate 
efferent neural activity. The methods used have been described 
previously (Grubb et al., 1991; Dowd et al., 1998a). Briefly, 
neural activity was recorded via bipolar extracellular wire 
electrodes, and recorded digitally on videotape. The neural 
signal was analysed off -line using a pulse -height voltage 
discriminator linked to a personal computer operating Spike2 
software (CED, Cambridge, U.K.). Single action potentials, 
identified by the size and shape of the spike, were counted 
separately. The receptive fields of the afferents were identified 
by probing the knee joint capsule with a hand held plastic 
probe (tip diameter 1 mm; Von Frey threshold for receptor 
activation >40 g ram-2). Conduction velocities were deter- 
mined at the end of experiments. 
Drug administration 
Agonists were injected in a volume of 0.1 ml, washed in with 
0.2 ml of saline (0.9% w/v sodium chloride), the i.a. injection 
being completed within 2 s. Repeatable responses to agonists 
were obtained before using antagonists. Antagonists were 
injected i.a. over 10 s (in a volume of 0.1 ml 100 g -' body 
weight) at least 10 min before agonists were re- tested. In three 
normal animals, drugs were administered by intra- articular 
injection into the knee joint using a 26 -gauge needle inserted 
through the infrapatellar ligament just beneath the patella. 
Data analysis 
The effect of a drug, or vehicle, injection was determined by 
comparing the action potential discharge frequency after drug 
injection with that in the 15 s pre -injection period. Data are 
expressed as the mean change in action potential frequency 
± s.e.mean. Differences between means were analysed statis- 
tically using the Mann -Whitney test and the null hypothesis 
rejected at the 0.05 level of probability. 
Drugs 
Adenosine, adenosine 5'- triphosphate disodium salt (ATP), 8- 
cyclopentyl- 1,3- dipropylxanthine (DPCPX), N6- cyclopentyla- 
denosine (CPA), bradykinin and 8- methyl- N- vanillyl -6 -none- 
namide (capsaicin) were purchased from Sigma; 2 -p -(2- 
carboxyethyl) phenethylamino -5' -N -ethylcarboxamidoadeno - 
sine hydrochloride (CGS- 21680) from RBI, and pyridoxalpho- 
sphate -6 - azophenyl -2', 4' - disulphonic acid tetrasodium 
(PPADS) from Tocris. N- [(IS,trans) -2- hydroxypentyl] adeno- 
sine (GR79236) was a gift from GlaxoWellcome, Stevenage, 
U.K. All drugs were dissolved in phosphate buffered saline 
(PBS) except for capsaicin, which was dissolved in Tween 80 
(10% v /v), ethanol (10% v /v) and PBS, and DPCPX which was 
dissolved in DMSO (8% v /v), 1 NI NaOH (2% v /v), and PBS. 
Results 
Action potentials were recorded from a total of 61 afferent 
nerve fibres, 25 innervating normal knee joints in I 1 rats, and 
41 innervating chronically inflamed joints in 13 rats; 48% of 
afferents innervating normal joints and 61% of those 
innervating arthritic joints were C -fibre polymodal nociceptors 
(mean conduction velocity: 1.08 ±0.17 m s -') which were 
excited by capsaicin (10 nmol i.a.) and mechanical stimulation 
of the joint capsule. The remaining 52% of afferents 
innervating normal joints and 39% innervating arthritic joints 
were A8- afferents (conduction velocity: 3.43 ± 0.54 m s -`) 
which were excited by mechanical stimulation of the joint, but 
not by capsaicin. 
Adenosine (370 nmol) evoked an increase in action 
potential discharge in 80% (8/10 afferents) of C -fibres and 
25% (3/12 afferents) of M-fibres innervating normal knee 
joints. It also increased activity in 77% (17/22 afferents) of C- 
fibres and 27% (3/11 afferents) of A8 -fibres innervating 
arthritic knee joints (Figure 1). Although the responses were 
similar in both fibre types, all the results presented in this paper 
are from C -fibres as there were too few adenosine -positive M- 
fibres to study systematically. The magnitude, onset latency 
and duration of the adenosine -evoked response did not differ 
significantly between normal and arthritic joints (Figure 2). 
The drug vehicle (PBS, 0.3 ml i.a.) had no effect on discharge 
in adenosine -sensitive afferents (mean increase 0.01 ±0.01 
impulses s -', n= 6). There was no evidence of desensitization 
when successive doses of adenosine were administered at 
intervals of 15 min. 
ATP (2000 nmol i.a.) evoked a biphasic increase in neural 
discharge consisting of a fast -onset response followed by a 
delayed or `slow' excitation (see Figure 1). We have previously 
shown that the fast desensitizing component is mediated by 
P2X receptors (Dowd et al., 1998a), and it will not be discussed 
further in this paper. The slow component was evoked in 78% 
(7/9 afferents) of C -fibres and 10% (1/10 afferents) of M-fibres 
innervating normal knee joints, and 83% (19/23 afferents) of 
C -fibres and 19% (3/16 afferents) of A8 -fibres innervating 
arthritic joints. The magnitude and duration of the slow ATP - 
evoked response in C -fibres was not significantly different for 
arthritic joints, in comparison with normal joints, but the 
latency to onset was significantly longer in the arthritic joints 
(Figure 2). There was no evidence for desensitization of the 




































Figure 1 Oscilloscope traces showing the discharge evoked from a nerve filament innervating a normal knee joint by i.a. injection 
(at arrow) of (a) adenosine (370 nmol) and (b) ATP (2000 nmol). The first panel shows control responses, the second shows the 
responses 10 -30 min after injection of DPCPX (3 µmol kg-1). Note that the slow responses to adenosine and ATP are 
antagonized by DPCPX while the fast -onset response to ATP is not. The third panel shows the C -fibre that responded to 
adenosine and ATP. 
In experiments during which adenosine and ATP were both 
tested, all the fibres that were excited by adenosine also 
responded with a delayed excitation to ATP (normal n = 8 
afferents; arthritic n = 22 afferents). In normal joints there was 
no significant difference with respect to response magnitude, 
latency and duration between the responses evoked by the 
purines (Figure 2). However, in arthritic joints, although there 
was no significant difference with respect to response 
magnitude and duration, the latency to onset of the slow ATP 
response was significantly longer than that of the adenosine 
response (Figure 2: ATP 2000 nmol 17.8 ±2.4 s; adenosine 
370 nmol 9.1 ±2.0 s, P <0.05 Mann -Whitney). 
In order to confirm that we were recording from afferents 
innervating the knee joint, we injected adenosine and ATP 
intra- articularly in three animals. Adenosine evoked a delayed 
increase in C -fibre afferent discharge when injected i.art., and 
ATP caused a biphasic increase (adenosine 370 nmol: 
2.05 ±0.59 impulses s -'; ATP (slow component) 2000 nmol: 
2.2 ±0.54 impulses s -'; PBS 0.1 ml: 0.01 ±0.02 impulses s -'; 
n =2 for each). 
We compared the latencies to onset of the slow excitation 
evoked by the purines with those of the directly acting 
algogens, bradykinin and capsaicin. In C -fibres innervating 
normal knee joints, the onset latencies for the purines did not 
differ significantly from that for bradykinin. However, they 
were significantly (P <0.05) longer in comparison with the 
capsaicin response (adenosine 370 nmol: 8.8 ± 1.9 s n= 4; ATP 
2000 nmol: 9.3 ±2.6 s n =8; bradykinin 9 nmol: 10.2 ±2.5 s 
5=12; capsaicin 10 nmol: 1.1 ±0.2 s n = 12). The latency of the 
fast ATP response was similar to that of the capsaicin response 
(Dowd et al., 1998a). 
We used selective purinoceptor agonists and antagonists to 
characterize the purinoceptor(s) mediating the delayed 
excitatory responses to adenosine and ATP. The adenosine 
A, receptor agonists, CPA (30 nmol i.a.) and GR79236 (85- 
285 nmol i.a.) also evoked a delayed increase in afferent 
discharge (CPA: see Figure 3; GR79236: 1.02 ±0.17 impul- 
ses s -', n= 6 afferents innervating normal joints). In contrast, 
the adenosine A2 receptor agonist CGS21680 (190 nmol i.a.) 
had no effect on afferent discharge (normal joint: 0.01 ±0.2 
impulses s -', n =2; arthritic: 0.02 ±0.1 impulses s -', n =2). 
The excitation evoked by adenosine and ATP was unaffected 
by the P2 receptor antagonist PPADS (16 pmol kg - i.a.), 
whereas, the adenosine A, receptor antagonist, DPCPX 
(3 pmol kg -' i.a.) blocked the slow excitation associated with 
adenosine, ATP and CPA (Figure 3). 
A significantly higher rate of spontaneous discharge was 
observed in C -fibre afferents innervating arthritic knee joints, 
in comparison with those recorded from normal joints (normal 
joints: 0.1 ±0.01 impulses s -'; arthritic: 0.39 ±0.01 impul- 
ses s -', P <0.05). To determine whether endogenous adeno- 
sine contributed to this increase in basal activity, we studied 
the effect of DPCPX on the spontaneous discharge recorded 
from afferents innervating arthritic joints. DPCPX (3 pmol 
kg -' i.a.) did not reduce the spontaneous discharge of 
adenosine -positive C -fibre afferents (spontaneous discharge 
before: 0.4 ±0.2 impulses s -'; after DPCPX: 0.3 ±0.2 im- 
pulses s -', n =6). 
Discussion 
Our main finding is that adenosine excites the majority of C- 
fibre polymodal nociceptors innervating the rat knee joint. It 
also activated some A(5 -fibre afferents, but detailed study of 
these was not feasible because of their small number. The 
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excitation of C -fibres appears to be mediated via adenosine Al 
receptors because it was antagonized by the selective A1 
receptor antagonist DPCPX, and mimicked by the A1 receptor 
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Figure 2 Summary of (a) amplitude (b) latency to onset and (c) 
duration of the response evoked in C -fibre afferents following i.a. 
injection of either adenosine (370 nmol) or ATP (2000 nmol). Data 
shown is from C -fibres innervating normal (adenosine: n=8; ATP 
n =4) or chronically arthritic (adenosine: n =10; ATP n =13) joints. 
Columns represent mean ±s.e.mean. *P <0.05 ATP response latency 
in arthritic joints compared to (i) ATP response latency in normal 
joints and (ii) compared to adenosine response latency in arthritic 
joints. 
biphasic increase in afferent discharge consisting of a fast -onset 
response, mediated by P2X receptors (Dowd et al., 1998b), and 
a slow -onset response from rat knee joint nociceptors. In 
normal knees the slow component was similar in size, latency 
and duration to the adenosine -evoked response, and was 
antagonized by DPCPX. Thus, the delayed increase was likely 
to be mediated by adenosine, produced by metabolism of ATP, 
acting at metabotropic adenosine At receptors. 
The latency to onset of the responses evoked by adenosine 
did not differ significantly from that of a directly acting 
algogen, bradykinin, a finding compatible with adenosine also 
having a direct mode of action on the primary afferent 
terminals. Excitation of joint nociceptors by adenosine and 
ATP could be evoked by intra- articular injection of the 
purines, suggesting that the excitatory responses obtained were 
not secondary to effects on the vasculature. The evidence 
obtained makes it probable that the excitation of nociceptive 
afferents evoked by adenosine, either injected or produced by 
the metabolism of ATP, resulted from a direct action on 
nociceptive nerve terminals. It has recently been reported that 
adenosine causes a delayed excitation of vagal pulmonary C- 
fibre sensory terminals in rats through activation of Al 













Figure 3 Slow -onset excitation evoked by intra- arterial injection of 
(a) adenosine (370 nmol), (b) ATP (2000 nmol) and (c) CPA 
(30 nmol) before and after either DPCPX (3 µcool kg-1) or PPADS 
(16 µcool kg -t). Pooled data from C -fibres innervating normal and 
arthritic knee joints (adenosine: control n =16, after DPCPX n =4, 
after PPADS n =4; ATP: control n =12, after DPCPX n =3, after 
PPADS n=5; CPA: control n=8, after DPCPX n=5). Columns 
represent mean ±s.e.mean. *P <0.05 compared to control responses, 
Mann -Whitney test. 
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The magnitude and duration of the Al- mediated afferent 
response to adenosine and ATP were unaffected by the 
presence of mild adjuvant -induced arthritis in the knee joint. 
However, the latency of the ATP -evoked slow response in 
arthritic knees was increased relative to its latency in normal 
joints, and also with respect to the latency for the response to 
adenosine in arthritic joints. This might be due to changes in 
the activity of ATP -metabolising enzymes in the arthritic knee 
joints because it is known that the half -life of ATP in the 
synovial fluid of patients with arthritis is increased (Park et al., 
1996), that is, it is metabolized more slowly. This could explain 
why the latency to onset of the ATP response is increased in 
arthritic joints but the latency to onset of the adenosine 
response is not. 
The finding that the adenosine AI receptor antagonist 
DPCPX did not reduce the elevated level of spontaneous 
activity observed in adenosine -sensitive nociceptive afferents 
recorded from chronically arthritic knee joints suggests that 
these afferents were not tonically activated by endogenous 
adenosine. However, this does not preclude a role for 
adenosine as a modulator of peripheral nociceptor sensitivity. 
The nucleoside may be released in a phasic manner, be 
enhancing the actions of another endogenous algogen, or 
influencing nociceptors over a longer time scale than the 3- 
4 hours that we were able to investigate in our experiments. 
Adenosine might also be important in the development of joint 
hyperalgesia, something our experiments on chronically 
inflamed joints did not address. 
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During studies on rat articular nociceptors (Dowd et al, 1997) we 
observed that the P2X purinoceptor agonist a i- methylene -ATP 
(aßMe) caused bradycar lia, hypotension and apnoea, which are 
characteristics of a Bezold -Jarisch -like (BJ) vagal reflex (see 
Krayer, 1961). It has been shown that activation of P2X receptors 
depolarises rat isolated vagal afferents and nodose neurones (see 
Khakh et al, 1995). We tested the hypothesis that a B -J reflex can 
be evoked in anaesthetised rats by activation of P2X receptors 
associated with vagal afferents. 
Male Wistar rats (376±19g, n =18) were anaesthetised with 
pentobarbitone (60 mg.kg-' i.p., supplemented hourly i.v.), and the 
trachea, femoral arteries and right jugular vein cannulated. 
Ventilation was monitored using an electrospirometer, arterial 
blood pressure via a pressure transducer, and the output signals 
recorded on a MacLab -8; bradycardia (A beats.miri'), apnoea 
(duration, s), and hyperventilation (A ml.miñ') were measured. 
Action potentials were recorded from sensory nerves using bipolar 
wire electrodes. Drugs were dissolved in 0.9% w/v NaC1 and 
injected i.v. as a bolus over 2s at intervals of 5 -10 min. 
ATP (0.2 -5 tmol i.v.) or aßMe (0.6 -594 nmol i.v.) evoked short- 
lasting (1 -IOs) dose -related bradycardia with associated 
hypotension, and apnoea; high doses caused desensitisation. 
Transient hyperventilation (1 -5s) preceded the apnoea. Bilateral 
mid -cervical vagotomy significantly reduced the bradycardia and 
apnoea; cutting the carotid sinus nerves (CSN) abolished the 
hyperventilation (Table 1). The P2 purinoceptor antagonist PPADS 
antagonised the reflex apnoea and bradycardia, but not the 
hyperventilation. Neural recordings showed that aßMe excited 
vagal inflation (e.g. 40 nmol: basal 11.8 increased to 25.6 
impulses.s', 5s duration) and arterial chemoreceptor (40 nmol: 
basal 3.4 increased to 14.2 impulses.s', 2.4s duration) afferents. 
Table 1. Apparent EDso values for aßMe (moles) before and after 
denervation or PPADS (10 mg.kg -1). Mean ± s.e.mean *P<0.05, 
Mann -Whitney test versus control in n experiments. 
Bradycardia Apnoea Hyperventilation 
Control 1.5±0.4x10'° 12 4.9±0.9x10" 13 2.3±0.6x104 15 
Vagi cut >1x104* 5 3.4±1.4x10-7* 5 3.5±1.6x10-9* 5 
CSN cut 4.4 ±2.8x104 3 4.2±1.Ox1O8 4 >1x10-6 * 4 
PPADS 4.4±2.8x10'* 3 >1x106* 3 2.4±1.6x109*3 
We conclude that activation of P2X purinoceptors on vagal 
afferents elicits a BJ reflex in rats; activation of P2X receptors in 
the carotid bodies causes hyperventilation. PPADS antagonises 
vagal but not chemoreceptor responses to aßMe. The BJ reflex 
could be useful for the functional study and characterisation of 
drugs acting at P2X receptors, and may be of patho-physiological 
importance if evoked by endogenous ATP. 
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Activation of P2X receptors for adenosine triphosphate evokes 
cardiorespiratory reflexes in anaesthetized rats 
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and E. Dowd 
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Pharmacology, University of Cambridge, Cambridge CB2 IQJ, UK 
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1. We tested the hypothesis that activation of P2X receptors associated with vagal afferent 
nerves can evoke a Bezold -Jarisch (B -J) depressor reflex in anaesthetized rats. 
2. Injection of aß- methylene ATP (aß- McATP; 0.6 -600 nmol i.v.) evoked a dose -dependent 
B -J reflex comprising bradycardia, hypotension and apnoea in rats anaesthetized with 
pentobarbitone. Apnoea was commonly preceded by hyperventilation. Bilateral vagotomy 
significantly reduced the bradycardia and most of the apnoeic response without affecting 
hyperventilation, and unmasked a vasopressor response. Hypotension and apnoea were 
subject to desensitization, and ATP was about 100 times less potent than aß -MeATP in 
evoking the B -J reflex. 
3. ED50 values for responses to aß -MeATP were: bradycardia 14.6 ± 3.8 nmol; apnoea 
47.1 + 8.5 nmol; hyperventilation 23.3 + 6.0 nmol, n = 14. The ED50 for apnoea was 
significantly greater than that for bradycardia or hyperventilation (P < 0.05). Atropine 
(2.8 /awl (kg body wt)-1 i.v.) antagonized the reflex bradycardia and hypotension. 
3. The P2 antagonists suramin (14,umol (kg body wt)-1 i.v.) and PPADS (17 ,umol 
(kg body wt)-1 t.v.) antagonized the bradycardie and apnoeic components of the reflex 
response to aß- MeATP, without reducing the vasopressor or hyperventilatory responses to 
the agonist. 
4. Recordings from vagal afferents showed that pulmonary inflation receptors were activated 
by afl-MeATP in 62 % of units recorded (ED50 22 ± 5 nmol) and this was blocked by PPADS 
(17 /Imo' (kg body wt)-1 i.v.); unidentified vagal afferents were also activated. 
5. aß -MeATP activated carotid chemoreceptor afferents (ED50 23 ± 9 nmol), an action that 
was unaffected by PPADS or suramin. 
6. The results support the hypothesis that P2X receptor subtypes for ATP are associated with 
specific sensory nerves that form part of the homeostatic mechanism for cardiovascular and 
respiratory regulation and these receptors therefore have physiological, pathological and 
therapeutic significance. 
P2X purinoceptors are multimeric ATP -gated cation 
channels (see recent reviews by Humphrey et al. 1995; North, 
1996; Buell, Collo & Rassendren, 1996) and seven separate 
P2X receptor subunits have been cloned (Valera et al. 1994; 
Suprenant, Rassendren, Kawashima, North & Buell, 1996). 
The distribution of these receptors has been studied by in 
situ hybridization, and in rat they are found in the brain 
and spinal cord, particularly within areas such as the 
substantia gelatinosa where primary afferent nerve fibres 
synapse (Collo et al. 1996). Autoradiographic studies have 
confirmed the presence of abundant P2X receptor binding 
sites in rat brain and spinal cord (Tuyau, Hansen, Dampney, 
Balcar & Bennett, 1997), and P2X receptors are also 
associated with sensory neurones in the periphery (Evans & 
Suprenant, 1996). For example, the nodose (vagal) ganglion 
expresses RNAs for six of the seven known P2X receptors, 
including the P2X3variant that appears only to be present 
in sensory ganglia (Kidd, Grahames, Simon, Michel, Barnard 
& Humphrey, 1995; Collo et al. 1996). P2X3 subunits have 
been detected immunohistochemically in small trigeminal 
nerve sensory fibres and endings in rat tooth pulp, and 
neurites of dissociated cultured neurones from the trigeminal 
ganglion were depolarized by pressure- ejected ATP (Cook, 
Vulchanova, Hargreaves, Elde & McCleskey, 1997). 
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Functional studies involving the vagus nerve have shown 
that intravenously administered ATP slows the cat heart 
via reflex actions involving vagal afferent and efferent nerve 
fibres (Emmelin & Feldberg, 1948), and ATP is known to 
activate a vagal reflex in dog and human (see Pelleg, Hurt & 
Michelson, 1990). More recently, Trezise, Kennedy & 
Humphrey (1993) and Trezise, Bell, Kennedy & Humphrey, 
(1994) demonstrated that activation of P2X receptors 
depolarizes nerve fibres in the rat isolated vagus. Whole -cell 
patch -clamp recordings from rat nodose neurones in culture 
confirmed that ATP depolarized neurones, as did the non- 
degradable agonist aft-methylene ATP (aß- McATP; Khakh, 
Humphrey & Suprenant, 1995) which activates a subset of 
P2X receptors, including P2X1, P2X3 and P2X,--P2X, 
heteromers (Buell, Collo & Rassendren, 1996). It has also 
been shown that ATP excites vagal C fibre nerve terminals 
in the dog lung, an effect that appeared to be mediated by 
P2X receptors because aft-McATP caused the same effect, 
which was antagonized by the P2 antagonist pyridoxal- 
phosphate-6-azophenyl-2',4'- disulphonic acid (PPADS; 
Pelleg & Hurt, 1996). 
The Bezold -Jarisch (B -J) reflex comprises a triad of 
apnoea, bradycardia and hypotension that was originally 
described as a cardiodepressor -vagal chemoreflex evoked via 
the stimulation of cardiac receptors by intravenously 
administered veratrine (Bezold & Hirt, 1867; Dawes & 
Comroe, 1954). ATP is reported to be one of the `detector 
substances' that can also activate this complex reflex 
( Jarisch, 1941; Dawes & Comroe, 1954). The B -J reflex 
involves various cardiopulmonary sensory receptors: most 
of the cardiodepression and vasodepression results from 
activation of vagal afferents in the heart, particularly the 
left ventricle (coronary chemoreflex, Dawes & Comroe, 
1954), whereas apnoea and about 10 % of the cardiovascular 
depression arise from stimulation of vagal sensory receptors 
in the lungs, in cats and dogs anaesthetized with pento- 
barbitone (Dawes, 1947). 
While studying the effects of purinoceptor agonists on 
nociceptor afferents in anaesthetized rats (Dowd, McQueen, 
Chessell & Humphrey, 1997), we observed that reflex 
bradycardia, hypotension and apnoea occurred in response 
to intra- arterial administration of a/3- MeATP. The reflex 
was obtained during some, but not all, of the experiments 
and it seemed to be influenced by the anaesthetic agent 
used. We have not found any reports concerning activation 
of the B -J reflex by ATP in rat, so the present investigation 
was undertaken to test the hypothesis that activation of 
P2X receptors associated with vagal afferents can evoke a 
B -J cardiorespiratory reflex in this species. We evoked 
cardiorespiratory reflexes by i.v. injection of a/3-McATP 
and other less stable P2 purinoceptor agonists, including 
ATP. However, since ATP is rapidly degraded by nucleotide 
enzymes in vivo (Holton, 1959), it is of limited use in 
experiments because the cardiovascular and respiratory 
effects seen following its injection will result from mixed 
actions on Pl and P2 purinoceptors for adenosine and ATP 
respectively: adenosine is a major metabolite of ATP and it 
causes bradycardia, hypotension and hyperventilation 
(Drury & Szent- Györgi, 1929; Reid, Watt, Penny, Newby, 
Smith & Routledge, 1991). We determined which sensory 
nerves contribute to the reflex in animals anaesthetized with 
pentobarbitone by using a combination of selective 
denervation and electrophysiological recordings from 
afferent nerves. The antagonists suramin and PPADS were 
used in conjunction with the purinoceptor agonists to 
characterize the type of purinoceptor associated with the 
sensory nerves involved in evoking the B -J reflex. A 
preliminary account of the work has been published 
(McQueen, Moores, Dowd, Bond, Chessell & Humphrey, 
1997). 
METHODS 
Animals and anaesthesia 
Experiments were licensed under UK Home Office regulations. 
Male Wistar rats ranging between 250 and 550 g in body weight 
were anaesthetized with either pentobarbitone (60 mg (kg body 
wt)-1 I.P., mean weight 361 -h 13 g, n = 26, followed at hourly 
intervals with 6 mg i.v., if necessary - dependent on response to 
applying pressure to a limb joint and the basal heart rate and blood 
pressure (BP)) or urethane (single dose 0.6 ml (100 g body wt)-1 I.P. 
of 25 % w/v aqueous ethyl carbamate; mean weight 374 ± 37 g, 
n = 6). In three experiments the rat (mean weight 374 ± 25 g) was 
anaesthetized with trichloroethylene and the brain and spinal cord 
destroyed by pithing, as described by Gillespie & Muir (1967). A 
servo -controlled heating blanket (Harvard) maintained rectal 
temperature at 38 °C. 
Ventilation and blood pressure 
The trachea was cannulated and connected to a pneumotachograph 
head linked to an electrospirometer (Mercury Electronics CS5) and 
a computerized recording system (MacLab -8 and Macintosh LC475 
computer) for measuring and recording tracheal air flow, 
respiratory frequency, tidal volume and respiratory minute volume 
(RMV). The animals breathed room air spontaneously, apart from 
the pithed rats and the majority of those used for neural recordings, 
which were artificially ventilated and neuromuscularly blocked 
with gallamine (8 mg i.v. at hourly intervals, together with 6 mg 
pentobarbitone in the neural experiments). Both femoral arteries 
were cannulated, one catheter being used to record arterial blood 
pressure via a BP transducer (Bell & Howell) linked to the MacLab, 
the other being used for taking samples (0.2 ml) of arterial blood for 
measurement of arterial oxygen pressure (Pa o,), and arterial 
carbon dioxide pressure (Pa,o,) and pH (Ciba Corning 238 analyser) 
during the experiment. Heart rate was measured from the BP 
recording, with the time scale expanded to allow the number of 
pulses in a fixed period to be counted pre- and post- injection. The 
right external jugular vein was cannulated for intravenous 
administration of drugs. 
Surgical procedures 
In five experiments the vagi were sectioned at mid -cervical level, 
and in two cases the nodose ganglia were subsequently excised. The 
carotid sinus nerves (left and right side) were identified at their 
junction with the glossopharyngeal (IX cranial) trunk and both the 
left and right nerves were sectioned in four experiments. 
Denervation was confirmed by the abolition of the reflex hyper- 
ventilation that was evoked before denervation by the peripheral 
chemoreceptor stimulant sodium cyanide (2 uumol i.v.). 
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Neural recording from arterial chemoreceptors 
The left carotid sinus nerve was sectioned at its junction with the 
glossopharyngeal trunk and the peripheral end desheathed. The 
nerve was immersed under paraffin oil and recordings of neural 
activity were made extracellularly from dissected nerve filaments 
using bipolar platinum- iridium electrodes connected to an 
amplifier (Neurolog NL104) and a computerized digital video 
recording system (Sony VCR EV- C500E; Dell 450/L PC). 
Individual action potentials from multi -unit (1 -4) recordings were 
counted via a pulse height voltage discriminator (Digitimer D130) 
and quantified using the PC and computer software developed in- 
house. The contralateral carotid sinus nerve remained intact and 
the animals breathed room air in two experiments, in one of which 
the rat was anaesthetized with urethane. In two further 
experiments under pentobarbitone both carotid sinus nerves were 
cut and the rat was artificially ventilated and the neuromuscular 
system was blocked with gallamine. 
Neural recording from vagal afferents 
The right vagus nerve was sectioned at mid -cervical level and 
recordings of neural discharge (1 -5 units) made from filaments 
dissected from the desheathed peripheral end in six rats, using the 
techniques described above. In some experiments gallamine was 
administered and the animals were artifically ventilated to prevent 
reflex cardiorespiratory changes from influencing the responses. 
Drugs 
The drugs used included: adenosine, adenosine 5'- triphosphate 
disodium (ATP), adenosine 5'- 0- (3- thiophosphate) (ATPyS), a/- 
MeATP (lithium salt) (all from Sigma); 2- methyl -5- hydroxy- 
tryptamine maleate (2- Me -5 -HT) and suramin hexasodium (from 
RBI); MDL72222 (a gift from Merrell Dow); trichloroethylene, 
atropine sulphate and sodium cyanide (from BDH); gallamine 
triethiodide (from May & Baker); PPADS (tetrasodium salt; from 
Tocris Cookson). Drugs were dissolved in saline (0.9% w/v aqueous 
sodium chloride) and injected in volumes of 0.1 ml, washed in with 
0.2 ml saline. The control was 0.3 ml saline and all injections were 
completed within 2 s, with the exception of antagonists which were 
slowly injected over 15 -30 s. Injections were i.v. (jugular) or I.A. 
(femoral catheter in some experiments) and the minimum interval 
between successive doses was 5 min. In order to minimize the 
number of animals used, more than one procedure was performed 
wherever this was feasible (in a total of eight experiments involving 
atropine or vagotomy after recovery from PPADS, cutting carotid 
sinus nerves after vagotomy or PPADS), but at least one 
experiment in each group was done without any pre- treatment as a 
check that pre- treatment had not influenced the responses 
obtained. 
Data and analysis 
Half- maximum response (ED50) values for bradycardia, apnoea and 
hyperventilation were calculated from individual log dose-response 
curves for the agonists before and after selective denervation or the 
administration of antagonist. As the concentration of the injected 
drug at the receptor site is not known, nor is it in equilibrium 
following a bolus injection, and because of difficulties in 
establishing a maximum response from receptors prone to 
desensitization, we minimized the number of doses used in vivo 
and the calculated ED50 was expressed as an apparent value, i.e. 
the best estimate. Results are presented as means ± S.E.M. 
Statistical analysis (generally ANOVA, Student's l test, or the non - 
parametric Mann -Whitney test (two -tailed) - when variances were 
significantly different) was used to determine whether differences 
between group means were statistically significant. The Null 
hypothesis was rejected at P 0.05. 
RESULTS 
Intravenous injection of aß -MeATP (0.6 -600 nmol) in 
animals anaesthetized with pentobarbitone evoked a rapid 
dose -dependent bradycardia, hypotension and apnoea, the 
latter preceded by a transient hyperventilation (Fig. 1 A). In 
approximately 20 % of experiments there was a delayed 
secondary hyperventilation after the apnoea. Repeating the 
doses at intervals of less than 5 -10 min led to a decrease in 
magnitude (total loss after high doses) of the apnoea, brady- 
cardia, and hypotension, but not the hyperventilatory 
component of the response. ATPyS (18 -366 nmol) caused 
similar responses, although it was less potent than 
aß -MeATP in evoking bradycardia. Although we did not 
study the nucleotide in detail, ATP in doses approximately 
100 -fold greater than those of a/i -MeATP also caused a 
slight hyperventilation, apnoea and bradycardia. Adenosine 
injected t.v. in high doses (4.7 -11.2 ,umol) resulted in a 
bradycardia without hyperventilation or apnoea, which 
unlike the bradycardia evoked by aß -MeATP was slightly 
delayed in onset and unaffected by bilateral vagotomy or 
atropine. Similar cardiorespiratory effects to those of 
aß -MeATP were evoked by the 5 -HT3 agonist, 2- Me -5 -HT 
(33 -330 nmol). 
Mean arterial BP was 106 ± 5 mmHg and respiratory 
minute volume 210 ± 27 ml min -1 in rats (n = 23) 
anaesthetized with pentobarbitone; arterial blood gases and 
pH did not differ significantly between the groups. In 
control animals (n = 23) mean pH was 7.44 ± 0.01, mean 
Pa.co2 was 35.9 ± 1.4 mmHg and mean Pa,02 was 
71.8 -I- 2.1 mmHg. Corresponding values for vagotomized 
rats (n = 10) were: 7.45 ± 0.02, 31.4 ± 2.0 and 75.3 ± 1.9; 
after cutting the carotid sinus nerves they were 7.39 ± 0.05, 
34.8 ± 1.9 and 67.0 ± 6.2 (n = 5). Changes in reflex 
responses obtained after selective denervation were therefore 
not secondary to alterations in basal conditions, as indicated 
by the stable arterial blood gas tensions and pH. 
In animals anaesthetized with urethane the reflex brady- 
cardia, hypotension and apnoea in response to aß -MeATP 
(20 -600 nmol) was attenuated or absent in four of five 
experiments although hyperventilation and vasopressor 
responses were present in them all, so pentobarbitone was 
used for the majority of our experiments. 
Reflex bradycardia and hypotension 
Injection of a/t -MeATP in anaesthetized rats caused dose - 
dependent bradycardia within the first 5 s following i.v. 
injection which lasted for up to 5 s (Figs 1 and 4). ATP 
injected in high doses (2 -5 ,umol) caused bradycardia, but 
this response was longer lasting in comparison with that 
evoked by a/3- MeATP; adenosine in high doses also caused 
delayed long -lasting bradycardia. Experiments in pithed 
rats showed that IN. aft-MeATP did not cause bradycardia, 
whereas high doses of ATP and adenosine caused similar 
responses to those observed in intact anaesthetized animals, 
namely bradycardia and hypotension (see Fig. 2). 
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There was a triphasic change in arterial BP following 
injection of aß- MeATP, comprising a transient hypotension 
associated with the bradycardia, and then a more prolonged 
(1 -2 min) vasopressor phase (see Fig. 1) and after higher 
doses (100 nmol or more), a longer lasting (up to 10 min) 
delayed -depressor phase was obtained; but high doses were 
not routinely tested because of concerns over receptor 
desensitization. ATPyS, ATP and adenosine (4.7 -11.2 umol) 
caused only hypotension, there being no vasopressor 
component; slight hypertension occurred after 2- Me -5 -HT, 
which also caused transient vasodepression secondary to the 
bradycardia. Intra- arterial injection of aß -MeATP also 

















tenth the potency of the same dose injected i.v., indicating 
that the sensory receptors were located in or near the heart 
and lungs. In pithed rats aß -MeATP caused only vaso- 
pressor responses, whereas injected ATPyS, ATP and 
adenosine were exclusively vasodepressor responses and 
lacked any vasopressor component (Fig. 2). Blood pressure 
responses were not studied in detail because the primary 
reflex vasodepression was entirely secondary to the 
bradycardia, but we noted that the vasopressor response to 
aß -MeATP in anaesthetized rats was not significantly 
affected by suramin or PPADS (mean rise in BP evoked by 
100 nmol aß -MeATP before suramin (14 /cmol (kg body 




























Figure 1. Cardiorespiratory effects of 
aß -MeATP 
Cardiorespiratory effects of a dose of 
aß -MeATP (100 nmol I.V. at continuous 
vertical line) in a rat anaesthetized with pento- 
barbitone. In each panel the upper trace from 
the computerized chart recorder is arterial BP, 
and the lower trace is respiratory airflow 
(inspiration downwards, arbitrary units (a.u.), 
mV). Heart rate was measured by counting 
individual beats in the BP trace. During the 
control state (A) bradycardia, transient hyper- 
ventilation, vasodepression and apnoea were 
obtained in response to the rapid injection of 
aß- MeATP. After cutting both vagus nerves at 
mid- cervical level (B) the bradycardia, 
hypotension, and apnoea were abolished, 
leaving hyperventilation and a vasopressor 
response to the same dose of agonist. Cutting 
both carotid sinus nerves (C) abolished hyper- 
ventilation without reducing the vasopressor 
response. The delayed arrhythmia seen in C 
differed from the reflex bradycardia observed 
in A, and was associated with the substantial 
rise in systemic blood pressure; the 
arrhythmia may result from activation of 
C fibre sympathetic cardiac afferents 
innervating the left ventricle (see Hainsworth, 
1991). 
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n = 3; BP caused by 40 nmol afl-MeATP before PPADS 
(17 µmol (kg body wt) -1) was 39 + 15 mmHg, and after 
was 39 ± 8.5 mmHg, n = 6). The reflex bradycardia was 
attenuated when successive high doses of aß -MeATP were 
injected at intervals of less than 10 min, with a tendency to 
generate bell- shaped log dose- response curves, and some 
reduction was evident even after delays of 10 -15 min. It 
was therefore necessary to avoid using high doses of P2 
receptor agonist, and to accept that it would not be possible 
to establish the true maximal responses. The bradycardia 
was calculated from log dose -response (Fig. 3) and 
expressed as an apparent ED50 for each experiment. 
Bradycardia evoked by aß -MeATP was significantly 
attenuated by atropine (2.8 µmol (kg body wt)-1) and by 
bilateral vagotomy (Fig. 1B), as well as by the P2 
purinoceptor antagonists suramin (14,umol (kg body wt)-1 
i.v.) and PPADS (17 ,umol (kg body wt)-1 i.v., but not by 
1.7 µcool (kg body wt)-1). Pooled ED50 data from all the 
experiments are shown in Fig. 4A. In some instances it was 
not possible to calculate the dose required to match the 
Figure 2. Cardiovascular effects 
in an artifically ventilated pithed 
rat in which reflex effects were 
abolished 
Effects of aß -MeATP (60 nmol i.v. at 
vertical line) (A) and adenosine 
(375 nmol i.v.) in an artificially 
ventilated pithed rat (B) in which 
reflex effects were abolished. The 
P2X receptor agonist gave a vaso- 
pressor response with no bradycardia, 
whereas adenosine caused 


















original ED50 for some responses after denervation or 
administration of an antagonist (e.g. after vagotomy the 
bradycardia was totally abolished, likewise after PPADS), 
so a minimum ED50 of 1 x 10 -6 mol was entered to allow 
statistical analysis using non -parametric tests. The transient 
vasodepression which occurred at the same time as the 
bradycardia was absent when the reflex bradycardia was 
prevented, and PPADS also blocked the delayed prolonged 
hypotension previously evoked by aß- MeATP. ATPyS was 
less effective than aß -MeATP in evoking reflex bradycardia 
(ED5C 78.1 ± 6.8 nmol, n = 4; P < 0.001 versus aß- MeATP, 
t test). High doses of ATP or adenosine caused a bradycardia 
that was unaffected by vagotomy, atropine, suramin or 
PPADS. Antagonism caused by the single dose of PPADS 
(17 µmol (kg body wt)-1 1.v.) was short lasting (10 -15 min) 
in some experiments, but longer in others (45 min) - even 
though the same batch of drug was used - so an additional 
dose of antagonist was administered when it was apparent 
that its effects were waning; suramin (14 µmol (kg body 
wt) -1) antagonism tended to last longer, up to about 60 min. 
5s 
5s 
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Activation of vagal 5 -HT3 receptors has been shown to elicit 
similar reflexes to those described above (Fozard, 1984), so 
the possibility that endogenous 5 -HT might be involved in 
the reflexes was tested. We used the 5 -HT3 receptor agonist 
2- Me -5 -HT and found it gave responses similar to those 
caused by aß- MeATP. The reflex bradycardia and apnoea 
were antagonized by MDL 72222, but not by the P2 
antagonists suramin or PPADS (data not shown). The mean 
ED50 for bradycardia evoked by aß -MeATP was not 
significantly affected by the 5 -HT3 antagonist (see Fig. 4). 
Respiratory effects 
Injections of aß -MeATP in rats anaesthetized with pento- 
barbitone evoked a complex dose -related change in 
ventilation, comprising a transient (2 -3 breaths) hyper- 
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dose -related apnoea lasting from 1 -20 s (see Fig. 1 and 3C). 
In some experiments a 5 -30 s period of delayed hyper- 
ventilation followed the apnoea, but as it usually coincided 
with delayed hypotension, we did not investigate it further 
during this study. When high doses of agonist were repeated 
at short (< 5 min) intervals, apnoea was attenuated, so 
10 -15 min were allowed to elapse between successive high 
doses. The hyperventilation was less prone to desensitization. 
Intra- arterial injections of aß -MeATP (200 nmol) or 
2- Me -5 -HT (33 µmol) evoked smaller respiratory responses 
to those obtained when the drugs were given 1.v. in the same 
animal, and the i.v. to I.A. equipotent molar ratio for aß- 
MeATP was approximately 10 (n = 2). Reflex apnoea 
following r.v. aß -MeATP was usually attenuated or absent 
when urethane was used as the anaesthetic, although dose - 
related increases in ventilation were obtained. 
Figure 3. log dose -response curves showing the effects of 
aß -MeATP 
Results from individual experiments illustrating the effects of 
aß -MeATP on heart rate (A), apnoea (B) and hyperventilation (C), 
before (0) and after (0) the purinoceptor antagonist PPADS 
(17 µmol (kg body wt)' i.v.) which reduced the bradycardia and 
apnoea components of agonist- induced responses, whereas the 
hyperventilation component was unaffected or even enhanced by 
PPADS. Apparent ED50 values were estimated from the 
log dose-response plots. 
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Apnoea. The ED50 for apnoea evoked by aß -MeATP was 
calculated from individual log dose-response plots (Fig. 3B). 
By pooling data from different experiments in which 
various procedures were performed we established that 
neither atropine (2.8 µmol (kg body wt)-' z.v.), MDL 72222 
(0.24 µmol (kg body wt)-' i.v.) nor cutting the carotid sinus 
nerves had any significant effect on the apnoea, as shown in 
Fig. 4B, although the dose of MDL 72222 used, abolished 
apnoea and bradycardia caused by 2- Me -5 -HT. Bilateral 
vagotomy significantly reduced the apnoea (Fig. 1 B), but 
did not eliminate it in all experiments - high doses of 
aß -MeATP still elicited a reduced apnoeic response in some 
experiments post -vagotomy, an effect which was abolished 
by surgical removal of both nodose ganglia. The P2 
purinoceptor antagonist suramin (14 µmol (kg body wt)-' 
i.v.) significantly reduced the apnoeic response to aß- 
MeATP (Fig. 5), and a similar effect was obtained with 
PPADS (17 ,amol (kg body wt)-' r.v.). Qualitatively similar 
respiratory responses were observed with ATPyS, and the 
compound did not differ significantly from aß -MeATP in 
evoking apnoea (EDSO (1.2 ± 0.6) x 10 -' nmol). ATP 
(maximum dose 5.4 x 10 -6 mol caused apnoea, with a slight 
hyperventilation. Adenosine in doses of up to 3.7 x 10 -e 
mol did not cause apnoea, but the nucleoside was similar to 
ATP in that it caused a slight hyperventilation. 
Hyperventilation. Increased ventilation within the first 5 s 
after an injection of aß -MeATP was a prominent feature of 
the response to the P2 agonist and was caused by an 
increase in depth and frequency of respiration (see Fig. 1). 
This response was generally followed by a period of apnoea 
(see above), depending on the dose of agonist administered: 
low doses usually only evoked hyperventilation. Injection of 
2- Me -5 -HT also evoked an increase in RMV. Delayed hyper- 
Figure 4. Summary of pooled ED60 data for bradhycardia, apnoea 
and hyperventilation evoked by aß -MeATP 
Mean apparent ED50 values ± S.E.M. for reflex changes evoked by i.v. 
aß -MeATP before (Control, n = 14) and after various procedures in rats 
anaesthetized with pentobarbitone. A, bradycardia was significantly 
reduced by atropine (2.8 µmol (kg body wt)-1, n = 4), bilateral vagotomy 
(n = 3), suramin (14 µmol (kg body wt)-1, n = 3) and by PPADS 
(17 µmol (kg body wt)-1, n = 4), but unaffected by MDL 72222 
(0.24 mol (kg body wt)-1, n = 2 ) or cutting the sinus nerves (Cut CNS, 
n = 3). B, apnoea was unaffected by atropine (n = 4), MDL 72222 (n = 3), 
or cutting the carotid sinus nerves (n = 4), but was reduced after 
vagotomy (n = 5), suramin (n = 4) or PPADS (n = 4). C, hyperventilation 
was reduced by cutting the carotid sinus nerves (n = 4), and slightly but 
significantly by MDL 72222 (n = 4). The response was potentiated by 
vagotomy (n = 5) or PPADS (n = 4), and unaffected by atropine or 
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ventilation was observed following aß- MeATP, but this effect 
commenced 8 -15 s after the injection, following a period of 
apnoea, and may have been secondary to the cessation of 
breathing or the hypotension. Cutting the carotid sinus 
nerves, thereby denervating the carotid bodies - confirmed 
by the lack of hyperventilation previously evoked by 
sodium cyanide (2 1umol r.v.) - significantly reduced the 
rapid -onset hyperventilation (n = 4), see Fig. 1C. Since the 
hyperventilatory response was substantially reduced by 
cutting the carotid sinus nerves it was not feasible to 
determine a post -denervation ED for a8- MeATP, so 
responses were expressed as being > 1 x 10 -6 mol. 
The primary increase in ventilation was measured during 
the 6 s period immediately following the injection and the 
mean apparent EDSC determined from individual 
log dose -response plots. The pooled data illustrated in Fig. 
4C showed that suramin and PPADS tended to potentiate 
the reflex hyperventilation evoked by aß- MeATP, and 
vagotomy also increased the response. There was a slight 
but statistically significant decrease in responsiveness to 
aß -MeATP following the 5 -HT3 receptor antagonist 
MDL 72222; atropine had no effect. Qualitatively similar 
responses were observed with ATPyS, and its ED50 
(2.8 x 10 
-8 
mol, n = 4) was not different from that of 
aft-MeATP; vagotomy also potentiated the increase in 
ventilation obtained with ATPyS. As described above, ATP 
caused a slight dose -related increase in ventilation when 







also a delayed slight hyperventilation accompanying the 
profound hypotension which was unaffected by cutting the 
carotid sinus nerves. Adenosine lacked any fast onset 
stimulant action on ventilation when given in doses up to 
3.7 x 10 -6 mol i.v., but did cause a slight delayed hyper- 
ventilation that persisted after denervation of the carotid 
bodies. 
ED60 values 
Analysis of the mean ED50 values for aßß- MeATP- induced 
bradycardia, apnoea and hyperventilation (see Fig. 4) 
showed that they differed significantly (ANOVA P = 0.003). 
Bonferroni's multiple comparison test indicated that the 
control ED50 value for apnoea was significantly higher than 
that for bradycardia (P <0.01) and hyperventilation 
(P <0.05), whereas those for bradycardia and hyper- 
ventilation did not differ from each other. 
Neural recordings 
Vagal afferents. Recordings were obtained mainly from 
vagal pulmonary inflation (slowly adapting stretch) receptors, 
whose discharge was in phase with inspiration and related 
to the stroke volume of the ventilator. Activity was also 
recorded from some spontaneously active vagal afferents 
which did not respond to pulmonary inflation, deflation, 
sodium cyanide, or to changes in mean BP. Overall, twenty - 
four multi -unit recordings were made and 62 % of these 
(mainly pulmonary inflation receptors, but also unidentified 
vagal afferents) were rapidly (within 2 -3 s of injection) 
-- 
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Figure 5. Activation of pulmonary vagal afferenta by a/ì -MeATP 
Multi -unit recording from vagal afferents which increased their discharge frequency without any rapid 
adaptation when the lungs were inflated, i.e. lung inflation receptors. Injection of the P2X agonist 
a/3 -MeATP increased firing of the three units counted by the spike voltage discriminator (O, continuous 
line) and PPADS (17 umol (kg body wt)-` i.v.) antagonized the response (0, dashed line). The upper 
neurogram shows the neural discharge before and after a control i.v. injection of 2 nmol a/3 -MeATP at 
arrow - note that bursts of activity occurred during inspiration. The lower inset shows a sample of 
superimposed action potentials (3) triggered by the injection of a/J- MeATP. The number of action potentials 
triggered during the 5 s period following onset of the response was plotted as the increase above basal 
values which a v e r a g e d 14.1 -I- 1.4 impulses s ' before, and 16.3 + 1.5 impulses s ' after PPADS. The 
respiratory pump was set to a stroke volume of 3 ml with a frequency of 84 strokes min-1. 
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excited by i.v. a/3 -MeATP (see Fig. 5), and also by 2 -Me -5- 
HT, whereas 38% of the afferents were unresponsive to these 
drugs, including four recordings (17 % of total population) 
that responded to lung inflation. The increase in discharge 
lasted from 2 -10 s, the longer duration being associated 
with high doses. The mean ED50 for a/3- MeATP- induced 
excitation was (2.2 ± 0.5) x 10 -8 mol (n = 4) before, and 
(1.4 ± 0.2) x 10 -' mol (n = 3) after PPADS (17 umol (kg 
body wt)-1; P < 0.05, paired t test n = 3). Vagal activation 
by 2- Me -5 -HT (a single dose of 33 µmol was unaffected by 
PPADS, although it was abolished by the 5 -HT3 antagonist 
MDL72222 (0.24 µmol (kg body wt)-1) which did not 
significantly affect the excitatory response to aß- MeATP. 
The ED50 for a/3- MeATP- induced apnoea or bradycardia 
did not differ significantly from the vagal neural ED50 
In one experiment under urethane anaesthesia two separate 
multi -unit recordings of vagal sensory discharge were made. 
In one of these recordings the afferents were unaffected by 
a/3- MeATP, but were strongly excited by 2- Me -5 -HT 
(33 µmol), whereas in the other they were activated by the 
purinoceptor agonist within 2 s of injection and the 
excitation lasted for 3 -10 s. The ED50 for a/ -MeATP was 
1.5 x 10 -' mol, and in this recording the afferents showed 
only a very weak excitatory response to 2- Me -5 -HT, either 
before or after excitation by a /3- MeATP. 
Carotid body chemoreceptors. Recordings from the 
peripheral end of sectioned carotid sinus nerves in four rats 
demonstrated that a/i -MeATP injected i.v. caused a rapid 
dose- related increase in chemosensory discharge, as 
illustrated in Fig. 6. Intra- arterial injection of afl -MeATP 
A 
also increased chemosensory discharge, but with only one- 
tenth of the potency of the same dose injected i.v.; high doses 
of ATP ((1.8 -5.5) x 10 -8 mol) were also chemo -excitatory. 
The mean apparent ED50 for chemo -excitation evoked by 
aß -MeATP was (2.3 ± 0.9) x 10 -8 mol (n = 4), which was 
not significantly different from (2.3 ± 0.6) x 10_8 mol 
(n = 14), obtained for hyperventilation. Neither suramin 
(14 µmol (kg body wt) -1) nor PPADS (17 µmol (kg body 
wt) -1) antagonized the chemo - excitant action of a/3- MeATP, 
nor did they affect the chemo- excitation evoked by sodium 
cyanide or asphyxia (stopping the respiratory pump for 
30 s). 
Fast onset chemo- excitation was also observed under 
urethane anaesthesia in the one experiment performed (ED50 
for aß -MeATP 1.8 x 10 -8 mol before and 4 x 10 -8 mol after 
suramin (14 mol (kg body wt)-1); ED50 for ATPyS was 
3.7 x 10 -8 mol before suramin). 
DISCUSSION 
The results obtained using a,8- MeATP, an agonist which is 
relatively selective for particular subtypes of P2X receptor, 
together with subsidiary evidence from the rather weak and 
non -selective P2 receptor antagonists, PPADS and suramin 
(see Introduction), support our working hypothesis that 
activation of vagal P2X receptors in anaesthetized rats 
evokes a B -J reflex. Carotid body arterial chemoreceptors 
are also excited by P2X receptor agonists, causing reflex 
hyperventilation, so the overall cardiorespiratory response 
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Figure 6. Activation of carotid body chemoreceptors by aß -MeATP and ATP, and the effect of 
P2 purinoceptor antagonist PPADS 
Multi -unit recording from carotid chemoreceptor afferent fibres in an artificially ventilated rat 
anaesthetized with pentobarbitone. A, all three afferents counted by the voltage discriminator were 
activated by afl -MeATP (O, continuous line), and PPADS (17 µmol (kg body wt)-1 1.v.) did not antagonize 
the response (D, dashed line). Responses evoked by ATP (A, dotted line) in the control state are also shown. 
B, three individual action potentials (successive triggered oscilloscope sweeps superimposed) sampled 
during their activation by aft- MeATP. The increase in total discharge above pre- injection basal frequency 
was plotted in A, and basal discharge from these afferents during ventilation with room air averaged 9.3 
impulses s' before and 9.9 impulses s' after PPADS. 
852 D. S. McQueen and others J. Physiol. 507.3 
anaesthetized rats is quite complex, and will be considered 
in relation to the individual sensory elements involved. ATP 
had similar effects to those evoked by a/3- MeATP, but we 
did not study the nucleotide in detail because it is rapidly 
inactivated by ecto- nucleotidases and it was not feasible to 
use selective ATPase inhibitors in vivo. 
Anaesthetic 
The vagal reflexes bradycardia and apnoea were seldom 
obtained under urethane anaesthesia, whereas both reflexes 
were invariably present during pentobarbitone anaesthesia. 
Other authors have noted that reflex responses to ATP are 
affected by the anaesthetic (e.g. Emmelin & Feldberg, 1948; 
comparing chloralose with decerebration in cats), and this 
could be due to block of central reflex pathways, or perhaps 
to some interaction of the anaesthetic agent with 
P2X receptors in the periphery. Neural recording from 
vagal afferents indicated a reduced responsiveness to aft- 
MeATP in one experiment under urethane, but more 
detailed studies would be required to establish the extent to 
which peripheral, as opposed to central, actions of the 
anaesthetic agent reduce responsiveness to P2X receptor 
agonists. We focused on studying the cardiorespiratory 
reflexes under pentobarbitone anaesthesia. 
Vagal afferents 
The rapid onset bradycardia and apnoea evoked by a/3- 
MeATP was abolished by atropine or bilateral vagotomy, 
indicating that it was a vago -vagal reflex. In some 
experiments some reduction in ventilation persisted after 
vagotomy, but this could be eliminated by surgical removal 
of both nodose ganglia, suggesting that the P2X agonist, 
particularly in high doses, can activate purinoceptors 
located in the sensory ganglion (see Khakh et al. 1995) as 
well as those at the peripheral nerve terminals. The 
antagonists PPADS and suramin were both capable of 
antagonizing the bradycardia and apnoea induced by 
aß- MeATP. Desensitization to the reflex changes tended to 
occur when injections of the agonist were repeated at 
intervals of less than 10 min. Experiments in pithed rats, 
where reflexes were abolished by destruction of the brain 
and spinal cord, showed that only vasopressor effects, 
without bradycardia or vasodepression, were observed in 
response to a/3- MeATP. This confirms that there is no direct 
cardiac action of the agonist. In contrast, ATP and 
adenosine caused bradycardia and hypotension which was 
still present after vagotomy in anaesthetized animals, and 
was also obtained in pithed rats. ATP is known to be 
predominantly vasodepressor, and a/3 -MeATP primarily 
vasopressor in rats, either when anaesthetized (Cox & Smits, 
1996) or pithed (Schlicker, Urbanek & Gothert, 1989). Thus 
a/3 -MeATP causes a vagally mediated reflex fall in BP, but 
the drug also raises BP by mechanisms that do not involve 
vagal afferents. We found that, in doses which antagonized 
the reflex bradycardia and apnoea, neither PPADS nor 
suramin reduced the vasopressor response to aß -MeATP in 
anaesthetized animals. We did not study the antagonists in 
pithed rat, a preparation in which Schlicker et al. (1989) 
reported that PPADS antagonized the vasopressor response 
to a/3- MeATP. Further information on the vascular aspects 
of the actions of ATP can be obtained from a recent review 
(Rongen, Floras, Lenders & Smits, 1997). 
Neural recordings confirmed what the reflex studies had 
suggested, namely that vagal afferents, particularly those 
associated with pulmonary function were activated by 
a/3- MeATP, and the mean ED50 value obtained for neural 
activation did not differ significantly from those for reflex 
bradycardia or apnoea. Not all vagal afferent fibres were 
excited by the P2X agonist, and it was not feasible in this 
study to establish whether cardiac as well as pulmonary 
vagal sensory nerves contribute to the reflex. More complex 
experiments involving local application of drugs and 
selective denervation of particular cardiac or pulmonary 
vagal branches would be necessary. Other workers have 
demonstrated that ventricular receptors, particularly those 
in the left ventricle, are activated by veratrine and are 
mainly responsible for the B -J reflex caused by this drug in 
cat (see Paintal, 1955). It has also been shown that vagal 
C fibre afferents from the lungs (Hurt, Wang, Xu, Strerious 
& Pelleg, 1994; Pelleg & Hurt, 1996) and the left ventricle 
(Taneyama, Benson, Hild & Goto, 1997) in dog can be 
activated by ATP, probably via P2X receptors (Pelleg & 
Hurt, 1996), and as reviewed in Introduction, rat nodose 
neurones and vagal afferent fibres possess P2X receptors. 
Ventricular afferents which travel to the spinal cord via 
sympathetic nerve tracts (see Hainsworth, 1991) may be 
affected by P2X agonists and so contribute to some of the 
cardiovascular changes observed, particularly following 
vagotomy and cutting the carotid sinus nerves (e.g. Fig. 1), 
but this possibility was not investigated during the present 
study. Thus, it is probable that cardiopulmonary vagal 
afferents in rats are similar to those in dog in having 
P2X receptors closely associated with at least part of the 
sensory fibre population, and the question of whether these 
purinoceptors have a discrete physiological role in activating 
or modulating input from particular sensory nerves is 
intriguing. 
The reflexes evoked by aß -MeATP were not secondary to 
release of endogenous 5 -HT because the B -J reflex evoked 
by 2- Me -5 -HT was antagonized by the 5 -HT3 antagonist 
MDL 72222, which had no significant effect on the responses 
to the P2X agonist, and PPADS antagonized vagal responses 
to aft-MeATP without affecting those to the 5 -HT3 receptor 
agonist. This evidence confirmed that cardiorespiratory 
reflexes evoked by a/3 -MeATP resulted from selective 
actions at P2X receptors associated with vagal afferents 
Arterial chemoreceptors 
Chemoreflexes were rapidly activated by intravenous a0- 
MeATP or, at 100 times the dose, ATP, and the mean ED50s 
for neural activation and reflex hyperventilation evoked by 
a/3 -MeATP were not significantly different. Cardio- 
respiratory reflexes evoked in the anaesthetized rat were 
therefore not confined to excitation of vagal afferents. ATP 
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excites carotid body arterial chemoreceptors in cat and dog 
(Jarisch, Landgren, Neil & Zotterman, 1952), and McQueen 
& Ribeiro (1983) proposed the presence of P2 purinoceptors 
in the cat carotid body based on results obtained using aß- 
MeATP. Recent studies on cat carotid body chemoreceptors 
in vitro showed that ATP surface receptors are present that 
can be transiently activated by an infusion of ATP, although 
the receptors were subsequently desensitized (Spergel & 
Lahiri, 1993). 
The respiratory reflex and neural data obtained during the 
present study strongly suggest that the rat carotid body 
contains P2X receptors which can activate arterial 
chemoreflexes. The rapid onset of chemo- excitation in 
response to P2X agonists shows that it is not secondary to 
vasoconstriction within the carotid body, since changes in 
discharge following injection of vasoconstrictors are 
sluggish, being much slower in onset (> 5 s) and tending to 
last longer - potent vasoconstrictors such as endothelin -1 
only evoke small increases in rat carotid chemoreceptor 
discharge (McQueen, Dashwood, Cobb, Marr, Bond & Spyer, 
1995) compared with those we obtained. The purinoceptors 
in the rat carotid body seem to be relatively insensitive to 
desensitization by a/f- MeATP, and neither PPADS nor 
suramin acted as antagonists in the doses used. This means 
that these carotid body purinoceptors differ from other 
aß- MeATP- sensitive P2X receptors that are antagonized by 
these compounds. It is possible to speculate that the 
receptors comprise different subunits (e.g. P2X4, whose 
responsiveness to ATP or aß -MeATP (weak agonist) is 
unaffected or potentiated by PPADS or suramin in 
recombinant expression of receptors in Xenopus oocytes in 
vitro (Bo, Zhang, Nassar, Burnstock & Schoepfer, 1995)), 
but it has yet to be established how the pharmacology of 
recombinant subunits correlates with that of the native 
receptors in vivo. Other actions of suramin or PPADS (e.g. 
inhibition of ecto -ATPase) may mask an antagonist action 
at P2 receptors in the carotid body, although this seems 
unlikely since the same argument would apply to the 
bradycardia and apnoea, which were antagonized. Also 
aß -MeATP is relatively resistant to breakdown so should be 
unaffected by enzyme inhibition (see Humphrey et al. 1995). 
The apparent potentiation of the respiratory response to 
aß -MeATP after PPADS or vagotomy is probably secondary 
to abolition or reduction in the apnoea which normally 
masks part of the hyperventilation, an interpretation which 
is supported by chemosensory discharge evoked by 
aß -MeATP being largely unaffected by PPADS. 
Our conclusions concerning P2X receptor subtypes located 
on a variety of sensory nerves being involved in triggering 
cardiorespiratory reflexes are based on indirect evidence 
obtained using agonists and relatively non -selective 
antagonists (Humphrey et al. 1995) in functional 
experiments in vivo. It is tempting to surmise that, because 
of their sensitivity to aß -MeATP the receptors associated 
with vagal afferents must be of the P2X1, P2X2, P2X3 or 
P2X213 subtype(s), but this needs further investigation. 
Further information from studies involving, for example, 
selective P2X receptor antagonists or, more directly, 
receptor autoradiography and immunocytochemistry, would 
provide useful additional evidence concerning the presence 
of particular a/3- MeATP- sensitive P2X receptor subtypes in 
the heart, lungs, and carotid body. 
Vagally mediated bradycardia and apnoea evoked during 
the B -J reflex, and also the carotid chemoreflex hyper- 
ventilation in vagotomized rats, could be utilized for 
convenient functional characterization of compounds 
affecting P2X receptors, in much the same way as this 
reflex was utilized in the development of 5 -HT3 receptor 
antagonists (Fozard, 1984). 
The physiological significance of the B -J reflex has been the 
subject of considerable debate during the 130 years since it 
was first described, and it is commonly regarded as being a 
pharmacological curiosity. However, the presence of fast 
ATP -gated cation channels on sensory terminals in vital 
structures (e.g. left coronary artery and /or ventricle; 
pulmonary system), together with the local presence of the 
endogenous ligand ATP, strongly suggests a functional 
signalling role for ATP (see Zimmermann, 1994) and these 
P2X receptors. Their presence in the cardiopulmonary 
system and the carotid body could have pathophysiological 
significance, particularly when hypoxaemia or tissue 
damage results in substantial release of ATP from cells and 
nerve terminals, such as during increased activity in 
adrenergic nerves (e.g. in stress) that leads to co- release of 
ATP with noradrenaline (see Burnstock, 1988). These 
conditions may be mimicked pharmacologically by a 
P2X agonist activating the B -J cardiac nociceptive reflex, 
even in the presence of an anaesthetic agent which will 
depress the reflex. Whether non -noxious low level neural 
activity in these sensory pathways is part of the 
interoceptive homeostatic mechanism regulating the cardio- 
vascular (e.g. see Linden, 1973; Hainsworth, 1991) and 
respiratory systems physiologically, and whether particular 
peripheral sensory receptors possess sub -populations of 
specific P2X receptors that enable locally released ATP to 
influence their sensitivity and activity discretely, are 
intriguing questions that require investigation. P2X 
receptors in the heart and lungs are potential therapeutic 
targets for the treatment of cardiovascular and respiratory 
disorders. 
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